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Background: Compression is an effective and recommended treatment for venous leg ulcers. Although
the four-layer bandage (4LB) is regarded as the gold standard compression system, it is recognised that the
amount of compression delivered might be compromised by poor application technique. Also the bulky
nature of the bandages might reduce ankle or leg mobility and make the wearing of shoes difficult.
Two-layer compression hosiery systems are now available for the treatment of venous leg ulcers. Two-layer
hosiery (HH) may be advantageous, as it has reduced bulk, which might enhance ankle or leg mobility and
patient adherence. Some patients can also remove and reapply two-layer hosiery, which may encourage
self-management and could reduce costs. However, little robust evidence exists about the effectiveness of
two-layer hosiery for ulcer healing and no previous trials have compared two-layer hosiery delivering ‘high’
compression with the 4LB.
Objectives: Part I To compare the clinical effectiveness and cost-effectiveness of HH and 4LB in terms of
time to complete healing of venous leg ulcers. Part II To synthesise the relative effectiveness evidence
(for ulcer healing) of high-compression treatments for venous leg ulcers using a mixed-treatment
comparison (MTC). Part III To construct a decision-analytic model to assess the cost-effectiveness of
high-compression treatments for venous leg ulcers.
Design: Part I A multicentred, pragmatic, two-arm, parallel, open randomised controlled trial (RCT) with
an economic evaluation. Part II MTC using all relevant RCT data – including Venous leg Ulcer Study IV
(VenUS IV). Part III A decision-analytic Markov model.
Settings: Part I Community nurse teams or services, general practitioner practices, leg ulcer clinics, tissue
viability clinics or services and wound clinics within England and Northern Ireland.
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v
Participants: Part I Patients aged ≥ 18 years with a venous leg ulcer, who were willing and able to
tolerate high compression.
Interventions: Part I Participants in the intervention group received HH. The control group received the
4LB, which was applied according to standard practice. Both treatments are designed to deliver 40mmHg
of compression at the ankle. Part II and III All relevant high-compression treatments including HH, the 4LB
and the two-layer bandage (2LB).
Main outcome measures: Part I The primary outcome measure was time to healing of the reference
ulcer (blinded assessment). Part II Time to ulcer healing. Part III Quality-adjusted life-years (QALYs)
and costs.
Results: Part I A total of 457 participants were recruited. There was no evidence of a difference in
time to healing of the reference ulcer between groups in an adjusted analysis [hazard ratio (HR) 0.99,
95% confidence interval (CI) 0.79 to 1.25; p= 0.96]. Time to ulcer recurrence was significantly shorter in
the 4LB group (HR= 0.56, 95% CI 0.33 to 0.94; p= 0.026). In terms of cost-effectiveness, using QALYs
as the measure of benefit, HH had a > 95% probability of being the most cost-effective treatment based
on the within-trial analysis. Part II The MTC suggests that the 2LB has the highest probability of ulcer
healing compared with other high-compression treatments. However, this evidence is categorised as low
to very low quality. Part III Results suggested that the 2LB had the highest probability of being the most
cost-effective high-compression treatment for venous leg ulcers.
Conclusions: Trial data from VenUS IV found no evidence of a difference in venous ulcer healing between
HH and the 4LB. HH may reduce ulcer recurrence rates compared with the 4LB and be a cost-effective
treatment. When all available high-compression treatments were considered, the 2LB had the highest
probability of being clinically effective and cost-effective. However, the underpinning evidence was sparse
and more research is needed. Further research should thus focus on establishing, in a high-quality trial,
the effectiveness of this compression system in particular.
Trial registration: Current Controlled Trials ISRCTN49373072.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 18, No. 57.
See the NIHR Journals Library website for further project information.
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Plain English summary
Venous leg ulcers are common, chronic wounds that are painful and reduce quality of life. The applicationof compression is known to assist in the healing of venous leg ulceration. The four-layer bandage (4LB)
(which delivers 40mmHg of compression at the ankle) is the current gold standard treatment for healing
venous leg ulcers. Two-layer hosiery (HH, i.e. below-knee stockings) has been designed to deliver the same
amount of compression as the 4LB with the potential advantages of being easier for patients to wear and
apply. At the start of this study it was thought that these factors may increase patient use of compression and
thus improve ulcer-healing rates and cost-effectiveness.
In total, 457 people agreed to take part in this study. Data showed that ulcers treated with the 4LB or with
HH took a similar amount of time to heal. More people in the HH changed from their treatment and
reported non-serious adverse events. On average, people receiving hosiery were less likely to experience
ulcer recurrence and the hosiery was shown to be more cost-effective.
We also investigated the clinical effectiveness and cost-effectiveness of all important high-compression
treatments [e.g. the short-stretch bandage and two-layer bandage (2LB)], using robust methods to
combine data from relevant studies [including Venous leg Ulcer Study IV (VenUS IV)]. Analyses suggested
that the 2LB system was the most clinically effective and cost-effective treatment for healing venous leg
ulcers. However, this finding is uncertain, reflecting the limited data for this treatment. More research on
the potential effectiveness of the 2LB would further inform decision-making in this area.
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Scientific summary
Background
Compression is an effective and recommended treatment for venous leg ulcers. Although the four-layer
bandage (4LB) is regarded as the gold standard compression system, it is recognised that the amount
of compression delivered might be compromised by poor application technique. Also, the bulky nature of
the bandages might reduce ankle or leg mobility and make the wearing of shoes difficult. Two-layer
compression hosiery systems are now available for the treatment of venous leg ulcers. Two-layer hosiery (HH)
may be advantageous, as it has reduced bulk, which might enhance ankle or leg mobility and patient
adherence. Some patients can also remove and reapply HH, which may encourage self-management and
could reduce costs. However, little robust evidence exists about the effectiveness of HH for ulcer healing and
no previous trials have compared HH delivering ‘high’ compression with the 4LB.
Objectives
The objectives of this study were to (1) compare the clinical effectiveness and cost-effectiveness of HH
with the 4LB in terms of time to complete healing of venous leg ulcers, cost of treatment, health-related
quality of life/utility and participant concordance with treatment; (2) conduct a mixed-treatment comparison
(MTC) meta-analysis of high-compression treatments for venous leg ulcers to estimate their relative
effectiveness for ulcer healing; and (3) construct a decision-analytic model to assess the cost-effectiveness
of high-compression treatments for venous leg ulcers.
Methods
Design
(1) A multicentred, pragmatic, two-arm, parallel, open randomised controlled trial (RCT) with equal
randomisation. Trial-level cost–utility and cost-effectiveness analyses were conducted. Assessment of the
primary outcome was undertaken using blinded assessment of photographs.
(2) MTC using all relevant RCTs, including data from the trial part of Venous leg Ulcer Study IV (VenUS IV).
(3) A decision-analytic Markov model utilising all available research evidence.
Setting
(1) The settings were acute and community settings (community nurse teams or services, general
practitioner practices, leg ulcer clinics, tissue viability clinics or services and wound clinics) within England
and Northern Ireland.
Participants
(1) Participants were eligible for inclusion within this trial if they had a venous leg ulcer, were at least
18 years of age, had an ankle–brachial pressure index of ≥ 0.8 and were willing and able to tolerate
high compression.
Interventions
(1) Participants in the intervention group received HH, which consisted of an understocking and
overstocking, applied according to manufacturer’s instructions. The control group received the 4LB,
which was applied according to standard practice. Both treatments were designed to deliver 40mmHg
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of compression at the ankle. Participants received their allocated treatment until the leg with the largest
eligible venous leg ulcer (the reference ulcer) healed and treatment was no longer required, they changed
treatment, or they died or were lost to follow-up.
Main outcome measures
The primary outcome measure was time to healing of the reference ulcer, as determined by blinded
assessment. Secondary outcome measures were time to healing of the reference ulcer, as determined by
unblinded assessment and participant concordance with treatment, ulcer recurrence, adverse events,
health-related quality of life/utility and resource use.
Results
In total, 457 participants were recruited into this trial, with 230 allocated to the HH group and 227 to the
4LB group. Using a Cox proportional hazards (CPH) model to adjust for baseline ulcer area, ulcer duration
and participant mobility, and with centre included as a random effect, there was no evidence of a difference
between HH and the 4LB in terms of time to ulcer healing [hazard ratio (HR) 0.99, 95% confidence interval
(CI) 0.79 to 1.25; p= 0.96]. More participants in the HH group (39.3%) changed from their allocated trial
treatment than in the 4LB group (27.8%; p= 0.01). Increasing age and previous reporting of a non-serious
adverse event (NSAE) were also significant predictors of treatment change. Following healing of the
reference leg, participants in the HH group demonstrated fewer ulcer recurrences than those in the 4LB
group (14.4% vs. 23.3%; p= 0.035). A CPH model adjusted for baseline ulcer duration, ulcer area and
participant mobility, both with and without shared centre frailty effects, also showed that time ulcer
recurrence was significantly shorter in the 4LB group (HR= 0.56, 95% CI 0.33 to 0.94; p= 0.026). There
was no statistically significant difference in the number of adverse events between groups but significantly
more participants in the HH group reported one or more NSAEs during the trial (70.0% vs. 58.0%;
p= 0.050). Adjusted health-related quality of life (as measured by the Short Form questionnaire-12 items)
over 12 months’ follow-up was also similar in both groups. In terms of cost-effectiveness, the mean annual
cost of HH per participant was £302.4 (bias corrected 95% CI −£716.3 to £96.5) less than that for the 4LB.
Participants in the HH group also had higher quality-adjusted life years (QALYs) than those allocated to the
4LB (annual difference in adjusted QALYs of 0.034, 95% bias corrected CI −0.0005 to 0.0778). Using
QALYs as the measure of benefit, compression hosiery had a > 95% probability of being the most
cost-effective treatment based on this within-trial analysis.
(2) The MTC suggested that the two-layer bandage (2LB) (two-component system, with a top component
that is a cohesive bandage) had the highest probability of healing compared with other high-compression
treatments. However, this evidence is categorised as low to very low quality.
(3) The cost-effectiveness model results suggested that the 2LB had the highest probability of being the
most cost-effective high-compression treatment for venous leg ulcers. However, evidence regarding
this treatment was limited. Value-of-information analysis suggested that further research that might resolve
existing uncertainties was likely to be worthwhile.
Conclusions
Trial data from VenUS IV found no evidence of a difference in ulcer healing for HH and 4LB treated venous
leg ulcers. However, there was evidence that HH may reduce ulcer recurrence rates when compared with
the 4LB and be a cost-effective treatment. We note that, when compared with the 4LB, more patients may
wish to change from HH treatment, especially older patients.
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In additional analyses (MTC meta-analysis and cost-effectiveness modelling) that considered all
high-compression treatments, the 2LB was shown to have the highest probability of being clinically
effective and cost-effective. However, these findings must be considered in light of contributing evidence
for this treatment, which is sparse and poor in some cases. Any possible guidance made at national
and/or local level regarding changes to practice should take estimate quality into account.
Implications for health care
Two-layer hosiery is as effective as the 4LB in healing venous leg ulcers, although more patients may
change from this treatment during the course of their ulcer episode. Patients wearing two-layer
compression hosiery received fewer nurse consultations and it appears to be a more cost-effective
treatment for venous ulcers than the 4LB.
Participants in the HH group also demonstrated lower rates of ulcer recurrence than those in the 4LB
group; an interesting finding, which we are not able to fully explain. It may be that patients who wear HH
as an ulcer treatment are more likely to wear compression stockings for secondary prevention after healing
(and may wear higher compression); we are unable to confirm this hypothesis using the trial data.
Two-layer hosiery that delivers 40mmHg pressure at the ankle can be considered as an effective
alternative to the 4LB; it has the additional benefit of appearing to reduce recurrence rates and being
more cost-effective. Although HH is not suitable for all patients (if they are unable to apply it or remove it
for example) it does appear to offer some advantages over the 4LB.
Although all current evidence suggests that the 2LB may be an effective and cost-effective treatment for
venous leg ulcers, this conclusion is associated with significant uncertainty, as the existing evidence
comprises small and low-quality trials.
Implications for future research
The cost-effectiveness analysis demonstrated that VenUS IV was worthwhile, as it determined the value of
HH in treating active venous ulceration. The value of further information analysis showed that the inclusion
of VenUS IV considerably reduced the consequences of decision uncertainty.
However, the findings of these analyses also highlight how tentative the findings are which support the
use of 2LB, and the impact of considering such low-quality findings in deciding which treatment should
be used in clinical practice. Further research should thus focus on establishing, in a high-quality trial,
the effectiveness of this compression system in particular.
Trial registration
This trial is registered as ISRCTN49373072.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Background
Venous leg ulcers
Venous leg ulcers are chronic wounds that generally occur within the gaiter region of the leg as a
consequence of venous insufficiency.1 The underlying venous insufficiency and associated venous
hypertension are generally caused by venous valve dysfunction, deep vein occlusion or failure of the calf
muscle pump.2,3 Venous leg ulceration typically presents as repeated cycles of ulceration, healing and
recurrence, with ulcers typically taking weeks or months to heal.1,4,5 Once healed, 12-month recurrence
rates have been estimated at between 18% and 28%.6,7
Venous leg ulcers are distressing to patients, painful, prone to infection, malodorous and have a severe
negative impact upon patients’ mobility and quality of life.8,9 These wounds are one of the most prevalent
chronic wound types in the UK, with an estimated point prevalence of 0.16%.10 There is a progressive
increase in venous leg ulceration with age and the annual UK prevalence in people of > 65 years is
estimated at 1.7%.11
Venous leg ulcers are costly to treat. In 2004, the Healthcare Commission estimated annual UK NHS leg
ulcer treatment costs of £300–600M.12 More recent data from UK venous leg ulcer studies indicates the
annual cost of treating one venous leg ulcer episode to be approximately £1300,7,13 with treatment costs
rising as ulcers increase in size and duration.14,15 In the UK, most leg ulcer patients are treated in the
community,16,17 and it is the nursing time that is associated with frequent treatment consultations that
drives these high costs.14,18 The significant morbidity, high prevalence and economic burden associated
with the treatment of venous leg ulceration1 highlights the need to identify the most clinically effective and
cost-effective treatments for these wounds.
Compression for venous leg ulcers
The management of venous leg ulcers aims to (1) provide a wound environment that supports healing
while avoiding excess moisture and tissue maceration and (2) improve venous return. Although there are
many types of wound dressings used in the management of venous leg ulcers, there is an absence of
evidence for their relative effectiveness.19 In contrast, evidence shows that compression is an effective
treatment for venous leg ulcers, as is recommended by major UK clinical guidelines for first-line use.20,21
Compression works by applying pressure to the leg, which may decrease vein diameter and improve valve
function thus increasing the blood flow towards the heart and reducing venous reflux.22,23 Compression
is normally applied to the lower leg with the most pressure exerted at the ankle, gradually lessening
towards the knee.21
Compression can be applied in a number of ways, most commonly using bandages or hosiery (stockings);
there are many different bandaging and hosiery systems available for use. The relative effectiveness of these
various systems on ulcer healing is summarised in a detailed systematic review reporting 59 comparisons
from a total of 4321 randomised controlled trial (RCT) participants.19 The review concluded that
multicomponent systems delivering ‘high’ compression (commonly recognised as delivering 40mmHg
at the ankle) are most effective in terms of healing venous leg ulcers.
Multicomponent compression bandage systems
In the UK, the most widely used multicomponent compression bandage system is the four-layer bandage
(4LB). The short-stretch bandage (SSB) is also widely used. Both systems were compared in VenUS
(Venous Ulcer Study) I, which randomised 387 participants with venous leg ulcers.7 The study found that
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the 4LB significantly reduced time to healing [median survival time 92 days in the 4LB group compared
with 126 days in the SSB group: adjusted hazard ratio (HR) 1.33, 95% confidence interval (CI) 1.05 to
1.67]. This study finding was supported in an individual patient data (IPD) analysis of all relevant RCTs,24
in which the 4LB was more effective in terms of ulcer healing than the short-stretch system (adjusted HR
1.31, 95% CI 1.09 to 1.58). Thus, the 4LB is considered a gold standard treatment for venous leg ulcers.
However, it is important to note that good clinical outcomes from bandaging (in terms of ulcer healing)
rely heavily on nurses’ application skills and patient concordance in wearing compression continuously.
Application and concordance are a particular issue for the 4LB, which consists of a wool component plus
three subsequent bandage components, making the final compression system time-consuming to apply
and bulky. This bulk may impact on concordance by reducing mobility, making shoes difficult to wear and
causing discomfort.25
Compression hosiery
Compression hosiery for treating venous leg ulcers
Single-layer compression hosiery can be used to treat venous leg ulcers – there are three UK standard classes
of hosiery that deliver increasing levels of compression: class I (14–17mmHg); class II (18–24mmHg) and
class III (25–35mmHg). Thus, no standard single hosiery achieves 40mmHg compression at the ankle.
Furthermore, the Class III stocking has been noted as being difficult to apply as it can be tight26,27 and,
anecdotally, application can also be painful for patients. Recently, new two-layer compression hosiery systems
(referred to hereafter as ‘HH’) have been marketed in the form of two stockings which, when worn
simultaneously, are designed to provide a total of 40mmHg compression. Furthermore, several of these
stocking systems have been designed with a smooth first layer (or understocking) providing light compression
over which a second overstocking (i.e. UK class II or III, depending on the understocking) slips on. In fact there
may be increased potential for patients with sufficient mobility and dexterity (using newly marketed applicator
devices) to remove and reapply the stockings themselves.
Five published RCTs28–32 have compared compression hosiery (minimum of 25mmHg compression at the
ankle) with compression bandaging for healing venous leg ulcers (Table 1).
Four of these RCTs compared compression hosiery with the SSB29–32 and one compared compression
hosiery with the 4LB.32 None of the compression hosiery products evaluated was the more recently
developed HH systems.
Findings for the compression hosiery compared with SSB have been summarised in a recently updated
systematic review.19 Briefly, of the four RCTs,29–32 three were identified as being at high risk of bias and
one at unclear risk of bias. Fixed-effects meta-analysis of ulcer-healed data from all four RCTs found that
significantly more ulcers healed in the compression hosiery group than in the bandage group at between
2 and 4 months’ follow-up, although heterogeneity between studies was high [relative risk (RR)= 1.62,
95% CI 1.26 to 2.10, I2= 60%]. A random-effects model also suggested that, on average, significantly
more ulcers healed with compression hosiery (RR= 1.66, 95% CI 1.07 to 2.58).
One RCT32 has compared compression hosiery with the 4LB for healing venous leg ulcers. As this study32
was recently published and is not included in the updated systematic review it is summarised here.
Finlayson et al.32 compared a single class III compression stocking with the 4LB in 103 participants with
venous leg ulcers. It is important to note that there may have been a difference in the level of compression
received between trial groups, as the compression hosiery was recorded as delivering 30−35mmHg,
whereas the 4LB aims to deliver up to 40mmHg of compression at the ankle.
Upon request, the author provided outcome data regarding ulcer healing for 98 participants for 24 weeks
of follow-up. In total, 72% (31/43) of compression hosiery-treated ulcers healed by 24 weeks compared
with 84% (38/45) of 4LB-treated ulcers [RR 0.85, 95% CI 0.68 to 1.07 (no statistically significant
difference)]. However, the adjusted HR (4LB vs. compression hosiery) reported was 2.1 (95% CI 1.4 to 4.3),
BACKGROUND
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suggesting that those in the 4LB group had twice the hazard of healing compared with the hosiery group,
with this finding being statistically significant.
Compression hosiery for preventing recurrence of venous leg ulcers
Venous leg ulcers occur as a result of underlying venous disease. Thus, once an ulcer has healed, if
compression therapy ceases (resulting in the re-establishment of high venous pressures) then ulcer
recurrence might be expected. Current guidelines state that ‘Below knee graduated compression hosiery is
recommended to prevent recurrence of venous leg ulcer (sic) in patients where leg ulcer healing has been
achieved’ (Scottish Intercollegiate Guidelines Network 2010, p. 4).21 This guidance is predominantly based
on three previous RCTs,33–35 summarised in a key review,36 where no RCT data were pooled. In summary,
one RCT (n= 153) reported statistically significant evidence that offer of a class III compression stocking
post healing prevented recurrence of venous leg ulcers compared with no compression at 6 months post
healing (RR 0.46, 95% CI 0.27 to 0.76; p= 0.003).33 However, the review authors judged this RCT as
being at high risk of attrition bias.36 Two further RCTs34,35 (n= 300 and n= 338) compared a UK class II
stocking with a UK class III stocking in preventing venous ulcer recurrence; both studies were classed as
being at possible high risk of bias owing to non-blinded outcome assessment for ulcer recurrence.
Nelson et al.35 reported that there was no evidence of a difference between the class II and III stockings in
terms of recurrence at 5 years (RR= 0.82, 95% CI 0.61 to 1.12; p= 0.22). They also reported that
compliance was higher with the class II stocking. Conversely, Milic et al.34 reported that allocation to
receive a class III stocking resulted in a significant reduction in ulcer recurrence when compared with a
class II stocking, with no difference in compliance (RR= 0.57, 95% CI 0.39 to 0.81; p= 0.002).
TABLE 1 Details of previous trials comparing compression hosiery with compression bandaging for healing venous
leg ulcers
Author (year),
country, n recruited
Details of
hosiery group
Details of
bandage groupa
Duration of
follow-up
Proportion of participants
with healed venous
leg ulcers
Junger 2004,28 Germany
and the Netherlands
n= 121
Bauerfeind
VenoTrain® ulcertec
(Birmingham, UK)
39mmHg
SSB: Roselastic® S,
Karl Otto Braun KG
(Wolfstein, Germany)
12 weeks Hosiery= 48% (29/61)
Bandage= 32% (19/60)
p= 0.01
Polignano 2004,29
Italy
n= 56
ConvaTec SurePress®
Comfort
35mmHg
SSB: Comprilan®, Smith
& Nephew (Hull, UK)
12 weeks Hosiery= 44% (12/27)
Bandage= 17% (5/29)
p= 0.03
Mariani 2008,30
Italy
n= 60
Sigvaris® Ulcer X
(Andover, UK)
39mmHg
SSB: (details
not reported)
16 weeks Hosiery= 83% (25/30)
Bandage= 70% (21/30)
p= 0.01
Taradaj 2009,31
Poland
n= 80
Sigvaris® 702
(Andover, UK)
25–32mmHg
SSB: (details
not reported)
2 months Hosiery= 37.5% (15/40)
Bandage= 12.5.0% (5/40)
p≤ 0.001
Finlayson 2012,32
Australia
n= 103
Class III system
(details not reported)
30–35mmHg
4LB (details
not reported)
24 weeks Hosiery: 72% (31/43)
Four layer: 84% (38/45)b
p= 0.24
a All SSB and 4LB systems are assumed to deliver 40mmHg at the ankle, unless stated otherwise.
b Data obtained from author.
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Investigating compression treatments for venous leg ulcers
There is limited evidence for the effectiveness of HH in terms of ulcer healing. However if, because of its
reduced bulk, this treatment can easily be worn with shoes and potentially enhance ankle/leg mobility and
patient compliance while also delivering a standardised level of compression (as bandager skill is not an
issue) and being easy to apply it may increase ulcer healing rates. Further potential benefits worth
investigating are the opportunity for patients to self care, leading to a possible reduction in nurse
consultations and the reusability of stockings compared with the disposable bandages. However, a
pragmatic trial is required, as it is plausible that HH may not yield improvements if patients do not like the
treatment, they remove and do not reapply the stockings, and/or the compression delivered does not
endure sufficiently after washing and reapplying the stockings over several months.
At the time this study was commissioned, our community nurse coapplicants had identified this as
an important area of clinical and economic uncertainty at a time when HH was being marketed as an
alternative to bandaging.
Finally, as noted above (see Compression hosiery for preventing recurrence of venous leg ulcers), there is
some evidence that the use of compression hosiery after healing prevents recurrence of venous leg
ulcers.37 In evaluating HH it seems relevant to investigate whether the offer of this treatment has any
impact, post healing, on ulcer recurrence, for example if those wearing hosiery as a treatment carry on
wearing it as a maintenance therapy.
Facilitating decision-making regarding compression treatments
for treating venous leg ulcers
Although the 4LB and HH are compression treatments of relevance to decision-makers, there are several
alternative compression systems available that nurses (and patients) may select, including the SSB system
and the two-layer bandage (2LB) system (bottom component with cohesive bandage top component). It is
therefore important that decision-makers consider all available evidence for all competing alternatives when
making treatment decisions, not just the evidence from a single RCT. RCTs are designed to compare two or
more alternative treatments; however, it is often not practical for one RCT to compare all available treatment
options. This means that for a decision-maker the information provided by head-to-head trial comparisons
can be limited and partial, i.e. we would like to know which treatment option is the most clinically effective
and/or cost-effective from among all treatments of interest. The limitations of head-to-head trial comparisons
can be overcome if available evidence from multiple RCTs can be considered collectively.
Thus, although a trial comparing any two compression treatments is very important, the value to clinical
(and societal) decision-making of assessment using all trial findings from all relevant trials regarding the use
of all high-compression treatments must also be recognised. However, the information from the trials must
be further evidence synthesised together using formal methods such as mixed-treatment comparison
(MTC) meta-analysis.
Mixed-treatment comparisons
Mixed-treatment comparison meta-analysis (also known as network meta-analysis) extends meta-analytic
methods by enabling the simultaneous comparison of multiple interventions in a single model.38,39
Mixed-treatment comparisons allow eligible RCTs to be included when they are linked by one or more
common comparator(s) in a network of evidence.40 As an example, assume three relevant treatments
(A, B and C) have been evaluated in two RCTs: one comparing A with B, and another B with C. A network
can be defined linking A to B to C. By linking RCT evidence, a consistent evidence base is created and
derived relative treatment effect estimates may be informed by direct, indirect or both direct and indirect
data. Indirect data can produce effectiveness estimates for pairs of treatments that have not been
BACKGROUND
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compared in head-to-head trials. In our example this means inferences over A vs. C can be generated
using the indirect evidence available through the network.
In practice, where multiple RCTs inform multiple network links, the synthesis can become complex,
as direct and indirect evidence contribute to estimating relative effectiveness for specific comparisons.
However, by simultaneously using all (direct and indirect) evidence forming the network, uncertainty is
appropriately considered for the comparisons of interest. Additionally, this approach provides an
opportunity for formal assessment of consistency between direct and indirect evidence. In all cases, the
validity of these methods depends on certain assumptions being held – some are common to standard
pairwise meta-analysis (e.g. ‘similarity’ between included trials) and others relate to the ‘consistency’
between the direct and the indirect estimates, which can be assessed within the network. In the presence
of heterogeneity, incorporating information on patients’ characteristics in the synthesis model has been
shown to improve estimates and, by doing so, possibly resolve inconsistencies.37,41,42
Decision-analytic modelling
Although MTCs are able to synthesise all RCT data, beyond trials, the relative cost-effectiveness of all
relevant treatments for a condition can be investigated in a decision-analytic model. Though within-trial
economic analysis offers the opportunity to evaluate cost-effectiveness in participants who contribute
resource-use data alongside effectiveness data, such analyses are also limited by the scope of the RCT in
which they sit. Decision-analytic models provide a structure within which both RCT and non-RCT evidence
from a range of sources can be synthesised to describe a specific problem, and through this framework
overall costs and effects can be estimated. The advantage of using this framework is that cost-effectiveness
results can be based on all available evidence, across the full range of possible alternative interventions and
clinical strategies over a relevant time horizon, and specific patient groups can be analysed separately.
Summary of main points
Venous leg ulcers are common chronic wounds that have a severe negative impact upon patients’ quality
of life and health. The treatment of these wounds costs the NHS hundreds of millions of pounds per year.
The application of compression is known to assist in the healing of venous leg ulceration. The 4LB
(which delivers 40mmHg of compression at the ankle) is the current gold standard treatment for healing
venous leg ulcers and is recommended by major UK clinical guidelines for first-line use.
Two-layer hosiery has been designed to deliver the same amount of compression as the 4LB, with the
potential advantages of being easier for patients to wear and apply. These factors may increase patient
concordance with compression and thus improve ulcer-healing rates. There is some evidence from RCTs
that compression hosiery may be effective in healing venous leg ulcers when compared with the SSB.28–30
However, only one RCT32 has compared compression hosiery with the 4LB, although the compression
hosiery used was not a two-layer system designed to deliver up to 40mmHg at the ankle.
Report structure
This work is presented in four parts:
l Part I relates to the conduct of a RCT comparing HH with the 4LB in people with venous leg ulcers.
l Part II relates to the conduct of a MTC meta-analysis of high-compression treatments for venous
leg ulcers.
l Part III relates to the conduct of a decision-analytic model to assess the cost-effectiveness of
high-compression treatments for venous leg ulcers.
l Part IV is an overall discussion of the work presented.
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Part I Venous leg Ulcer Study IV (VenUS IV) trial
We undertook a RCT to evaluate the clinical effectiveness and cost-effectiveness of HH in the treatmentof venous leg ulcers.
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Chapter 2 Research objectives
To compare the clinical effectiveness and cost-effectiveness of compression hosiery with the 4LB in termsof time to complete healing of venous leg ulcers, cost of treatment, health-related quality of life and
participant concordance to treatment.
Primary objective
To compare the effects of compression hosiery with the 4LB on time to healing of the reference ulcer
(the largest eligible venous leg ulcer).
Secondary objectives
To compare the:
l cost-effectiveness of compression hosiery with the 4LB
l effects of compression hosiery with the 4LB on the time to healing of the reference leg
l effects of compression hosiery and the 4LB on health-related quality of life
l effects of compression hosiery and the 4LB on participant concordance to treatment
l effects of compression hosiery and the 4LB on reported adverse events
l effects of compression hosiery and the 4LB on ulcer recurrence.
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Chapter 3 Methods
Trial design
We conducted a pragmatic, multicentred, two-arm, parallel, open RCT with equal randomisation.
Participants with venous leg ulcers were randomised (1 : 1) to receive either:
l the 4LB (aiming to deliver 40mmHg at the ankle), or
l the HH (consisting of a two-layer compression stocking system aiming to deliver 40mmHg
at the ankle).
Approvals obtained
This study was approved by the University of York Health Sciences Research Governance Committee on
8 June 2009 and by the Northern and Yorkshire Research Ethics Committee (REC) on 26 September 2009
(REC reference number 09/H0903/25). The North East Yorkshire and Northern Lincolnshire Comprehensive
Local Research Network completed their global checks on 21 October 2009; thereafter research
management and governance approval was obtained for each trial centre (see Appendix 1). This trial was
assigned the International Standard Randomised Controlled Trial Number of ISRCTN49373072.
Duration of follow-up
Planned participant follow-up was for a maximum of 12 months. However, when it became necessary to
extend the trial recruitment phase the participants who were recruited during the final 12 months of
recruitment (from 30 June 2012) were followed up for between 4 and 12 months.
Trial centres
The study was conducted by 34 study centres within England and Northern Ireland (see Appendix 2).
Centres were recruited throughout the trial. Centres recruited participants from various sources, including
community nurse teams/services, general practitioner (GP) practices, leg ulcer clinics (community and
outpatient), tissue viability clinics/services and wound clinics.
Participant eligibility
Inclusion criteria
People for whom all of the following criteria applied:
l At least one venous leg ulcer. A venous leg ulcer was defined as any break in the skin which had either
(1) been present for > 6 weeks or (2) occurred in a person with a history of venous leg ulceration.
Ulcers were considered purely venous if, clinically, no other aetiology was suspected. The ulcer was
required to be venous in appearance (i.e. moist, shallow, of an irregular shape) and was to lie wholly or
partially within the gaiter region of the leg.
l An ankle–brachial pressure index (ABPI) of ≥ 0.8, taken within the previous 3 months.
l Able and willing to tolerate high compression.
l Aged ≥ 18 years.
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Exclusion criteria
Potential participants were excluded if they fulfilled any of the following exclusion criteria:
l An ABPI of > 1.20 (taken with the previous 3 months) and, in the treating nurses’ clinical judgement
and/or according to local guidelines, the potential participant should not receive high compression.
l A leg ulcer of non-venous aetiology (i.e. arterial).
l Wound exudate levels too high for the use of HH (decision made according to the nurses’
clinical judgement).
l Unwilling to give informed consent to participate within this trial.
l Unable to give informed consent to participate within this trial.
l Currently in another study evaluating leg ulcer therapies.
l A known allergy to any trial product.
l Gross leg oedema.
l Previously been recruited into this trial.
l Another reason that excluded them from participating within this trial (decision made according to the
nurses’ clinical judgement).
Sample size
We estimated that 489 participants were required for Venous leg Ulcer Study IV (VenUS IV). The sample
size calculation was based upon VenUS I,7 which assessed the clinical effectiveness and cost-effectiveness
of the 4LB compared with the SSB in people with venous leg ulcers. In VenUS I,7 386 participants were
recruited over 20 months from nine UK centres. The primary outcome measure was time to healing of the
reference leg. The HR was 1.33 (95% CI 1.05 to 1.67) and the median survival times were 92 days for
the 4LB group and 126 days for SSB.
For VenUS IV, the primary outcome was also time to healing. However, the aim was to estimate the size of
the difference between the compression systems, rather than to look for a difference of any given size.
In VenUS I,7 the upper 95% CI of 1.67 was a 25% increase in the point estimate of 1.33. Therefore, a trial
with similar size, population, outcome and treatments was also expected to allow estimation of the HR to
within 25%. Power calculations suggested that 400 participants, a median survival in the control group of
100 days and follow-up of one year would provide 90% power to detect an increase in median time to
healing of 41 days and a decrease in the HR for healing to 0.72, or a decrease in median time to healing
of 72 days and an increase in the HR to 1.42. Assuming 10% attrition, this meant 444 participants
were required.
The original Venous Ulcer Study (VenUS I7) analysis treated centre as a fixed effect, after checking for
a centre by treatment interaction, which was not significant. Using log area of the original ulcer as a
covariate and mobility as a three-level factor, the standard error (SE) of the log HR for the treatment effect
was 0.119, with centre as a fixed effect. However, for the purpose of the current sample size calculation,
the possibility of centre effect was also considered by assuming robust SEs with centre as a cluster.
This inflated the variance compared with a fixed-effects model. In this case the SE was 0.129 (making the
treatment effect not significant; p= 0.07). The square of the ratio of these SEs was 1.19. Therefore, if
centre effects in VenUS IV were similar to those in VenUS I7 then we estimated that the sample size would
need to be increased by 19% to maintain the same power.
However, in terms of potential centre effects we noted that in VenUS I7 there were reasons to suspect that
there would be variation in bandaging skill, with some centres having prior experience in at least one type
of treatment being compared. In VenUS IV, the intervention (HH) did not require special skill to apply
and all centres were expected to be experienced in use of the standard treatment (4LB), although some
variation in its application was possible. Because of the differences between VenUS I7 and IV, we expected
there to be less variation between centres in VenUS IV than in VenUS I.7 Thus, in order to look for centre
METHODS
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effects in the VenUS IV analyses, adjusting for them using robust SEs and accounting for the loss of power
this may produce, we estimated that the sample size be inflated by 10% to 489 participants.
Recruitment into the trial
Patients were screened for eligibility by study research nurses or designated health-care professionals,
according to the trial inclusion and exclusion criteria. Patients were screened from a wide range of sources:
community nurse teams/service, GP practices, joint tissue viability/vascular clinics, leg ulcer clinics, outpatient
clinics, outpatient leg ulcer clinics, tissue viability clinics/services, treatment room clinics and wound clinics.
The reason(s) for a patient’s ineligibility were recorded (see Appendix 3). When a patient’s sole reason for
exclusion was high wound exudate levels or gross leg oedema, nurses were encouraged to rescreen for trial
eligibility once exudate levels or oedema had been managed. Decisions regarding the management of
exudate and/or oedema were left to the discretion of the treating health professional.
Those patients who fulfilled all of the eligibility criteria were approached by the study research nurse and
provided with both verbal and written information about the trial in a face-to-face meeting (see Appendix 4,
Patient information sheet). Patients were then given adequate time to consider participation within the trial.
Study research nurses then obtained voluntary verbal assent and full written consent from those patients
who wished to enter the trial (see Appendix 4, Consent form).
Baseline assessment
After obtaining written consent and verbal assent from the participant, baseline data were collected by
the study research nurse using the patient record form (see Appendix 5) and from the participant via the
participant baseline questionnaire (see Appendix 6).
Participant details
Participants’ contact details (name, address, telephone numbers and e-mail address), date of birth and GP
details (name of GP, name of GP surgery and address) were recorded.
Ulcer history and assessment
The most recent ABPI measurement and the date it was taken were recorded. Also recorded were the total
number of ulcer episodes (n); time since development of the first ulcer (years and/or months); duration of
the reference ulcer (years and/or months) and duration of oldest ulcer (years and/or months).
To measure ulcer area, a tracing of the reference ulcer (the largest eligible ulcer) and all other ulcers on the
reference leg (the leg that contained the reference ulcer) was taken using a fine-nibbed marker pen on to
a wound measurement grid composed of 1-cm2 squares (P12v2, ConvaTec, Uxbridge, Middlesex, UK).
Ulcer area was determined by totalling the number of squares and/or partial squares on the grid contained
within the traced ulcer area. At the end of the trial, ulcer area was calculated from the wound grid by the
use of a software program (Mouseyes, version 3.1, Dr Robert John Taylor, Salford, UK).43
All ulcers on both legs were drawn onto a leg diagram and the reference ulcer was clearly labelled using an
identification code. The reference ulcer was coded as either R1 (located on the right leg) or L1 (located on
the left leg). If there was more than one ulcer, the ulcers were coded according to descending area – the
next largest as R2 (if located on the right leg) or L2 (if located on the left leg) and so on.
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Participant mobility, anthropometry and glycated haemoglobin measurements
The level of participant mobility (walking and ankle mobility) was noted as was the participant’s height
(feet/inches or centimetres), weight (stones/pounds or kilograms) and ankle circumference (centimetres).
Body mass index (BMI, kg/m2) was calculated using the formula ‘weight (kg) divided by [height (m)]2’. If the
participant was diabetic then their glycated haemoglobin (%) was recorded with the measurement date.
However, as the trial progressed, some centres found it difficult to obtain this measurement. As it was not
considered necessary for the trial analyses, the collection of this measurement was stopped following a
decision by the Trial Management Group (TMG).
Current treatments received
Participants’ current treatment(s) for their venous leg ulcer(s) were recorded.
Treatment preference
Each participant’s trial treatment preference (i.e. no treatment preference, prefer to receive HH or prefer to
receive the 4LB) was recorded.
Digital photographs
Study research nurses took a digital photograph of the reference ulcer and reference leg using a
Nikon digital camera (Coolpix L20 or Coolpix L22, Nikon Corporation, Tokyo, Japan) according to the
protocol developed for taking digital photographs during the trial (see Appendix 7). These anonymised
photographs were uploaded onto an online management system and sent securely to the York Trials Unit
(University of York).
Health-related quality of life/health utility
Participants completed a baseline questionnaire consisting of 12-Item Short Form Health Survey (SF-12)
(Short Form questionnaire-12 items, version 2, standard recall, QualityMetric, Lincoln, RI, USA)
and the EQ-5D™ (European Quality of Life-5 dimensions questionnaire, EuroQol Group, Rotterdam,
The Netherlands).
The SF-12 measures eight health areas, which can be used to calculate a Physical Component Summary
(PCS) score (based upon physical functioning, role limitations due to physical health, bodily pain and
perceptions of general health) and a Mental Component Summary (MCS) score (based upon vitality, social
functioning and role limitations owing to emotional health and mental health). The SF-12 is well validated
in a variety of UK populations, including older people and leg ulcer patients.44,45
The EQ-5D questionnaire measures five domains of health and provides an assessment of mobility,
individual’s ability to self care, ability to perform usual activities, and evaluation of pain/discomfort and
anxiety/depression. It is a widely recognised and validated generic measure of health utility and has been
assessed for acceptability and validity in patients with venous leg ulcers,44,46–48 as well as being validated in
other patient groups.49–57
Ulcer-related pain
Participants were asked to rate the intensity of any leg ulcer-related pain that they had experienced in the
previous 24 hours using the 21-point Box Scale (BS-21). The BS-21 pain scale was divided into units of five,
and ranged from a value of 0 (no pain) to 100 (the worst pain imaginable).
Resource use
Participants provided details of any care received from the NHS within the past 3 months, recording the
number of consultations the participants had with health professionals at different locations. Participants
were asked to record details according to whether the consultation was related to their leg ulcer or a
different reason.
METHODS
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Randomisation
Randomisation was carried out using an independent, remote telephone randomisation service
(freephone telephone number), based at the York Trials Unit, or via an online randomisation
service (URL: www.yorkrand.com/). Randomisation was conducted using a prevalidated computer
program to ensure complete allocation concealment. Randomisation was stratified by ulcer duration
(≤ 6 months or > 6 months) and ulcer area (≤ 5 cm2 and > 5 cm2) using permuted blocks (block sizes four
and six), as these variables are known predictors of healing.58 The computerised randomisation system was
checked periodically during the trial following standard operating procedures.
The study research nurse called a freephone telephone number to speak to an operator independent
to the trial at the York Trials Unit, or accessed the online randomisation service and provided details of
the participant. The study research nurse was informed of the participant’s allocated trial treatment
(HH or 4LB) and given a unique identification number, which was used to identify the participant
throughout the trial.
Trial interventions
Control group
Participants in the control group were allocated to receive the 4LB (standard/usual care). Nurses were
allowed to choose which 4LB system the participant should receive, as long as it was designed to deliver
40mmHg at the ankle and adhered to recommendations shown in Table 2. Examples of key 4LB
components are shown in Table 3. The treatment was applied according to standard practice, either
by the participant’s usual treatment nurse or by a study research nurse.
Intervention group
Participants in the intervention group were allocated to receive HH. This was a two-layer compression
hosiery kit, consisting of an understocking (or liner) and an overstocking, worn over the understocking.
The two stockings were designed to deliver sustained, graduated compression of up to 40mmHg
(and no less than 35mmHg) at the ankle (Table 4).
The size of the HH kit used depended upon the participant’s ankle circumference (cm), calf circumference
(cm) and/or foot length (cm); nurses consulted product-specific measurement tables to ensure that the
participants received the correctly sized kit. Made-to-measure HH was obtained for participants who
require this. HH was applied and worn according to manufacturer’s instructions. Participants were told
they could remove the overstocking only at night, if deemed necessary by the treating nurse.
TABLE 2 Recommended 4LB systems
Ankle
circumference Layer 1 Layer 2 Layer 3 Layer 4
< 18 cm Wool to make leg circumference
a minimum of 18 cm
Crepe
bandage
Class 3a
bandage
Cohesive bandage,
class 3b
18–25 cm Wool Crepe
bandage
Class 3a
bandage
Cohesive bandage,
class 3b
25–30 cm Wool Class 3c
bandage
Cohesive
bandage
N/A
> 30 cm Wool Class 3a
bandage
Class 3c
bandage
Cohesive bandage,
class 3b
N/A, not applicable.
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Participants were expected to receive their allocated trial treatment immediately after randomisation.
However, where a treatment was not available for immediate application (e.g. if a participant required a
made-to-measure HH kit), the participant was treated with an appropriate treatment in the interim, as
dictated by the treating nurse, until the allocated trial treatment became available. The interim treatment
received was recorded in a treatment log (see Appendix 5, Treatment log: trial dressing log booklet).
Participant follow-up
Appendix 8 shows a summary flow chart of participant follow-up processes.
Participants were allocated their trial treatment and received this treatment until (1) they were no longer
able to continue receiving their allocated trial treatment and instead changed to another treatment that
replaced the allocated compression treatment (designated the ‘non-trial’ treatment); (2) their reference leg
healed and treatment was no longer required; (3) they were lost to follow-up; or (4) they died.
During the trial, every nurse consultation for treatment of the reference leg was recorded in a treatment
log until healing of the reference leg, along with location of consultations, and dressing(s) and treatment(s)
applied (see Appendix 5, dressing log booklets).
TABLE 3 Examples of 4LB components
Wool K-Soft® (Urgo, Loughborough, UK); Profore® #1 (Smith & Nephew)
Light support bandage K-Lite® (Urgo); Profore #2 (Smith & Nephew)
Class 3a bandage K-Plus® (Urgo); K-Plus® Long (Urgo); Profore #3 (Smith & Nephew); Elset®
(Mölnlycke, Dunstable, UK); CliniPlus (CliniSupplies, Harrow, UK)
Class 3b bandage Ko-Flex® (Urgo); Profore #4 (Smith & Nephew); Coban® (3M, Bracknell, UK);
Ultra Fast® (Robinsons, Worksop, UK)
Class 3c bandage Mölnlycke Setopress®; Tensopress® (Smith & Nephew); Profore+® (Smith & Nephew)
TABLE 4 Trial compression hosiery kits
Brand
Understocking
(mmHg)
Overstocking
(mmHg)
Total compressiona
(mmHg)
Made-to-measure
service available
Carolon Multi-Layer Compression
System (H&R Healthcare, Hull, UK)
16–18 19–22 35–40 No
Clini Duo40 (CliniSupplies) 10 30 40 No
Mediven Ulcer kit (medi UK,
Hereford, UK)
20 20 40 Yes
Activa leg ulcer hosiery kit (Activa
Healthcare, Burton-on-Trent, UK)
10 25–35 35–45 Yes
Jobst UlcerCARE (BSN medical,
Hull, UK)
10 30 40 Yes
VenoTrain ulcertec (Bauerfeind UK) 10 30 40 No
a Total compression for both understocking and overstocking.
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Trial completion and exit
Participants were deemed to have exited the trial when they:
l withdrew consent [wished to exit the trial (ulcer unhealed) and have no further data collected]
l had been in the trial for 12 months post randomisation
l had reached the end of the trial
l died
l were lost to follow-up
l had another reason for exit, according to the clinical judgement of the study research nurse.
Nurses were required to complete a participant event form (see Appendix 5), giving the main reason for
the participant’s exit from the trial. No further clinical data were collected from these participants and they
were not sent any further participant questionnaires.
Rather than completely withdrawing from the trial, participants could opt to selectively withdraw from
(1) clinical data collection (i.e. still remain in the trial and receive participant questionnaires only) or
(2) receiving participant-completed questionnaires (i.e. still remain in the trial and allow clinical data
collection to continue).
Measurement and verification of primary outcome measure
Time to healing of the reference ulcer (blinded)
The primary outcome measure of this study was time to healing of the reference ulcer. Healing was defined
as complete epithelial cover in the absence of a scab (eschar) with no dressing required. When the treating
nurse considered the reference ulcer to have healed, a digital photograph was taken of the healed
reference ulcer site. Additional photographs were then taken of the same site, once per week for 4 weeks;
photographs were taken regardless of whether the reference ulcer was considered to have recurred during
this time period. Digital photographs were uploaded onto a secure server at the York Trials Unit using a
secure online management system.
All digital images were assessed by two experienced Tissue Viability Specialist Nurses, who were blinded
to treatment allocation. Independently, assessors determined whether they considered a participant’s
reference ulcer to have healed, not healed or were unsure whether healing had occurred. When an ulcer
was deemed to have healed, the appropriate date (based on date of photograph in which healing was
recorded) was then taken to be the date of healing for the reference ulcer. A set of decision rules were
made for resolving disagreements between assessors (see Appendix 9). In cases when one assessor
considered the ulcer to have healed and the second assessor considered the ulcer unhealed, a third
assessor was consulted, who determined whether healing had occurred.
Measurement and verification of secondary outcome measures
Time to healing of the reference ulcer (unblinded)
Although the primary outcome measure for this trial was time to healing of the reference ulcer
(as determined by assessors blinded to treatment allocation), time to healing of the reference ulcer as
determined by the treating nurse was used as a secondary outcome measure. When the treating nurse
considered the reference ulcer to have healed, she/he telephoned the York Trials Unit randomisation line
to report the date of healing.
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Time to ulcer-free reference leg
Nurses reported the date on which they thought the reference leg was ulcer free, and this was reported by
telephone to the York Trials Unit randomisation line; this information was also captured via the ulcer
healed form (see Appendix 5).
Health-related quality of life/utility and resource use
Post randomisation, participants’ health-related quality of life and resource use were measured at 3, 6, 9
and 12 months using postal questionnaires. Each quarterly questionnaire was identical in content and
contained the same health-related quality-of-life/utility instruments as the baseline questionnaire
(EQ-5D and SF-12) and the same tools for measuring ulcer-related pain (BS-21 and verbal descriptor
pain scales) and resource use (see Appendix 5).
Post-randomisation questionnaires were posted to participants from the York Trials Unit, along
with a pre-addressed and prepaid envelope. Where necessary, reminder letters were sent by post to
participants at 2 and 4 weeks had questionnaires not been returned. A systematic review assessing ways
to increase participant response to postal questionnaires59 reported that response rates could be almost
doubled by the use of monetary incentives (odds ratio 1.99, 95% CI 1.81 to 2.18) and could also be
increased if the incentive was unconditional. Participants were therefore sent £5 with their final
questionnaire and were informed that this was an unconditional token of appreciation for the time they
had taken to complete questionnaires throughout the study.
Briefly, we also collected disease-specific health-related quality-of-life data using the VEINES quality-of-life
questionnaire (VEINES-QOL) instrument at baseline and 4 months. These data were collected as part of a
substudy that was aiming to conduct a validation study of this measure in patients with venous leg ulcers.
This substudy is reported separately; however, we report summary data in this report for reference.
Participant concordance to treatment
In order to monitor treatment concordance and patterns of compression use, study nurses recorded in a
treatment log when a participant was no longer receiving their allocated trial treatment but rather was
receiving a non-trial treatment, i.e. change to a leg ulcer treatment that was different from that to which
the participant was allocated at randomisation and the reason for this change (see Appendix 5, Trial
dressing log booklet). Participants were also asked about their opinions and use of their allocated trial
treatment via a treatment-specific 1-month participant questionnaire (see Appendix 6).
Ulcer recurrence
One month after the reference leg was reported as healed, nurses undertook a monthly assessment for
ulcer recurrence (see Appendix 5, Monthly nurse assessment form); this monthly assessment continued
until the participant had exited the trial. Where there had been a recurrence of venous leg ulceration
on the reference leg, the date of recurrence was also recorded. To maximise data collection participants
with a healed reference leg were also provided with a reference leg-specific postcard (see Appendix 6)
to complete if they had a recurrence. This was then returned in a pre-addressed and postage-paid
envelope to the York Trials Unit.
Adverse events
An adverse event is defined as any undesirable medical experience occurring to a participant, whether
or not considered related to the trial treatment.60 Adverse events were classified as serious (death,
life- or limb-threatening event, hospitalisation required/prolonged, persistent or significant disability/
incapacity or other medically important condition) or non-serious (all other adverse events).60
Nurses were asked to report adverse events (see Appendix 5). The treating nurse was also required to
make an assessment regarding the relationship between the adverse event and trial treatment (HH or 4LB)
assessed by a set of decision rules (see Appendix 10). All adverse event forms were returned to the York
Trials Unit. Serious adverse events (SAEs) were also reported directly to the York Trials Unit via a telephone
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call to the trial coordinator and/or via fax to the York Trials Unit. Nurses reviewed adverse events until they
had resolved (see Appendix 5).
All SAEs were reported to the Trial Steering Committee (TSC), trial centre research and development offices
and the North East Yorkshire and Northern Lincolnshire Comprehensive Local Research Network. The local
REC was notified of any unexpected SAEs that were considered to be related to trial treatment. Expected
events in this study population were defined using previous research data. Participants in previous VenUS
trials have been generally elderly (mean ages of 71, 74 and 69 years, respectively, in VenUS I–III7,13,61) and
VenUS IV participants were expected to be similar. As one might expect, people with venous leg ulceration
have been shown to present with other co-morbidities, including hypertension, congestive heart failure and
osteoarthritis;62 these and other medical conditions may require hospitalisation. A small percentage of
participants would also be expected to die during the study, as reported in previous VenUS trials.7,13,61
For analyses, all adverse events were reviewed by the TMG (blinded to allocation), which made the final
decision regarding the relationship between an adverse event and trial group. Furthermore, all non-serious
adverse events (NSAEs) that were considered to be definitely or probably related to trial treatment were
reviewed by a tissue viability research nurse and categorised for analysis (Box 1).
Clinical analyses
Analyses were conducted following the principles of intention to treat, with all events analysed according to
the participant’s original randomised treatment allocation, irrespective of deviation based on non-concordance.
Analyses were performed using Stata version 12 (StataCorp, College Station, TX, USA). Treatment effects are
presented as HRs together with their 95% CIs; p-values of < 0.05 for two-tailed tests were taken to indicate
statistical significance.
Baseline data
All categorical baseline variables were summarised as a frequency (n, %) by treatment group. Continuous
variables were summarised using descriptive statistics [n, mean, standard deviation (SD), minimum,
maximum, interquartile range (IQR) and median]. No formal statistical analyses were conducted.
BOX 1 Categories used to define definitely and probably related NSAEs
l Alternative non-trial treatment initiated by participant or another.
l Bandage or hosiery failure.
l Bandage or hosiery related pain and/or discomfort.
l Dryness.
l Excoriation.
l Infection.
l Maceration.
l Medical event relating to leg.
l Non-surgical hospitalisation related to leg ulceration.
l Occurrence of new ulcer.
l Skin damage.
l Skin deterioration.
l Surgical intervention to leg.
l Ulcer deterioration.
l Ulcer-related pain.
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Trial completion
Details of trial exit were taken from the Trial Exit form. When an exit form had not been completed, data
were derived from the length of time a participant was in the study from randomisation to their last clinical
follow-up documenting healing status, together with data on deaths.
Primary analyses
Time to healing of the reference ulcer (blinded)
The primary outcome was time to healing of the reference ulcer, measured in days from date of randomisation.
A healed event and date of healing were obtained through central, independent, blinded assessment of
digital photographs. The time to reference ulcer healing was right censored in participants who (1) withdrew
from the study; (2) were lost to follow-up; (3) died; or (4) reached the end of trial follow-up.
For each interventional group, the distribution of time to ulcer healing was described using Kaplan–Meier
survival curves. Treatment differences were evaluated using the Cox proportional hazards (CPH) model
adjusted by baseline factors – ulcer area, ulcer duration and participant mobility7,61 – with shared centre
frailty effects.63–65 Ulcer area and duration were logarithmically transformed because these data, as in
previous VenUS trials, were highly skewed. Participant mobility was a three-level factor (participant walks
freely, walks with difficulty, is immobile).
The shared frailty effect is a random effect in the CPH model, which has a multiplicative effect on the
hazard of healing. In this case, the frailties were modelled specific to each centre and thus described
the degree of correlation between participants within centres. The need for a centre frailty effect in the
model was assessed using a likelihood ratio test that evaluated whether the frailty variance was zero using
a 50 : 50 mixture of chi-squared distributions. If a non-significant frailty effect was found then the CPH
model would be fitted without centre frailty effects (but still adjusted for baseline factors).
An unadjusted analysis was also performed using the CPH model. Log-rank and Wilcoxon survival
comparisons were made, and median time to healing was calculated with 95% CI for each
treatment group.
For each CPH model, the proportional hazard assumption was evaluated through inspection of log–log
plots and formally by a statistical test using Schoenfeld residuals.66
Secondary analyses
Time to healing of the reference ulcer (non-blinded)
Time to healing of the reference ulcer, where healing was assessed by nurses during follow-up
(i.e. non-blinded time to ulcer healing), was evaluated using the same methods and processes described
for the primary analyses with an identical censoring strategy.
Time to ulcer-free reference leg
Time to an ulcer-free reference leg [the leg with the largest eligible ulcer (reference ulcer)] was defined
as time from randomisation to the time when the participant was assessed as having an ulcer-free
reference leg. The time to reference leg healing was right censored in participants who (1) withdrew from
the study; (2) were lost to follow-up, (3) died; or (4) reached the end of trial follow-up – whichever came first.
This outcome was analysed like the primary outcome with identical censoring strategy and adjustments.
Health-related quality of life
The SF-12 questionnaires were scored67 and the PCS and MCS scores were summarised with descriptive
statistics (n, mean, SD, minimum, maximum, IQR and median) by treatment group at baseline, month 3,
month 6, month 9 and month 12. As the PCS and MCS scores were measured longitudinally with time,
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the relationship between PCS or MCS scores with treatment was evaluated through a linear mixed model
(LMM) to account for the dependence of PCS or MCS scores measured within the same participant as
described by Fitzmaurice et al.68 and Verbeke and Molenberghs.69 In the LMM, the PCS or MCS score was
adjusted by ulcer area, ulcer duration, time, centre and participant mobility. To assess whether there were
differences between the treatments during time of follow-up, an interaction between treatment and time
was tested for inclusion in the models.
The VEINES-QOL questionnaire was scored as T-score, with mean set to 50 and SD to 10. Each sample was
standardised to itself, so that only comparisons within the sample are meaningful.
Leg ulcer-related pain
At the same time as completing the SF-12, participants were asked to rate the intensity of any leg
ulcer-related pain that they had experienced in the previous 24 hours using a scale from 0 (no pain) to
100 (the worst pain imaginable) in steps of 5 (i.e. there were 20 categories to choose from). These data
were presented descriptively as (n, mean, SD, minimum, maximum and median).
Participant use of compression treatments
In the HH group, data were presented regarding the proportion of participants at 1 month
from randomisation:
1. wearing their allocated bandaging during the day in each of the four measured categories
(everyday/most days/some days/never)
2. wearing one or two layers
3. applying the HH themselves or having it applied by a carer.
For the 4LB group, data were presented regarding the proportion of participants at 1 month
from randomisation:
1. wearing their allocated bandaging in each of the four categories (everyday/most days/some days/never)
2. removing their bandages either never or at least once.
Additionally, participant use of treatment was summarised as the proportion of participants changing from
their randomised treatment to another treatment (designated the non-trial treatment) within each
treatment group.
Adverse events
It was envisaged that the total number of adverse events would be compared by treatment group,
considering clustering by participant, using a random-effects Poisson regression model adjusting for ulcer
area, ulcer duration, centre and participant mobility. However, if the variability in the data was found to
be higher than that modelled (as had been noted in previous studies, VenUS II61 and VenUS III13) then a
random-effects negative binomial regression model would be used, adjusting for the same covariates.
If a large number of participants reported no adverse events (as found in VenUS III),13 a zero-inflated
random-effects Poisson regression model or a zero-inflated random-effects negative binomial regression
model70,71 would be fitted to the adverse events data, adjusting for the same covariates. This analytic
strategy was repeated for NSAEs and SAEs separately.
Non-serious adverse events and SAEs were further summarised by classification and by treatment group.
The blinded assessment of relationship of adverse event to treatment were summarised by treatment
group. At the suggestion of the TSC, if the numbers of adverse events per participant were found to be
small throughout follow-up then these data would also be analysed using a by random-effects logistic
regression, with treatment differences compared adjusting for ulcer area, ulcer duration, centre and
participant mobility.
DOI: 10.3310/hta18570 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 57
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Ashby et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
21
Ulcer recurrence
The proportion of participants having a recurrence of an ulcer on the reference leg, post healing, was
presented by treatment group. Time to recurrence was defined as time from an ulcer-free reference leg to
date of recurrence, or censored in those who had healed with an ulcer-free reference leg until they were
withdrawn from the study, died from any cause or reached the end of the study – whichever came first.
This outcome was analysed in the same way as the other survival analyses using a CPH model adjusted for
baseline ulcer area, ulcer duration and participant mobility, also testing for shared centre frailty effects.
The distribution of time to recurrence from healing was described using Kaplan–Meier survival curves by
treatment group.
Sensitivity analyses and handling of missing data
Survival data were assumed to be completely known (data collection was designed to be complete).
Adverse event reporting was also assumed to be complete. Missing data on covariates included as
adjusting factors in the statistical models were to be assumed missing at random. Sensitivity analyses
were carried out:
1. for comparison of results with and without a centre random effect
2. where there were missing data on the covariates, comparison of results from the best model chosen in
(1) with and without multiple imputation.
Economic analyses
The economic analysis was conducted in the form of cost-effectiveness and cost–utility analyses using IPD
collected during the RCT. In the cost-effectiveness analysis, health benefits were measured as incremental
ulcer-free days, whereas incremental quality-adjusted life years (QALYs) were used in the cost–utility
analysis. The QALY combines survival and health-related quality of life into a single measure, thereby
providing a common currency to enable comparisons across different health conditions and interventions.
The perspective of the economic analysis was that of the NHS and Personal Social Services (PSS)
[as recommended by the National Institute for Health and Care Excellence (NICE)].72 The time horizon for
the analysis was 12 months from the date of randomisation, which was also the maximum duration of
follow-up; hence, neither costs nor health benefits (ulcer-free days and QALYs) were discounted.
The analysis was conducted in Stata version 12.1.
Details of each constituent component of the economic analysis, i.e. health benefits and costs, and their
estimation methods are discussed below (see Resource use and unit costs). This is followed by a
description of the statistical methods used. Finally, we detail the methods implemented to presenting
cost-effectiveness and cost–utility results and decision uncertainty.
Resource use and unit costs
The cost of resources used for each trial participant was calculated as the product of resources used during
the trial follow-up period and the relevant unit costs. Three different elements of resource use were
considered in the estimation of ulcer-related treatment costs:
l use of allocated compression treatments during trial (compression hosiery, 4LB and any other
compression treatments used, e.g. while waiting for the trial treatments to become available)
l use of non-trial treatments (for participants who changed to a non-trial treatment)
l health-care consultations (visits to/from health-care provider for ulcer-related reasons).
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Other treatments, such as primary and secondary contact dressings or skin preparations, were assumed to
be used equally across treatment groups and these resources were not included in the economic analyses.
Unit costs for the compression treatments were based on the NHS prescription cost data for 2010–11,73
and all values are in British pound sterling (£).
Compression treatments
The number and type of compression treatments used in the trial, and thus costed, were taken
from the treatment logs completed by a nurse at each ulcer-related consultation until healing of the
reference leg.
For the HH group, data were recorded on the brand of compression hosiery kit from the following choices:
mediven, Activa, VenoTrain ulcertec, Jobst and ‘other’. For the ‘other’ category of kits, the unit price was
based on the type of kit specified in the text box. When the brand of kit was not available, we assumed it to
be Activa, which was the most frequently used kit in this study. Also, the numbers of new understockings
and overstockings were recorded where relevant. When only understockings (liners) were given/applied, the
cost of liner-only packs was used. For the four-layer group, the type of product was recorded as either a kit
or individual bandaging components and unit costs were applied accordingly (Table 5). Made-to-measure
kits were costed appropriately. The treatment logs also recorded other treatments and procedures applied
to the reference leg during the visit. These included alternate compression treatments used when the
randomised treatment was not available for a short period. Delivery of all compression treatments
(including made-to-measure hosiery) reported by the nurse in this question were costed and included in the
cost analysis.
If and when participants changed to a non-trial treatment details of any new therapy were recorded:
the SSB, the 2LB, three-layer reduced compression bandaging, the 4LB, low-compression bandaging,
high-compression bandaging, low-compression hosiery or other system. Nurses continued to record
consultations and treatments delivered as before. Non-trial treatments were also costed.
TABLE 5 Unit costs of trial and non-trial treatments
Type of dressing Cost Source
HH
Mediven Kit £30.43; liner only £16.30 NHS prescription costs
Activa Kit £21.56; liner only £16.12 NHS prescription costs
Ulcertec Kit £27.1 NHS prescription costs
Jobst Kit £29.95; liner only £18.09 NHS prescription costs
Altipress 40, Altimed
(Loughborough, UK)
Kit £13.89; liner only £10.99 NHS prescription costs
Carolon Kit £26.5; liner only £7.33 NHS prescription costs
Clini Duo Kit £13.07; liner only £10.34 NHS prescription costs
Made to measure Kit £40.09 Cost provided by supplier
(Actilymph, Activa)
Weighted mean cost Kit £21.54; liner only £15.93 NHS prescription costs
continued
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TABLE 5 Unit costs of trial and non-trial treatments (continued )
Type of dressing Cost Source
4LB
K-Four, Urgo £6.67 NHS prescription costs
Profore £8.80 NHS prescription costs
System 4, Mölnlycke £7.49 NHS prescription costs
Ultra four, Robinson £5.69 NHS prescription costs
Weighted mean cost £7.63 NHS prescription costs
Individual components of 4LB
K-Soft, Urgo £0.45 NHS prescription costs
K-Lite, Urgo £0.98
K-Plus, Urgo £2.22
Ko-Flex, Urgo £2.93
Profore #1 £0.67
Profore #2 £1.29
Profore #3 £3.77
Profore #4 £3.12
SSB
Actiban, Activa £3.44 NHS prescription costs
Actico, Activa £3.22
Comprilan, Smith & Nephew £3.25
Rosidal K®, Activa £3.39
Silkolan, Urgo £3.39
Weighted mean cost £3.23
2LB kits
ProGuide®, Smith & Nephew £9.77 NHS prescription costs
Coban £8.08
K-Two, Urgo £8.18
Weighted mean cost £8.20
Other bandages
K-band, Urgo £0.29 NHS prescription costs
Three-layer reduced (or low)
compression bandaging
£4.01
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Consultations with health-care providers
Data on the number of consultations with health-care providers were available from quarterly
participant-reported questionnaires. Each participant recorded the following resource-use data, referring
to the previous 3 months (participant-reported data): number of GP consultations at doctor’s surgery and
at home; number of nurse consultations at doctor’s surgery and at home; number of hospital outpatient
visits with a doctor or nurse; number of hospital day admissions for minor day procedure or day surgery;
and number of hospital inpatient nights. The number of ulcer-related and non-ulcer-related health
consultations were recorded separately and only the ulcer-related health consultations were included
in the economic analysis.
A second source of data regarding the number of ulcer-related nurse consultations was available from
treatment logs that were completed by nurses (nurse-reported data) (see Appendix 5). However, since this
nurse-reported data capture only recorded consultations until the reference leg was healed, it did not count
any consultations related to ulcer recurrence. Because of this, using nurse-reported data had the potential
to underestimate the total number of ulcer-related consultations, thus participant-reported data were used
as the base case. A sensitivity analysis was conducted that used number of nurse-reported consultations.
With regards to ulcer-related hospital inpatient stay, two sources of data for hospitalisations were
interrogated: adverse events data and participant reported information.
The unit costs used to calculate the cost of health service consultations in the trial are summarised
in Table 6.
TABLE 6 Unit costs for health service consultations
Parameter description Value Source
GP visit
Doctor’s surgery/clinic visit, cost per minute £2.5 PSSRU 2011 (GP unit cost per consultation minute, without
qualification costs but including direct care staff costs)
Duration of clinic visit, minutes 11.7 As above
Home visit, cost per minute £4.3 As above
Duration of home visit, minutes 23.4 As above
Nurse visit
At doctor’s surgery, cost per minute £0.7 PSSRU 2011 (Nurse unit cost per consultation minute,
without qualifications costs)
Duration of clinic visit, minutes: HH 25.4 VenUS IV
Duration of clinic visit, minutes: 4LB 30.1 VenUS IV
Nurse visit at home, cost per minute £1.1 VenUS III13
Duration of home visit, minutes: HH 34.2 VenUS IV
Duration of home visit, minutes: 4LB 36.2 VenUS IV
Outpatient visit
Doctor (consultant or non-consultant) £105.1 NHS Reference Costs 2010–11.a Unit cost of face-to-face
outpatient attendance (based on weighted average)
Nurse £61.8 As above
Hospital admission
Without overnight stay £368.8 NHS Reference Costs 2010–11.a Weighted average of
day-case HRG data and outpatient procedures
HRG, Healthcare Resource Group; PSSRU, Personal Social Services Research Unit.
a Source: www.gov.uk/government/publications/2010-11-reference-costs-publication (accessed 27 May 2014).
DOI: 10.3310/hta18570 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 57
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Ashby et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
25
Health benefits
Mean time to healing
Incremental ulcer-free days (the measure of benefit in the cost-effectiveness analysis) were derived using
the primary trial outcome, i.e. healing of the reference ulcer. Although time to healing is known for
participants who heal during the trial period, non-healing participants are subject to censoring (as we do
not know if and when their reference ulcer healed, just that it was not healed by a certain point). In a
standard clinical analysis where not all participants have the event of interest in a given time period, the
median time to event is the preferred summary statistic. However, for the economic analyses it is the mean
time to healing that provides the most useful information to the decision-maker (on the expected health
benefits associated with health technologies) and thus was used here. Methods to deal with censoring that
allow a mean time to healing to be calculated are detailed in the section on statistical methods. Mean time
to healing as an effectiveness outcome was reported as gain in ulcer-free days which is equal to the
difference in mean time to healing between the HH and 4LB groups (same absolute value). However, it
should be noted that data were not available on ulcer-free days beyond initial healing of the reference
ulcer; hence, the impact of ulcer recurrence was not evaluated in this analysis.
Utility and quality-adjusted life-year scores
The outcome for the cost–utility analysis was the QALY measured over 12 months (maximum period of
follow-up). The health state descriptor measure used was the EQ-5D, a widely recognised and validated
descriptive system of health utility.74,75 EQ-5D data were collected at baseline and at 3, 6, 9 and 12 months.
The EQ-5D questionnaire has five questions, each relating to a different health dimension: mobility, self-care,
ability to undertake usual activity, pain and anxiety/depression. Each question has three possible response
levels: no problems, moderate problems and severe problems (the new five-response version of the EQ-5D
was not available at the start of this study). Based on their combined answers to the EQ-5D questionnaire,
participants could be classified as being in 1 of 243 possible health states. Each of these health states has an
associated utility weight, which denotes the impact this state will have on health-related quality of life. Utility
weights were calculated using an independent predefined algorithm obtained by the elicitation of societal
preferences for the health dimensions in a random population sample through a time trade-off technique.76
Perfect health has a weight of ‘1’, which decreases as health becomes impaired. In the case of participants
who died, utility values were assigned a value of ‘0’.
For this study, given the quarterly timings for EQ-5D data collection, the study time horizon was partitioned
in homogeneous subintervals and utility scores computed (from EQ-5D scores) for each 3-monthly time
point. QALYs were estimated using time-weighted averages of the utility scores measured at the beginning
and end of each interval. Hence, QALY for each quarter was equal to the product of the mean utility score
during the interval and the duration of interval.77
As with self-report resource-use data, participants were asked to continue providing quarterly EQ-5D data
until the end of the study regardless of healing state. This is important because participants may have
higher utility levels after healing in which case the benefit of treatment in reducing the time to healing will
be reflected in higher total QALYs.
Statistical methods for within-trial economic analysis
Estimating mean time to healing, costs and quality-adjusted life-years
Not all study participants experienced healing during the study period; some were censored due to dropout
from the study, loss to follow-up, death or conclusion of the study before healing occurs. Traditional statistical
methods for survival analysis are based on the assumption that the reason for censoring is independent of the
outcome – non-informative censoring. However, this assumption is not valid for cost data.78 The primary
reason is that individuals accrue costs at different rates: individuals in poor health may accumulate costs at
higher rates – and in turn have higher cumulative costs at censoring time and event time – than those in better
health. The cost at the time of censoring is thus informative of the latent cost at healing, even if censoring is
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independent of the survival time.79 Therefore, using traditional methods of survival analysis to analyse cost data
will produce biased results in presence of censoring; and the same can be demonstrated for QALYs.
To account for censoring, inverse probability weighting (IPW) was used in the estimation of mean time to
healing, mean costs and mean QALYs. This method has been used in the literature80,81 and was previously
used in VenUS II61 and III.13 In the IPW approach, only the participants with the observed outcome of
interest (for instance, observed healing data in the time-to-healing model) contribute to the analysis, and
their contributions are inversely weighted by their probability of being observed. The censoring distribution
is estimated through the Kaplan–Meier estimator.
Baseline covariates expected to influence cost and outcomes were included in the models. These covariates
were the same as those used in the clinical analysis and included (log of) ulcer area, (log of) ulcer duration and
participant mobility level; in addition, baseline utility was used in the QALY regression – discussed later.
However, although the IPW method can be used non-parametrically, this approach does not allow for the
covariate adjustment required here. Rather, linear regression methods with IPW weighting have been proposed
in the literature.80 Furthermore, as noted in the clinical analyses, there was reason to anticipate that there could
be heterogeneity of treatment effects across centres, i.e. there may be a centre effect. To account for centre
effect, LMMs have been suggested.82 LMMs are characterised as containing both fixed effects (similar to
standard linear regression coefficients) and random effects. Here, centre was treated as a random effect.
This treatment of centre effect is equivalent to the shared frailty approach used in the clinical analysis, which
assumes group-specific random effect (describing the degree of correlation of participants within centres).
Thus, in this analysis we specifically used IPW-weighted LMMs to estimate the difference in mean cost, mean
ulcer-free days and mean QALYs. The overall error distribution in mixed effects models was assumed to be
Gaussian. However, as the distribution of costs and outcomes may not follow parametric assumptions,
the CIs were estimated using the non-parametric bootstrap method, which assumes that the empirical
distribution of the data is an adequate representation of the true distribution of the data.77
Cost-effectiveness analysis
Although the regression models above estimate the difference in costs and health benefits between
treatment groups (and the statistical significance of this difference), for decision-making it is the expected
value of this difference that is of interest. To assess incremental cost-effectiveness and cost utility, we
compared the expected value of the mean difference in costs between trial groups to the expected value of
the mean difference in the number of ulcer-free days and QALYs, respectively. There are four possible
scenarios from such an analysis (shown using a cost-effectiveness plane in Figure 1). HH may be estimated to
be (on average) more expensive and bring fewer health benefits than the 4LB (HH is dominated by the 4LB).
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FIGURE 1 Cost-effectiveness plane showing cost and benefit differences between alternative treatments.
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In this case, the decision regarding preference of 4LB over HH seems straightforward, as HH is more costly
and refers less benefit to patients.
A similarly straightforward scenario is the reverse, i.e. if HH is expected to be less costly and more
beneficial than the 4LB (HH dominates the 4LB). However, if HH were expected to be more costly and
more beneficial than the 4LB, or less costly and less beneficial, it is necessary to evaluate whether the
increased cost of the new intervention is worth the increased benefit, or if the reduced benefit associated
with the new treatment is justified by the reduced costs.
To ascertain the cost-effectiveness of a health-care intervention relative to another in the absence of
dominance, one needs to combines costs and health benefit in a single measure to which a decision rule
regarding cost-effectiveness can be applied. The incremental cost-effectiveness ratio (ICER) is commonly
used, and is the ratio of the mean difference in cost between alternative treatments being compared to
the mean difference in health benefits:
ICER ¼ C1−C0
B1−B0
(1)
where:
l C1=mean cost associated with the use of HH
l C0=mean cost associated with the use of the 4LB
l B1 =mean health benefit associated with HH
l B0 =mean health benefit associated with the 4LB.
The decision rule for cost-effectiveness on the basis of the ICER indicates that a treatment strategy can be
considered cost-effective only if the decision-maker’s willingness to pay for an additional unit of health
benefit (QALY, ulcer-free day) is greater (or equal) to the ICER. According to NICE, the willingness to pay
for an additional QALY ranges between £20,000 and £30,000.83 Therefore, if the result of cost–utility
analysis (the estimated cost per QALY) is below this threshold, the intervention will be considered
cost-effective. Caution is required when interpreting the cost-effectiveness results, as there is no
established threshold for cost per ulcer-free day gained. Without this information we cannot determine
whether or not the new intervention is cost-effective – a decision-maker interested in the results will
be responsible for establishing the threshold.
Decision uncertainty assessment
All presented analyses are based on sampled data collected within this RCT. Thus, if this trial were
repeated using a different study sample we would expect different mean incremental cost and benefit
values to been observed, resulting in a different ICER estimate. Thus to fully understand inferences
made from our data, the expected costs and benefits calculated must be estimated with uncertainty.
Furthermore, although decision-makers can then decide on the provision of services, using expected
cost-effectiveness findings in the presence of uncertainty, it is vital that the consequences of this
uncertainty, and the extent to which it impacts on the adoption decision, should be investigated to
inform whether further research is needed.84
Confidence intervals
Uncertainty was assessed using a non-parametric bootstrap resampling technique.77 The bootstrap
technique samples (with replacement) from the observed cost and benefit pairs while maintaining the
correlation structure between costs and benefits.
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For each bootstrap resample, an IPW estimate of expected total mean costs, expected mean QALYs and
expected ulcer-free days was calculated, which allowed computation of cost-effectiveness and cost–utility
outcome replicates. The 95% CIs for the differential costs and QALYs were then calculated using
bias-corrected non-parametric bootstrapping.77
Cost-effectiveness acceptability curves
As discussed, in the presence of uncertainty it is important to evaluate the joint distribution of costs
and benefits to inform decision uncertainty. This evaluation is often presented as the probability that
an intervention is cost-effective when compared with an alternative treatment for predefined
cost-effectiveness threshold values.
To explore decision uncertainty regarding the cost-effectiveness of HH, the joint distribution of mean cost and
mean outcomes was evaluated using cost-effectiveness acceptability curves (CEACs) from the bootstrapped
cost-effectiveness pairs. The CEAC expresses the likelihood that the cost-effectiveness estimate reflects a
cost-effective intervention, based on the existing evidence.85 The CEAC summarises – for every value of
willingness-to-pay thresholds – the evidence in favour of the intervention being cost-effective. In this case,
given the trial data, the CEAC for HH represents the probability of this therapy being cost-effective compared
with the 4LB for a range of willingness-to-pay values for an ulcer-free day/QALY.
Subgroup analysis
A post hoc subgroup analysis was conducted to investigate whether total cost varied based on participant
baseline characteristics; hence, cost per participant was evaluated based on age (≤ 60, 61–70, 71–80,
> 80 years), BMI [underweight (< 18.5 kg/m2), normal healthy weight (18.5–24.9 kg/m2), overweight
(25–29.9 kg/m2), obese classes I–II (30–39.9 kg/m2) obese class III (40+ kg/m2)86] and mobility (walks freely
vs. walks with difficulty or immobile). To investigate potential interaction between treatment and baseline
characteristics in the cost regression, separate interaction terms were included for treatment and age,
BMI or mobility in the model used in the primary analysis (see Estimating mean time to healing, costs and
quality-adjusted life-years, above). As in the primary analysis, an IPW-weighted mixed-effects model was
used to evaluate costs at all quarterly time points at which cost data were collected. This post hoc analysis
was initiated after unblinding of the primary results to the investigators and should therefore be regarded
as exploratory in nature.
Sensitivity analysis
Nurse consultation recorded in treatment logs (nurse reported)
As highlighted previously, data on number of nurse consultations was available, as well as being self-reported
by participants in quarterly questionnaires. This source of nurse consultation data was explored in a sensitivity
analysis. Nurses also recorded the duration and location of nurse consultation. For costing purposes, the
location of nurse consultations was simplified as either a home visit or health facility visit (unit cost assumed
to be that of a nurse consultation at GP surgery). The duration of a consultation was calculated as the
difference between the arrival and departure times recorded on the treatment log.
Other
Finally, if there were an imbalance in baseline costs between HH and the 4LB (based on the number of
participant-reported health-care consultations in the 3 months before randomisation) then a further
sensitivity analysis was planned using baseline cost as a covariate in the cost regression.
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Chapter 4 Protocol changes
The following changes were made to the original trial protocol, after it was initially approved by theREC on 26 September 2009.
Inclusion and exclusion criteria
In the original protocol, patients were excluded if they had very bony prominences at risk of pressure damage.
The rationale behind this was that participants who were treated with 4LBs would have a protective soft
wool layer applied (as part of the 4LB system), whereas participants who received HH would not receive such
padding. The TMG and TSC were concerned that this exclusion criterion could mean excluding patients who
would benefit from the trial treatment. After consultation with clinician colleagues, and scrutinising the
HH manufacturers’ guidelines (which do not mention the presence of bony prominences as a contraindication
to wearing HH), it was concluded that the original risk of wearing HH was overestimated and patients with
very bony prominences should not be excluded from the trial.
Patients with diabetes mellitus, whose blood sugar was not well controlled (unstable diabetes mellitus),
were originally excluded from this trial. However, according to published literature,3 expert clinical opinion
from a consultant vascular surgeon (who was also Independent Chair of the TSC) and guidelines from
manufacturers of HH, participants with diabetes who present with a venous leg ulcer can be treated with
high compression as long as their ABPI falls within normal limits. Patients with diabetes mellitus whose
blood sugar was not well controlled were therefore eligible for inclusion within this trial, as long as nurses
followed standard practice of regularly re-assessing diabetic patients for the presence of neuropathy,
ischaemia or other indications that could make compression unsafe in this patient group.
During the course of the trial, the trial inclusion criterion regarding the ABPI measurement was altered.
Originally, patients were included only if their ABPI was between ≥ 0.8 and < 1.20. Clinicians informed us
that the use of the upper limit of 1.20 did not reflect current practice regarding compression use, and
eligible patients were being unnecessarily excluded from this trial. Indeed, although a lower limit of 0.8 is
widely recognised and cited in robust guidelines,21 there is no agreed upper ABPI at which high
compression should not be delivered.
To investigate this in more detail, we surveyed to 27 trial centres regarding their practice. Of the
26 respondents, 24 (92%) said they would use high compression on patients with an ABPI of > 1.20.
Clinicians said that, in practice, the decision to apply high-compression treatment to patients with an ABPI
of > 1.20 would be dictated by clinical judgement and local guidelines. The exclusion criterion regarding
ABPI was therefore altered to exclude patients with an ABPI of > 1.20 (taken within the last 3 months)
only if in the nurse’s clinical judgement and/or according to local guidelines that patient should not
receive high compression.
In order to capture all reasons for excluding patients from this trial, a new pre-trial exclusion was created.
This allowed nurses to exclude those patients who met all of the inclusion criteria and none of the
exclusion criteria but, in the clinical opinion of the nurse, could not be included in the trial for another
reason. The same approach was used in VenUS III.13
Treatments
In the trial protocol we specified that all compression hosiery kits must consist of a two-layer compression
system delivering up to 40mmHg at the ankle. The ConvaTec SurePress Comfort Pro compression
hosiery kit did not fulfil these criteria, as it delivered a maximum of 35–36-mmHg compression.
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Moreover, it did not come with a self-applicator; therefore, application of this treatment could prove
difficult for some trial participants. Therefore, this compression hosiery kit was removed from the list of
hosiery kits that could be used during the trial.
Serious adverse events
Any unexpected SAEs considered to be related to the trial treatment were required to be reported to the
REC. In order to define which events would fit this definition, the protocol needed to contain a description
of those SAEs that would be expected but unrelated to the trial treatment in this study population.
The protocol was therefore amended to provide a description of these events.
Gaiter region
During recruitment it became apparent that nurses were unsure if they could recruit patients with a venous
leg ulcer on, or extending below, the submalleolar region (i.e. below the ankle). To clarify this, the wording
in the protocol was changed to describe the gaiter region in which the venous leg ulcer must be present
either fully or partially.
Data collection processes
We changed the protocol to reflect a change to the collection of healing data. Rather than report healing
via the ulcer healed form (see Appendix 5), we also asked trial nurses to telephone the York Trials Unit
when they considered the reference ulcer (and leg) to have healed. The operator who took the call entered
the date(s) of healing into the Trial Management Database. This change ensured data were captured
accurately and also acted as a prompt for trial nurses to receive electronic reminders to inform them of
when post-healing photographs were due.
Recruitment and follow-up
Recruitment for this trial was due to start on 1 October 2009 and finish on 28 February 2011; this was to
be followed by a 12-month follow-up period from 1 March 2011 to 29 February 2012. The trial was due
to end on 30 June 2012. This was modified owing to slow recruitment (only 34% of target recruited for
31 October 2010).
Recruitment was initially extended by 8 months and planned to continue into the follow-up period.
Recruitment was therefore due to end on 31 October 2011, with participant follow-up continuing until
29 February 2012. This meant that follow-up was reduced for those participants who were recruited
towards the end of the proposed extended recruitment period. The recruitment period was revised again
in November 2011 owing to poor recruitment (406/489 participants recruited by 31 November 2011,
83% of expected sample size). A 4-month extension to the study was approved by the National Institute of
Health Research. This meant that recruitment continued until 29 February 2012, participant follow-up
ended on 30 June 2012 and the trial ended on 31 October 2012. Consequently, some participants
recruited at the end of the recruitment period were only followed up for a maximum of 4 months.
Similar protocol amendments were made in VenUS II61 and III.13
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Participant questionnaires
In the original protocol, participants who complete their final 12-month questionnaire were sent £5
reimbursement for completion of this questionnaire. This was changed to include a £5 reimbursement for
all participants upon completion of their final questionnaire, if that happened to be completed before
12 months. This change reflected the variations in final follow-up.
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Chapter 5 Clinical results
Recruitment
Recruitment began in November 2009 and ceased in February 2011. In total, 3411 patients with leg ulcers
were screened as potential participants and of these 457 (15.5%) were randomised. Over the course of
the trial there were 34 participating UK centres (two centres recruited no participants): this recruitment
was staggered with centres joining and leaving the trial over its course. The number of participants
recruited per centre ranged from 1 to 55 (Figure 2). The rate of recruitment is shown in Figure 3. Further
details of the recruiting centres are presented in Appendix 1.
Of the 457 participants randomised, 230 were allocated to the HH group and 227 to the 4LB group.
Three participants were excluded because they were found to be ineligible after randomisation, and thus
the number of eligible, randomised participants was 454 (224 4LB, 230 HH). Only one participant (4LB)
provided no follow-up beyond baseline. Therefore, 453 (223 4LB, 230 HH) contributed data to the analysis
of the primary outcome.
The flow of participants through the trial is presented in a Consolidated Standards of Reporting Trials
(CONSORT) flow diagram87 (Figure 4). This shows the total number of participants screened for eligibility,
randomised into each treatment group, post-randomisation exclusions and changes from allocated
trial treatment.
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FIGURE 2 Participant recruitment by centre. PCT, primary care trust.
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Assessed for eligibility
(n = 3411)
Excluded (n = 2954)
Reasons for exclusion
• fulfilled multiple exclusion criteria,
n = 667a
• other clinical reason that excluded
  participant from the trial, n = 614b
• patient was unable or unwilling to
  tolerate high compression, n = 464
• patient has an ABPI<0.80 (taken
  within the last 3 months), n = 458
• patient was unwilling to give
  informed consent, n = 246
• wound exudate levels were too high
  for the use of compression hosiery,
  n = 183
• patient had gross leg oedema, n = 102
• patient was unable to give informed
  consent, n = 98
• patient had a leg ulcer of non-venous
  aetiology, n = 79 
• patient had an ABPI>1.20 and in
  nurse’s clinical judgement should not
  receive high compression, n = 20
• patient was currently in another
study evaluating leg ulcer therapies,
  n = 12
• patient was allergic to any trial
  product, n = 9
• patient has been in VenUS IV trial
  previously, n = 2 
• patient was < 18 years of age, n = 0  
Analysed (n = 230)
      Excluded from analysis
                     (n = 0) 
No follow-up data after
baseline (n = 0)
Discontinued intervention
(moved to non-trial treatment)
(n = 90)
Reasons
• increase in ulcer area for
   two consecutive weeks, n = 2
• ulcer deterioration, n = 15
• found compression
   uncomfortable/painful, n = 37
• was not concordant with
   compression treatment for
   another reason, n = 10
• other reason for treatment
   change, n = 26
Reasons
• increase in ulcer area for
   two consecutive weeks, n = 1
• ulcer deterioration, n = 4
• found compression
   uncomfortable/painful, n = 16
• was not concordant with
   compression treatment for
   another reason, n = 9
• other reason for treatment
   change, n = 40
Allocated to intervention
(HH)
(n = 230)
Received allocated intervention
(n = 230)
Did not receive allocated
intervention (n = 3)
Reasons
• nurse recorded wrong
   treatment allocation
   (i.e. 4LB), n = 2
• patient preferred their
   current treatment (SSB), n = 1
No follow-up data after
baseline (n = 1)
Discontinued intervention
(moved to non-trial treatment)
(n=70)
 
Allocated to standard care
(4LB)
(n = 227)
Received allocated intervention
(n = 216)
Did not receive allocated
intervention (n = 11)
Reasons
• patient preference for
   compression hosiery, n = 8
• patient did not fulfil
   inclusion criteria, n = 3
Analysed (n = 224)
Excluded from analysis (n = 3), as
did not fulfil inclusion criteria
Randomised
(n=457)
FIGURE 4 VenUS IV CONSORT flow diagram. a, Of the 667 participants who fulfilled more than one exclusion
criterion, the following number of participants fulfilled two (n= 537); three (n= 107); four (n= 18); five (n= 4)
or six (n= 1) exclusion criteria; b, further details on the 614 patients who were excluded on other clinical grounds:
ulcer was not a venous leg ulcer (n= 203); ulcer healed or close to healing (n= 94); treatment preference (n= 62);
other condition excluded patient from study (n= 53); unable to obtain ABPI measurement (n= 45); ulcer was not in
gaiter region (n= 33); patient could not tolerate or apply trial treatments (n= 32); health-care provider decided
venous leg ulcer treatment (n= 32); patient was referred elsewhere for treatment (n= 30); patient was
non-compliant with treatment (n= 24); no reason given (n= 5); other reason (n= 1).
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Baseline demographics and clinical characteristics
The baseline data are summarised in Tables 7–10 and show demographic and clinical characteristics to be
fairly well balanced between the treatment groups. Table 7 summarises the participant characteristics.
Overall, the trial had a similar proportion of male and female participants (50.7% and 49.3%, respectively).
The mean age of participants was 69 years, with a range from 26.4 to 99.3 years. The mean participant
BMI was 31 kg/m2 (obese) and 63.8% of participants had no mobility problems.
Tables 8 and 9 summarise ulcer- and limb-related clinical characteristics. At randomisation participants were
stratified by ulcer size (≤ 5 cm2 or > 5 cm2) and duration of the reference ulcer (≤ 6 months or > 6 months)
and therefore these prognostic factors were balanced. In total, 67.2% of participants had ulcers of ≤ 5 cm2,
and 64.5% had ulcers present for ≤ 6 months. The distribution of the actual size and duration of ulcers was
positively skewed, with a small number of participants having very large or old ulcers. The number of ulcer
episodes since the first occurrence was similar between groups with an overall median of 1 (range 0 to 70),
indicating that for at least 50% of participants this was their second episode of leg ulceration. The mean ABPI
of the reference limb (the leg with the reference ulcer) was 1.1, with a range from 0.7 to 1.5.
Table 10 shows a fair balance between treatment preferences at baseline by allocated treatment group,
with 49% of participants preferring compression hosiery. However, only 6.8% of participants had a current
treatment of compression hosiery before starting the trial, whereas 48.7% were being treated with the 4LB.
TABLE 7 Baseline data: participant characteristics
Characteristic HH (n= 230) 4LB (n= 224) Overall (n= 454)
Gender
Male 117 (50.9%) 113 (50.4%) 230 (50.7%)
Female 113 (49.1%) 111 (49.6%) 224 (49.3%)
Age
Mean (SD) 68.3 (15.1) 68.9 (13.8) 68.6 (14.5)
Median (min., max.) 71.1 (26.4, 96.7) 71.1 (29.1, 99.3) 71.1 (26.4, 99.3)
IQR (25–75%) 59.2–79.9 62.0–78.7 60.4–79.4
Missing 0 0 0
BMI (kg/m2)
Mean (SD) 30.9 (7.9) 31.2 (8.0) 31.0 (8.0)
Median (min., max.) 29.5 (16.2, 64.7) 29.4 (17.7, 60.5) 29.5 (16.2, 64.7)
IQR (25–75%) 25.5–34.6 25.4–34.9 25.5–34.9
Missing 3 (1.3%) 3 (1.3%) 6 (1.3%)
Mobility
Participant walks freely 139 (60.7%) 150 (67.0%) 289 (63.8%)
Participant walks with difficulty 89 (38.9%) 71 (31.7%) 160 (35.3%)
Participant is immobile 1 (0.4%) 3 (1.3%) 4 (0.9%)
Diabetic
Yes 32 (13.9%) 46 (20.5%) 78 (17.2%)
No 198 (86.1%) 178 (79.5%) 376 (82.8%)
max., maximum; min., minimum.
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TABLE 8 Baseline data: ulcer related
Characteristic HH (n= 230) 4LB (n= 224) Overall (n= 454)
Size of ulcer (cm2)
≤ 5 cm2 156 (67.8%) 149 (66.5%) 305 (67.2%)
> 5 cm2 74 (32.2%) 75 (33.5%) 149 (32.8%)
Mean (SD) 9.4 (15.4) 9.3 (21.2) 9.4 (18.5)
Median (min., max.) 4.1 (0.1, 135.5) 3.7 (0.1, 185.7) 3.9 (0.1, 185.7)
IQR (25–75%) 1.6–8.7 1.6–8.2 1.6–8.7
Missing 1 (0.4%) 0 1 (0.2%)
Ulcer duration (months)
≤ 6 months 148 (64.4%) 145 (64.7%) 293 (64.5%)
> 6 months 82 (35.7%) 79 (35.3%) 161 (35.5%)
Mean (SD) 10.8 (20.0) 12.3 (25.6) 11.5 (22.9)
Median (min., max.) 4.0 (1.0, 204.0) 4.0 (1.0, 204.0) 4.0 (1.0, 204.0)
IQR (25–75%) 3.0–12.0 2.0–9.0 2.0–11.0
Missing (%) 1 (0.4%) 2 (0.9%) 3 (0.7%)
Total of ulceration episodes since first episode
Mean (SD) 3.1 (6.0) 2.7 (3.7) 2.9 (5.0)
Median (min., max.) 1.0 (0.0, 70.0) 1.0 (0.0, 20.0) 1.0 (0.0, 70.0)
IQR (25–75%) (1.0–3.0) (1.0–3.0) (1.0–3.0)
Missing 11 (4.8%) 13 (5.8%) 24 (5.3%)
Time since first ulcer (months)
Mean (SD) 98.5 (155.4) 96.2 (144.7) 97.3 (150.1)
Median (min., max.) 36.0 (1.0, 840.0) 36.0 (0.0, 696.0) 36.0 (0.0, 840.0)
IQR (25–75%) 4.0–120.0 4.5–120.0 4.0–120.0
Missing 3 (1.3%) 4 (1.8%) 7 (1.5%)
Duration of oldest ulcer on reference leg (months)
Mean (SD) 13.7 (37.5) 12.1 (25.5) 12.9 (32.1)
Median (min., max.) 5.0 (1.0, 480.0) 4.0 (0.0, 204.0) 5.0 (0.0, 480.0)
IQR (25–75%) 3.0–12.0 2.0–9.0 2.0–12.0
Missing 7 (3.0%) 6 (2.7%) 13 (2.9%)
Total number of ulcers per participant (reference leg)
Mean (SD) 1.5 (1.0) 1.6 (1.3) 1.6 (1.2)
Median (min., max.) 1.0 (1.0, 8.0) 1.0 (1.0, 11.0) 1.0 (1.0, 11.0)
IQR (25–75%) 1.0–2.0 1.0–2.0 1.0–2.0
Missing 0 0 0
max., maximum; min., minimum.
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TABLE 9 Baseline data: limb related
Characteristic HH (n= 230) 4LB (n= 224) Overall (n= 454)
Reference leg
Left 135 (58.7%) 121 (54.0%) 256 (56.4%)
Right 95 (41.3%) 103 (46.0%) 198 (43.6%)
Ankle circumference (cm)
Mean (SD) 24.3 (3.0) 24.7 (3.5) 24.5 (3.3)
Median (min., max.) 24.0 (18.0, 36.0) 24.0 (12.0, 43.0) 24.0 (12.0, 43.0)
IQR (25–75%) 22.0–26.0 22.3–26.5 22.0–26.0
Missing 3 (1.3%) 4 (1.8%) 7 (1.5%)
Ankle mobility of reference leg
Participant has full range of motion 159 (69.1%) 154 (68.8%) 313 (68.9%)
Reduced range of ankle motion 65 (28.3%) 67 (29.9%) 132 (29.9%)
Participant’s ankle is fixed 6 (2.6%) 3 (1.3%) 9 (2.0%)
ABPI
Mean (SD) 1.1 (0.1) 1.1 (0.1) 1.1 (0.1)
Median (min., max.) 1.1 (0.8, 1.5) 1.1 (0.7, 1.5) 1.1 (0.7, 1.5)
IQR (25–75%) 1.0–1.2 1.0–1.2 1.0–1.2
Missing 3 (1.3%) 9 (4.0%) 12 (2.6%)
max., maximum; min., minimum.
TABLE 10 Baseline data: participant preference and current treatments
Characteristic HH (n= 230) 4LB (n= 224) Overall (n= 454)
Preference
Compression hosiery 108 (47.4%) 112 (50.7%) 220 (49.0%)
4LB 29 (12.7%) 29 (13.1%) 58 (12.9%)
No preference 91 (39.9%) 80 (36.2%) 171 (38.1%)
Current treatments
4LB 119 (51.7%) 102 (45.5%) 221 (48.7%)
SSB 15 (6.5%) 14 (6.3%) 29 (6.4%)
Compression hosiery 18 (7.8%) 13 (5.8%) 31 (6.8%)
Other compression bandage 31 (13.5%) 38 (17.0%) 69 (15.2%)
Not receiving compression 37 (16.1%) 41 (18.3%) 78 (17.2%)
Other treatment 5 (2.2%) 8 (3.6%) 13 (2.9%)
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Trial completion and trial exit
Participants were followed up for up to 12 months, irrespective of whether they healed or not during this
time. Data on reason for trial exit are presented in Table 11 by treatment group. This was returned for just
over half of all participants, with the reasons for trial exit being fairly evenly balanced between groups.
As these data were not returned for a large number of participants, status in terms of whether or not
participants healed according to the trial nurses and the status of participants who left the study unhealed
is also given in the table.
Primary outcome: ulcer healing (blinded)
The primary outcome was time to healing of the reference ulcer, for which healing was judged from dated
photographs by independent assessors who were blind to treatment allocation. The unadjusted analysis of
time to healing used a log-rank test to compare the survivor functions of the treatment groups. There was
no evidence of a difference between the treatment groups in time to ulcer healing [log-rank test statistic
0.23, degrees of freedom (df)= 1; p= 0.63] (Table 12). Figure 5 shows the Kaplan–Meier survival curves
for each treatment.
We then implemented a CPH model adjusted for baseline ulcer area, ulcer duration and participant
mobility with shared centre frailty effects. A significant frailty effect for centre was shown, meaning the
within-centre correlation needed to be accounted for and that this model was appropriate. The results,
given in Table 13, do not demonstrate evidence of a treatment effect for HH compared with the 4LB in this
adjusted model, with a HR of 0.99 (95% CI 0.79 to 1.25). Both baseline ulcer area and ulcer duration were
included in the model after logarithmic transformation and were statistically significant predictors of time to
healing (p< 0.001) with larger ulcers and those of a longer duration having a reduced risk of healing.
TABLE 11 Reasons for trial exit and participant status in terms of nurse-reported healing outcome
Reasons HH (n= 230) 4LB (n= 224) Overall (n= 454)
Exit data (healed and unhealed)
Exit data not returned 91 (39.6%) 102 (45.5%) 193 (42.5%)
Wishes to exit (ulcer unhealed) 8 (3.5%) 7 (3.1%) 15 (3.3%)
Dieda 7 (3.0%) 3 (1.3%) 10 (2.2%)
In trial for 12 months 86 (37.4%) 75 (33.5%) 161 (35.5%)
Lost to follow-upb 2 (0.9%) 0 (0.0%) 2 (0.4%)
Trial end reached 31 (13.5%) 35 (15.6%) 66 (14.5%)
Other 5 (2.2%) 2 (0.9%) 7 (1.5%)
Participant status (reference ulcer)
Reference ulcer healedc 174 (75.7%) 182 (81.3%) 356 (78.4%)
Died (unhealed) 5 (2.2%) 2 (0.9%) 7 (1.5%)
Exited (unhealed) 8 (3.5%) 7 (3.1%) 15 (3.3%)
Lost to follow-up (unhealed) 15 (6.5%) 15 (6.7%) 30 (6.6%)
Completed follow-up (unhealed)d 28 (12.2%) 18 (8.0%) 46 (10.1%)
a Two participants who died did not have exit forms completed.
b As reported by completion of the appropriate tick box on the form for Trial Exit (by nurse).
c As reported by nurse (unblinded assessment).
d Defined as last actual date of follow-up being within 1 week of the participant’s last potential trial exit date.
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TABLE 12 Healing estimates (blinded) by treatment group
Characteristic HH (n= 230) 4LB (n= 223)
No. healing 163 (70.9%) 157 (70.4%)
Median time to healing (survival time in days) (95% CI) 99 (84 to 126) 98 (85 to 112)
HR from unadjusted Cox model (95% CI) 0.95 (0.76 to 1.18)
Log-rank test statistic, p-value 0.23 (1 df), 0.63
Wilcoxon test statistic, p-value 0.13 (1 df), 0.71
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FIGURE 5 Kaplan–Meier plot of time to healing (blinded) by treatment group.
TABLE 13 Adjusted analysis of time to ulcer healing (blinded) with centre frailty effect
Parameter Estimate (SE) HR (95% CI) p-value
HH vs. 4LB −0.01 (0.12) 0.99 (0.79 to 1.25) 0.96
Log (area) −0.31 (0.05) 0.73 (0.66 to 0.81) < 0.001a
Log (duration) −0.51 (0.06) 0.60 (0.53 to 0.68) < 0.001a
Mobility
Participant walks freely 0.00 1.00
Participant walks with difficulty −0.13 (0.13) 0.88 (0.68 to 1.13) 0.31
Participant is immobile 0.67 (0.72) 1.95 (0.47 to 8.05) 0.36
Theta 0.06 (0.04)
a Test of significance of frailty parameter: Ho: Theta= 0 χ2 (1 df)= 4.66; p= 0.015.
Note: standard errors of HRs are conditional on theta.
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Further (post hoc) analyses were carried out to investigate the centre effect. First, the analysis was repeated
excluding the 12 centres that had < 5 participants randomised. This produced very similar estimates of
effect and the centre frailty remained significant (p= 0.01). Second, the analysis was repeated including a
covariate that adjusted for the number of participants per centre. Again, similar results were observed,
the centre effect for the overall model remained (p= 0.04) and there was no evidence of an association
between centre size and time to healing (HR= 1.00, 95% CI 0.99 to 1.01; p= 0.57). In our next analysis,
we repeated the primary analysis of time to healing stratified for each treatment group. In this case, area
and duration of ulcer remained significantly associated with risk of healing. In the 4LB group, the test of
significance of frailty parameter showed weak evidence of a centre effect (p= 0.08), whereas in the HH
group there was no evidence of a centre effect (p= 0.20). In the design of VenUS IV there was a prior
assertion that centre effect may be related to bandager skill and these results are not inconsistent with
this assertion. However, it should be noted that these analyses were conducted in smaller groups of
participants and may be underpowered to detect true differences.
In the primary analysis, visual inspection of the survival function and log–log plots indicated potential
non-proportionality of hazards for the treatment groups; however, the test using Schoenfeld residuals was
not statistically significant (p= 0.79 in the unadjusted model and p= 0.07 overall in the adjusted model).
The only variable that did appear to violate the proportional hazards (PH) assumption was log(ulcer area).
A sensitivity analyses was performed, which removed ‘ulcer area’ from the model and this did not alter the
conclusions; the HR for HH compared with 4LB was 0.94 (95% CI 0.75 to 1.19).
Finally, because there was some change baseline imbalance in the proportion of people with diabetes
in treatment arms, we repeated the primary analysis adjusting for diabetes (yes/no). Being diabetic was not
found to be significantly associated with time to healing (p= 0.182), and it made very little difference to
the overall treatment effect (HR= 1.01, 95% CI 0.80 to 1.26).
Ulcer healing (unblinded)
Time to healing as assessed by the nurses during the course of the trial was analysed using the same
methods as those for the primary outcome. The unadjusted analyses are presented in Table 14. There was
no significant centre frailty effect found (p= 0.25) and the models with and without centre frailty effects
gave very similar results. In line with our analysis plan, we therefore present the model without centre
frailty effects in Table 15. Again, there was no evidence of a treatment effect for HH compared with the
4LB in this adjusted model, with a HR of 0.91 (95% CI 0.73 to 1.12).
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Healing of the reference leg
As the intention was for all participants to remain in the trial for up to 12 months, regardless of healing
status, we were able to investigate time to healing of the reference leg. This assessment was unblinded
and recorded by nurses during the trial. At the end of follow-up 343 participants’ (76.1%) reference legs
were completely healed, representing 72.9% (167/229) in the two-layer group and 79.3% (176/222) in
the 4LB group. Median time to reference leg healing was 84 days overall (95% CI 70 to 97 days): 77 days
in the 4LB group (95% CI 63 to 92 days) and 91 days in the compression hosiery group (95% CI 70 to
126 days), log-rank test p= 0.12. There was no significant centre frailty effect found (p= 0.17) in the case
of unblinded reference leg healing, and the models with and without centre frailty effects gave very similar
results. The results are given in Table 16 and are consistent with those presented in Table 15 for unblinded
reference ulcer healing.
Health-related quality of life and leg ulcer-related pain
The SF-12 questionnaire was used to assess self-reported health-related quality of life at baseline, and
months 3, 6, 9 and 12. Descriptive statistics of the PCS and MCS scores are presented in Tables 17 and 18
and Figures 6 and 7. In all cases the minimum, and worst, score possible was ‘0’ and the maximum ‘100’.
The mean baseline PCS score the of the trial study population was 38.4 (SD 11.2) and the mean baseline
MCS score was 49.6 (SD 11.3). In general, the study population seemed to have a lower quality of life in
terms of physical health but similar mental health compared with the US reference population sample who
have a mean of 50 (SD 10) for both components of the SF-12, although the PCS score was similar to the
SF-12 reference population for individuals aged > 75 years61 (mean 37.9, SD 11.16).
TABLE 15 Adjusted analysis of time to ulcer healing (unblinded)
Parameter Estimate (SE) HR (95% CI) p-value
Compression hosiery vs. 4LB −0.10 (0.11) 0.91 (0.73 to 1.12) 0.36
Log (area) −0.34 (0.05) 0.71 (0.65 to 0.78) < 0.001a
Log (duration) −0.44 (0.05) 0.65 (0.58 to 0.72) < 0.001a
Mobility
Participant walks freely 0.00 1.00
Participant walks with difficulty −0.11 (0.12) 0.90 (0.71 to 1.13) 0.35
Participant is immobile 0.89 (0.59) 2.44 (0.77 to 7.70) 0.13
a Note: p-value is < 0.05.
TABLE 14 Unblinded, unadjusted healing estimates by treatment group
Characteristic HH (n= 230) 4LB (n= 223)
No. healing 174 (75.7%) 182 (81.6%)
Median time to healing (survival time in days) (95% CI) 84 (64 to 106) 73 (62 to 88)
HR from unadjusted Cox model (95% CI) 0.85 (0.69 to 1.05)
Log-rank test statistic, p-value 2.33 (1 df); p= 0.13
Wilcoxon test statistic, p-value 1.39 (1 df); p= 0.24
CLINICAL RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
44
TABLE 17 Short Form questionnaire-12 items: PCS scores
Timeline/statistic HH, n= 230 4LB, n= 224 Overall, n= 454
Baseline 222 216 438
Mean (SD) 38.1 (10.8) 38.8 (11.7) 38.4 (11.2)
Median (range) 38.5 (9.7–64.8) 39.1 (11.9–62.1) 39.0 (9.7–64.8)
Missing n (%) 8 (3.5) 8 (3.6) 16 (3.5)
3 months 190 186 376
Mean (SD) 39.4 (12.0) 38.2 (12.6) 38.8 (12.3)
Median (range) 40.2 (8.7–62.0) 39.9 (6.0–59.5) 40.2 (6.0–62.0)
Missing n (%) 40 (17.4) 38 (17.0%) 78 (17.2%)
6 months 163 164 327
Mean (SD) 38.8 (11.7) 37.8 (13.9) 38.3 (12.9)
Median (range) 39.6 (14.4–65.3) 38.2 (8.7–60.5) 39.5 (8.7–65.3)
Missing n (%) 67 (29.1) 60 (26.8) 127 (28.0)
9 months 145 142 287
Mean (SD) 39.1 (12.6) 39.2 (12.8) 39.2 (12.7)
Median (range) 39.6 (4.8–63.0) 37.6 (16.0–61.2) 39.5 (4.8–63.0)
Missing n (%) 85 (37.0) 82 (36.6) 167 (36.8)
12 months 119 123 242
Mean (SD) 39.1 (11.9) 38.5 (12.4) 38.8 (12.1)
Median (range) 39.4 (14.9–60.2) 39.4 (11.9–59.9) 39.4 (11.9–60.2)
Missing n (%) 111 (48.3) 101 (45.1) 212 (46.7)
TABLE 16 Adjusted analysis of time to healing of the reference leg (unblinded)
Parameter Estimate (SE) HR (95% CI) p-value
HH vs. 4LB −0.11 (0.11) 0.90 (0.72 to 1.11) 0.33
Log (area) −0.31 (0.05) 0.73 (0.66 to 0.80) < 0.001a
Log (duration) −0.43 (0.06) 0.65 (0.58 to 0.72) < 0.001a
Mobility
Participant walks freely 0.00 1.00
Participant walks with difficulty −0.06 (0.12) 0.94 (0.74 to 1.19) 0.60
Participant is immobile 0.93 (0.59) 2.53 (0.80 to 8.00) 0.11
a Note: p-value is < 0.05.
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FIGURE 6 Short Form questionnaire-12 items: MCS scores over time (mean and 95% CI).
TABLE 18 Short Form questionnaire-12 items: MCS scores
Timeline/statistic HH (n= 230) 4LB (n= 224) Overall (n= 454)
Baseline 222 216 438
Mean (SD) 48.6 (12.0) 50.5 (10.4) 49.6 (11.3)
Median (range) 51.0 (9.1–70.9) 52.7 (17.3–68.3) 52.0 (9.1–70.9)
Missing n (%) 8 (3.5) 8 (3.6) 16 (3.5)
3 months 190 186 376
Mean (SD) 49.1 (10.9) 50.5 (11.2) 49.8 (11.0)
Median (range) 50.9 (18.0–67.7) 53.0 (14.3–68.3) 52.2 (14.3–68.3)
Missing n (%) 40 (17.4) 38 (17.0) 78 (17.2)
6 months 163 164 327
Mean (SD) 51.1 (11.3) 50.8 (10.5) 50.9 (10.9)
Median (range) 54.1 (15.9–72.1) 54.0 (16.0–67.9) 54.1 (15.9–72.1)
Missing n (%) 67 (29.1) 60 (26.8) 127 (28.0)
9 months 145 142 287
Mean (SD) 49.8 (11.1) 50.3 (10.1) 50.1 (10.6)
Median (range) 52.4 (17.6–70.1) 52.4 (24.1–64.8) 52.4 (17.6–70.1)
Missing n (%) 85 (37.0) 82 (36.7) 167 (36.8)
12 months 119 123 242
Mean (SD) 49.3 (10.8) 50.9 (11.6) 50.1 (11.2)
Median (range) 51.1 (17.3–68.3) 54.0 (18.0–68.5) 52.6 (17.3–68.5)
Missing n (%) 111 (48.3) 101 (45.1) 212 (46.7)
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There was no evidence of a statistically significant relationship of PCS or MCS score with treatment over
12 months when investigated using LMMs, adjusting for baseline ulcer area, ulcer duration, participant
mobility, centre, baseline scores (PCS and MCS scores, respectively) and time. Interaction between
treatment and time was also investigated and this was not significant for the MCS model analyses
(p= 0.45). For PCS, there was some evidence of significant interaction of treatment with time (p< 0.01).
At 3 months those allocated to the HH had a significantly higher PCS score (suggesting better physical
health) than those allocated to the 4LB after adjustments were taken into account. At the other time
points, PCS score was also higher for the compression hosiery group but these differences were not
statistically significant. In the PCS and MCS analyses, reduced participant mobility was associated with
reduced PCS and MCS scores overall (p< 0.001 in both cases).
It should be noted that, due to the varying follow-up period, 151 participants randomised after
30 June 2011 had varying trial exit dates, ranging from 4 to 12 months post randomisation and this
explains some of the missing health-related quality-of-life data. Taking this into account, in terms of
missing SF-12 data, of the participants who healed, 39.1% in the HH group and 43.4% in the 4LB group
did not return forms subsequent to healing up to their trial exit dates. For those participants who did not
heal 32.1% in the HH group and 23.8% in the 4LB group had SF-12 missing at time of trial exit.
The mean (SD) VEINES-QOL scores at baseline were 49.8 (10.0) (n= 228) for compression hosiery and 50.2
(10.0) (n= 221) for 4LB, at 4 months they were 49.8 (9.9) (n= 167) and 50.2 (10.1) (n= 168), respectively.
The estimated difference after 4 months, 4LB minus compression hosiery, was 0.0 scale points, (SE= 1.1,
95% CI−2.2 to 2.2; p= 1.0), adjusted for baseline VEINES-QOL score and clustering. Hence for VEINES-
QOL the difference between treatment arms was estimated to be less than one-quarter of a SD.
Ulcer-related pain in the previous 24 hours was also measured at baseline, and months 3, 6, 9 and 12.
Although these pain scores improved in both groups over time there was no evidence of difference in
change in pain score between treatment groups (Table 19).
0
M
ea
n
 P
C
S 
sc
o
re
30
35
40
45
3 6
Time of follow-up (months)
9 12
4LB
Compression hosiery
FIGURE 7 Short Form questionnaire-12 items: PCS scores over time (mean and 95% CI).
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TABLE 19 Participant leg ulcer-related pain over past 24 hours
Timeline/statistic HH (n= 230) 4LB (n= 224) Overall (n= 454)
Baseline 221 218 439
Mean (SD) 28.0 (27.1) 35.5 (30.4) 31.7 (29.0)
Median (range) 20.0 (0.0 –100.0) 30.0 (0.0 –100.0) 25.0 (0.0 –100.0)
Missing, n (%) 9 (3.9) 6 (2.7) 15 (3.3)
3 months 119 117 236
Mean (SD) 17.1 (22.2) 21.5 (27.6) 19.2 (25.1)
Median (range) 5.0 (0.0 –90.0) 10.0 (0.0 –100.0) 10.0 (0.0 –100.0)
Missing, n (%) 111 (48.3) 107 (47.8) 228 (50.2)
6 months 86 85 171
Mean (SD) 15.3 (21.8) 22.5 (27.5) 18.9 (25.0)
Median (range) 5.0 (0.0 –100.0) 15.0 (0.0 –100.0) 5.0 (0.0 –100.0)
Missing, n (%) 144 (62.6) 139 (62.1) 283 (62.3)
9 months 64 74 138
Mean (SD) 14.8 (22.3) 19.4 (27.3) 17.2 (25.1)
Median (range) 5.0 (0.0 –85.0) 5.0 (0.0 –95.0) 5.0 (0.0 –95.0)
Missing, n (%) 166 (72.2) 150 (67.0) 316 (69.6)
12 months 51 57 108
Mean (SD) 18.0 (24.6) 18.6 (27.6) 18.3 (26.1)
Median (range) 5.0 (0.0 –95.0) 5.0 (0.0 –100.0) 5.0 (0.0 –100.0)
Missing, n (%) 179 (77.8) 167 (74.6) 346 (76.2)
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Participant use of compression treatment
Table 20 details how participants recorded their use of the therapy 1 month from randomisation.
Details of change from allocated trial treatment were noted in the treatment logs completed by nurses at
each visit until healing. In total, 152 (33.6%) participants were recorded as changing to a non-trial
treatment before healing, with a higher proportion changing in the HH group than in the 4LB group
[39.3% vs. 27.8%, χ2= 6.69 (1 df) p= 0.01]. Reason for treatment change is given in Table 21.
TABLE 20 Concordance with treatment intervention at one month from randomisation
Characteristic HH (n= 193) Characteristic 4LB (n= 200)
Frequency of HH wearing during day Frequency of 4LB wear
Every day 159 (90.7%) Every day 188 (96.9%)
Most days 4 (2.3%) Most days 0 (0.0%)
Some days 6 (3.4%) Some days 2 (1.0%)
Did not wear 6 (3.4%) Not all 4 (2.1%)
HH layer during the day Removed 4LB yourself?
One layer 24 (13.9%) Yes 41 (21.1%)
Two layers 149 (86.1%) No 153 (78.9%)
Frequency of HH wear during night – –
Every night 127 (72.2%) – –
Most nights 7 (4.0%) – –
Some nights 6 (3.4%) – –
Did not wear 36 (20.5%) – –
Layers of HH worn at night – –
One layer 58 (38.7%) – –
Two layers 92 (61.3%) – –
Who normally applies HH? – –
Nurse 95 – –
Yourself 85 – –
If yourself, HH easy to apply? – –
Yes 67 (55.4%) – –
No 54 (44.6%) – –
If friend/relative, HH easy to apply? – –
Yes 9 (19.2%) – –
No 38 (80.9%) – –
Did not wear my HH 11 – –
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Duration of treatment with allocated compression treatment
Time to treatment change was investigated in post hoc analyses and was defined as time from randomisation
until date treatment change was recorded. There were 16 participants (6 HH, 10 4LB) noted to have had a
change of treatment on the day of randomisation (11 participants never received their allocated treatment
and five tried their allocated treatment but changed to another treatment on the same day of randomisation).
Time to treatment change was investigated using a CPH regression, in which the 16 participants who
changed treatment on the day of randomisation were given an arbitrary time to treatment change of 0.1 day
(one-tenth of a day) and data were right censored in participants who (1) withdrew from the study;
(2) were lost to follow-up; (3) died; (4) healed; or (5) reached the end of the trial – whichever came first.
Median time to treatment change was 133 days in the HH group (95% CI 91 days, upper limit not estimable)
and 213 days in the 4LB group (95% CI 182 days, upper limit not estimable). Treatment allocation, age and
whether or not a participant had experienced a NSAE were included as covariates in this analysis. All of these
factors were found to be associated with time to treatment change, with evidence of a shorter time to
treatment change (from allocated trial treatment to non-trial treatment) in the HH group (HR 1.59, 95% CI
1.14 to 2.21; p= 0.005), those who were older (HR 1.02, 95% CI 1.00 to 1.03; p= 0.003) and those with at
least one NSAE (HR 1.75, 95% CI 1.18 to 2.59; p= 0.005). The model was repeated including baseline ulcer
area, duration, participant mobility and centre, but there was no evidence to suggest that these were
associated with time to treatment change, and the associations between time to treatment change allocated
treatment, age and NSAEs remained.
Adverse events
Adverse event data were collected by treating nursing staff. Nurses classified events SAE or NSAE and
treatment related or non-treatment related. These data are described in Tables 22 and 23. In total,
300 participants had 895 adverse events. Of these, 9.5% were classed as serious.
Serious adverse events
For SAEs, the numbers, classification and relationship to treatment overall were fairly well balanced
between the treatment groups, with a slightly higher number of deaths reported in the HH group
(see Table 22). There were no SAEs that were definitely related to treatment: only one was probably
related (4LB group) and 16.5% of SAEs (14.0% HH, 19.1% 4LB) were possibly related. No participant had
more than two SAEs reported during the course of study.
TABLE 21 Change from allocated treatment
Characteristic HH (n= 230) 4LB (n= 224) Overall (n= 454)
Treatment change 88 (38.3%) 62 (27.8%) 150 (33.0%)
Reason for change
Increase in ulcer area 2 (2.2%) 1 (1.6%) 3 (2.0%)
Ulcer deterioration 15 (16.7%) 4 (6.5%) 19 (12.5%)
Compression uncomfortable 37 (41.1%) 15 (24.2%) 52 (34.2%)
Participant not concordant 10 (11.1%) 8 (12.9%) 18 (11.8%)
Other 24 (27.3%) 34 (54.8%) 58 (38.7%)
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Non-serious adverse events
A higher proportion of participants in the HH group experienced one or more NSAEs compared with those
allocated to the 4LB group [70.0% compared with 58.0%, χ2= 3.86 (1 df); p= 0.050]. We also compared
the total number of events experienced by participants (HH vs. 4LB) adjusting for the prognostic factors
(baseline ulcer area, duration, participant mobility) and using robust SEs for centre effects in a zero-inflated
negative binomial regression. There was no statistically significant difference between groups with a RR of
1.12 (95% CI 0.95 to 1.32). The proportion of events classified (by blinded assessors) as probably or
definitely related to trial treatment was 41.7% in the HH group and 37.8% in the 4LB group. These
probably or definitely related events were also classified into types of event, blind to treatment allocation.
Of these events a higher number were classified as failure in the HH group, but more new ulcer
occurrences were recorded in the 4LB group.
TABLE 22 Serious adverse events
Characteristic HH (n= 230) 4LB (n= 224) Overall (n= 454)
SAEs
No. of participants with an SAE 33 (14.3%) 33 (14.7%) 66 (14.5%)
No. of SAEs 43 42 85
Classification
Death 9 (20.9%) 3 (7.1%) 12 (14.1%)
Life- or limb-threatening event 1 (2.3%) 2 (4.8%) 3 (3.5%)
Hospitalisation required/prolonged 32 (74.4%) 32 (76.2) 64 (75.3%)
Persistent or significant disability/incapacity 1 (2.3%) 0 (0%) 1 (1.2%)
Other medically important condition 7 (16.3%) 9 (21.4%) 16 (18.8%)
Outcome of event
Recovered fully 6 (14.0%) 11 (26.2%) 17 (20.0%)
Recovered partially 5 (11.6%) 8 (19.1%) 13 (15.3%)
Died 9 (20.9%) 3 (7.1%) 12 (14.1%)
Ongoing 22 (51.2%) 17 (40.5%) 39 (45.9%)
Missing 1 (2.3%) 3 (7.1%) 4 (4.7%)
Relationship of SAE to treatment (blinded)
Unrelated 27 (62.8%) 28 (66.7%) 55 (64.7%)
Unlikely to be related 10 (23.3%) 5 (11.9%) 15 (17.7%)
Possibly related 6 (14.0%) 8 (19.1%) 14 (16.5%)
Probably related 0 (0%) 1 (2.4%) 1 (1.2%)
Definitely related 0 (0%) 0 (0%) 0 (0%)
Not able to assess if related 0 (0%) 0 (0%) 0 (0%)
Missing 0 (0%) 0 (0%) 0 (0%)
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Recurrence
As participants were followed up beyond healing of the reference leg, it was possible to report recurrence
of an ulcer in those participants who healed, up until the last date that the participant was involved in the
study. In total, 65 recurrences on the reference leg were observed in the 343 participants who healed
during the course of study. In the HH group, 14.4% (24/167) of participants with a healed reference leg
were observed to recur compared with 23.3% (41/176) in the 4LB group. Time to recurrence was
compared using a CPH model adjusting for baseline prognostic factors (ulcer area, duration, participant
mobility), testing for shared centre frailty effects, using the same approach as the previous survival
analyses. There was no significant centre frailty effect found (p= 0.38) in this analysis of time to recurrence
from healing, and the models with and without centre frailty effects gave the same estimate for the
treatment effect and very similar results for the adjusting factors. The results without centre frailty effects
are given in Table 24. The results indicate a greater hazard of recurrence when allocated to the 4LB but
with wide CIs and imprecision around the size of this effect, with a HR of 0.56 (95% CI 0.33 to 0.94,
TABLE 23 Non-serious adverse events
Characteristic HH (n= 230) 4LB (n= 224) Overall (n= 454)
NSAEs
No. of participants with a NSAE 154 (67.0%) 130 (58.0%) 284 (62.6%)
No. of NSAEs 463 347 810
Relationship of NSAE to treatment (blinded)
Unrelated 62 (13.4%) 50 (14.4%) 112 (13.8%)
Unlikely to be related 26 (5.6%) 35 (10.1%) 61 (7.5%)
Possibly related 173 (37.4%) 120 (34.6%) 293 (36.2%)
Probably related 85 (18.4%) 72 (20.8%) 157 (19.4%)
Definitely related 108 (23.3%) 59 (17.0%) 167 (20.6%)
Not able to assess if related 8 (1.7%) 11 (3.2%) 19 (2.4%)
Missing 1 (0.2%) 0 (0%) 1 (0.1%)
Classification (definitely/probably related)
Alternative non-trial care initiated by participant or other 8 (4.1%) 4 (3.1%) 12 (3.7%)
Bandage/hosiery failure 47 (24.4%) 23 (17.6%) 70 (21.6%)
Bandage-/hosiery-related pain/discomfort 39 (20.2%) 27 (20.6%) 66 (20.4%)
Dryness 0 (0.0%) 1 (0.8%) 1 (0.3%)
Excoriation 1 (0.5%) 0 (0.0%) 1 (0.3%)
Infection 11 (5.7%) 9 (6.9%) 20 (6.2%)
Maceration 2 (1.0%) 0 (0.0%) 2 (0.6%)
Medical event relating to leg 0 (0.0%) 1 (0.8%) 1 (0.3%)
Occurrence of new ulcer 26 (13.5%) 30 (22.9%) 56 (17.3%)
Skin damage 27 (14.0%) 16 (12.2%) 43 (13.3%)
Skin deterioration 8 (4.2%) 6 (4.6%) 14 (4.3%)
Ulcer deterioration 17 (8.8%) 13 (9.9%) 30 (9.3%)
Ulcer-related pain 7 (3.6%) 1 (0.8%) 8 (2.5%)
Total 193 (100%) 131 (100%) 324 (100%)
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p= 0.026). The Kaplan–Meier survival curves by treatment group are given in Figure 8. Because of the
limited number of recurrence events, median time to recurrence from healing could not be estimated.
In further exploratory post hoc analyses, we investigated the relationship between age, BMI and treatment
change (from trial to non-trial treatment) with recurrence by adding these into the CPH model along with
the other adjusting baseline covariates (ulcer area, ulcer duration and participant mobility). The association
of allocated treatment with recurrence remained and there was no evidence of an association of age,
BMI or treatment change with recurrence.
Proportional hazards, sensitivity analyses and multiple imputation
The PH assumption was tested for each survival analysis and none was found to be significant overall.
However, there was evidence that the log transformation of ulcer area was not proportional within the
adjusted models for each of the survival outcomes, except that of recurrence. Sensitivity analyses were
carried out excluding the term from the model. This approach did not alter the interpretation of
the results.
TABLE 24 Adjusted analysis of time to recurrence from reference leg healing (unblinded)
Parameter Estimate (SE) HR (95% CI) p-value
HH vs. 4LB −0.58 (0.26) 0.56 (0.33 to 0.94) 0.03a
Log (area) −0.08 (0.10) 0.92 (0.76 to 1.12) 0.42
Log (duration) 0.31 (0.12) 1.36 (1.07 to 1.72) 0.01a
Mobility
Participant walks freely 0.00 1.00
Participant walks with difficulty 0.75 (0.26) 2.12 (1.26 to 3.56) 0.004a
Participant is immobile 1.23 (1.02) 3.41 (0.46 to 25.02) 0.23
a Note: p-value is < 0.05.
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FIGURE 8 Kaplan–Meier plot of time to recurrence by treatment group.
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Analyses were repeated with and without centre effects. For all unblinded time-to-event outcomes
(ulcer healing, leg healing and recurrence), the analyses with and without shared centre frailty effect gave
similar results and the shared centre frailty effect did not need to be taken into account. However, for the
primary outcome, for which ulcer healing was assessed blind to allocation, the centre effect was significant
and therefore results are presented from the analyses that accounted for this. For adverse events, results
were similar with and without centre; however, the prespecified analysis was to include random effects for
centre and therefore these results were presented.
Data were assumed to be complete for time-to-event outcomes (ulcer healing, leg healing and recurrence)
and for adverse events. Data were available for over 98% of adjusting covariates. Therefore, it was not
necessary to repeat analyses using multiple imputation for these outcomes.
Summary of clinical findings
l Median times to healing were 99 days (95% CI 84 to 126 days) for HH and 98 days (95% CI 85 to
112 days) for the 4LB. There was no evidence of a difference between HH and the 4LB in terms of
ulcer healing with adjustment for baseline ulcer area, ulcer duration and participant mobility and centre
included as a random effect (HR of 0.99, 95% CI 0.79 to 1.25; p= 0.96). Nor was there a difference in
time to healing of the entire reference leg (p= 0.33).
l Initial ulcer area and ulcer duration were both statistically significant predictors of time to healing.
l There was no evidence of a statistically significant relationship of PCS or MCS score with treatment
over time when investigated using LMMs, adjusting for baseline ulcer area, ulcer duration, participant
mobility and centre.
l In total, 39% of those allocated to HH moved from trial treatment to a replacement treatment
(non-trial treatment) compared with 28% of those allocated to the 4LB. The median time to treatment
change was 133 days in the HH group compared with 213 days in the 4LB group.
l Although there was no evidence of a difference in the number of people reporting one or more SAEs
between trial groups (14.4% HH, 14.7%, 4LB; p= 0.91), more participants in the HH group
experienced one or more NSAEs compared with those allocated to the 4LB group (70.0% compared
with 58.0%; p= 0.05). However, when results were investigated for the total number of events per
person and adjustments made, there was no statistically significant difference in the number of adverse
events between groups.
l Post ulcer healing, fewer ulcer recurrences were observed in the HH group (14.4%) than in the 4LB
group (23.3%). This difference was maintained and shown to be statistically significant in a survival
analysis of time from healing of reference leg to recurrence (HR= 0.56, 95% CI 0.33 to 0.94;
p= 0.026) when adjusted for baseline ulcer duration, ulcer area and participant mobility, both with and
without shared centre frailty effects. Initial ulcer duration and the participant having reduced mobility
were also statistically significant predictors of time to recurrence. It is important to note that as this
analysis was undertaken in a subgroup (only those whose reference leg had healed) and does not
represent all of those randomised, the advantages of unbiased analyses gained from randomisation are
not maintained here.
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Chapter 6 Economic results
A total of 454 participants were recruited: 230 were randomly allocated to receive HH and 224 toreceive the 4LB. There were 63 participants (34 in HH and 29 in 4LB group) for whom self-reported
resource-use data were not available at any time point (recorded as missing values throughout). The mean
duration of follow-up for the self-reported cost and utility data was 9.83 months.
Resource use and costs
Compression treatments
Participants were allocated to their compression treatment at randomisation (the ‘trial treatment’) and
received this treatment until they changed to another treatment (designated the ‘non-trial treatment’);
their reference ulcer leg healed (i.e. treatment was not needed any more); or they were lost to follow-up
or died.
Number of trial treatments received
During each treatment consultation, the existing compression treatment (if any) was checked, and if
needed, new compression treatment/s were applied or given to the participant. The mean number of
treatment applications per participant was 3.0 (SD= 3.87) in the HH group and 15.08 (SD= 17.98) in the
4LB group (Table 25). In the HH group a total of 662 compression treatments were applied/given in a total
of 2627 nurse consultations, whereas in the 4LB group new compression treatments were applied/given in
most of the 3453 recorded nurse consultations.
It is possible that, during ‘trial treatment’, participants received other treatments or procedures, including
compression treatments, to the reference leg, for example because the allocated compression treatment
was unavailable for a short period of time. A total of 226 participants received other compression
treatments during their trial treatment period (151 in the HH group and 75 in the 4LB group); these were
included in the cost analysis.
Number of non-trial treatments received
There were 2706 consultations in 148 participants classed as have moved from receiving trial treatment
to receiving non-trial treatments (90 in the compression hosiery group and 58 in the 4LB group).
The mean number of consultations for these participants during the non-trial treatment period was 18.3
(SD= 24.65); however, there were more non-trial treatments per participant recorded for those in the
compression hosiery group who changed treatment (mean= 20.2; SD= 25.0) compared with the 4LB
group (mean= 12.8; SD= 19.0).
Cost of compression treatments
The type and frequency of compression treatments given/applied to participants was reported by nurses
until healing of the reference leg (Table 26: unadjusted costs). The mean costs of compression treatments
during the trial treatment period per participant (including trial treatment and other compression
treatments) were £99.0 (SD= 107.3) and £136.7 (SD= 157.4) for the hosiery and four-layer groups
respectively. However, there were more non-trial treatments in the hosiery arm and the overall mean costs
(including the trial and non-trial treatments) per participant were similar between treatment groups
(£155.9 compared with £155.6). The mean estimated costs of trial compression treatment per application
during the trial treatment phase were £27.89 (SD= £27.41, minimum–maximum= £7.63–646.8) for HH,
and £8.55 (SD= 0.81, minimum–maximum= £0.29–8.84) for 4LB. Note that participants could be given
more than one HH packs for self-application at home.
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TABLE 25 Number of compression treatment applications received during trial treatment (nurse-reported data)
No. of applications HH (n= 230) 4LB (n= 224)
Trial treatment applications per participant
Mean (SD) 3.0 (3.87) 15.08 (17.98)
Median (min. to max.) 2 (0 to 31) 9 (0 to 108)
n (%) 221 (96.1) 218 (97.3)
Other compression applications during trial treatment per participanta
Mean (SD) 2.23 (4.89) 0.55 (0.98)
Median (min. to max.) 1 (0 to 52) 0 (0 to 6)
n (%) 221 (96.1) 218 (97.3)
Non-trial applications in participant who switcheda
Mean (SD) 20.2 (25.0) 12.8 (19.0)
Median (min. to max.) 11 (1 to 186) 5.5 (1 to 112)
n (%) 88 (38.3) 54 (24.1)
max., maximum; min., minimum.
a Other trial treatments and non-trial on treatments were costed based on the unit costs in Table 5.
TABLE 26 Unadjusted treatment cost of trial and non-trial treatment (data from nurses)
Cost HH (n= 230) 4LB (n= 224)
Trial treatment (all compression treatments)
Mean (SD) 99 (107.3) 136.7 (157.4)
Median (min. to max.) 64.7 (3.23–718.2) 88.4 (3.23–933.6)
n (%) 220 (95.7) 218 (97.3)
Non-trial treatment
Mean (SD) 151.1 (187.9) 90.8 (126.7)
Median (min. to max.) 80.2 (0.48–1095.5) 43.1 (0.48–710.4)
n (%) 88 (38.3) 54 (24.1)
Total compression treatment (trial and non-trial treatments)
Mean (SD) 155.9 (177.8) 155.6 (175.5)
Median (min. to max.) 93.3 (4.01–1480.4) 97.1 (8.8–991.0)
n (%) 225 (97.8) 223 (99.6)
max., maximum; min., minimum.
ECONOMIC RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
56
Consultations with health-care providers
Consultations with health-care providers were reported by participants in quarterly questionnaires and
these participant data were used in the base-case analysis. Participants reported both ulcer-related
and non-ulcer-related consultations; however, only ulcer-related consultations were used in the
economic analysis as differences across groups were expected only for ulcer-related resource use.
Participant self-reported data suggested that the number of ulcer-related consultations with health-care
professionals was lower in the HH group in all categories of consultations except for the hospital day
admissions, which were marginally higher in the HH group. The number of non-ulcer-related visits was
similar across the treatment groups (Table 27).
The proportion of consultations taking place in participant’s homes was similar between groups (29.3%
for the HH group and 28.6% for the 4LB group). Doctor consultations accounted for a small proportion of
the total number of consultations, and the number of such consultations was marginally lower in the
HH group.
There were few hospital admissions (day cases and inpatient admissions). In total, 14 hospitalisations in the
4LB group and five in the HH group were reported by participants; therefore, as anticipated, there were
small and potentially random differences in the number of stays that could result in large differences in
costs and bias the results. Furthermore, evaluation of nurse-reported hospitalisation data revealed poor
consistency with the participant-reported inpatient data (only 6/19 hospitalisations were also recorded in
SAE forms by nurses and only one seemed to be related to leg ulcer based on the description of SAEs).
We attribute these inconsistencies to the fact that participants may not easily be able to distinguish
ulcer-related and unrelated hospital inpatient admissions. It was decided to exclude inpatient
hospitalisation costs from the analysis.
Ulcer-related nurse consultations
The total number of participant-reported ulcer-related nurse consultations differed across treatment
groups (mean of 19.2 consultations in the HH group and 25.0 in the 4LB group) (Table 28). Using this
participant-reported data we calculated number of nurse consultations per week for the duration of
follow-up. Again consultations with nurses were more frequent in the 4LB group (see Table 29).
Nurse-reported data on number of ulcer-related consultations are also presented for reference (see Table 28).
The trial design specified that nurse-reported ulcer-related consultations were recorded only until the time of
first healing of the reference leg. However, it is possible that this approach underestimated the number of
consultations as it did not consider the impact of ulcer recurrence (hence participant-recorded data were
used for the base-case analysis). Indeed, this view would explain the lower total mean number of nurse
consultations in the four-layer group for nurse-reported data (the 4LB group had more ulcer recurrence than
the HH group).
The difference between treatment groups in number of consultations per week was similar for nurse- and
participant-reported data in that there were more nurse consultations per week in the 4LB group than
in the HH group (see Table 28). However, the mean number of nurse consultations per week was lower in
participant-reported data than in nurse-reported data. This is because the denominator in the nurse-reported
consultations per visits was the duration until the last compression treatment was delivered. As the
participant-reported data were collected at quarterly intervals, the duration denominator for consultations per
week was always 12 weeks, even if the participant had healed after 6 weeks and did not have any further
ulcer-related consultations.
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TABLE 27 Number of consultations with health-care providers during follow-up (participant-reported data)
No. of visits
Related to ulcers Not related to ulcers
HH (n= 230) 4LB (n= 224) HH (n= 230) 4LB (n= 24)
GP, surgery
Mean (SD) 0.9 (2.5) 1.8 (4.8) 3.4 (4.5) 3.8 (6.7)
Median (min. to max.) 0 (0–17) 0 (0–35) 2 (0–24) 2 (0–54)
n (%) 196 (85.2) 195 (87.1) 196 (85.2) 195 (87.1)
GP, home
Mean (SD) 0.1 (0.8) 0.2 (1.2) 0.3 (1.1) 0.7 (3)
Median (min. to max.) 0 (0–8) 0 (0–12) 0 (0–8) 0 (0–33)
n (%) 196 (85.2) 195 (87.1) 196 (85.2) 195 (87.1)
Outpatient doctor visits
Mean (SD) 0.5 (1.1) 1.1 (5.2) 2.1 (4.7) 2.1 (5.5)
Median (min. to max.) 0 (0–6) 0 (0–60) 0 (0–32) 0 (0–43)
n (%) 196 (85.2) 195 (87.1) 196 (85.2) 195 (87.1)
Nurse surgery visits
Mean (SD) 5.5 (11.6) 9 (19) 2.6 (6.8) 3.1 (9.9)
Median (min. to max.) 0 (0–88) 1 (0–155) 0 (0–80) 1 (0–122)
n (%) 196 (85.2) 195 (87.1) 196 (85.2) 195 (87.1)
Nurse home visits
Mean (SD) 5.9 (19.1) 7.8 (17.5) 1.5 (7.4) 1.3 (6.1)
Median (min. to max.) 0 (0–216) 0 (0–112) 0 (0–90) 0 (0–60)
n (%) 196 (85.2) 195 (87.1) 196 (85.2) 195 (87.1)
Outpatient nurse visits
Mean (SD) 7.8 (13.3) 8.2 (13.4) 2.8 (9) 1.8 (6.2)
Median (min. to max.) 0 (0–76) 2 (0–77) 0 (0–90) 0 (0–44)
n (%) 196 (85.2) 195 (87.1) 196 (85.2) 195 (87.1)
Hospital day admissions
Mean (SD) 0.5 (2.7) 0.2 (1.2) 0.6 (2.4) 0.5 (1.8)
Median (min. to max.) 0 (0–25) 1.2 (0–11) 0 (0–26) 1.8 (0–18)
n (%) 196 (85.2) 195 (87.1) 196 (85.2) 195 (87.1)
max., maximum; min., minimum.
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Duration of nurse consultation
Data suggest that the duration of ulcer-related nurse consultations differed slightly between treatment
groups (Table 29), this difference being more marked for clinic visits. A summary of the unadjusted
ulcer-related costs of health-care provider consultations for each of the trial groups is presented
in Table 30.
Total costs
Baseline costs and quarterly estimates during the follow-up are presented in Table 31. In the base-case
analysis, participant-reported data on number of ulcer-related consultations with health-care providers
were combined with compression treatment costs (trial and non-trial treatments). The cost of nurse
consultations was the major cost driver of total costs. As no imbalance was found in baseline costs,
sensitivity analysis using baseline cost as a covariate was not required.
To account for the censored nature of the data, mean differences in ulcer-related costs between treatments
were estimated using IPW regression estimates of time to survival. The results of the base-case analysis
show that those allocated to the HH group incurred, on average, £302.4 less per participant per year
(95% bias corrected CI –£697.6 to £96.2) than with the 4LB group (Table 32). This difference was not
statistically significant.
TABLE 29 Duration of ulcer-related nurse consultations for each treatment group (nurse-reported data)
Type of visit
Duration of nurse treatment visit (minutes), mean (SD)
HH 4LB
All visits 32.1 (16.3) 32.9 (15.2)
Trial treatment visit 30.9 (18.4) 33.4 (15.5)
At a clinic 25.4 (16.3) 30.1 (12.9)
At home 34.2 (20.3) 36.2 (17.6)
TABLE 28 Ulcer-related nurse consultations (participant and nurse reported)
Ulcer-related nurse consultations
Participant reported Nurse reported
HH (n= 230) 4LB (n= 224) HH (n= 230) 4LB (n= 224)
Total no.
Mean (SD) 19.2 (25) 25.0 (29.1) 19.67 (23.6) 19.12 (22.24)
Median (min. to max.) 12 (0–240) 16 (0–196) 11 (1–257) 11.5 (0–135)
n (%) 196 (85.2) 195 (87.1) 230 (100) 223 (99.6)
Mean no. of visits per week
Mean (SD) 0.57 (0.7) 0.69 (0.8) 1.26 (0.84) 1.31 (0.82)
Median (min. to max.) 0.35 (0–5.0) 0.47 (0–5.08) 1.15 (0.15–7) 1.17 (0.15–7)
n (%) 196 (85.2) 195 (87.1) 228 (99.1) 219 (97.7)
max., maximum; min., minimum.
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TABLE 30 Unadjusted costs of ulcer-related health-care provider consultations (participant-reported data)a
Visits HH 4LB
Ulcer-related, GP surgery (£)
Mean (SD) 25.1 (72.2) 53.1 (139.7)
Median (min. to max.) 0 (0–497.3) 0 (0–1023.8)
n (%) 196 (85.2) 195 (87.1)
Ulcer-related, GP home (£)
Mean (SD) 14.9 (80.5) 24.8 (121.4)
Median (min. to max.) 0 (0–805) 0 (0–1207.4)
n (%) 196 (85.2) 195 (87.1)
Ulcer-related, outpatient department, with a doctor (£)
Mean (SD) 47.7 (115.3) 116.4 (547.8)
Median (min. to max.) 0 (0–630.6) 0 (0–6306)
n (%) 196 (85.2) 195 (87.1)
Ulcer-related, nurse surgery (£)
Mean (SD) 97.4 (205.7) 189.1 (400.5)
Median (min. to max.) 0 (0–1564.6) 21.1 (0–3265.9)
n (%) 196 (85.2) 195 (87.1)
Ulcer-related, nurse home (£)
Mean (SD) 222.8 (719.8) 311.4 (698.6)
Median (min. to max.) 0 (0–8125.9) 0 (0–4459.8)
n (%) 196 (85.2) 195 (87.1)
Ulcer-related, outpatient department, with a nurse (£)
Mean (SD) 484 (819.7) 506.4 (830.5)
Median (min. to max.) 0 (0–4696.8) 123.6 (0–4758.6)
n (%) 196 (85.2) 195 (87.1)
Ulcer-related, hospital day admissions (£)
Mean (SD) 175 (1012.2) 81.3 (441.1)
Median (min. to max.) 0 (0–9220) 0 (0–4056.8)
n (%) 196 (85.2) 195 (87.1)
Total cost over the follow-up period
Mean (SD) £1066.9 (1681.1) £1282.6 (1551.9)
Median (min. to max.) £568.4 (0–14,872.2) £775 (0–10,659.9)
n (%) 196 (85.2) 195 (87.1)
max., maximum; min., minimum.
a These statistics are based on available cases, i.e. missing responses were assumed to be zero when there was at least
one non-missing response in the same questionnaire for a particular participant.
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TABLE 31 Base-case analysis: total and quarterly unadjusted costsa
Time/statistic HH 4LB
Baseline
Mean (SD) 669.5 (710.1) 687.3 (1022.6)
Median (min. to max.) 480.7 (0–7546.6) 488.3 (0–12,821)
n (%) 228 (99.1) 220 (98.2)
Months 0–3
Mean (SD) 588.2 (615.8) 618.3 (551.1)
Median (min. to max.) 430.8 (0–4477) 564.6 (12.68 to 3746)
n (%) 190 (82.6) 192 (85.7)
Months 3–6
Mean (SD) 349.2 (702.1) 410.5 (749.1)
Median (min. to max.) 61.8 (0 to 5712.2) 99.5 (0–6726.8)
n (%) 162 (70.4) 166 (74.1)
Months 6–9
Mean (SD) 278.5 (986.5) 393.3 (1052.3)
Median (min. to max.) 0 (0–10,793.8) 21.1 (0–9256.6)
n (%) 145 (63) 144 (64.3)
Months 9–12
Mean (SD) 239 (576.2) 298.5 (662.9)
Median (min. to max.) 0 (0–4826.5) 0 (0–4225)
n (%) 122 (53) 125 (55.8)
Total over 12 monthsa
Mean (SD) 1222.1 (1787) 1446.6 (1643.1)
Median (min. to max.) 658 (0–15,483.4) 918.3 (12.68–10,813.5)
n (%) 196 (85.2) 195 (87.1)
max., maximum; min., minimum.
a These statistics are based on available cases, i.e. missing observations were assumed to be zero when there was at least
one non-missing response in the same questionnaire.
TABLE 32 Adjusteda annual costs (base-case analysis)
Treatment group Mean (£) 95% bias corrected CI (£)
HH 1492.9 1187.3 to 1954.3
4LB 1795.3 1559.7 to 2185.0
Difference −302.4 −697.6 to 96.2
MLM, multilevel model.
a Adjustment for ulcer duration (logarithmic), ulcer area (logarithmic), participant mobility and centre [participant mobility
was defined as dichotomous variable (i.e. walk freely vs. walk with difficulty or immobile)]; centre has been adjusted for
using MLM with centre used as a random effect.
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Health benefits
Mean time to healing
On average, participants allocated to the HH group healed 1.4 days later than those allocated to the 4LB
group. However, this difference was not statistically significant (95% bias corrected CI of the difference
was from 36.8 days to –29.3 days) (Table 33).
Utility and quality-adjusted life-years
Quarterly utility scores (per participant by treatment group) were calculated using EQ-5D responses,
and quarterly QALYs were computed using time-weighted averages of the utility scores measured at the
beginning and end of each interval. Quarterly utility scores are presented in Table 34 and unadjusted
TABLE 33 Adjusteda mean time to healing (base-case analysis)
Treatment group Mean (days) 95% bias corrected CI (days)
4LB 129.2 98.1 to 142.6
HH 130.6 105.9 to 142.4
MLM, multilevel model.
a Adjustment for ulcer duration (logarithmic), ulcer area (logarithmic), participant mobility, centre [participant mobility was
defined as dichotomous variable (i.e. walk freely vs. walk with difficulty or immobile)]; centre has been adjusted for
using MLM with centre used as a random effect.
TABLE 34 Unadjusted utility weights (EQ-5D) by treatment group and by time
Time/statistic HH 4LB
Baseline
Mean (SD) 0.618 (0.294) 0.607 (0.306)
Median (min. to max.) 0.725 (−0.074 to 1) 0.71 (−0.358 to 1)
n 219 215
3 months
Mean (SD) 0.668 (0.289) 0.675 (0.310)
Median (min. to max.) 0.725 (−0.126 to 1) 0.725 (−0.594 to 1)
n 184 177
6 months
Mean (SD) 0.696 (0.277) 0.674 (0.309)
Median (min. to max.) 0.727 (−0.181 to 1) 0.726 (−0.239 to 1)
n 157 158
9 months
Mean (SD) 0.713 (0.261) 0.646 (0.339)
Median (min. to max.) 0.727 (−0.016 to 1) 0.691 (−0.594 to 1)
n 139 141
12 months
Mean (SD) 0.714 (0.271) 0.682 (0.303)
Median (min. to max.) 0.71 (−0.239 to 1) 0.727 (−0.239 to 1)
n 113 120
max., maximum; min., minimum.
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average QALYs per group described in Table 35 (note: only 41% of the sample had complete cases,
i.e. utility scores available at all time points). There is a trend for an increase in quality of life over follow-up
time for participants allocated to HH; however, this trend is less clear in the 4LB group.
After adjustment for baseline utility scores and stratification covariates, and after accounting for the
censored nature of data, individuals in the HH group had, on average, more QALYs than individuals in the
4LB group [annual difference in QALYs of 0.034 (95% CI –0.0006 to 0.0778): Table 36].
TABLE 35 Quarterly and annual unadjusted QALYs by treatment group and by time
Timeline/statistic HH 4LB
0–3 months
Mean (SD) 0.161 (0.062) 0.164 (0.065)
Median (min. to max.) 0.177 (−0.011 to 0.25) 0.181 (−0.071 to 0.25)
n 176 172
3–6 months
Mean (SD) 0.171 (0.067) 0.172 (0.071)
Median (min. to max.) 0.179 (−0.025 to 0.25) 0.186 (−0.060 to 0.25)
n 149 143
6–9 months
Mean (SD) 0.178 (0.062) 0.165 (0.076)
Median (min. to max.) 0.182 (0.011 to 0.25) 0.176 (−0.067 to 0.25)
n 132 126
9–12 months
Mean (SD) 0.180 (0.062) 0.168 (0.072)
Median (min. to max.) 0.179 (−0.025 to 0.25) 0.179 (−0.060 to 0.25)
n 106 110
Annual (complete case analysis)
Mean (SD) 0.705 (0.234) 0.688 (0.234)
Median (min. to max.) 0.746 (−0.066 to 1) 0.714 (−0.232 to 1)
n 95 89
max., maximum; min., minimum.
TABLE 36 Adjusteda annual QALYs (base-case analysis)
Treatment group Mean QALYs (years) 95% bias corrected CI (years)
HH 0.685 0.665 to 0.716
4LB 0.651 0.619 to 0.682
Difference 0.034 −0.0006 to 0.0778
MLM, multilevel model.
a Adjustment for baseline utility, ulcer duration (logarithmic), ulcer area (logarithmic), participant mobility, centre
[participant mobility was defined as dichotomous variable (i.e. walk freely vs. walk with difficulty or immobile)];
centre has been adjusted for using MLM with centre used as a random effect.
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Cost-effectiveness and uncertainty
Our adjusted base-case analysis showed that participants randomised to receive HH for the treatment of
venous leg ulcers had, on average, slightly more QALYs over the duration of the trial, but incurred lower
costs than those participants allocated to receive the 4LB. Although these differences were not statistically
significant at the conventional 5% significance level, the joint distribution of mean costs and mean QALYs
suggest that HH is likely to be, on average, more effective and less costly than the 4LB over a 12-month
time horizon, i.e. HH is the dominant treatment. If, based on these costs utility results, the NHS were to
decide on these alternative treatments, HH should be recommended for use in patients with venous
leg ulcers.
To investigate the uncertainty over the mean difference in costs and health benefits between trial groups,
we used the incremental cost-effectiveness plane, where we graphically plotted the results of 1000
replicates of the non-parametric bootstrap of the mean difference in cost and QALYs. As Figure 9a shows,
most of the cost and QALY pair replicates (i.e. 92%) fall in the bottom right (south-east) quadrant of the
plane, suggesting that differential costs and QALY gains favour HH over the 4LB. The CEAC (see Figure 9b)
confirms that, based on the cost–utility analysis, HH is cost-effective at the conventional thresholds of
willingness-to-pay per QALY. This result is in line with the observed distribution of the cost-effectiveness
scatterplot, which suggests that HH is less costly and is likely to produce more QALYs than the 4LB.
We also evaluated the mean number of ulcer-free days (based on time to first healing of the reference
ulcer, and thus ignoring recurrence), which are slightly higher in the 4LB group, although this difference is
highly uncertain and far from being statistically significant. This is consistent with the clinical trial findings
from VenUS IV. However, the cost savings associated with HH remains the same as in the cost–utility
analysis, i.e. £302 in favour of HH. In circumstances when the intervention is likely to be cheaper but is
expected to be less effective than a comparator, we apply a decision rule to assess whether the
intervention is cost-effective at different thresholds for willingness to pay; we do this by combining our
estimates of differential costs and health benefits to estimate the ICER. The ICER associated with HH was
estimated at £219.2 per ulcer-free day. As noted earlier, the observed difference in ulcer-free days is highly
uncertain, which leads to high uncertainty on whether to adopt hosiery (probability of hosiery being
cost-effective, rather than 4LB, is close to 50%: Figure 10); however, there is much more certainty
around potential cost savings associated with HH (see Figure 10). More importantly, it should be reinforced
that, unlike QALY assessments, the analysis of ulcer-free days was based on time to first healing of the
reference ulcer, and ulcer recurrence was not considered in this health outcome measure. However, we
know that recurrence was more common in the 4LB group. Thus, any relative benefit of lower recurrence
rates in the HH group is not represented in this analysis.
Sensitivity analysis
We investigated the impact of using nurse-reported data on ulcer-related consultations (rather than
participant-reported) on the results. Unadjusted and adjusted total costs for this scenario are shown in
Tables 37 and 38. The adjusted mean costs per participant per year for the HH group was £982.7 (95%
bias corrected CI: £758.7 to 1310.3) compared with £1096.8 for the 4LB (95% bias corrected CI £909.4
to £1388.5). The difference in means between the two groups was –£114.1 (95% bias corrected
CI –£418.4 to £182.3). The estimated difference in this scenario was lower than that in the base case.
As only the costs were subjected to sensitivity analysis, the health benefit estimates were equivalent to
base case. In terms of cost-effectiveness, results here were similar to those observed in the base-case
analysis. HH was cost-effective compared with the 4LB, and is the dominant strategy in the cost–utility
analysis. Based on the sensitivity analysis, the probability of HH being cost-effective compared with 4LBs is
98.2% at £20,000/QALY and 98.1% at £30,000/QALY.
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FIGURE 9 Cost-effectiveness plane (a) and acceptability curve (b) for cost per QALY analysis (base case). The dashed
line represents a probability of cost-effectiveness of 0.5.
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FIGURE 10 Cost-effectiveness plane and acceptability curve for cost per ulcer-free day analysis (base case).
The dashed line represents a probability of cost-effectiveness of 0.5.
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TABLE 37 Unadjusted cost for each treatment group (nurse-reported data)
Timeline/statistic HH (£) 4LB (£)
Months 0–3
Mean (SD) 441.1 (484.3) 443.2 (308.6)
Median (min. to max.) 335.6 (38.79–4685.7) 384 (29.87–2083.7)
n (%) 230 (100) 223 (99.6)
Months 3–6
Mean (SD) 220.1 (508.9) 236.8 (447.2)
Median (min. to max.) 88.9 (0–5139.9) 48.6 (0–4687.4)
n (%) 195 (84.8) 190 (84.8)
Months 6–9
Mean (SD) 183.6 (801.6) 242.7 (839.5)
Median (min. to max.) 0 (0–9112.2) 0 (0–7326.5)
n (%) 159 (69.1) 151 (67.4)
Months 9–12
Mean (SD) 159 (535.3) 130.4 (300.6)
Median (min. to max.) 0 (0–4968.7) 0 (0–1868.1)
n (%) 127 (55.2) 132 (58.9)
Total over 12 months
Mean (SD) 842.4 (1429.8) 886.5 (1179.8)
Median (min. to max.) 443.4 (39.34–12,019.1) 504.8 (29.87–8705.4)
n (%) 230 (100) 223 (99.6)
max., maximum; min., minimum.
TABLE 38 Adjusted annual cost per participant for each treatment group (nurse-reported data)
Treatment group Mean (£) 95% bias corrected CI (£)
HH 982.7 758.7 to 1310.3
4LB 1096.8 909.4 to 1388.5
Difference −114.1 −418.4 to 182.3
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Subgroup analysis and interaction effects with
baseline characteristics
Tables 39–41 present total cost per participant based on age groups, BMI and participant mobility. The
summary statistics suggest no indication of a relationship between cost and age or BMI; however, costs
were found to be higher in less mobile participants than in those who walked freely. This confirms the
rationale behind including mobility as a covariate in the primary analysis of cost.
We also investigated any potential interaction between baseline characteristics and treatment in cost
regressions at each quarterly time point at which participant data were collected. There was no evidence
of interaction between BMI and treatment or mobility and treatment in the cost regression (p> 0.05 at all
quarterly time points). The interaction between age and treatment was significant at 9 months (p= 0.02);
however, the interaction was not significant at other time points.
TABLE 41 Total cost (£) per participant, based on mobility
Mobility Mean Median SD Min. Max. n
Walks freely 1125.2 723.8 1287.8 0 9522.7 253
Walks with difficulty or immobile 1717.0 1093.1 2263.9 0 15,483.4 138
max., maximum; min., minimum.
TABLE 39 Total cost per participant, based on age groups
Age groups (years) Mean Median SD Min. Max. n
0–60 1235.9 895.4 1296.6 0 7002.9 79
61–70 1124.4 633.9 1574.3 28.2 10,813.5 92
71–80 1576.3 943.6 2024.4 21.6 15,483.4 127
> 80 1294.1 746.7 1700.3 12.7 10,943.1 93
max., maximum; min., minimum.
TABLE 40 Total cost (£) per participant, based on BMI category
BMI category Mean Median SD Min. Max. n
Underweight 565.8 606.3 351.7 151.5 899.1 4
Normal weight 1434.7 892.0 1832.6 0.0 10,943.1 86
Overweight 1149.6 717.6 1316.5 0 7232.9 113
Obese classes I and II 1529.4 799.1 2131.9 17.6 15,483.4 134
Obese class III 1162.3 884.1 1030.3 56.8 4477.0 49
max., maximum; min., minimum.
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Summary of within-trial cost-effectiveness findings
l The estimated mean annual per participant cost was £302.4 less for the HH group compared with the
4LB group; although this difference was not statistically significant (bias corrected 95% CI –£697.6 to
£96.2). The main driver for this cost difference was the higher number of nurse consultations in the
4LB group.
l On average, participants allocated to the HH group had higher QALYs than those allocated to the
four-layer group [annual difference in adjusted QALYs of 0.034 (95% bias corrected CI −0.0006
to 0.0778)].
l Participants allocated to HH incurred lower mean annual costs compared with the 4LB group and
higher QALYs. Based on QALYs as the measure of benefit, HH has over a 95% probability of being the
most cost-effective treatment based on this within-trial analyses.
l The analysis using ulcer-free day as measure of benefit evaluated the treatments to have similar
effectiveness (1.4 ulcer-free days difference in favour of 4LB), with wide uncertainty. Despite the lower
expected costs associated with the use of HH, the uncertainty in effectiveness meant there was high
uncertainty regarding its cost-effectiveness in this analysis. However, this analysis did not capture
recurrence. Given that within VenUS IV there were fewer recurrences in the hosiery arm, the estimate
of ulcer-free days in this analysis could have been biased against hosiery.
l The sensitivity analysis based on nurse-reported resource use showed that the use of hosiery was still
associated with lower costs than four-layer bandaging, although the cost difference was probably
underestimated, as resource use during recurrence was not considered.
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Chapter 7 Discussion
This is the first RCT to compare HH (designed to deliver 40mmHg compression at the ankle), with the4LB in the treatment of venous leg ulcers. As both treatments are in current clinical use in the UK and
elsewhere, our findings are important for decision-makers – both as stand-alone RCT data and via
subsequent incorporation into further evidence synthesis (see Parts II and III).
Clinical effectiveness
Ulcer healing
We found no evidence of a difference in time to ulcer healing between HH and the 4LB. The HR for
healing was 0.99 (95% CI 0.79 to 1.25) meaning there is almost the same hazard (or ‘chance’) of healing
in the HH group and the 4LB group. The CI indicates that HH may reduce the hazard (or ‘chance’) of
healing by as much as 21% or increase it by as much as 25%.
This imprecision was observed despite this being one of the largest RCTs comparing compression
treatments for venous leg ulcers ever conducted.19 Although undertaking further large RCTs may reduce
uncertainty around this treatment decision, it is important to consider the cost of investing in a further RCT
in relation to the value collected data might have in improving decision-making. These issues will be
investigated further in relation to high-compression treatments for venous leg ulceration in Part III of this
report, where the amount of uncertainty around treatment effects will be investigated when all available
data are synthesised and the value of further research considered.
The median time to healing in the 4LB group in VenUS IV was similar to that in VenUS I7 (99 days
compared with 92 days, respectively) and both were pragmatic trials with wide inclusion criteria. However,
the VenUS IV estimate was higher than the 70-day median time to healing reported for 4LB participants
in the only other RCT comparing this treatment with HH.32 However, this study excluded participants
with clinical signs of infection so it may have evaluated a participant population with less-complex ulcers.
Additionally, we note that Finlayson et al.32 reported that the hazard of healing in the 4LB group was twice
that of the HH group when their HH delivered a maximum of 35mmHg compression at the ankle. Given
trial findings from VenUS IV, one further interpretation may be that HH used to treat venous leg ulcers
should aim to deliver 40mmHg at the ankle in order to achieve similar time to healing as the 4LB.
As observed in VenUS I–III,7,13,61 as well as several other studies,88–90 we found that baseline ulcer area and
duration were statistically significant predictors of time to healing (p≤ 0.001). We also found that study
centre is a significant predictor of ulcer healing, a finding that remained when adjusted for the number of
participants per centre. As the application of compression bandaging requires skill, with the bandager
relying almost entirely on technique for correct application, we postulated at the start of the study that a
centre effect may be driven by differing bandaging skills between centres. This notion was supported by
our tentative post hoc analysis, which suggested stronger evidence for a centre effect in the 4LB group
than the HH group (which does not require the same skill level in application).
The decision to account for a potential centre effect in our sample size calculation was shown to be valid.
We suggest that triallists planning future RCTs with a bandaging arm should consider the possibility of a
centre effect and take this into account in sample size calculations and analyses.
Health-related quality of life
Changes in health-related quality of life over the duration of the trial were measured using the SF-12. At
baseline the study population had a low quality of life in terms of physical health as observed in previous
studies,7,13,61 whereas the MCS score was similar to population norms.
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There was little change in the PCS and MSC scores over time in both the HH and the 4LB group of
VenUS IV. The adjusted analysis showed slightly higher (all non-significant except at 3 months) scores in
the HH group compared with the four-layer group, which agrees with the EQ-5D results reported in the
cost-effectiveness analysis. There was a reduction in mean ulcer-related pain scores (over previous 24-hour
period), during the trial but with no evidence of a difference between groups.
Although previous work has shown that the SF-12 is responsive to changes in the health-related quality of
life of patients with venous leg ulcers upon ulcer healing,44 we note here that although 70% of trial
participants had a reference ulcer heal during the study, there was no perceptible impact on mean PCS
scores over time. It is important to acknowledge that it is people with a number of underlying physical
comorbidities who are at increased risk of develop venous ulceration; these conditions include congestive
heart failure, diabetes, peripheral vascular disease of the lower extremity and rheumatoid arthritis.62
Adverse events
Although several adverse events were reported in VenUS IV, this had been anticipated given the older study
population at risk of a number of comorbidities.7,13,61 There was no statistically significant difference in
the number of participants with one or more SAEs between trial groups, neither was there a difference
in the total number of SAEs reported. Conversely, more participants in the HH group experienced one or
more NSAEs compared with participants in the 4LB group (67.0% compared with 58.0%; p= 0.050);
although again there was no evidence of a difference in the total number of NSAEs reported between
each group (RR 1.12, 95% CI 0.95 to 1.32). Neither was there a difference in the total number of NSAEs
recorded as being probably or definitely related to trial treatment (41.7% HH, 37.8% 4LB; p= 0.26).
Within the NSAEs that were probably or definitely related to trial treatment, the most common event
across trial groups was bandage/hosiery failure (22%). It is not clear if these treatments were considered as
failing from the perspective of the treating health professional or the participant themselves. A potential
issue with the HH may have been difficulty in self-application, especially for those with grip and/or
coordination problems, as the hosiery remain relatively tight and can require some dexterity to apply.
Application aids are available but we did not record the level of their use in this trial.
Bandage- or hosiery-related pain and discomfort were also commonly reported as definitely or probably
treatment-related NSAEs across trial groups (20%). Potential reasons for pain and/or discomfort with
hosiery may have related to presence of friction via rubbing on bony prominences/discomfort caused by
the hosiery top band and the lack of a padding layer as used in many bandaging systems. It is also possible
that issues of discomfort could be related to the accuracy of measurement for hosiery wear. These issues
would need to be investigated further.
Participant use of compression treatments
Although 61% of participants in the HH group remained on their allocated treatment, there was evidence
that significantly more participants in this group changed from their trial treatment to a non-trial treatment
compared with those allocated to the 4LB (where 72% remained on allocated treatment). A post hoc
analysis showed that as well as being allocated to HH, a previous NSAE and age were also predictive of a
shorter period on trial treatment. The most common specified reason given for the treatment change
across groups was ‘compression uncomfortable’ and 71% of these reports were from the HH group. These
data triangulate with the NSAE findings, further suggesting that, for some people, HH is not an optimal
treatment, especially in terms of comfort.
The increased treatment change in the HH compared with the 4LB group was somewhat contradictory to
what we had postulated before starting this RCT. Previously, reasons for patient non-compliance with
compression bandages have been reported as pain, discomfort, application difficulty, discomfort with
footwear and poor physical appearance of legs.91 We suggested that HH might be more acceptable to
venous leg ulcer patients because it is less bulky than bandages, as well as potentially easier to apply and
less reliant on bandager skill. Indeed upon entry into the trial (but prior to randomisation) 50% of trial
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participants expressed a preference for HH over the 4LB (compared with 13% expressing a preference for
four layer and 37% having no preference). In reality there may be people for whom HH is not an optimal
treatment (e.g. in those who cannot apply it easily themselves).
Recurrence
In VenUS IV there was a statistically significant reduction in the chance of recurrence with HH compared
with 4LB (HR 0.56, 95% CI 0.33 to 0.94; p= 0.026). This translates to a reduction in the chance of
recurrence of ulceration for people allocated to HH of between 6% and 67%. This estimate was relatively
imprecise as the sample size was limited to only those whose reference leg completely healed during the
trial. Additionally, we acknowledge that this analysis was not of the population as randomised and thus
must be interpreted with some caution. However, given that the same number of participants healed in
these two groups, recurrence results would have been affected only if the characteristics of participants
healing differed across the two groups, which is unlikely.
Although VenUS IV focused on HH as a treatment for healing ulcers, when planning the study we
hypothesised that perhaps those who become used to wearing HH and healed were more likely to wear
compression hosiery post healing (and perhaps more likely to stay in HH than those moving maintenance
hosiery following treatment with a compression bandage) and thus have a reduced risk of recurrence.
This hypothesis may potentially explain the results observed with those who found HH an agreeable
(and effective) treatment and continuing to wear it. However, we did not collect data on use and
adherence to maintenance compression treatments in this trial so could not investigate this hypothesis
further. We also note that our protocol gave no guidance as to the provision of maintenance compression
therapy and we assumed that standard procedures would be followed. We note there are currently limited
data available on the proportion of people with a previous venous leg ulcer who are compliant with
wearing compression hosiery as a maintenance treatment. A national audit conducted over 10 years ago
reported that of patients with venous leg ulcers, on whom data were received, 88% had be given
prophylactic compression hosiery (level of compression not reported).92 However, the uptake, and use of
these stockings was not assessed/reported.
Likewise, there are few data reporting how widely HH is currently used as a treatment for active venous
leg ulceration. However, we know from VenUS IV that only 6.5% of trial participants were receiving
compression hosiery as a treatment prior to entering the trial (compared with 49% receiving the 4LB).
Although we acknowledge that these figures could be an underestimate (if people currently receiving HH
did not enter the trial so as not to ‘risk’ randomisation to a non-hosiery treatment), if we accept the 6.5%
figure as a guide to current HH use for the treatment of venous leg ulcers we can postulate that use is
low. Yet, based on findings regarding recurrence here, even with the levels of treatment change recorded,
HH may be the better treatment of choice for some patients in terms of reducing overall time spent with
venous leg ulcers.
It is important to note that we do not suggest that there is no place for other compression therapies in
the treatment of venous leg ulcers. By default those coming into this study would have been considered
eligible for treatment with either of the trial compression therapies. There will be other patients,
for example those with large, oedematous or awkwardly shaped legs, for whom experienced health
professionals may select other compression therapies from the different options available.
Cost-effectiveness
To aid decision-making, it is important to assess the value for money – in terms of costs and benefits – that
alternative treatments offer. We conducted a cost–utility analysis and a cost-effectiveness analysis – both
utilising the cost data from ulcer-related health-care consultations and the number of ulcer-related
treatments. The base-case analysis found that, on average, participants allocated to the HH group ‘cost’
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£302 less (per participant) than those allocated to the 4LB group. The cost difference was driven by the
reduction in nurse consultations in the HH group over the duration of the trial.
The cost–utility analysis used QALYs as the measure of benefit. QALYs are often the recommended
measure of benefit for societal decision-makers, as they are generic and thus allow comparisons to be
made across different treatments, conditions and patient populations. In this analysis, HH was shown to
have marginally higher QALYs of 0.034 compared with the 4LB group. This QALY difference, despite being
mathematically small, may represent a significant benefit in terms of health-related quality of life – it is
equivalent to every participant receiving HH spending 36 more days in full health per year, rather than
spending those days with a less optimal utility score (here assumed to be 0.65, the mean baseline utility
score at trial entry).
The difference in QALYs between treatment groups, as measured by the EQ-5D, may be related to the
increased recurrence rates in the 4LB group. Alternatively participants may have found HH to be less bulky
and thus less limiting with regards footwear and mobility. The direction of the difference in QALYs is
consistent with the small, predominantly, non-statistically significant difference in PCS scores (also
favouring HH at all time points).
If we assume HH and 4LB to be equivalent in terms of effectiveness then HH should be recommended for
use in this patient population because patients are expected to incur fewer costs with HH than when using
the 4LB. However, despite the study reporting similar health benefits for both treatments, it was not
designed as an equivalence trial and there is still some uncertainty associated with the clinical and cost
results. Exploration of this uncertainty using joint uncertainty analysis of cost and QALY estimates showed
there was a > 95% probability of HH being the most cost-effective treatment at willingness-to-pay
thresholds of £20,000–30,000 (used by NICE).
We also conducted a cost-effectiveness analysis using the difference in time to initial healing of the
reference ulcer as the outcome measure. The analysis found a small but highly uncertain difference of
1.4 ulcer-free days (fewer days in the hosiery group). However, this analysis did not consider recurrence
events during the follow-up period, which were more common in the 4LB group. As a result, ulcer-free
days were likely to be underestimated in the HH group in the cost-effectiveness analysis, and, as a
consequence, this analysis has limited interpretability in the context of VenUS IV study findings. In contrast,
the cost–utility analysis included utility data beyond initial healing and during recurrence, and this may
partly explain why outcomes in cost–utility and cost-effectiveness analyses provide different results.
A sensitivity analysis considered the number of nurse-reported consultations (rather than participant
reported) and showed that HH incurred costs of £114 less per participant than the 4LB. Although the cost
analysis still favoured HH, this difference in cost was smaller than the base-case analysis, mainly because
the nurse-reported data were recorded for only the initial healing phase and not the recurrence period.
Consequently, the nurse-reported data are likely to underestimate the resource use, especially in the 4LB
group. We recommend that future trial designs should record treatment-related data beyond the time of
initial healing (i.e. during the entire duration of the study) to capture any relevant differences in costs and
outcomes especially regarding recurrence.
The economic analysis concluded that, given the trial data available from VenUS IV, HH is highly likely to
be cost-effective compared with the 4LB, even given the larger number of changes from trial treatment in
the HH group. The cost-effectiveness of hosiery is mainly driven by reduced costs attributable to fewer
nurse consultations, and also due to a small improvement in health-related quality of life (we hypothesise
that these differences are related to the difference in recurrence observed). A further potential advantage
of HH is that, as less variation in application skills is expected with HH, the choice of this treatment may
reduce variation of treatment effect across centres (i.e. centre effect) and promote homogeneity of
outcomes between participants.
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Finally, when changing recommendations for treatments, the potential implementation costs in the
NHS should also be considered. As HH is used in practice, we do not envisage significant implementation
costs. However, additional efforts may be required to reduce any delays in making HH available when
recommended (especially in made-to-measure cases).
Strength and limitations of the study
Sample size
As far as we are aware this is the largest, individually randomised RCT that has been undertaken to
evaluate leg ulcer interventions, although we fell just short of our recruitment target of 489. Even so, it is
important to note that we did obtain the precision around the point estimate that was planned for in our
original sample size calculation.
Blinded outcome assessment
We were unable to conduct blinded outcome assessment of wounds in person for VenUS IV as the
provision of a community-based blinded assessor across all trial centres would have been too resource
intensive. Additionally, as described previously, the actual logistics of performing blinded outcome
assessment would be challenging.61 Thus, blinded outcome assessment was conducted centrally with two
blinded assessors examining digital photographs taken monthly from baseline until healing, and then
weekly from healing for 4 weeks. This frequency of data collection was implemented in this study for the
first time and was based on our previous experience of the blinded outcome assessment processes used in
VenUS II61 and III.13
The use of sequential images from the healing period was found to work extremely well, as it allowed
blinded outcome assessors to give a healed date subsequent to that given by the treating nurse if required.
In VenUS IV we also implemented an electronic system for uploading pictures that helped to ensure that
we received most photographs and had limited missing data.
A recent study examined data from 21 RCTs (4391 participants) that had conducted both blinded and
unblinded assessment of their binary, subjective outcomes. The study reported that, on average,
non-blinded outcome assessment exaggerated the odds ratio by 36% when compared with blinded
outcome assessment.93 However, this meta-epidemiological study included data from our previous study,
VenUS II,61 which, like VenUS IV, found little difference in blinded and unblinded outcome assessments of
healing. In VenUS IV, the unblinded assessment of ulcer healing resulted in slightly more ulcers recorded as
healed, and the corresponding HR was slightly lower than the blinded assessment (HR 0.91, 95% CI 0.73
to 1.12). Thus there was still no statistically significant treatment effect although there was greater
precision around the point estimate. Although giving similar results, blinded outcome assessment remains
an important strength of our venous ulcer trials.
Attrition
Attrition was not an issue in analysis of the trial primary outcome (with 453/454 patients contributing at
least some follow-up in the survival analysis and 6.5% of 2LB and 6.7% of four-layer hosiery patients
being classified as lost to follow-up during the study), however, as with VenUS trials I–III;7,13,61 we observed
a marked reduction in participant response rates for postal questionnaire containing SF-12, EQ-5D and
resource-use data. This drop in response occurred despite using strategies that aimed to maximise
response with the use of a £5 incentive, as well as reminders to return questionnaire. As in VenUS II,61
analysis suggested that participants were less likely to return questionnaires if they had not healed,
meaning that we may have overestimated health-related quality-of-life estimates, although there was little
change in these estimates during the trial. In non-healing participants there was some evidence of lower
return rates in the HH group; it is unclear whether this might led to an overestimate of health-related
quality of life in this group.
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Generalisability of the results
VenUS IV was a pragmatic trial with broad eligibility criteria and a protocol that aimed to minimise the
influence of the different service delivery models in operation across the participating centres (including
outpatient clinics, general practice, district nursing teams, specialist community and tissue viability teams).
Trial data for VenUS IV was collected from 32 centres across England and a centre in Northern Ireland. Of
these centres there were 10 that recruited 72% of all participants. The results of this trial should therefore
be highly generalisable to similar patient populations across the UK and probably to other areas of the
world where care is delivered by nurses and where the clinical profiles of the patients are similar.
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Part II Mixed-treatment comparison meta-analysis
of high-compression treatments for venous leg ulcers
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Chapter 8 Introduction
Part I provides evidence about the relative effectiveness of HH and the 4LB for healing venous leg ulcers.In practice, however, health professionals and patients have other compression treatments available to
them which are thought to deliver compression of a similar magnitude (40mmHg of compression at the
ankle or high compression). Important competing alternatives to HH and the 4LB are:
l The SSB An inelastic bandage system for which one to three rolls of bandage are applied over
orthopaedic wool.
l The zinc paste bandage An inelastic system consisting of a paste bandage, often with a support
bandage on top.
l The 2LB system Bottom layer with cohesive compression bandage.
From a decision-making perspective, using research evidence to inform the optimal treatment choice from
all high-compression systems is important. However, this can be difficult when faced with several choices
variously compared in a number of two-arm RCTs. Thus, to aid decision-making there is potential value in
synthesising trial effectiveness data from VenUS IV with other relevant RCTs’ data within a MTC. MTCs are
an extension of standard meta-analysis and allow RCT data for three or more relevant treatments to be
linked in a network (via common comparators). Once linked, relative effects estimates can be produced for
all included treatments – even where head-to-head trials for comparisons do not exist. However, it is
important to note that although MTCs use the existing RCT evidence base to maximally inform clinical
(and societal) decision-making (based on clinical effectiveness data), a number of assumptions are required.
Fundamentally, a MTC assumes that features of included RCTs are homogeneous, as, theoretically, its
results are considered equivalent to results from a single trial with a group for each treatment included in
the network.
In this chapter all available RCTs evaluating high-compression treatments for venous leg ulcers were
synthesised in a MTC with the aim of better informing decision-making regarding which treatment is likely
to be most effective in terms of healing venous leg ulcers.
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Chapter 9 Research objectives
To estimate the relative effectiveness of high-compression treatments for healing venous leg ulcers usingall available RCT evidence.
To evaluate how the inclusion of evidence from VenUS IV (on the comparison of HH vs. the 4LB) informs
estimate of treatment effects, consequent treatment recommendations and the uncertainty
regarding these.
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Chapter 10 Methods
Identification of relevant randomised controlled trials
The objectives of the MTC work were focused on compression systems aiming to deliver high compression
(classed as ≥ 40mmHg compression at the ankle) in the treatment of venous leg ulcers. However, at this
identification stage all RCTs evaluating compression treatments [high and non-high compression
(< 40mmHg)] for venous leg ulcers were included so as to assess their potential contribution to the
MTC network.
Randomised controlled trials were identified from the most recent version of an ongoing Cochrane review
update available to us (search dates May 2012).19 We did not conduct this review but rather utilised
aspects of the search and results here. Given the recency and rigour of this Cochrane review, it was used
as the sole source of RCTs for the MTC – thus we broadly adopted its eligibility criteria.19 Please refer to
the Cochrane review19 for additional information on each trial. However, as the primary outcome of the
MTC was ulcer healing (time to healing and/or number of ulcers completely healed within a specific time
period), RCTs from the source review were excluded if they did not report at least one of these outcomes.
Ulcer healing (effectiveness) data were extracted from the source review directly as was information
regarding treatment type, number of participants allocated to each treatment group and trial duration.
The latter was assumed to be the trial follow-up time unless otherwise stated.
Description of available data
Initial classification
Data were obtained from 40 RCTs (Table 42; for further details see Appendix 11), but three were excluded
as they did not report suitable endpoints for the MTC analysis (e.g. reduction in wound area reported
rather than time to healing or proportion of participants healed). Of the remaining 37 RCTs, many
evaluated well-established compression treatments that were recognised as aiming to deliver either high
(≥ 40mmHg) or non-high (< 40mmHg) compression. However, a number evaluated ad hoc treatments, for
example hybrids of compression components, with a compression level that we could not easily classify.
Thus, to formally establish whether evaluated treatments aimed to deliver high compression (or not)
an internationally recognised expert (Hugo Partsch) in compression systems classified each compression
treatment, based on its component composition (Box 2) [see Table 42, ‘(2)’]. Subsequently, the expert
classified each treatment as high or not high compression, based on the number of components, the initial
pressure (reported or estimated by expert depending on detail report) and stiffness of the final treatment
(estimated by expert). Among all available 82 treatment groups, 45 treatment groups were classified as
high compression and 37 as non-high compression [see Table 42, ‘(I)’].
Further grouping
Subsequently, where possible, treatments were further grouped into key categories consistent with current
practice. For example treatments defined as ‘Beec’ and ‘Beea’ were grouped into the 4LB group. Similarly,
‘Bii’, ‘Biic’ and ‘Bc’ were all grouped into a SSB group; ‘Bzc’ and ‘Bza’ into a zinc paste group (referred to as
‘paste’); ‘HH’ grouped as ‘HH (two-layer: aiming to deliver 40mmHg compression at the ankle)’ and ‘Bic’
grouped as the 2LB system (subcompression wadding and cohesive bandage). The remaining, generally ad
hoc, systems were not grouped further. This classification process was checked with members of the TMG,
cross-checked with the source review and judged as valid. After this further grouping process the evidence
evaluated 24 unique treatments, 13 of which were classed as high compression (see Table 42, ‘3’).
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BOX 2 Strategy to define compression systems
Details on classification system for the initial classification
Type of treatment:
l B= bandage
l H= hosiery
l V=Velcro device.
Details of layers:
l a= adhesive
l c= cohesive
l e= elastic
l i= inelastic
l z= zinc paste.
In the case of multilayer bandaging, the first letter B denotes treatment type. Details of subsequent ‘active’
components are then recorded. Thus a 4LB classification starts with ‘B’ followed by details of the type of
bandages, e.g. ‘Beec’ (two elastic and a cohesive bandage).
Hosiery is denoted as ‘H’ (HH for HH) and Velcro devices by ‘V’.
Note that some unusual compression treatments exist, e.g. the combinations of bandage and hosiery (BheH) or
hosiery with Velcro device (HV).
Also note that some treatments of the same class (e.g. HH) could be classified as non-high compression or as
high compression. These were here considered as unique treatments due to different level of compression they
were judged to deliver.
Details on further grouping of high-compression systems of interest
l 4LB= ‘Beec’ and ‘Beea’.
l SSB= ‘Bii’, ‘Biic’ and ‘Bc’.
l Paste= ‘Bzc’ and ‘Bza’.
l Multicomponent hosiery= ‘HH’.
l 2LB= ‘Bic’.
METHODS
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TABLE 42 Classification of treatments
ID Studies n High or not (1) Initial classification (2) Further grouping (3)
2 Cordts 199294 23 Not Bc Bc
20 Not Bz Bz
3 Eriksson 198695 17 High Bza Paste
17 Not Be Be
6 Nelson 200796 128 Not Ba Ba
117 High Beec 4LB
7 Danielsen 199897 23 Not Be Be
20 Not Bi Bi
8 Moody 199998 26 Not Bi Bi
26 Not Be Be
9 Moffatt 200399 57 High Beec 4LB
52 Not Be Be
10 Callam 1992100 65 Not Bee Bee
67 High Bic 2LB
11 Gould 1998101 19 Not Bze Bze
20 Not Bzee Bzee
12 Meyer 2002102 57 Not Bzee Bzee
55 Not Bzie Bzie
15 Moffatt 1999103 115 High Beec 4LB
117 High Beec 4LB
16 Vowden 2000104 50 High Beec 4LB
50 High Beea 4LB
49 High Beec 4LB
24 Meyer 200325 64 Not Bzee Bzee
69 High Beec 4LB
27 Hendricks 1985105 10 Not Bzee Bzee
14 Not H H
28 Koksal 2003106 27 Not Bz Bz
26 Not H H
30 Polignano 200429 29 Not Bi Bi
27 Not HH HH
31 Junger 2004107 88 Not H H
90 Not Bi Bi
32 Milic 2007108 75 Not BeH BeH
75 High Bee Bee
33 Harley 2004109 16 High Beec 4LB
14 Not Be Be
35 Mariani 200830 26 Not HH HH
30 Not Bi Bi
continued
DOI: 10.3310/hta18570 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 57
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Ashby et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
85
TABLE 42 Classification of treatments (continued )
ID Studies n High or not (1) Initial classification (2) Further grouping (3)
36 Taradaj 200931 40 Not H H
40 Not Bi Bi
37 Milic 2010110 42 Not BeH BeH
46 Not BeH BeH
43 High BeHe BeHe
38 Brizzio 2010111 28 Not H H
27 Not Bi Bi
1 Kralj 1996112 20 High Beec 4LB
20 High Ba Ba
5 Colgan 1995113 10 High BzeaH BzeaH
10 High Beec 4LB
10 Not Be Be
13 Duby 1993114 25 High Bii SSB
25 High Beec 4LB
26 Not Bzee Bzee
14 Wilkinson 1997115 17 High Beec 4LB
18 High BHeH BHeH
17 Scriven 1998116 32 High Beec 4LB
32 High Biic SSB
18 Partsch 2001117 53 High Beec 4LB
59 High Bii SSB
19 Ukat 2003118 44 High Beec 4LB
45 High Bii SSB
20 Franks 2004119 74 High Beec 4LB
82 High Bc SSB
21 Iglesias 20047 195 High Beec 4LB
192 High Bii SSB
23 Polignano 2004120 39 High Beec 4LB
29 High Bzc Paste
26 Blecken 2005121 12 High HV HV
12 High Beec 4LB
29 Junger 200428 61 High HH HH
60 High Bii SSB
34 Moffatt 2008122 42 High Beec 4LB
39 High Bic 2LB
39 Szewczyk 2010123 15 High 4LB 4LB
16 High 2LB 2LB
40 Wong 2012124 107 High 4LB 4LB
107 High SSB SSB
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Formation of analytic sample
Although all included 37 RCTs (evaluating both high and non-high-compression treatments) formed a
network of evidence (see Appendix 12), treatments not connected to the main network were excluded
(‘BeHe’ and ‘Bee’). Additionally, given the focus of this MTC work on high-compression treatments, non-
high-compression treatments were excluded unless they formed indirect links between high-compression
treatments and thus contributed to inferences on these (i.e. ‘Bzee’, ‘H’, ‘Bi’, ‘Be’). These decisions resulted
in the exclusion of 11 further RCTs, leaving an analytic sample for the MTC comprising 26 RCTs (Table 43).
TABLE 42 Classification of treatments (continued )
ID Studies n High or not (1) Initial classification (2) Further grouping (3)
Studies excluded (did not report suitable endpoints to contribute to analyses)
25 DePalma 1999125 19 Not Bze Bze
19 High V V
4 Travers 1992126 15 High Ba Ba
12 Not Bzee Bzee
22 Knight 1996127 5 High Beec 4LB
5 Not Bz Bz
TABLE 43 Analytic data set
ID Study
Final
groups
Follow-up
(weeks) n
Duration
(months) Size
No.
healed
Availability
of evidence
Included in
base-case
analysis
13 Duby 1993114 4LB 12 25 20.5 11.9 11 AD Yes
SSB 12 25 26.7 13.1 10 Yes
Bzee 12 26 34.5 12.3 6 No
17 Scriven 1998116 4LB 52 32 13 13.3 17.6 AD Yes
SSB 52 32 21 8.3 18.24 Yes
18 Partsch 2001117 4LB 16 53 1.25 1.5 33 AD Yes
SSB 16 59 1 1.9 43 Yes
19 Ukat 2003118 4LB 12 44 – 17.7 13 AD Yes
SSB 12 45 – 12.2 10 Yes
20 Franks 2004119 4LB 24 74 2 5 59 AD Yes
SSB 24 82 2 3.5 62 Yes
29 Junger 200428 SSB 12 60 5.57 5.95 19 AD Yes
HH 12 61 4.14 5.62 29 Yes
1 Kralj 1996112 4LB 24 20 7.9 18.6 7 AD Yes
Ba 24 20 6.9 17.2 8 Yes
23 Polignano
2004120
4LB
Paste
24 39 – 10.1 29 AD Yes
24 29 – 9.3 19 Yes
14 Wilkinson
1997115
4LB 12 17 – 11.2 8 AD Yes
BHeH 12 18 – 8.6 8 Yes
continued
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TABLE 43 Analytic data set (continued )
ID Study
Final
groups
Follow-up
(weeks) n
Duration
(months) Size
No.
healed
Availability
of evidence
Included in
base-case
analysis
5 Colgan 1995113 4LB 12 10 9.3 27.5 6 AD Yes
BzeaH 12 10 66.5 48.5 7 Yes
Be 12 10 53.5 42.8 2 No
26 Blecken 2005121 4LB 12 12 – 50.08 4 AD Yes
HV 12 12 – 48.98 4 Yes
34 Moffatt 2008122 4LB 4 42 48.8 5.7 3 AD Yes
2LB 4 39 46.6 11.8 6 Yes
39 Szewczyk
2010123
4LB 12 15 – 6 9 AD Yes
2LB 12 16 – 5.3 10 Yes
40 Wong 2012124 4LB 24 107 – – 72 AD Yes
SSB 24 107 – – 77 Yes
21 Iglesias 20047 4LB 52 195 3 3.81 107 IPD Yes
SSB 52 192 3 3.82 86 Yes
3 Eriksson 198695 Paste 12 17 – – 7 AD No
Be 12 17 – – 9 No
7 Danielsen 199897 Be 52 23 22.2 19.7 12 AD No
Bi 52 20 27.8 16.5 3 No
8 Moody 199998 Bi 12 26 – – 8 AD No
Be 12 26 – – 8 No
9 Moffatt 200399 4LB 12 57 1.5 – 40 AD No
Be 12 52 1.5 – 30 No
24 Meyer 200325 Bzee 52 64 19.8 – 51 AD No
4LB 52 69 14.8 – 45 No
27 Hendricks
1985105
Bzee 78 10 29.5 28.28 7 AD No
H 78 14 11.9 45.35 10 No
31 Junger 2004107 H 12 88 1.45 2.4 51 AD No
Bi 12 90 1.5 2.4 51 No
33 Harley 2004109 4LB 30 16 – – 13 AD No
Be 30 14 – – 8 No
36 Taradaj 200931 H 8 40 30.54 20.57 15 AD No
Bi 8 40 30.11 20.33 5 No
38 Brizzio 2010128 H 24 28 – 13.1 14 AD No
Bi 24 27 – 12.2 18 No
41 VenUS IV 4LB 52 224 12.29 9.30 157 IPD Yes
HH 52 230 10.82 9.41 163 Yes
AD, aggregate data.
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Finally, although treatments ‘Ba’, ‘BzeaH’, ‘HV’ and ‘BHeH’ were classed as high compression, they were
considered as ad hoc treatments that were not widely used in clinical practice. Because of this they
were included in the MTC but their results are not reported here in detail.
Implementation of the mixed-treatment comparison
The evidence in the analytic data set (see Table 43) was organised into two MTC networks, as shown in
Figure 11. One network included only treatments classified as aiming to deliver high compression (Figure 11a)
and another where both high and non-high-compression treatments were included (Figure 11b). Given
the focus of this work on high-compression treatments, the base-case analysis used the network with
high-compression treatments only (see Figure 11a). This network encompassed five standard treatments
(34,39)
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(13,17–21,
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(29)
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FIGURE 11 Network of RCTs. In the network, a unique treatment category is indicated by a circle: high
compression=green circles, non-high-compression treatments= smaller grey circles. Arrows between circles
indicate that these treatments had been compared in a trial [trials are identified using ‘( )’, numbered as in column
‘ID’ in Table 43]. (a) Base-case analysis; (b) scenario analysis.
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(4LB, SSB, paste, HH and the 2LB) and four ad hoc systems (Ba, HV, BzeaH and BHeH) (see Figure 11a).
This base-case network consisted of 32 groups (data points) from 16 trials (including VenUS IV).
The scenario model was evaluated in a sensitivity analysis, which is detailed later.
In this MTC the most populated comparison was the 4LB compared with SSB, which was informed by
seven RCTs, six of which had aggregate (trial summary) data114,116–119,124 and one of which had IPD data.7
The comparison between the 4LB and HH was also populated by IPD from VenUS IV. The link between
the 2LB and 4LB systems was informed by two RCTs, and each of the remaining six comparisons in the
evidence network of the base-case analysis were informed by aggregate information extracted from one
trial in each case (see Figure 11a).
Although this base-case analysis included trial data from VenUS IV, the model was also run excluding
these trial data to provide an insight into the contribution of VenUS IV data in the conclusions drawn from
the MTC.
Statistical model for the data
For each included RCT, the most complete ulcer healing outcome data available were used in the MTCs:
for two studies time to ulcer healing and time to censoring were available as IPD (VenUS I7 and VenUS IV);
for the remaining RCTs, outcome data were reported as the number of healed ulcers by study group
[aggregate data (AD)]. We maximally drew on all available data by statistically synthesising the AD with the
IPD, extending the methodology described in Smith et al.129 and Saramago et al.130
Briefly, data were synthesised by assuming that the time to healing underlying both AD and the IPD was
described by the same parametric distribution. For the IPD, where time to healing (under censoring) was
observed for each RCT participant – these data could directly inform the distribution of the time to healing
(the likelihood). For the AD, by assuming a binomial likelihood, the number of participants healed was used
to inform the probability of participants being healed. In turn, the probability of participants being healed
was related (algebraically) to the common distribution of time to healing taking into account the duration of
follow-up in each study (analogous to the synthesis models defined by Soares et al.131 This approach
allowed all ulcer healing data (proportion of ulcers healed and time to ulcer healing) to be defined as time
to ulcer healing thus the measure of effectiveness used to report MTC findings was the HR.
Had we only considered aggregate information (reducing the information on studies with available IPD to
AD and synthesising this in the standard way with the remaining aggregate information), the synthesis
would have been constrained to use of the exponential distribution, which imposes a constant hazard of
healing over time (the hazard of healing at any instant is constant). The use of IPD here allowed more
complex time-to-event distributions, namely the Weibull and Gompertz distributions, to be investigated.
Both these distributions are flexible when compared with the exponential, in that they can reflect an
increasing, decreasing or constant hazard of healing over time.63 In addition to Weibull and Gompertz, we
recognise that there is other time-to-event distributions such as the log-normal or the generalised gamma,
which could potentially have provided a better fit to the time-to-healing data. However, given that these
distributions do not allow the probability of healing over time to be expressed in a closed form (key to the
approach proposed here for the joint synthesis of IPD and AD), we opted to use the Weibull distribution,
as implementation issues prevented us from using the Gompertz distribution. Further work is required in
this area to embrace these other modelling frameworks.
The parametric survival modelling of the IPD studies was implemented using regression analysis that allowed
for baseline covariate adjustment. All relative treatment effects were presented as HRs with the 4LB arbitrarily
chosen as reference treatment in all cases. As several of the treatment comparisons in the MTC network were
populated by a single RCT (exceptions are SSB vs. 4LB and 2LB vs. 4LB), a fixed-effects modelling approach
was used. In additional analysis (not reported here), we also considered the use of a random-effects model.
We found no significant gains in quality of fit, and thus adopted the more parsimonious fixed-effects
approach throughout. This is consistent with previous published work synthesising evidence on the
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comparison between SSB and 4LB,24 which also chose to undertake a fixed-effects approach because there
was no significant evidence of between-study heterogeneity. The baseline covariates considered were
participant mobility, duration and area of ulcer and centre, all available in VenUS I7 and VenUS IV. The effects
of these covariates on the hazard of healing were assumed equal in both IPD studies (both studies were used
to estimate the covariate effects). The effect of centre was described using a common frailty effect across
the IPD trials.
Besides adjusting for baseline covariates, we tested the inclusion of interaction terms between alternative
treatments and baseline ulcer area and duration simultaneously in the RCTs with IPD and aggregate
outcome data – as described by Cooper et al.41 and Saramago et al.130 In considering treatment–effect
interactions, the use of IPD allows individual patient covariate information to be modelled and,
consequently, avoids potential ecological fallacy.132 Interaction terms were not found to be important in
explaining the hazard of healing over time in this case study and were excluded from the final model.
All analyses were conducted from a Bayesian perspective, using WinBUGS software version 1.4.3
(MRC Biostatistics Unit, Cambridge, UK. URL: www.mrcbsu.cam.ac.uk/bugs/WinBUGS/contents.shtml).
Alternative model specifications were implemented to assess the inclusion of baseline covariates and
treatment–interaction terms. Goodness of fit was assessed using the deviance information criterion
(DIC).133 The DIC is a measure that balances fit and complexity, allowing parsimony to be considered in
model choice. Alternative model specifications were used (see Appendix 12) and model fit was assessed
using DIC. Results for the best fitting model only are presented along with 95% credible intervals (Crls),
the Bayesian equivalent of CIs.
The treatment with the lowest HR estimated in the MTC (with respect to the reference compression
system, the 4LB) is expected to have the highest effectiveness in healing venous leg ulcers. However, it is
important to be fully aware of uncertainty around these estimates. Thus, in addition to presenting CrIs,
for the selected model in the base-case analysis we explored uncertainty regarding treatment choice,
presenting this as the probability that each compression system was the ‘best’ treatment in terms of being
the most effective (when compared with all other evaluated treatments).
Quality assessment and consistency of evidence
As with other methods of evidence synthesis, the quality of the data included in the model must be
reflected in conclusions made. Although there is no recognised system to undertake such quality
assessment for MTC we have previously published a modified Grading of Recommendations Assessment,
Development and Evaluation (GRADE) approach (we called this iGRADE) to allow us to assess and
communicate the quality of MTC-derived evidence.134 The iGRADE approach uses the five GRADE
categories that allow the quality of evidence to be decreased, with focus of some categories altered to be
relevant for MTC assessment (see Appendix 12 for further information). We conducted a cautious
application of iGRADE (see Appendix 13) to the key estimates of this base-case analysis MTC, in which
estimates could be graded as very low-quality evidence, low evidence, moderate evidence and
high-quality evidence.
One of the dimensions assessed in the iGRADE is of evidence inconsistency, i.e. discrepancy between the
direct and the indirect evidence in existing evidence loops.135 We formally assessed for inconsistencies
using the back calculation method suggested by Bucher et al.136 Briefly, within an evidence loop, direct
and indirect estimates of a pairwise treatment effect were compared against a null hypothesis that there
would be no difference between them.
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Sensitivity analysis
Inclusion of non-high-compression treatments in the
mixed-treatment comparison
Despite findings from non-high-compression treatments being less relevant here, it is possible that
the inclusion of data from RCTs evaluating these treatments could impact on inferences on the
high-compression treatments of interest. For this reason a network of evidence with non-high-compression
treatments was also considered as a secondary ‘scenario’ analysis (studies numbered 3, 7–9, 24, 27, 31,
33, 36, 38, as shown in the network diagram in Figure 11b). In addition to the nine high-compression
treatments, the network consisted of four non-high-compression treatments (Bzee, H, Bi and Be), adding
10 further RCTs and 22 additional treatment groups to the network (where two of the additional RCTs
were three armed).
This analysis tested the robustness of the evidence synthesis findings for the base-case analysis by assessing
how any supplementary indirect evidence had an impact in the estimation of treatment effects for
high-compression treatments.
The effectiveness of the two-layer bandage
Because the quality of RCT data driving the relative effectiveness of the 2LB to the 4LB was so low, we
conducted a post hoc sensitivity analysis assuming that there was no difference in the effectiveness of
these treatments.
Additional analyses
Presentation of mixed-treatment comparison results in terms of probability
of healing over time
Mixed-treatment comparison results were initially presented using the HR. However, the hazard (and its
ratio) can sometimes be a difficult measure to interpret, as it reflects the instantaneous risk of healing,
which is a somewhat abstract (but mathematically useful) measure of the likelihood of healing. In order to
aid the interpretation of the MTC, the hazard of healing findings was mathematically transformed to give
the probability of participants healing over time for each of the high-compression systems of interest.
The data were presented in this way to aid the interpretation of findings and the implications of these to
clinical practice.
Uncertainty over the probability of healing with four-layer bandage
(reference treatment)
As the 4LB group was a reference treatment in the MTC analyses, its estimates were not shown as
uncertain. For completeness, we also presented uncertainty over the probability of healing in the 4LB
group (taken from the MTC model as previously described).
Determinants of ulcer healing
Finally, for general interest to the field, and to aid analysis in Part III regarding the cost-effectiveness of
subgroups of venous ulcer patients, we explored the implication adjustments made in the MTC for
participant’s baseline characteristics (ulcer area, ulcer duration at baseline and mobility), which investigate
whether these have an impact on healing. This analysis indicates which participants characteristics are
expected to be associated with a higher, or lower, probability of healing over time. For the characteristics
deemed relevant (those that showed statistically significant effects) we illustrated how the probability of
healing over time was affected, using inferences obtained in the MTC (note that these parameters were
informed by the IPD trials, VenUS I7 and VenUS IV).
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Chapter 11 Results
Base-case analysis including VenUS IV data
Table 44 shows the HR estimates for each alternative high-compression treatments evaluated in existing
studies, compared with the 4LB. Where HR> 1, the treatment is deemed more effective (higher hazard
of healing) than the reference 4LB; where HR< 1, the treatment is deemed less effective than the 4LB
and a HR of ‘1’ means that the treatments are deemed the same in terms of effectiveness. Generally, the
network included small studies, which led to high imprecision around the point estimates for some
relative treatment effects – particularly for some ad hoc high-compression treatments.
From the set of high-compression treatments of interest (4LB, SSB, HH, paste and 2LB), the 2LB (where a
2LB system was a subcompression wadding layer and cohesive bandage aiming to deliver 40mmHg
compression at the ankle) is expected to be most effective (2LB vs. 4LB HR: 1.40, 95% CrI 0.65 to 3.05).
However, it is important to note that direct data for this estimate come from two small RCTs;
consequently, uncertainty around this estimate is considerable. For this reason, the quality of the evidence
is crucial in aiding the interpretation of these findings and is considered later.
TABLE 44 Parameter estimates from MTC synthesis models
HRs
Base-case analysis Scenario analysis
Including VenUS
IV (1)
Excluding VenUS
IV (2)
Including VenUS
IV (3)
HR 95% CrI HR 95% CrI HR 95% CrI
Treatment effects (vs. 4LB) SSB 0.88 0.76 to 1.03 0.92 0.79 to 1.07 0.89 0.77 to 1.04
HH 1.05 0.85 to 1.29 1.57 0.87 to 2.90 1.05 0.85 to 1.29
Paste 0.77 0.41 to 1.42 0.78 0.41 to 1.43 0.68 0.39 to 1.18
2LB 1.40 0.65 to 3.05 1.38 0.63 to 3.08 1.39 0.64 to 3.14
Ba 1.19 0.43 to 3.47 1.20 0.41 to 3.43 1.22 0.42 to 3.50
BHeH 0.93 0.34 to 2.62 0.93 0.34 to 2.61 0.93 0.33 to 2.61
BzeaH 1.33 0.42 to 4.51 1.36 0.42 to 4.55 1.98 0.65 to 6.02
HV 1.00 0.23 to 4.22 0.99 0.22 to 4.32 1.01 0.22 to 4.48
Baseline characteristics Log(area) 0.71 0.66 to 0.76 0.69 0.62 to 0.77 0.71 0.66 to 0.76
Log(duration) 0.92 0.90 to 0.94 0.94 0.92 to 0.96 0.92 0.90 to 0.94
Difficulty in walking 0.71 0.60 to 0.85 0.71 0.55 to 0.91 0.72 0.60 to 0.85
Immobile 0.67 0.23 to 1.52 0.51 0.11 to 1.45 0.66 0.22 to 1.48
Notes
Covariate effects are assumed to be common across all treatments. Centre frailty parameter is estimated at 0.05 when
including VenUS IV, 0.08 when excluding this RCT (both base case) and 0.05 (sensitivity analysis). Note that these values
cannot be compared.
Shape parameter is estimated at 1.07 (95% CrI 1.01 to 1.13) when including VenUS IV, 0.92 (95% CrI 0.84 to 1.00) when
excluding this RCT (both base case) and 1.07 (95% CrI 1.00 to 1.13) (sensitivity analysis). Note that these values cannot
be compared.
Deviance information criterion statistics is 5396 when including VenUS IV, 2763 when excluding this RCT (both base case)
and 5528 (sensitivity analysis). Note that these values cannot be compared.
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The SSB is expected to be less effective than the 4LB (HR 0.88, 95% CrI 0.76 to 1.03); there is little
uncertainty, although CrIs do include ‘1’. This is the most precise treatment comparison in the network.
The HR estimated for the comparison of HH with the 4LB is close to ‘1’ (HR 1.05, 95% CrI 0.85 to 1.29);
existing evidence does not suggest that the effectiveness of these treatments differs for treatment of
venous leg ulcers in terms of ulcer healing.
Probability of treatments being best
An important feature of the Bayesian methodology used here is the ability to assess the probability that
each relevant treatment is the best with respect to the primary endpoint (i.e. time to ulcer healing). When
making recommendations on which treatment to use, this measure reflects the impact of uncertainty on
the relative treatment effects. In the base-case analysis model (including VenUS IV data) the treatment
associated with greater probability of healing was the 2LB (71.9%) (Table 45), reflecting the fairly high
relative effect point estimate and the wide uncertainty around this from available evidence (see Table 44).
Quality assessment and consistency of evidence
Interpretation of the MTC evidence must consider also its quality. The overall quality of the evidence for
each treatment comparison was assessed using the iGRADE approach. Table 46 shows the result of this
assessment together with the effect estimates from comparison of the five main ulcer treatments.
Although the MTC model finds that 2LB was associated with a higher hazard of healing than the other
treatments, quality assessment shows that these findings were driven by direct, but low-quality, evidence
encompassing two studies [see Table 42, study numbers 34122 and 39123 with unclear/high risk of bias
TABLE 45 Treatment rankings for the base-case analysis and scenario analysis
Compression type
Base-case analysis Scenario analysis
%a including VenUS IV (1) %a excluding VenUS IV (2) %a including VenUS IV (3)
4LB 5.5 1.1 6.1
SSB 0.3 0.1 0.6
HH 16.1 58.4 17.8
Paste 6.2 1.9 1.8
2LB 71.9 38.5 73.7
a Probability of being the best treatment choice in terms of healing.
TABLE 46 Base-case HR estimates and uncertainty for model including VenUS IV
Compression type 4LB SSB HH Paste 2LB
4LB 1
SSB 0.885 H
(0.76 to 1.03)
1
HH 1.045 H
(0.85 to 1.29)
1.183 L
(0.93 to 1.49)
1
Paste 0.772 M
(0.41 to 1.42)
0.874 L
(0.46 to 1.61)
0.737 M
(0.38 to 1.41)
1
2LB 1.395 L
(0.65 to 3.05)
1.574 L
(0.72 to 3.5)
1.333 VL
(0.6 to 3.02)
1.819 VL
(0.68 to 5)
1
Includes iGrade classification: H, high-quality evidence; L, low-quality evidence; M, moderate-quality evidence;
VL, very low-quality evidence.
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(one study was particularly small, with 31 participants)]. Inferences on the 4LB compared with SSB were
made using data from multiple RCTs; however, the results are driven by a high-quality study for which IPD
were available7 and the quality classification for this estimate is high. Except for the two treatment
comparisons informed by a high-quality study available in IPD format, estimates were considered to be of
medium to very low quality.
In the network of evidence there was one closed loop through which both direct and indirect data informed
relative treatment effect estimates. Thus, the existence of inconsistency was explored. There was no
evidence of statistically significant discrepancies between the direct and the indirect data. However,
we note, given the fairly high uncertainty in the evidence base and the obtained estimates, only large
differences in direct and indirect data within the loop would have returned a statistically significant result.
Overall, the quality of the evidence limits the confidence that we have in some MTC findings. Although
estimates for the 2LB suggest that it has the highest probability of being the most effective, these findings
are supported by low- or very low-quality evidence. Estimates for the SSB and HH indicate that they have a
fairly low probability of being the best; however, these estimates are informed by high-quality evidence.
Contribution of VenUS IV to the mixed-treatment comparison
The MTC model was also run excluding trial data from VenUS IV [see Table 44, (2)]. This shows that
inferences on HH were altered by the inclusion of VenUS IV evidence. When VenUS IV data were
‘excluded’, estimates were driven by indirect evidence from small RCTs and the model suggested that HH
was more effective than the 4LB. In this model, the treatment associated with the highest probability of
ulcer healing was HH [58.4%, see Table 45, (2)]. The inclusion of trial data from VenUS IV, which found
no evidence of a difference in ulcer healing between HH and the 4LB, reduces the uncertainty surrounding
point estimates.
Further results (not shown) indicate that the hazard of healing was expected to decrease over time when
VenUS IV data were excluded, implying that it was expected that ulcers were less likely to heal as
time goes on. When including VenUS IV, the hazard of healing was expected to be approximately
constant over time.
Sensitivity analysis
Inclusion of non-high-compression treatments in the mixed-treatment
comparison
The results of the sensitivity analysis considering evidence on both high-compression and non-high-
compression treatments [see Table 45, (3)] show that extending the network had a very limited effect,
with the relative effect estimates of the main five high-compression treatments remaining similar
(see Table 45, (3) vs. (1)].
Sensitivity analysis regarding the effectiveness of two-layer bandage
Because the quality of RCT data driving the relative effectiveness of the 2LB to the 4LB was so low we
conducted a post hoc analysis, assuming that there was no difference in the effectiveness of these
treatments. In this scenario the high-compression treatment with highest estimated probability of being
best was HH, with approximately 67% probability of being best (the 4LB and the 2LB, together,
would have 5.5% probability of being best).
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Additional analyses
Presentation of mixed-treatment comparison results in terms of probability
of healing over time
For ease of interpretation we also present MTC findings as the probability of healing over time (Figure 12).
In Figure 12a, point estimates for the probability of healing are plotted showing that, at any time point,
the 2LB is expected to be the most effective high-compression treatment and paste is the least effective
one. The expected probability of healing for HH is equivalent to that of the 4LB.
Parts (b) to (e) of Figure 12 illustrate the uncertainty around the probability of healing using 95% credibility
bands (the equivalent to confidence bands) represented by shaded areas. Thus, for a given time point and
with 95% confidence, current RCT evidence indicates that the probability of a cohort of participants
healing lies somewhere in the shaded area. As the 4LB group was a reference treatment in the MTC
analyses, its estimates were not shown as uncertain here. Parts (b) and (c) of Figure 12 show that
uncertainty regarding the relative probability of healing with the SSB and HH is less marked than with
other treatments – the confidence bands are narrower in parts (b) and (c) than in parts (d) and (e). The
expected probability of healing with the 4LB is on the upper bound of the shaded area for SSB (reflecting
the upper bound of the CrI for the HR of approximately ‘1’). For paste and the 2LB, uncertainty in their
HRs translates into a large uncertainty in the probability of healing over time – the full line in parts (d) and
(e) is inside the shaded areas, indicating that no evidence of a statistically significant difference from 4LB.
In both these cases, estimated uncertainty is particularly large at between 5 and 20 months after
treatment initiation.
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FIGURE 12 Reflecting uncertainty over relative treatment effects in the probability of healing over time for the
five main high-compression ulcer treatments. (a) The expected probabilities of healing (point estimates) across time
(25 months); (b) to (e) compare the expected values for 4LB with the healing probability (point estimates and
uncertainty) of each of the other four high-compression treatments. Estimates reflect the average participant in
the trial data from VenUS IV (mean ulcer area at baseline of 9.4 cm2 and ulcer duration at baseline of
11.5 months). (continued )
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FIGURE 12 Reflecting uncertainty over relative treatment effects in the probability of healing over time for the
five main high-compression ulcer treatments. (a) The expected probabilities of healing (point estimates) across time
(25 months); (b) to (e) compare the expected values for 4LB with the healing probability (point estimates and
uncertainty) of each of the other four high-compression treatments. Estimates reflect the average participant in
the trial data from VenUS IV (mean ulcer area at baseline of 9.4 cm2 and ulcer duration at baseline of 11.5 months).
DOI: 10.3310/hta18570 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 57
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Ashby et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
97
Uncertainty over the probability of healing with four-layer bandage
(reference treatment)
All findings to this point have been based on the relative treatment effects in relation to the 4LB, the
common comparator. For this reason, 4LB estimates shown in the plots of Figure 12 were not uncertain.
However, the synthesis models also evaluated uncertainty over the probability of healing in the 4LB group,
controlling for centre effect and participants’ baseline characteristics. The estimated probability of healing
associated with the 4LB over time (specifically for a participant with area and duration of ulcer equal to the
mean values observed in VenUS IV) is represented in Figure 13 and uncertainty in the estimates is shown in
the shaded area.
Determinants of ulcer healing
For completeness it is important to understand how patient characteristics might impact on venous ulcer
healing and the models here provide an ideal opportunity to investigate this given the available baseline
and healing data for VenUS I7 and IV. The base-case analysis model, including trial data from VenUS IV,
suggests that no matter the compression treatment used, log baseline ulcer size and log ulcer duration are
important predictors of ulcer healing time (HR of approximately 0.71 and 0.92, respectively, CrIs do not
include 1 – Table 44), with increased time to ulcer healing as ulcer area and duration increase. Based on
VenUS I7 and VenUS IV data, we found that an individual with a venous leg ulcer of one month’s duration
(all remaining characteristics assumed at their average value, i.e. ulcer duration at baseline of 11.5 months
approximately 36% possibility of having limited mobility and 0.1% of being immobile), who starts using
the 4LB, is expected to heal within 12 months (with a probability of 0.92). If, instead, a patient has an
ulcer of approximately 5cm2 and starts treatment with the 4LB, the probability that this ulcer heals within
six months is 0.55. For all sizes or durations of the baseline ulcer considered, patients that started
treatment with the 4LB are expected to have healed with probability of 0.88 or higher at 36 months.
Figure 14 shows additional information on the impact of these two factors on the effect of treatment with
the 4LB. Participant mobility was also seen to be a relevant factor to explain time to ulcer healing as
participants with ‘difficulty in walking’ were associated with slower healing than those that ‘walk freely’
(HR of 0.72 in Table 44).
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FIGURE 13 Probability of healing across time (36 months) for the 4LB considering baseline heterogeneity. (For an
average participant with a mean ulcer area at baseline of 9.4 cm2 and ulcer duration at baseline of 11.5 months.)
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baseline and (b) different ulcer sizes at baseline. All remaining characteristics assumed at their average value.
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Chapter 12 Discussion
In this work, the evidence from RCTs regarding the effectiveness of alternative high-compressiontreatments for healing leg ulcers was synthesised using a MTC approach. This resulted in data for all
relevant health technologies (4LB, SSB, HH, paste bandage and the 2LB) being evaluated simultaneously as
a network of evidence. We note that the process used to classify treatments as high, and not high
compression, was novel, and, given the limited information reported regarding compression treatments
investigated in included RCTs, assumptions were required and the process had subjective elements.
However, classification had excellent face validity given what are commonly recognised as
‘high’-compression treatments.
Relative effectiveness of high-compression treatments
The analyses showed that network-derived relative effectiveness estimates considered to be of high or
medium quality (i.e. those from comparison of the 4LB with the SSB and the 4LB with the HH) are akin to
the results of the individual VenUS studies (I and IV) that drive these findings. Although the evidence
did not demonstrate a difference between HH and the 4LB, the SSB was expected to be less effective
than both of these treatments.
The MTC estimates highlight the considerable uncertainty for many treatment comparisons, reflecting the
fact that many of these were populated by small studies. However, although uncertainty in the evidence
base was reflected in the wide CrIs, the effect of including low-quality studies was less transparent,
and could not easily be adjusted for. Hence, we evaluated the quality of MTC-derived estimates using an
exploratory approach based on GRADE. We acknowledge that this method has not been fully evaluated
and that this is an area of ongoing work. However, based on this assessment it was clear the some relative
effectiveness estimates were being driven by low- or very low-quality evidence (at a high risk of bias).
Given the evidence considered in the MTC, the treatment expected to be most effective was the 2LB
system. However, this finding was driven by estimates judged as being of low or very low quality with
large uncertainty. As with all models, the outputs from MTCs are limited by the type and quality of the
data that informs them, hence here the 2LB findings should be interpreted with caution as demonstrated
by our post hoc analysis, which suggests that were these systems to be considered to have the same
effectiveness then the results of the model would favour HH.
Although the results of this analysis are based on the most complete synthesis of available RCT evidence,
a key message for all decision-makers is the importance of having appropriately sized and robust RCTs
available for evidence synthesis. The output of MTCs can be incredibly useful for clinical and policy
decision-making; however, when important links are informed by poor-quality studies it is difficult to
control for the potential bias. There are methods proposed in the literature for bias adjustment that down
weigh the contribution of evidence with a high risk of bias,137–139 but more research is needed on how to
generate the appropriate weights. Alternatively, evidence at high risk of bias could have been excluded
from the analysis, in which case results would no longer reflect all available evidence. Also, in this MTC,
although there are links informed by reasonable evidence, other links, informed by potentially biased
estimates, are still required to maintain a network where there is relatively sparse data. Consequently, as
with previous work,134 we suggest that, in addition to being a useful meta-analytical tool, exploration of
MTC outputs can provide increased understanding regarding how study and data quality are driving the
estimate of relative effectiveness across a clinical area.
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Methodological approach
Within this work we applied a series of novel MTC models that synthesised time-to-event (healing) data
while considering baseline participant-level covariates. The developed methodology also allowed IPD
to be included alongside AD, thus allowing maximal use of data available. The time-to-event models
implemented were fully parametric and the Weibull distribution was used; this allowed flexible
assumptions over how the hazard of healing changes over time. It was not possible to apply alternative
flexible distributions within this MTC model: the Gompertz distribution cannot be implemented with
censoring within the software, and others, such as the log-logistic or the log-normal, do not allow the
probability of healing over time to be expressed in a closed form, and hence impede the approach
proposed here for the joint synthesis of IPD and AD (AD). In the different analyses implemented, vague or
non-informative priors were used – the use of these is not expected to influence the interpretation
of results.
By including evidence in IPD format we were able to model this evidence in a more complete way,
for example it was possible to describe baseline hazard of healing over time. In doing so we followed
some of the same conventions and assumptions as IPD meta-analysis (given the similarity of approach).
For example, we assumed the shape parameter of the time-to-event distribution to be common across
studies, or a common effect of baseline covariates on the hazard of healing. For this reason, analyses
explored only covariates that were available in both individual level data sets: duration and size of the
reference ulcer at baseline. Additionally, and considering the same variables, the inclusion of treatment
interactions was explored. Within this example, these were not deemed important.
DISCUSSION
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Part III Cost-effectiveness of high-compression
treatments for venous leg ulcers
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Chapter 13 Introduction
P art I of this VenUS IV report includes trial-based findings regarding the comparative cost-effectivenessof HH and the 4LB. However, because other high-compression options are available for the treatment
of venous leg ulcers this pairwise comparison alone does not fully inform clinical and societal
decision-making. Thus, in Part II we presented synthesis of all RCT evidence on the relative effectiveness
(in terms of ulcer healing) of high-compression treatments for treating venous leg ulcers.
In Part III, we extend the VenUS IV analysis further by using a decision-analytic model to estimate the
cost-effectiveness of all relevant high-compression treatments for venous leg ulcers. This approach utilises
trial data from Part I and evidence synthesis data from Part II, as well as additional relevant evidence from
the literature, ensuring that uncertainty over parameter values is assessed across all inputs. The advantages
of extending the analysis, besides the value of considering cost-effectiveness and uncertainty for all
relevant alternative treatments, are the ability to explicitly include other key health benefits (such as
recurrence) in the estimation process while also extending the time frame of existing studies to evaluate
longer-term effects.
In this section we report (1) our specification of the decision problem; (2) our review of previously
published decision models to inform the structure of our model; (3) our searches for sources of evidence
that could inform our model;140 (4) a detailed description of our final model and (5) the results of model
implementation. All stages of work were discussed with the TMG for feedback on specific aspects of the
analyses, including the model structure, data inputs and assumptions.
Specification of the decision problem
The study population was patients with (one or more) venous leg ulcers. The health technologies evaluated
were the key treatments explored in Part II: the 4LB; the SSB; HH; the paste bandage and the 2LB
(see Parts I and II for more complete definitions of these treatments). All of these treatments are used with
the aim of healing venous leg ulcer(s); however, the costs associated with use of each treatment and their
relative effectiveness may differ. We simultaneously assessed these two interrelated dimensions – the costs
and benefits of each treatment – from the perspective of the NHS and PSS.
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Chapter 14 Informing and structuring the
decision model: review of existing economic
modelling evidence
A review of cost-effectiveness models potentially relevant to this work was undertaken to help informour final model structure.
This review aimed to (1) evaluate published decision-analytic models in the area of leg ulcers (regarding
both high compression and other interventions) in order to identify structural assumptions and data
sources potentially relevant to our own decision model; (2) highlight key areas of uncertainty and potential
data gaps; and (3) identify key parameter inputs requiring additional systematic reviews and/or analyses of
primary data.
Reviewing methods
A search was constructed by the Cochrane Wounds Group information specialist in conjunction with
modelling specialists (see Appendix 13 for search strategy used). Three data sets were searched:
MEDLINE, EMBASE and the NHS Economic Evaluation Database (NHS EED). Two reviewers (JD and LHC)
independently screened resulting titles and abstracts against a set of predefined study eligibility criteria:
The study:
1. considered venous leg ulcers
2. included a full economic evaluation (i.e. include both costs and benefits)
3. used a model as a method to represent disease progression.
Any potentially eligible studies were obtained in full and were again screened against the eligibility criteria
for inclusion by two reviewers (JD and LHC). A third reviewer (MS) resolved disagreements.
Data regarding model structure and specifications were then extracted from included studies. This included
information on time horizon, perspective, model structure, model states, study populations and outcome
of interest. Features of each reviewed model were then assessed for relevance to our decision problem.
A summary of this assessment was presented as a narrative synthesis.
Review results
In total, 1038 title and abstract records were identified. After screening against the eligibility criteria,
19 studies were obtained as full papers, after further screening 10 studies were excluded (three of these
were duplicates, two reported only costs and five did not involve decision modelling). Nine studies were
therefore included in the review141–149 (Table 47).
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The time horizons for the included models ranged from 4 weeks to 12 months. The perspectives used
included payer’s, insurer’s, societal or health service (e.g. NHS). Of the nine studies,141–149 only four143,146–149
reported cost per QALY as the outcome measure; the remainder used more specific outcomes, such as
cost per ulcer healed, cost per week in healed state, and cost associated with a prespecified reduction in
wound area. Markov models were used in six141,143,145–147,149 out of the nine141–149 studies; however, the
model structures varied.
In populating the models, various sources of information were used. Effectiveness parameters were most
commonly informed by published evidence with some studies using results from individual trials. For cost
parameters, most studies gathered information on resource use and unit costs separately with resource use
informed/elicited from experts or based on findings from the literature. Studies that evaluated QALYs
utilised published quality-of-life scores.
Description of models’ key characteristics
All decision models included ulcer healing as a key event (by means of defining an unhealed and healed
health states). Of the nine included studies, five also considered other events such as ulcer recurrence,141
complications and adverse events,141 compliance/treatment change142 and degree of improvement of the
ulcer.147 From these studies we selected four model structures that could, potentially, have applied to our
decision problem (Figure 15). Each structure was considered in more detail with key features
outlined below.
Ulcer recurrence
The main goal of treating venous leg ulcers is ulcer healing. However, many (possibly most) ulcers recur
post healing. Although the frequency and speed of recurrence may not be determined by initial ulcer
treatment, quantifying recurrence is important, as the event may affect the level of health after treatment:
i.e. health-related quality of life after first healing should consider the possibility of a recurrence, otherwise
QALY gains of treatment may be overestimated. In decision models, recurrence was represented using a
transition backwards from the health state ‘healed’ to ‘unhealed’ (see Figure 15a).7 Alternatively,
recurrence was assumed to be a distinct state (see Figure 15b), allowing for healing or death to occur at
different rates after recurrence.
Adverse events/complications
Complications and severe adverse events related to treatments are often relevant for economic analyses
owing to the relative high cost of negative events compared with other categories of resource use.
One of the models reviewed,142 which evaluated a surgical intervention, set up an additional health state
representing the discontinuation of treatment after occurrence of such events. In this way, the model
allowed for distinct costs and healing (and/or death) rates in patients with severe adverse events/
complications. Figure 15c presents an adapted diagrammatic representation of how a model considering
both recurrence and adverse events could be specified.
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FIGURE 15 Alternative decision model structures. Adapted from Carr et al.141 and Schonfeld et al.142
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Compliance
Compliance with venous leg ulcer treatments may vary. Compliance is here used to describe the degree to
which a patient uses the treatment as prescribed, with variations mainly concern duration of treatment.
Poor compliance with treatment may reduce or annul the effectiveness of a treatment. However, delivery
of treatments to non-compliant patients may still incur costs. The model reported by Korn et al.143
examines the impact of compliance with venous leg ulcer treatments. Here patients entering the model are
classed as compliant or non-compliant and undergo distinct transition rates to reflect this. Following this
design, the model could be expressed by the diagram in Figure 15d.
Final model structure and parameters
Given the decision problem at hand, it was decided that the most relevant model structure was Figure 15a,
which was adopted (its structure is shown again in Figure 16 with further annotation).
Key events in this model were healing and recurrence. Patients initiated the model in the unhealed state
with the occurrence of healing tracked over time. Once healed, ulcers could recur over time. The model
also considered a probability of patients dying over time, and defined death as a health state. Utility scores,
resource use and costs were assigned to the length of stay in the different states, or to treatments, thus
allowing evaluation of total costs incurred over time and quality adjustment of the lifetime estimated in the
model. Table 48 presents a description of the parameters required to define the model.
We did not expect severe adverse events or complications to differ across high-compression treatments,
thus the decision model did not consider that occurrence of adverse events affected transition to healing
or death. However, the model did evaluate treatment-specific costs in which costs from adverse events
were considered. Additionally, the selected decision model did not explicitly consider that compliance
affected healing or recurrence – we knew from Part II that RCTs rarely reported compliance information
clearly (the exception was trial data from VenUS IV). Instead, compliance was modelled implicitly (through
the intention-to-treat analysis), and thus healing and recurrence rates depend on compliance within
individual trials. However, the decision model did evaluate the effect of compliance on treatment costs by
defining a ‘duration of treatment’ parameter that could differ among compression treatments. The impact
and consequences of this parameter will be discussed in the final section of Part III.
Unhealed Healed
Death
tp_recur
tp_death tp_death
tp_healtreat
treat
FIGURE 16 Decision model structure.
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TABLE 48 Description of decision model parameters
Parameter Parameter description
Specification of patient population
Ulcer duration Duration in months of reference ulcer at start of treatment
Ulcer area Size of the reference ulcer at start of treatment
Patient mobility Patient mobility categorised: ‘walks freely’, ‘walks with difficulty’ and ‘immobile’
Age Age of the patient at start of treatment (years)
Transitions
tp_healtreat Transition probability from unhealed to healed
tp_recurtreat Transition probability of having a recurrent ulcer, i.e. from healed to unhealed
tp_death Transition probability of dying from any cause
Costs and resource use
Costs while unhealed, not related to treatment
Hospv Average monthly ulcer-related hospital outpatients visits
Clinv Number of ulcer-related doctor consultations per month
c_hospv Cost of hospital visits
c_clinv Cost of ulcer-related doctor consultations
Costs while unhealed, related to treatment
T_durtreat Duration of compression treatment with treat
nursevtreat Average monthly number of ulcer-related nurse consultations while receiving treatment (treat)
c_nursev Cost of a nurse consultation (excludes costs of treatments)
c_bandtreat Cost of compression treatment (treat), per consultation
nursev_after Average monthly number of ulcer-related nurse consultations while patient receives standard care
c_band_after Cost of standard care (bandages and stockings) per consultation
Quality-of-life score
u_decunh EQ-5D scores for unhealed ulcer patients
u_pop EQ-5D scores for healed leg ulcer patients
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Chapter 15 Literature searches for decision
model input parameters
Based on the selected model, further literature searching was conducted to identify evidence on thefollowing categories of model parameters: health-related quality of life/utility, costs and resource use,
ulcer recurrence and mortality. Effectiveness (ulcer healing) evidence had been sought and synthesised
separately (methods and results of this analysis are reported in Part II of this report).
Specially, in terms of further evidence, key data of interest were for (1) health-related quality of
life/utility – data regarding possible changes to health-related quality of life/utility for a patient whose
ulcer heals; (2) resource use – data regarding the costs incurred by patients with an unhealed ulcer;
(3) recurrence – data regarding whether recurrence depends on the treatment received for the primary
ulcer; whether recurrence is likely to increase, decrease or stay constant over time (from healing); any data
regarding recurrence rate and whether recurrent ulcers differ from primary ulcers in terms of healing times
or impact on death rates; and (4) mortality – evidence regarding a relationship between having an unhealed
ulcer and increased mortality risk.
Searching methods and data extraction
Multiple searches were conducted by researchers at the Centre for Reviews and Dissemination using eight
relevant databases (see Appendix 14). Two reviewers (JD and LHC) screened the abstracts independently
against the eligibility criteria specified in Table 49. Disagreements were resolved by a third reviewer (MS).
Abstracts that failed to meet the above criteria were excluded. The full papers of the selected studies were
TABLE 49 Aims of searches for each parameter type
Parameter type Aim to identify evidence on Inclusion criteria
Health-related
quality of
life/utility
Health-related quality-of-life
scores of patients with venous
leg ulcers both healed
and unhealed
Studies were included if they:
l included or related to people with, or who had previously had,
venous leg ulcers
l presented quantitative health-related quality-of-life/utility data
for people with venous leg ulcers or a history of venous
leg ulcers
Costs and
resource use
Costs/resource use by patients
with an unhealed venous
leg ulcer
Studies were included if they:
l included or related to people with venous leg ulcers
l presented costs/resource-use data regarding venous leg ulcers
in the UK
Recurrence Recurrence rates of patients
with venous leg ulcer
Studies were included if:
l they included or related to UK study populations with, or who
had previously had, venous leg ulcers
l participants were treated with a relevant form of compression
l details regarding prevention treatments were reported/
considered standard practice
l they measured (or may have measured) recurrence
Mortality Whether having a venous leg
ulcer affects the patient’s
mortality
Studies were included if they:
l included or related to people with, or who had previously had,
venous leg ulcers
l reported mortality data
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obtained (agreed by both reviewers) and rescreened for a final decision regarding inclusion. Again any
disagreements were resolved by a third reviewer. Data were extracted on the parameters of interest and
presented descriptively.
Results of the review
Health-related quality of life/utility
In total, 72 citations were initially identified and full papers were obtained for 33 of these after which a
further 30 studies were excluded (see Appendix 15). The main characteristics of the three included
studies44,48,150 are described in Table 50. The study by Walters et al.48 reported the health-related
quality-of-life results from a RCT that investigated the clinical effectiveness of community compared with
home-based service in England. All trial participants received the 4LB and were asked to report their EQ-5D
index score at 12 weeks and 12 months. The study also reported the proportion of healed and unhealed
patients at 12 months. However, the analysis methods utilised was unclear from the RCT report and utility
results across the 12-month assessment appeared inconsistent. We noted a bigger decrease in utility
score at 3 months for healed participants compared with unhealed participants (suggesting decreased
health-related quality of life), whereas overall a positive average utility gain per month up to 12 months
was estimated for healed patients (Table 51). We did not contact the authors for further details. The two
more recent studies were National Institute for Health Research-funded RCTs, one comparing the clinical
effectiveness and cost-effectiveness of the 4LB with the SSB (VenUS I),7 and the other comparing the
effects of silver-donating with non-silver low-adherent dressings in the treatment of venous leg ulcers
(VULCAN trial).150 All participants in the VULCAN trial150 wore multilayer compression bandage or hosiery
over their dressing. Both studies reported EQ-5D scores separately for healed and unhealed ulcers,
and could be used to establish an effect of ulcer healing on health-related quality of life (see Table 51).
These results were used to inform the decision model, for which an increase in health-related quality-of-life
score for a patient whose ulcer healed was estimated to be 0.00251 in the VULCAN trial150 and 0.11 in
VenUS I7 (adjusted analysis).
Costs and resource use
In total, 72 citations were identified. After screening, 25 full papers were obtained. Following further
screening, 16 studies were excluded; these were studies conducted outside of the UK and those studies
that did not include information relevant for our model (see Appendix 16). Thus two studies informed our
model for this parameter: VenUS I7 and VULCAN150 (details of these RCTs have been described elsewhere).
Based on the trial-level cost-effective analysis of VenUS IV (see Part I) nurse consultations for ‘unhealed’
participants was known to be a key cost driver; consequently, data relating to this cost component was of
particular interest. However, of the two studies identified, only VenUS I7 assessed the number of visits for
specific compression treatments, reporting a mean of 5.1 consultations per month in the 4LB arm
and 6.0 in the SSB arm. No similar evidence was available for the paste and 2LB.
TABLE 50 Main characteristics of studies reporting utility data in people with venous leg ulcers
Study Evaluated treatments n Instruments Assessment time
Walters 199948 4LBs 233 EQ-5D/SF-36 Baseline, 12 weeks, 12 months
(healed vs. unhealed)
Iglesias 200544 Four-layer vs. SSBs 387 EQ-5D/SF-36 Baseline, every 3 months up to 1 year
(healed vs. unhealed)
Michaels 2009150 Multilayer compression
bandages or hosiery
213 EQ-5D/SF-36 Baseline, 1, 3, 6 and 12 months
(healed vs. unhealed)
SF-36, Short Form questionnaire-36 items.
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Ulcer recurrence
In total, 182 citations were identified. Of these, 147 were excluded and full papers were obtained for
35 studies. Upon further screening 29 studies were subsequently excluded for a variety of reasons
(see Appendix 17): 17 studies were either not primary research or did not report recurrence results,
eight studies were conducted outside of the UK, four studies evaluated surgical treatments (data from
these were thus considered to potentially misrepresent recurrence rates in patients using compression),
two studies assessed prevention strategies not used in current clinical practice, and four studies did not
report whether participants were routinely offered the use of prevention compression and were considered
too old to be able to provide data that was contemporary to VenUS IV regarding routine use of prevention
treatments. It was for this last reason that VenUS I7 was excluded.
Details of the six included studies6,150,151–154 all relevant to the UK, are shown in Table 52 (all were RCTs).
Three RCTs examined the effectiveness of surgical approaches (i.e. venous surgery and grafting) in
preventing ulcer recurrence. Surgery is not commonly used in the UK as a treatment to heal venous
ulcers thus we extracted data from only the control arms here (where participants received compression
treatments). The proportion of participants with a recurred ulcer ranged from 30% at 6 months, 28–36%
at 1 year and 56% at 4 years. The RCTs by Brooks et al.152 and by Nelson et al.153 investigated the effect
of using hosiery after healing in preventing recurrence. Brooks et al.151 suggest that a nurse education
programme significantly improved ulcer recurrence rates but there was no association with the time spent
in maintenance hosiery. Nelson et al.153 found no evidence of a difference in recurrence rates between
class 2 and class 3 compression hosiery. The final included study was the VULCAN RCT,150 in which all RCT
participants were advised to wear hosiery after healing to prevent recurrence.
TABLE 51 Summary of the utility evidence in studies identified from the literature review
Study Status Baseline 3 months
Mean gain
per month
Disutility of patients
with unhealed ulcers
at 3 monthsa
Walters 199948 Unhealed 0.57, SD= 0.18,
n= 233
0.55 –0.03 –
SD= 0.16 SD= 0.13
n= 161 n= 78
Healed 0.53 0.02 –
SD= 20 SD= 0.14
n= 37 n= 69
Iglesias 200544 Unhealed 0.62, SE= 0.02,
n= 328
0.64 – 0.1100, SE= 0.02848
SD= 0.02
n= 151
Healed 0.75 – –
SD= 0.03
n= 110
Michaels 2009150 Unhealed 0.5792 0.6474 – 0.00251, SE= 0.04556
n= 59
Healed 0.6978 0.753 – –
n= 987
a Adjusted analysis.
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Although our decision model explicitly accounts for the possibility of a recurrence, it does not differentiate
between primary ulcers and recurrent ulcers in terms of differential times to healing or impact on death
rates. First, this was because we found no evidence of such an effect (the studies reviewed did not
investigate whether risk of ulcer recurrence depended on the treatment received for the primary ulcer).
Second, the population of interest within the current evaluation included people with venous leg
ulceration that could be primary or recurrent.
Regarding the rate of recurrence, studies were heterogeneous and results varied significantly across studies.
VULCAN,150 the most recent study, reported the lowest recurrence rate. We postulated that developments
in the management of patients at risk of venous leg ulceration may have led to a reduction in recurrence
rates in more recent years – thus, in addition to trial data from VenUS IV, we used only evidence from
VULCAN149 to inform the decision model for recurrence data. Despite the evidence suggesting that the
likelihood of recurrence may decrease as time from healing increases (see Barwell et al.),151 the data
available in the literature alone was insufficient to allow this issue to be considered explicitly.
Mortality
A total of 414 citations were identified (see Appendix 18). After initial screening, six studies were obtained
in full;155–160 however, we were unable to retrieve one paper.155 Of the remaining five studies,156–160 three
were conducted in Sweden,154–159 one in Austria160 and one in the UK.159 Subsequently, we focused on
the UK study.159 This was a RCT that evaluated the effect of a national community intervention programme
on healing rates of chronic leg ulcer in Scotland.
In this cluster RCT, 3949 participants were registered and followed up using quarterly surveys over a
30-month period. Overall, there were 489 deaths and 65 amputations, corresponding to a quarterly
rate of death of 3.7%. The study found no evidence of a difference between the two treatment
groups – participants subject to a programme of nurse training that was specific for leg ulcer care
(intervention), which included workshops, lecture material, and a range of dressing and bandaging
material, among other items compared with no training (control).
TABLE 52 Main characteristics of UK RCTs reporting ulcer recurrence in patients with venous leg ulcers
Study (year) Technology n
Max.
follow-up
(months) Recurrence rate
Barwell 20046 Surgery 428 14 The 12-month recurrence rate for patients in the surgery
arm vs. compression arm was 12% vs. 28%
The 14-month recurrence rate for patients in the surgery
arm vs. compression arm was 15% vs. 34%
Gohel 2007154 Surgery 500 48 Ulcer recurrence rates at 4 years were significantly lower in
the compression plus surgery group than in the compression
group (31% vs. 56%)
Barwell 2000151 Surgery 669 Up to 36 Recurrence rates at 1, 2 and 3 years were 14%, 20% and
26%, respectively, for operated legs, and 28%, 30%
and 44%, respectively, for non-operated legs
Brooks 2004152 Prevention 49 12 There was only one leg ulcer recurrence (4%) in the
experimental group compared with 15 in the control (36%)
Nelson 200635 Prevention 382 60 Over 5 years, 107 patients (36%) had ulcer recurrence.
Moderate- and high-compression hosiery did not differ for
recurrence of venous ulceration (39% vs. 32%)
Michaels 2009150 Compression
treatment
213 12 A total of 24 patients had recurrent ulcers within 1 year: the
recurrence rates were 11.6% (n= 11) for the intervention
and 14.4% (n= 13) for the control dressings
Max., maximum.
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Implications of additional evidence obtained for the decision model
The searches show that the data for key inputs for the decision model were sparse. Regarding
health-related quality of life, although we identified some evidence regarding improved health-related
quality of life upon ulcer healing (VenUS I7 and VULCAN150) it remains unclear how health-related
quality-of-life changes over time for patients with unhealed ulcers. The same two RCTs provided estimates
of the resource use associated with unhealed patients.
For ulcer recurrence, the literature suggests that the likelihood of an ulcer recurring decreases as time since
healing increases. However, the data available were not sufficient to consider this explicitly in the decision
model. Evidence on ulcer recurrence was heterogeneous. We note that clinical practice with respect to
prevention of recurrence in venous leg ulcers has changed substantially over the last decade with the
routine introduction of effective strategies such as the use maintenance therapies (i.e. hosiery after
healing). It is not clear whether such changes explain the heterogeneity of recurrence figures across
studies; however, we decided to consider evidence from the most recent study only.150 There was no
current evidence that having a venous leg ulcer directly affects (or not) mortality but there was some
evidence that the population of patients with an ulcer may differ from the general population (matched by
age and gender) that needed to be considered in the mortality rate.
The evidence gathered from the searches was further used to inform the decision model. How specifically
this evidence was transformed (if needed) and included in the model is described in the following section.
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Chapter 16 Cost-effectiveness analyses methods
Framework of analysis
The cost-effectiveness of alternative high-compression treatments for venous leg ulcers was evaluated
using a decision model, where costs and benefits associated with patients’ use of treatments of interest
were evaluated. The model structure is shown below (see Figure 17) and a list of parameters in Table 48.
The decision model was implemented in the software package R, version 2.13.1 (The R Foundation for
Statistical Computing, Vienna, Austria).
The model was defined using monthly cycles; this was deemed an appropriate duration reflecting the
potential transitions between model states. The model considered a time horizon of 12 years, after which
time it was anticipated that most individuals in the cohort would have healed (owing to the high mean
age of the cohort at baseline, most patients were likely to have died before the end of the time horizon).
Costs were evaluated from the perspective of the NHS and PSS, expressed in UK pounds sterling at 2011
prices. Both expected costs and outcomes were discounted using a 3.5% annual discount rate, in line with
current NICE guidelines72 for technology assessment in the UK. The cost-effectiveness measure considered
was ICER=ΔC/ΔE (where ΔC is the mean difference in costs, and ΔE is the mean difference in QALYs), or
its reformulation, the net benefit (NB) measure. A full incremental analysis was carried out due to multiple
treatments being assessed. The net monetary benefit (NMB) is defined as Tr ×ΔE−ΔC and the new
technology is accepted if NMB> 0, where Tr is the predefined threshold value used by NICE to establish
value for money of health technologies in the NHS (i.e. willingness to pay).72
The model was probabilistic, hence uncertainty around the expected value of the inputs and its impact on
decision uncertainty was considered. In practice, uncertainty around each parameter was described using
probability distributions and this uncertainty was then propagated through the model using Monte Carlo
simulation (5000 iterations). Considerations regarding uncertainty surrounding a decision to reject a
technology were based on CEACs, as in Part I. The CEAC is more informative than CIs, and has a natural
Bayesian interpretation: it represents the probability of a treatment being cost-effective,85,161 estimated
using the proportion of Monte Carlo samples that lie below a specific Tr.
Where uncertainty over an adoption decision based on existing information exists, the expected
consequences of this uncertainty can be quantified using expected value of perfect information (EVPI)
methods.162 EVPI informs the decision-maker of the consequences for the health-care system (in £s) of the
possibility of making the wrong decision, and informing the maximum value of conducting further research
to reduce uncertainty and improve decision-making.163 The EVPI should be considered for the total and
future patient population who may gain from additional information over the expected lifetime of the
technology – the population EVPI. The decision-maker should consider conducting the research only if the
costs of the research are lower than the EVPI.
Scenario and subgroup analyses
The base-case model presents the results of the analysis including VenUS IV evidence. A further scenario
was considered (without VenUS IV scenario) where trial data from VenUS IV was excluded from the model,
thus allowing us to compare these results with the base case to assess the contribution of VenUS IV data
to decision-making in the area.
Also, subgroup cost-effectiveness analyses were implemented. It is important to assess the
cost-effectiveness of interventions by population subgroup, as an intervention may be cost-effective for
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one subgroup of the population and not for another. Thus, there may be population health gains from
stratifying treatment decisions based on subgroup membership. This analysis explored (1) the average
patient population with venous leg ulcers (no subgroups); (2) subgroups specified according to baseline
duration of the reference ulcer, specifically at 1, 3, 6, 12, 24 and 48 months; and (3) subgroups specified
according to the baseline area of the reference ulcer, specifically at 1, 5, 25 and 75 cm2.
Incorporating evidence into the model
Evidence from VenUS IV, Part II and studies identified in literature searches was used to populate the
decision model. This section describes how the evidence was used in the decision model, specifically
regarding the (1) specification of the patient population; (2) transitions from unhealed to healed;
(3) transitions from healed to unhealed (ulcer recurrence); (4) transitions to death; and (5) costs and
resource use and health-related quality of life/utilities.
Specification of the patient population
In Part II, we have seen that the probability of healing is determined by ulcer duration and area. It is
intuitive that the probability of dying is determined by the age of the cohort. It is thus important to specify
the key characteristics of our model population using values representative of venous leg ulcer patients.
For the base case VenUS IV information was used, whereas the scenario analysis (without VenUS IV
scenario) reflected participant characteristics observed in VenUS I.7 Table 53 shows detailed information on
the values assumed.
Transitions from unhealed to healed
Effectiveness evidence was synthesised in a MTC as described in Part II. The Weibull MTC model was used
to define the transition probabilities to healing. The base case included IPD trial data from VenUS IV and
the scenario analyses excluded it. The MTC results were incorporated into the decision model using the
posterior samples or predictive distributions when a random effect across centres had been considered
[extracted from the Convergence Diagnostic and Output Analysis WinBUGS output (CODA)].
Specifically, the probability of healing for patients starting treatment with the 4LB was specified according
to the patient’s ‘baseline’ mobility status, ulcer area and duration. The mean values (section 1 of Table 53)
and the regression coefficients estimated in the MTC (βlog_ulcer_area, βlog_ulcer_duration, βmobility_difficult, βimmobile, μ and
βnew_centre) were linearly combined on the log scale to generate λ (representing the scale of the ulcer healing
time distribution), which was used, in turn, to calculate the transition probability to healing according to
the following formula:
tp4LBheal(tu)=1− expfλ  ((t −u)γ− tγ)g (2)
where tp4LBhealðtuÞ is the transition probability for 4LB for each cycle (where the cycle length was 1 month, and
thus the times at each cycle u were represented by tu) and the (ancillary) γ parameter defines the shape of the
distribution. The relative effects of the remaining treatments compared with the 4LB were then applied to
this baseline value as follows:
tpiheal(tu)=1− expfλ  HRi  ((t −u)γ− tγ)g (3)
where HRi is the HR of treatment i in relation to the 4LB. Figure 17 illustrates the cumulative probability of
ulcer healing with the 4LB in the model, for the base case (with trial data VenUS IV, reproducing Figure 15)
and for the scenario analysis (without VenUS IV). Uncertainty in the estimates is shown in the shaded
areas. As expected, for the majority of the time points considered, uncertainty is higher when excluding
VenUS IV evidence than when including it.
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TABLE 53 Specification of the patient population
Evidence from literature plus from VenUS IV
(base-case analysis) Evidence from literature (scenario analysis)
1. Specification of patient population
Descriptive statistics from
VenUS IV (n= 454),
mean (SE)
Ulcer duration
(months)= 11.54 (1.08)
Descriptive statistics from
VenUS I7 (n= 397),
mean (SE)
Ulcer duration
(months)= 9.41 (0.53)
Ulcer area (cm2)= 9.35
(0.8676)
Ulcer area
(cm2)= 10.22 (1.1830)
Patient mobility, %: Patient mobility, %:
Walks freely= 63.80 Walks freely= 62.14
Walks with
difficulty= 35.32
Walks with
difficulty= 37.08
Immobile= 0.88 Immobile= 0.78
Age (years)= 68.61
(0.6791)
Age (years)= 71.59
(0.6714)
2. Transition probabilities from unhealed to healed
Transition probabilities are
based on a MTC synthesis
model using Weibull
regression of healing
outcome data from
multiple studies in the
literature (including
VenUS IV; see base-case
MTC analysis in
Chapter II), mean (SE)
βlog_ulcer_area= –0.34 (0.0362) Transition probabilities are
based on a MTC synthesis
model using Weibull
regression of healing outcome
data from multiple studies in
the literature (not including
VenUS IV; see base-case MTC
analysis in Chapter II),
mean (SE)
βlog_ulcer_area= –0.37 (0.0562)
βlog_ulcer_duration= –0.08
(0.0104)
βlog_ulcer_duration= –0.06
(0.0110)
βmobility_difficult= –0.34
(0.0905)
βmobility_difficult= –0.35
(0.1308)
βimmobile= –0.44 (0.4847) βimmobile= –0.74 (0.6545)
μVenUS IV= –3.34
(0.1390)
μVenUS I= –3.09 (0.2020)
βnew_centre= –0.004 (0.2269) βnew_centre= –0.0001
(0.2863)
γ (ancillary
parameter)= 1.07 (0.0320)
γ (ancillary
parameter)= 0.92 (0.0412)
HRSSB= 0.89 (0.0671)
HRHH= 1.05 (0.1122)
HRpaste= 0.81 (0.2584)
HR2LB= 1.51 (0.6264)
HRSSB= 0.92 (0.0720)
HRHH= 1.65 (0.5257)
HRpaste= 0.82 (0.2629)
HR2LB= 1.50 (0.6313)
3. Transition probability from healed to unhealed (ulcer recurrence)
Hazard of recurrence
modelled using VenUS IV
data by a Gompertz
survival regression,
mean (SE)
β0: –2.80 (0.2460)
βmobility_difficult: 0.77 (0.2595)
βimmobile: 1.20 (1.0150)
γ (ancillary parameter):
–0.28 (0.0571)
HRHH= 0.56 (0.1482)
Constant rate of recurrence
throughout time and the
same for all treatments,
VULCAN,164 mean (SE)
tp_recurr= 0.012
(3.412× 10–5)
4. Transition to death
Same as scenario analysis From population statistics
adjusted for mortality rate of
leg ulcer patients from
Brown et al. (2002)159
Office for National
Statistics (2011)165
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Transitions from healed to unhealed (ulcer recurrence)
For the base-case analysis, trial data from VenUS IV alone was used to inform this parameter, where
approximately 19% of participants recurred during follow-up (65 out of 343). Additionally, differences
were found between treatment arms with respect to recurrence (approximately 15.0% of participants
allocated to the HH group had a recurrence event compared with 23.5% in participants allocated to the
4LB group). Given the availability of IPD, the probability of recurrence parameter was evaluated using
time-to-event models. This analysis was parametric and we evaluated the following alternative distributions
of time to event: exponential, Weibull, Gompertz, log-logistic, log-normal and gamma. The selection of the
distribution was based on values of the Akaike information criterion (AIC),166 considering goodness of fit
and penalising model complexity (Table 54). All regression models adjusted for baseline participant mobility
(categorical variable) and baseline reference ulcer duration (months). Baseline ulcer area was removed from
the model based on the lack of statistical significance.
The Gompertz regression was selected based on lower AIC value, which indicates a better fit
(see Table 54). Figure 18 shows the cumulative probability of ulcer recurrence for the 4LB arm of VenUS IV,
based on the selected model. This shows that, on average, 12 months after healing the probability of observing
an ulcer recurrence was estimated to be approximately 27.0% in participants allocated to 4LB compared with
17.7% for participants allocated to HH. Again, uncertainty in the estimates is shown in the shaded areas.
The distribution chosen to represent time to recurrence – the Gompertz distribution – assumes that the
hazard of recurrence depends on time since healing. This time dependency was built into the decision
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FIGURE 17 Probability of healing with the 4LB for the base-case and scenario analyses.
TABLE 54 Goodness of fit of alternative time to recurrence models
Time-to-event model AIC
Exponential PH 538.8
Weibull PH 520.9
Gompertz 510.7
Log-logistic AFT 517.5
Log-normal AFT 513.5
Generalised gamma AFT 513.8
AFT, accelerated failure time.
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model structure using tunnel states to relax the Markov assumption. Tunnel states are a modelling ‘trick’,
for which one state is split into as many states as the number of cycles for which we wish to consider
the time dependency. In this case, the initial healed state was transformed into 13 states: ‘healed 1’,
‘healed 2’, etc. Patients were allowed to remain in states for only one cycle (1 month), after which they
either recurred (transit to the unhealed state) or died. In this way, the time patients spent healed was
tracked and the probability of recurrence depended on this duration. If, after 12 months, patients had not
recurred or died then they transitioned into a ‘healed’ state for which the probability of ulcer recurrence
was assumed null. The transition probability for recurrence, tpirecurr, was defined using the parameter
estimates in Table 54 using the following relation:
tpirecurr (tu) =1−exp

λ  HRi  fexp(γ  (t−u))−1g
γ
−
λ  HRi  fexp(γ  t)−1g
γ

(4)
where λ is a scale parameter (a linear combination, on the log scale, of the average population
characteristics and estimated coefficients: β0, βmobility_difficult, βimmobile), γ the shape parameter of the Gompertz
distribution and ‘HR’ the HR for recurrence of treatment i relative to the 4LB (note that only HH was
assumed to affect recurrence, thus all remaining compression treatments for which models were run were
assigned a HR of ‘1’).
In the scenario analysis, evidence from the VULCAN trial150 was the source of recurrence data (and trial
data from VenUS IV were not included). The VULCAN trial150 observed that 13% of participants recurred
within 12 months (24 from a sample of 185 participants healed within the study). This information was
used in the model by defining a transition probability for recurrence using:
tprecurr ¼ 1−expflog(1−precurr )g (5)
where precurr represents the probability of recurrence observed in the study (0.13). In this scenario analysis;
recurrence was not assumed to depend on treatments used for ulcer healing as the evidence from the
review conducted did not indicate that such an effect might exist.
Transition to death
Most ulcer patients are elderly and they generally have more comorbidities than the average
population.7,13,61 Although the presence of an ulcer may not directly affect patients’ mortality, the
characteristics of this population may imply a higher mortality rate that the general population.
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FIGURE 18 Probability of recurrence for the 4LB and hosiery from VenUS IV (base-case analysis).
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Transitions probabilities to the absorbing state (death) were informed by official population statistics165 and
adjusted using the mortality ratio of a population of patients with ulcers (calculated from Brown et al.,159
taken to be 2.36 times higher than of the general population). Mortality was not assumed to depend on
the treatments evaluated. The same information was used in both the base-case and scenario analyses.
Costs, resource use and health-related quality of life/utilities
Table 55 identifies the evidence used for costs and resource use and health-related quality of life for both
the base-case and scenario analyses. Two main cost components were defined:
1. Costs dependent on health state (healed and unhealed) The model considered only ulcer-related costs,
so once a patient had healed then no costs were incurred in the model. When patients had an ulcer,
i.e. were in the unhealed health state, clinician and hospital consultations were considered (assumed to
be not treatment dependent) (see Table 55).
TABLE 55 Summary of the evidence used for costs and resource use and health-related quality of life for base-case
and scenario analyses, respectively
Evidence from literature plus from VenUS IV
(base-case analysis) Evidence from literature (scenario analysis)
Costs and resource use
Depending on treatment
Treatment duration,
VenUS IV, mean (SE)
Tdur4LB= 2.48 (0.1819) Treatment duration Tdur=while unhealed
TdurSSB= Tdur4LB
Tdur HH= 3.06 (0.2066)
Tdurpaste= Tdur4LB
Tdur2LB= Tdur4LB
No. of nurse visits, VenUS I7
and VenUS IV, mean (SE)
nursev4LB= 5.68 (0.2401) No. of nurse visits,
VenUS I, mean (SE)
nursev4LB= 5.10
(0.2335)
nursevSSB= 6.00
(0.2952)
nursevHH= nursev4LB
nursevpaste= nursev4LB
nursev2LB= nursev4LB
nursevSSB= 6.00 (0.2952)
nursevHH= 5.16 (0.1499)
nursevpaste= nursev4LB
nursev2LB= nursev4LB
Depending on health state (healed, unhealed)
No. of clinician visits,
VenUS IV evidence, mean (SE)
clinv= 0.26 (0.1302) No. of clinician visits,
VenUS I, mean (SE)
clinv= 0.25 (0.1600)
No. of hospital visits,
VenUS IV, mean (SE)
hospv= 0.12 (0.0498) No. of hospital visits,
VenUS I, mean (SE)
hospv= 0.35 (0.0800)
Health related quality-of-life scores
Population utility scores (u_pop),
UK population norms per year
of age adjusted for baseline
utility values from VenUS IV
Kind et al.74 and
VenUS IV
Population utility scores (u_pop),
UK population norms per year of
age adjusted for baseline utility
values from Michaels et al.
(2009)164
Kind et al. (1996)74
and Michaels et al.
(2009)164
Utility decrement of patient with
unhealed ulcer, VULCAN trial
(Michaels et al. 2009),164 VenUS
I (Iglesias et al. 2004)7 and
VenUS IV, mean (SE)
u_decunh= 0.0820
(0.02143)
Utility decrement of patient with
unhealed ulcer, VULCAN trial
(Michaels et al. 2009),164 and
VenUS I (Iglesias et al. 2004)7
mean (SE)
u_decunh= 0.0800
(0.02423)
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2. Costs dependent on treatment Treatment costs were a function of the average number of nurse
consultations per month for each patient, the cost of each of those nurse contacts and the cost of the
treatment applied in each visit (see Table 5), i.e. mean number of nurse consultations × (cost of nurse
visit+ cost of applied treatment).
The mean number of nurse consultations while unhealed was derived from VenUS IV (see Table 28) in the
base case and VenUS I11 in the scenario analysis. Given the scarcity of information on resource use for
other compression treatments, in the ‘without VenUS IV’ scenario, the number of nurse consultations while
on HH, paste and the 2LB was assumed to be the same as the 4LB. The number of nurse consultations for
the SSB group was assumed to differ (based on data from VenUS I). In the base case, the number of nurse
consultations while on the paste and the 2LB were again assumed to be the same as the 4LB owing to
absence of information. Consultations for HH were informed by VenUS IV (see Table 28) and consultations
for SSB were again informed by VenUS I.
The ‘without VenUS IV’ scenario considered that treatments of interest were provided to patients
throughout the unhealed period. Evidence from VenUS IV, however, established that the same treatments
are not used throughout an ulcer episode. As this is relevant for costs, it was considered in the base-case
analysis by costing the treatment of interest for a period of time (Tdurtreat) after which ‘standard treatments’
were costed. These standard treatments were costed as an average of the compression treatments reported
in VenUS IV after the allocated treatment was discontinued. In VenUS IV, duration of treatment was found
to differ between the 4LB and HH. No evidence was available with respect to the duration of treatment
for SSB, paste and 2LB. Thus duration of these treatments was assumed to be the same as the 4LB
(see Table 55).
The health-related quality-of-life/utilities scores of healed patients were assumed to vary with time
according to UK population utility score norms (per year of age) [Centre for Health Economics (CHE)
report, 1999].167 These values were adjusted by baseline utility values from VULCAN150 for the ‘without
VenUS IV’ scenario and for the base case, to reflect the fact that a patient population with venous leg
ulcers is expected to have worse health than the general population.
Patients with unhealed ulcers were assigned a decrement in utility. In the scenario without VenUS IV,
adjusted estimates at 12 weeks from VULCAN trial150,164 and VenUS I7 – 0.00251 and 0.11,
respectively – were pooled. To pool, a weighted average of the study estimates was used, with the weights
being the inverse of the variance for each of the study estimates (i.e. the larger the variance, the smaller
the weight, and vice versa). The pooled value obtained for this scenario was 0.08 (SE= 0.024, Table 56).
For the base case, VenUS IV was used in addition to the other two studies; the pooled statistic assumed a
value of 0.082 (SE= 0.021), a similar value to that of the scenario analysis.
TABLE 56 Summary of the utility evidence that informed the decision modelling
Study/studies
Mean adjusted utility decrement
at 3 months (SE)
Michaels 2009 (VULCAN trial)164 0.0025 (0.04556)
Iglesias 2004 (VenUS I trial)7 0.1100 (0.02848)
VenUS IV trial 0.0894 (0.04504)
VULCAN164 trial+VenUS I7 (scenario analysis) 0.0800 (0.02423)
VULCAN164 trial+VenUS I7+VenUS IV trial (base-case analysis) 0.0820 (0.02143)
DOI: 10.3310/hta18570 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 57
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Ashby et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
125
Specification of distributions for probabilistic analysis
To perform probabilistic analysis input parameters were represented as a probability distribution. The type
of distribution was dictated by the nature, characteristics and method of estimation used to derive the
evidence for each parameter (Table 57). Once the type of distribution was defined, the mean statistics and
SE were used to define the distribution parameters using the method of moments. For the ‘without
VenUS IV’ scenario analysis, the probability of ulcer recurrence was modelled through a standard beta
distribution parameterised by the number of individuals that recurred given those healed at 3 months
(see Table 57). Consultations with health-care professionals were represented by a normal distribution,
parameterised using evidence in Table 55. Adjusted utility decrements for unhealed ulcer patients were
represented by a standard beta distribution. Adjusted population utility scores per year of age and
decrements due to having an unhealed ulcer were also modelled using normal distributions.
TABLE 57 Distributions used to represent parameter uncertainty
Model input parameter
Distributional assumption
Evidence from literature plus from VenUS IV
(base-case analysis)
Evidence from literature
(scenario analysis)
1. Specification of patient population
Descriptive statistics Non-stochastic Non-stochastic
2. Transition probabilities from unhealed to healed
Transition probabilities
(see Part II)
MCMC simulations used MCMC simulations used
3. Transition probability from healed to unhealed (ulcer recurrence)
Rate of recurrence
(tp_recurr)
Multivariate normal distribution (mean estimates
and variance/covariance matrix used) defined to
characterise each of the Gompertz
regression parameters
Beta (r_recur+ 1, n_recur - r_recur+ 1;
see Table 53)
4. Transitions to death
tp_death Non-stochastic
5. costs and resource use and health-related quality of life/utilitiesa
tdurtreat Normal distribution (see Table 55) –
nursevtreat Normal distribution (see Table 55) Normal (Table 55)
clinv Normal distribution (see Table 55) Normal (Table 55)
hospv Normal distribution (see Table 55) Normal (Table 55)
u_decunh Beta (see Tables 55 and 56) Beta (see Tables 55 and 56)
u_pop Normal distribution (CHE report, 1999167) Normal (CHE report, 1999167)
MCMC, Markov chain Monte Carlo.
a Note that the SEs are small compared with the point estimates, thus rather than using a distribution with a positive
support we were able to use the normal distribution (simulations do not return negative values).
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Chapter 17 Cost-effectiveness analyses: results
Base-case analysis
The base-case mean cost, benefits and ICERs for each of the evaluated compression therapies are shown
in Table 58. The estimated mean costs for the 2LB (two-component systems, with a top component that
is a cohesive bandage) were lower than those of other treatments, and its benefits were, on average,
the highest. Thus, all remaining interventions were dominated by this treatment.
Figure 19 summarises the main cost-effectiveness results. The 2LB, identified by an inverted triangle in the
figure, had the highest expected NBs. The 2LB system had the highest probability of being cost-effective
(between 70% and 80%) for threshold values from £0 to £100,000, whereas the HH achieved the second
highest probability of being cost-effective with values of between 20% and 30% (results not shown).
The estimated per-patient EVPI for the base case was approximately £1680 at a £20,000 threshold ratio
(Table 59). Considering the high incidence of venous leg ulcers (estimated at 365,000 per year), the
population EVPI was estimated to be approximately £2.9B for the same threshold value.
TABLE 58 Results of the base-case analysis
Intervention
Benefits (QALYs) Costs (£s)
Mean
incremental
benefits
(QALYs)
Mean
incremental
costs (£s) ICER (£s)Mean 95% CI Mean 95% CI
2LB 3.8595 3.329 to
4.3218
16,174.0 7565.5 to
31,534.3
– – Dominant
HH 3.8524 3.3619 to
4.3001
18,434.8 12,103.7 to
28,670.8
–0.0072 2261 Dominated
4LB 3.8061 3.278 to
4.2703
19,505.2 12,146.9 to
32,531.3
–0.0534 3331 Dominated
SSB 3.7769 3.2245 to
4.291
20,847.7 12,882.4 to
34,495.6
–0.0826 4674 Dominated
Paste 3.7322 3.1018 to
4.2343
23,196.1 12,154.7 to
40,226.3
–0.1274 7022 Dominated
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FIGURE 19 Effectiveness vs. costs (a) and NMB vs. probability of being cost-effective (b) for base-case analysis
(£20,000 threshold).
TABLE 59 Patient and population EVPI estimates for £20,000, £30,000 and £50,000 threshold values: both scenarios
under considerationa
Expected value of perfect information
Cost-effectiveness
threshold value (£)
Base-case analysis Scenario analysis
Per patient
Population
(× 1,000,000) Per patient
Population
(× 1,000,000)
20,000 1677 2866 3804 6501
30,000 1957 3346 4525 7734
50,000 2525 4315 6001 10,257
a The technology time horizon is assumed to be 5 years and the annual effective population (i.e. expected number of new
leg ulcer patients per year in the UK) considered is approximately 365,000 (based on estimated prevalence of 0.16%
and median time to healing of 99 days in VenUS IV).
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Contribution of VenUS IV to cost-effectiveness: the ‘without
VenUS IV’ scenario
In this scenario analysis, the decision model was run without evidence from VenUS IV. The results indicated
that, consistent with the base-case analysis, the 4LB, SSB and paste bandage were dominated by HH and
the 2LB. Contrary to the base case, HH (rather than the 2LB) was expected to offer the highest mean
QALYS (approximately 4.80 QALYs gained), but given its costs, HH was not deemed cost-effective at usual
threshold values (£20,000 to £30,000).
The 2LB system had the highest probability of being cost-effective, but without the information from
VenUS IV, uncertainty regarding the use of hosiery was higher (the probability of being cost-effective
would be 36%, Figure 20). Irrespective of the threshold value considered, individual and population EVPI
estimates for the scenario analysis were always higher than those estimated for the base-case analysis
(see Table 59). This indicates that the supplementary information provided by VenUS IV was valuable in
reducing the consequences of decision uncertainty.
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FIGURE 20 Effectiveness vs. costs (a) and NMB vs. probability of being cost-effective (b) for scenario analysis
(£20,000 threshold).
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Subgroup cost-effectiveness analysis: the impact of determinants
of ulcer healing and recurrence
With respect to the impact of baseline patient characteristics on the cost-effectiveness of treatments,
the base-case model suggests that, for all baseline ulcer durations analysed, decisions would be the same
as for the average patient population; i.e. the 2LB dominates all of the other treatment alternatives
(Table 60). However, as ulcer duration increases, the benefits from HH are more evident. For an ulcer with
24 months’ duration HH is still not cost-effective, but its ICER is estimated at approximately £38,000 per
QALY gained, a value closer to the range of £20,000–30,000, which NICE used to guide cost-effectiveness
decision-making. The 2LB was the treatment of choice for the range of reference ulcer sizes analysed.
Baseline ulcer area and duration determine two key components of health benefit in the decision model,
ulcer healing and recurrence probabilities. In Table 61 it is shown how these two factors may concurrently
influence the two model components.
Rather than looking at the impact of each subgroup specification individually, Table 62 shows how these
specifications may simultaneously affect adoption decisions. For smaller ulcers and ulcers of short duration,
the 2LB dominates all other comparators (with approximately 70% probability of being cost-effective at
£20,000), but for reference ulcers of 5 cm2 and of longer duration HH is far from being considered
cost-effective relative to the 2LB, with an estimated ICER of approximately £42,000 per QALY gained.
If the reference ulcer is large in size and of long duration, HH is also not cost-effective relative to the 2LB,
as decision-makers would need to be willing to pay approximately £95,000 per additional QALY.
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TABLE 61 Probability of ulcer healing and recurrence at 12 months, for 4LB, conditional on baseline area
(1, 5 and 25 cm2) and baseline duration (1, 3, 6, 12 and 24 months)
Area of
reference
ulcer (cm2)
Duration of
reference
ulcer (months)
No. (%) of patients (VenUS IV,
n= 451)
Probability (%) of
4LB ulcer healing
(12 months)
Probability (%) of
4LB ulcer recurrence
(12 months)
1 1 0–2 cm2 and 0–2 months: 20 (4.4) 97.6 25.1
3 0–2 cm2 and 2–4 months: 54 (12) 96.6 25.5
6 0–2 cm2 and 4–8 months: 31 (6.9) 95.9 27.2
12 0–2 cm2 and 8–16 months: 28 (6.2) 95.1 34.8
24 0–2 cm2 and > 16 months: 13 (2.9) 94.2 74.9
5 1 2–8 cm2 and 0–2 months: 11 (2.4) 88.2 25.1
3 2–8 cm2 and 2–4 months: 65 (14.4) 85.8 25.5
6 2–8 cm2 and 4–8 months: 46 (10.2) 84.2 27.2
12 2–8 cm2 and 8–16 months: 28 (6.2) 82.5 34.8
24 2–8 cm2 and > 16 months: 30 (6.7) 80.7 74.9
25 1 > 8 cm2 and 0–2 months: 5 (1.1) 70.9 25.1
3 > 8 cm2 and 2–4 months: 40 (8.9) 67.6 25.5
6 > 8 cm2 and 4–8 months: 36 (8) 65.5 27.2
12 > 8 cm2 and 8–16 months: 16 (3.5) 63.4 34.8
24 > 8 cm2 and > 16 months: 28 (6.2) 61.3 74.9
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Sensitivity analysis regarding the effectiveness of
two-layer bandage
In Part II we saw that the current relative effectiveness estimates for the 2LB (in terms of healing) are
low- or very low-quality estimates, in part due to the limited quality of the two direct RCTs driving these
estimates. Thus in Part II an extra ‘post hoc’ sensitivity scenario was used, which considered equivalent
effectiveness in healing for the 2LBs and 4LBs. Cascading these results here showed that, in this particular
situation, HH becomes the cost-effective treatment, dominating the remaining health interventions.
Figure 21 shows that, at a £20,000 ceiling ratio, HH is the treatment with highest probability of being
cost-effective (approximately 60%) and the one that provides higher net gains.
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FIGURE 21 Net monetary benefit vs. probability of being cost-effective for the scenario in which healing effect of
2LB is equivalent to 4LB (£20,000 threshold).
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Chapter 18 Discussion
Assessing the cost-effectiveness of alternative high-compression treatments for venous leg ulcers isimportant in a health-care system operating under a fixed budget. This work extended the within-trial
analyses presented in Part I by allowing other relevant alternatives (SSB, paste and two-layer system) to be
considered and by allowing a longer time frame to be considered. Moreover, the decision model allows
other health benefits, such as the effect of hosiery on recurrence, to be explicitly considered. To our
knowledge this is the first decision model analysis undertaken for high-compression treatments.
Cost-effectiveness of high-compression treatments
Current evidence suggests that the 2LB is the most cost-effective compression system to treat venous leg
ulcers (base-case analysis). However, this result is determined by ‘low-quality’ evidence on the relative
effectiveness on healing of 2LB (see discussion section of Part II). Thus, we conducted an alternative
scenario analysis, in which 2LB was assumed to be as effective as 4LB: the results demonstrated that 2LB is
no longer cost-effective (actually, the probability of this treatment being cost-effective is close to zero in
this scenario) and HH becomes cost-effective, as its benefits in terms of recurrence ‘compensate’ for its
additional costs in relation to other available treatments such as the 4LB.
We also evaluated the cost-effectiveness results for subgroups of the population using the base-case
analysis. We used determinants of healing and recurrence (baseline ulcer area and duration) to define such
subgroups. This analysis showed that, under current evidence, 2LB was cost-effective in all subgroups.
However, for patients with a longer duration of the ulcer and smaller area (e.g. ulcer size of 5 or 25 cm2
and 24 months’ ulcer duration), the probability of HH being cost-effective increases (to approximately
30%). However, in these cases, for HH to be adopted, decision-makers need to be ‘willing to pay’ or
displace large amounts of funds.
Study strengths and limitations
In the assessment performed in this work, the evidence base on effectiveness was sparse, as many of the
comparisons within the network contained only a small number of trials (see Part II). This led to high
uncertainty in some effectiveness estimates which, in turn, were propagated throughout the decision
model, affecting the estimates of costs and QALYs. Additional studies may be required to augment the
evidence base and reduce uncertainty over decisions on the cost-effectiveness of alternative strategies in
this area. Moreover, there were numerous decision model input parameters for which limited data existed.
This was addressed by imposing conservative assumptions of equivalence between some compression
treatments for some specific model parameters (e.g. treatment duration and nurse visits for 2LB were
assumed equivalent to the 4LB).
A fully parametric distribution (i.e. Gompertz) was assumed to adequately represent the time to recurrence
of healed ulcers. Other distributions were not attempted, as although the effect of a different distribution
could affect absolute outcomes, it is less likely that incremental cost-effectiveness would be affected.
Twelve tunnel states (representing 12 months) were incorporated in the decision model to reflect this time
dependency after healing, after which the probability of recurrence was assumed null. This assumption
was based on lack of evidence on recurrence after 12 months and the fact that it is known a priori that a
proportion of patients do not recur. This null recurrence after 12 months’ assumption could have been
relaxed by assuming a constant probability of recurrence, equal to one at 12 months, for all of the
subsequent model cycles.
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Value of further research
Given the uncertainty in the available data, and, consequently, in the decision regarding treatment choice,
it is important to explore whether investing in further research to reduce such uncertainty is worthwhile.
The maximum potential value of additional evidence was estimated to be approximately £2.9B at the
population level (for a cost-effectiveness threshold value of £20,000 and considering the potential users of
this technology, estimated at 365,000 per year). This represents the maximum value of further research
that might resolve existing uncertainties. Because this value exceeds the likely costs of further investigation,
additional research in this area is potentially worthwhile.
DISCUSSION
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Part IV Overall discussion
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Chapter 19 Overall discussion
Summary of findings from Parts I, II and III
Part I
Trial data from VenUS IV suggests that there is no evidence of a difference in time to ulcer healing for
people treated with HH and the 4LB (HR of 0.99, 95% CI 0.79 to 1.25; p= 0.96). More participants in the
HH group (39.3%) changed from their allocated trial treatment compared with the 4LB group (27.8%;
p= 0.01) and although there was no statistically significant difference in the number of adverse events
between groups – significantly more participants in the HH group reported one or more NSAEs during the
trial (70.0% vs. 58.0%; p= 0.050). However, time to recurrence might be lower in those allocated to HH
(HR 0.56, 95% CI 0.33 to 0.94; p= 0.026). Additionally, based on within-trial data alone, HH is very likely
to be cost-effective compared with the 4LB owing to a reduction in the number of nurse consultations
associated with hosiery and potentially, a reduction in recurrence.
Part II
When the evidence on effectiveness (in terms of healing of venous leg ulcers) was evaluated in the context
of all other high-compression treatments (through a MTC meta-analysis), the two-layer compression
bandage (two-component system with a top component that is a cohesive bandage) had the highest
probability of ulcer healing (72%) compared with the HH (16% probability), paste bandage (6%), 4LB
(6%) and SSB (0%). However, the evidence regarding the 2LB is categorised as low to very low quality.
We are far more confident in the MTC’s finding that the SSB is less effective than both the 4LB and HH.
This evidence is categorised as medium to high quality, partly owing to the presence of VenUS I7 and IV data.
Part III
When analyses were extended to include all potential health benefits and the costs incurred by patients
with venous leg ulcers, results suggest that the 2LB system (two-component system with a top component
that is a cohesive bandage) had the highest probability of being the most cost-effective high-compression
treatment for venous leg ulcers. As in Part II, the low quality of the RCT data for the effects of the 2LB
mean that considerable uncertainty remains. Balance must be sought between acknowledging the
comprehensiveness of this model in terms of utilising all available evidence to inform decision-making and
recognition of the limitation of available evidence regarding some treatments.
Conclusions
Trial data from VenUS IV found no evidence of a difference in venous ulcer healing between HH and
four-layer bandaging. The results also suggested that HH may reduce ulcer recurrence rates when
compared with the 4LB and be a cost-effective treatment. However, more people allocated HH changed to
another treatment and more participants in the two-layer compression hosiery group reported NSAEs.
In additional analysis, when all high-compression treatments were considered, the 2LB had the highest
probability of being clinically effective and cost-effective. However, the quality of the underlying
evidence was sparse and poor overall.
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Contribution of this study to the evidence
This RCT addressed an important clinical uncertainty in leg ulcer care. We also considered these new
trial data in conjunction with those from all other relevant RCTs of high-compression treatments.
Furthermore, we combined these data with all other evidence relevant to this decision problem in order to
estimate the most cost-effective high-compression treatment.
Together, these three stages [(1) RCT; (2) synthesis of effectiveness evidence; and (3) cost-effectiveness
modelling] provide the most comprehensive evidence up-to-date evidence regarding the relative
clinical effectiveness and cost-effectiveness of high-compression treatments for active venous
leg ulceration.
Implications for health care
The results of this study (which incorporates a RCT, a MTC and a cost-effectiveness model) suggest that
hosiery is as effective as the 4LB in healing venous leg ulcers, although more patients may change from HH
during the course of treatment thus it may not be the optimal treatment for all patients. Importantly,
while wearing HH, participants were seen by nurses on fewer occasions and so this treatment was more
cost-effective than the 4LB. Participants in the HH group also demonstrated lower rates of ulcer recurrence
than those in the 4LB group; an interesting finding that we are not able to fully explain. It may be that
patients who wear HH as an ulcer treatment are more likely to wear compression stockings for secondary
prevention after healing (and may wear higher compression); we are unable to confirm this hypothesis
with the trial data.
Two-layer hosiery is a cost-effective alternative to four-layer bandaging and can be considered as a
treatment for those people with venous leg ulcers who are suitable for this treatment, for example if they
or a carer are able to apply the hosiery. We have limited information regarding the practicality of using HH
with different dressing types (in terms of ease of hosiery application while keeping specific dressings
in place).
Although all current evidence suggests that two-layer compression bandaging may be an effective and
cost-effective treatment for venous leg ulcers, this conclusion is associated with significant uncertainty as
the existing evidence comprises small and low-quality trials.
Recommendations for future research
Analyses presented in this report demonstrate that VenUS IV was worthwhile, as it determined the value
of HH in treating active venous ulceration. The value of further information analysis showed that the
inclusion of VenUS IV considerably reduced the consequences of decision uncertainty.
The findings of Parts II and III emphasise the tentative nature of the evidence supporting the use of 2LB.
As the 2LB is in current clinical use, even although there is uncertainty regarding its clinical effectiveness
and cost-effectiveness, we suggest that important further research is required. This further research should
focus on establishing the comparative effectiveness of the two-layer compression bandage with HH.
OVERALL DISCUSSION
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Appendix 1 Details of regulatory approvals
obtained for each trial centre
Centre name
Date approvals
secured
Organisation that gave NHS
RM&G approval
Time taken
for approvals
(days)a
Bolton 4 May 2010 Bolton PCT 165
Bradford 13 May 2010 Bradford Teaching Hospitals NHS Trust 91
Brightonb 14 April 2010 Sussex NHS Research Consortium 160
Cambridgeb 10 November 2010 NHS Cambridgeshire 65
Cornwall 13 April 2010 Cornwall and Isles of Scilly PCT 98
Danetre 3 March 2011 NHS Northamptonshire 90
Dereham 19 October 2010 Norfolk Community Health and Care 12
Diss 22 October 2010 Norfolk Community Health and Care 2
Epsom 16 June 2010 Epsom and St Helier University Hospitals NHS Trust 118
Hainault 13 December 2010 NHS Havering 136
Harrogate Hospital 16 April 2010 Harrogate and District NHS Foundation Trust 92
Harrogate (GP Buckley) 4 May 2011 NHS North Yorkshire and York 20
Harrogate (GP Robinson) 22 June 2011 NHS North Yorkshire and York 72
Harrogate (GP Taylor) 6 May 2011 NHS North Yorkshire and York 25
Hull 11 January 2010 Hull and East Yorkshire Hospitals NHS Trust 160
Kent 2 March 2010 Eastern and Coastal Kent Community Services 19
Kingston 2 December 2009 NHS Kingston 97
Lancashire 15 January 2010 NHS Central Lancashire 37
Latham house 24 January 2011 NHS Leicestershire County and Rutland 26
Leeds 22 October 2009 NHS Leeds 113
Mid Yorkshireb 12 August 2010 Mid Yorkshire Hospitals NHS Trust 212
Mowbray Square 5 December 2011 NHS North Yorkshire and York 47
Nantwich 14 October 2011 Central and Eastern Cheshire PCT 81
Northern Ireland 14 January 2010 Western Health and Social Care Trust 79
North Lancashire 19 November 2010 NHS North Lancashire 37
North Yorkshire 14 December 2009 North Yorkshire and York PCT 102
Northumberland 18 April 2011 Newcastle PCT 46
Norwich 19 October 2010 Norfolk Community Health and Care 1
Nottingham 23 April 2010 NHS Nottinghamshire County and NHS
Nottinghamshire City
218
Sedgefield 18 October 2010 County Durham PCT 7
South of Tyne and Wear 26 July 2010 NHS South of Tyne and Wear 12
DOI: 10.3310/hta18570 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 57
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Ashby et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
155
Centre name
Date approvals
secured
Organisation that gave NHS
RM&G approval
Time taken
for approvals
(days)a
Suffolk 8 December 2010 NHS Suffolk 9
Whitby 22 December 2010 NHS North Yorkshire and York 163
York Hospital 20 May 2010 North Yorkshire and York PCT 14
PCT, Primary Care Trust; RM&G, research management and governance.
a Median= 75.5 days; 25–75th percentiles= 20–113 days; minimum–maximum= 1–218 days.
b During this study, these centres recruited from more than one site. In these cases, the reported time taken for approvals
reflects the longest time taken to issue approvals.
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Appendix 2 Details of trial centres
Centre name Sources of recruitment
Date recruited
First participant Last participant
Bolton CN team/service, leg ulcer clinics, tissue viability
clinics, treatment room clinics
1 June 2010 3 February 2012
Bradford Outpatient clinics 17 June 2010 24 January 2012
Brightona CN teams/service, GP practices and leg
ulcer clinics
5 May 2010 28 February 2012
Cambridgea CN teams/service, GP practices and tissue
viability clinics/services
10 January 2011 3 October 2011
Cornwall CN teams/service, GP practice, tissue
viability/vascular clinic and leg ulcer clinics
18 June 2010 28 February 2012
Danetre GP practice N/A N/A
Dereham Outpatient leg ulcer clinic 21 December 2010 28 February 2012
Diss Leg ulcer clinics 5 January 2011 23 February 2012
Epsom and St Helier Outpatient leg ulcer clinic 9 July 2010 19 August 2011
Hainault Leg ulcer clinic 15 March 2011 12 May 2011
Harrogate Hospital Outpatient leg ulcer clinic 7 July 2010 10 October 2011
Harrogateb GP practice 10 June 2011 27 July 2011
Harrogatec GP practice 11 November 2011 11 November 2011
Harrogated GP practice 17 June 2011 17 June 2011
Hull Outpatient leg ulcer clinics 26 March 2010 12 April 2011
Kent GP practices and leg ulcer clinics 2 June 2010 5 October 2011
Kingston Leg ulcer clinics 18 October 2010 18 October 2010
Lancashire GP practices and leg ulcer clinics 22 February 2010 27 February 2012
Latham house GP practice 1 March 2011 5 December 2011
Leeds CN teams/service, GP practices, leg ulcer clinics
and tissue viability clinics/service
16 November 2009 17 February 2012
Mid Yorkshirea CN teams/service, plastic dressing clinics and
vascular clinics
1 September 2010 24 February 2012
Mowbray Square GP practice 18 January 2012 18 January 2012
Nantwich GP practice 17 November 2011 17 November 2011
Northern Ireland Outpatient leg ulcer clinics 6 April 2011 22 February 2012
North Lancashire GP practice and wound clinics 2 February 2011 2 February 2011
North Yorkshire CN teams/service, GP practices and tissue
viability clinics/services
30 April 2010 19 July 2011
Northumberland CN teams/service, leg ulcer clinics and
wound clinics
28 June 2011 29 February 2012
Norwich Outpatient leg ulcer clinic 11 January 2011 8 February 2012
Nottingham CN teams/services and leg ulcer clinic 24 June 2010 20 April 2011
Sedgefield GP practice 21 June 2011 21 June 2011
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Centre name Sources of recruitment
Date recruited
First participant Last participant
South of Tyne and Wear CN teams/service, GP practices, leg ulcer clinics
and tissue viability clinics/services
9 November 2010 31 January 2012
Suffolke N/A N/A N/A
Whitby GP practice 10 January 2011 11 July 2011
York Hospital Outpatient clinic 2 July 2010 25 November 2011
CN, Community Nurse/nursing; N/A, not applicable.
a During this study, these centres recruited from more than one site.
b GP Buckley.
c GP Robinson.
d GP Taylor.
e Centre withdrew prior commencing screening participants.
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Appendix 3 Pre-trial screening form
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Appendix 4 Patient information sheet and
consent form
Patient information sheet
 
 
Patient Information Sheet  
 
VenUS IV Leg ulcer 
study: Patient 
Information sheet 
 
Please read this document 
carefully. 
We would like to invite you to 
take part in a research study.  
Before you decide whether to 
take part, it is important for you to 
understand why the research is 
being done and what it will 
involve.  Please take time to read 
the following information 
carefully. Feel free to discuss this 
with anyone else you wish, for 
example, a friend / nurse / doctor 
or relative.  Ask us if there is 
anything that is not clear.  We are 
happy to provide more 
information. Take as much time 
as you need to decide whether 
you want to take part.   
Thank you for reading this. 
 
What is the purpose of this 
study? 
Applying compression to the leg 
is an important treatment in leg 
ulcer care, since it can help to 
improve blood flow. Compression 
can be applied in the form of 
bandages, with up to four  
 
bandages being applied to the 
leg at the same time, or in the 
form of compression hosiery 
(also called compression 
stockings).  Both the bandaging 
and stockings approaches are 
used in the NHS and we are not 
sure which is best at healing 
ulcers. This is why we are 
conducting this study, to find out 
how effective compression 
stockings are in the treatment of 
venous leg ulcers when 
compared to compression 
bandaging. 
 
What is the treatment being 
studied? 
Traditionally, compression has 
been applied to the leg using 
layers of bandages. 4-layer 
compression bandaging is where 
four different bandages are 
applied to the leg, one-on-top of 
the other. However, more 
recently, compression stockings 
have been developed which 
deliver the same amount of 
compression as layers of 
bandages. Compression 
stockings are made of two 
stockings that are worn over one 
another at the same time. These 
stockings have been specially 
designed so that the second 
layer is able to slip easily over 
the first. We are comparing 
compression stockings with 4-
layer compression bandaging.  
Why have I been chosen? 
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Your nurse and / or doctor think 
that the type of leg ulcer you 
have means that you could take 
part in this study.   We hope 
about 490 people with leg ulcers 
will take part in this study from 
across the UK.  
Do I have to take part? 
Participation in this study is 
entirely voluntary.  It is up to you 
to decide whether or not to take 
part.  If you do decide to take 
part, you will be given this 
information sheet to keep and 
you will be asked to sign a 
consent form.  If you do agree to 
take part in this study and decide 
at a later time that you would like 
to withdraw from the study, then 
you are free to do so at any time. 
Your decision will not influence 
your future care or treatment. 
  
What will happen to me if I 
agree to take part? 
We are interested in how quickly 
leg ulcers heal, and also in your 
opinion about the compression 
treatment you receive.  If you 
agree to take part in this study 
you will be allocated to one of 
two treatments: treatment with 4-
layer compression bandaging or 
treatment with compression 
stockings. The decision regarding 
which treatment you receive will 
be made after you agree to take  
part. The choice of treatment will 
be determined at random, that is, 
no-one,  including your doctor or 
nurse, can predict which 
treatment you will receive. You 
will have an equal chance of 
receiving either treatment, in the 
same way that tossing a coin 
gives an equal chance of getting 
‘heads’ or ‘tails’. This type of 
study where the treatment is 
determined randomly is called a 
randomised controlled trial. One 
out of every two people in this 
trial will receive compression 
stockings.    
What do I have to do? 
You will continue seeing your 
nurse for your leg ulcer 
treatments. We do not anticipate 
that you will have to see the 
nurse or doctor more frequently 
than you would normally do.  
At the start of the study, your 
ulcer will be measured and 
photographed, and then 
photographed again at regular 
intervals. We will send you a 
questionnaire 1 month after you 
start the study to ask you about 
your views on your treatment. At 
3, 6, 9 and 12 months after you 
start the study, a questionnaire 
will be sent to you, asking about 
your general health.  
We are also testing a new 
questionnaire which measures 
the impact of leg problems upon 
your daily life. We will send you 
this questionnaire 2 weeks and 4 
months after you start the study.   
The study will last for 12 months. 
If your ulcer heals during the 
study, we will still send you 
questionnaires and your nurse 
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will also be in contact with you to 
monitor your progress.  
There are no restrictions on your 
activity when you are in this 
study.  You will continue with any 
other medical care or treatments, 
such as taking regular 
medication, as you would 
normally do. There are no 
limitations on you seeking other 
medical advice, if you need to, 
whilst you are taking part in this 
study.  
 Why are we doing the study? 
Compression stockings may or 
may not be more effective than 
using 4-layer compression 
bandaging but we do not know if 
this is the case. It is therefore 
important to carry out this study 
so leg ulcer patients can be 
provided with the most 
appropriate and effective care. 
Without this information patients 
may receive inefficient care, and 
precious NHS money may be 
wasted. 
 
Are there any alternatives to 
the treatments being studied? 
There are alternative treatments 
available for the treatment of 
venous leg ulcers and your nurse 
will be happy to discuss other 
treatment options with you, if you 
wish. However, compression 
therapy is currently the most 
effective treatment for venous leg 
ulcers. Compression therapy can 
be applied using either bandages 
or stockings, but we do not know 
which of these is the best for 
treating venous leg ulcers.   
 
Are there any side effects from 
the treatments being 
investigated? 
Side effects to either treatment 
being used in this trial are 
uncommon. Whilst we do not 
anticipate any specific side 
effects as a result of taking part 
in this trial, in extremely rare 
circumstances, some patients 
may be allergic to materials 
which are contained within the 
bandages or hosiery. If this is the 
case, we will use another product 
which does not contain that 
material.  
 
Are there possible 
disadvantages to taking part? 
We do not anticipate that being in 
this trial will harm you.  Should 
this occur, however, normal NHS 
negligence procedures apply. If 
you have any medical queries or 
in an emergency you should 
contact your doctor or nurse as 
you would normally do. The 
name of a contact research nurse 
responsible for this research 
study in your area and the 
telephone number where they 
can be reached is provided 
below. We have also provided 
the number of the person 
responsible for running this 
study, who is based at The 
University of York. We can not 
guarantee that the research 
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nurse or person running the trial 
will always be available to take 
your call (some research nurses 
work part-time) but we will always 
return your call as quickly as we 
can.  
 
What are the possible 
advantages of taking part? 
We hope that your ulcer will 
improve with either of the 
treatments being tested 
(compression bandages or 
compression stockings). 
Although we are unable to 
guarantee that your ulcer will 
improve by your being in the trial, 
the information we get from this 
study may help us to better treat 
people with venous leg ulcers.   
What if new information 
becomes available? 
Sometimes during a research 
project, new information 
becomes available.   If this 
happens, your nurse / doctor will 
tell you about it.   They will 
discuss with you whether you 
want to continue in the study. If 
you decide to withdraw from the 
study your care will continue as it 
would normally. If you decide to 
continue, then you will be asked 
to sign an updated consent form.   
If new information means that 
your nurse / doctor decides to 
take you out of the study, then 
she / he will discuss this with you. 
He/she will explain the reasons 
for this and arrange for your leg 
ulcer care to continue as it 
normally would outside of the 
study.  
 
What happens when the 
research study stops? 
Both treatments being evaluated 
are available to every nurse / 
doctor in the UK.  After the 
research stops both treatments 
are likely to continue to be 
available throughout the UK.  
 
What if something goes 
wrong? 
If taking part in this research 
project harms you, there are no 
special compensation 
arrangements.  If you are harmed 
due to someone’s negligence, 
then you may have grounds for 
legal action but you may have to 
pay for it.  Regardless of this, if 
you wish to complain, or have 
any concerns about any aspect 
of the way you have been 
approached or treated during the 
course of this study, the normal 
National Health Service 
complaints mechanisms should 
be available to you. 
 
Will my taking part in this 
study be kept confidential? 
All information that is collected 
about you during the course of 
the research will be kept strictly 
confidential.  At the beginning of 
the trial we will record your name 
and address and ask you to sign 
a consent form. This information 
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will be stored securely at the 
University of York.  We will also 
let your GP know that you are 
taking part in the trial, and which 
treatment you are receiving. All 
further information about you that 
leaves hospital/surgery/home will 
not contain your name or 
address, so you cannot be 
recognised from it.  This includes 
digital photographs of your ulcer 
that will be taken during the 
study. These will be sent by e-
mail or posted. Again, these 
images will not have your name 
or any details about you on them.  
 
If you consent to take part in the 
research, the University of York 
(for purposes of checking data 
collection) may inspect your 
medical and nursing records. 
People from regulatory 
authorities may also look at your 
records to check that the study is 
being carried out correctly.   
 
What will happen to the results 
of the study? 
The results of the study will be 
published in medical and nursing 
journals.   You will be able to 
obtain a copy of the results from 
the University of York upon 
request, when these become 
available.  You will not be 
identified in any publication 
arising from this study.   
 
Who is organising and funding 
the research? 
The study is being funded by the 
National Institute for Health 
Research. Your nurse or doctor 
is not personally receiving any 
money for including you in the 
trial. The study is being 
organised by researchers from 
the University of York.   
 
Who has reviewed the study? 
Your Local Research Ethics 
Committee has approved this 
study.  
 
What do I do now? 
If you are interested in taking part 
please sign the consent form, 
returning it to your study nurse. 
 
Where can I get more 
information about the study? 
If you do not understand anything 
on this information sheet or 
would like further information, 
please contact your nurse on the 
telephone number below.   
 
Research nurse:   
 
 
Alternatively you can contact the 
Study Coordinator:  
Rebecca Ashby:    
York Trials Unit, Area 4,  
Seebohm Rowntree Building,  
The University of York, YO10 
5DD 
Telephone: (01904) 321 904 
Email: ra529@york.ac.uk 
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Where can I get more 
information about taking part 
in research?  
If you would like general advice 
about taking part in research, you 
can contact the Patient Advice 
and Liaison Service (PALS). You 
can contact you local PALS by 
phoning your local hospital, clinic, 
GP surgery or health centre and 
asking for PALS, or by phoning 
NHS Direct on 0845 4647, or via 
the web at  
http://www.pals.nhs.uk/ 
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Consent form
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Appendix 5 Data collection forms
(forms completed by health-care professionals)
Patient record form
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Treatment log: trial dressing log booklet
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Treatment log: non-trial dressing log booklet
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Participant event form
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Serious adverse event form
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Review of serious adverse event form
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Non-serious adverse event form
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Review of non-serious adverse event form
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Ulcer healed form
DOI: 10.3310/hta18570 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 57
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Ashby et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
189
Monthly nurse assessment form
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Appendix 6 Data collection forms
(questionnaires completed by participants)
Participant baseline questionnaire
DOI: 10.3310/hta18570 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 57
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Ashby et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
191
APPENDIX 6
NIHR Journals Library www.journalslibrary.nihr.ac.uk
192
DOI: 10.3310/hta18570 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 57
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Ashby et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
193
APPENDIX 6
NIHR Journals Library www.journalslibrary.nihr.ac.uk
194
DOI: 10.3310/hta18570 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 57
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Ashby et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
195
APPENDIX 6
NIHR Journals Library www.journalslibrary.nihr.ac.uk
196
DOI: 10.3310/hta18570 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 57
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Ashby et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
197
APPENDIX 6
NIHR Journals Library www.journalslibrary.nihr.ac.uk
198
DOI: 10.3310/hta18570 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 57
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Ashby et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
199
APPENDIX 6
NIHR Journals Library www.journalslibrary.nihr.ac.uk
200
DOI: 10.3310/hta18570 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 57
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Ashby et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
201
APPENDIX 6
NIHR Journals Library www.journalslibrary.nihr.ac.uk
202
DOI: 10.3310/hta18570 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 57
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Ashby et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
203
Participant 1-month questionnaire: four-layer bandage
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Participant 1-month questionnaire: compression hosiery
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Participant 3-month questionnaire (same as 6-, 9- and
12-month questionnaires)
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Participant postcard
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Appendix 7 Digital photography protocol
Every digital photograph must include the colour reference target card, which includes a centimetremeasuring scale and colour targets. The patient’s trial number and date must always be clearly written
on the colour target card. Please make sure that the colour target card is included in the photograph
otherwise the photograph cannot be used as data collected.
l Please take two photographs at baseline of the reference ulcer and the reference leg.
l Each month you will need to take a photograph of the reference ulcer.
l Please take a photograph of the reference ulcer site when the reference ulcer is reported as healed.
You will also need to take a photograph of the healed site once per week for 4 weeks.
Please always try to take a photograph of the reference leg ulcer from directly above the wound; if it is
photographed at an angle then it may be difficult to assess the wound accurately.
In the case of circumferential wounds additional adjacent photographs may be required.
Every reasonable effort must be made to take all consecutive photographs from the same viewpoint and
distance using the same camera and same zoom facility.
Please ensure that the ulcer and surrounding area are cleaned thoroughly before taking the photograph.
This is to reduce the possibility of blinded assessors being able to predict the treatment received by
the patient.
All consecutive views of the reference ulcer area to be photographed using the trial camera.
All cameras have been calibrated so they are standardised to the same specification – please do not
change any of these settings at any time. All cameras have been calibrated to the same specification as
follows: Easy Auto mode – the camera responds to the shooting conditions at the time and controls
the majority of camera settings. White balance is automatically set and used to preserve the natural
colours under types of lighting.
The flash is set to automatic.
All digital photographs to be kept confidential and secure for the duration of the trial. Patient
confidentiality will be maintained throughout trial by the use of unique trial numbers.
No film, recording media or data to be manipulated or changed in any way with the intention of affecting
the results of the trial.
All photographs taken during the trial will be uploaded on to the management database system.
When you have uploaded the photograph, please delete it from the memory card. DO NOT COMPRESS
PHOTOS – Upload them straight from the camera on to the management database.
All cameras are supplied with a guide and it might be helpful to read this before you start to use
the camera.
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Taking photographs: framing the picture
Switch the camera ON. You may need to set the date and time. Press the picture/scene button and choose
the Easy Auto mode. Hold the camera steadily in both hands about 18 inches to 2 feet away from the
patient. Zoom in using the optical zoom facility on the camera (press ‘T’), ensuring that the whole of
the wound area and the colour reference target card are included in the picture.
When you press the ‘T’ button, a white oblong box will appear in the top of the viewfinder and a bar will
move towards the line (two-thirds along the box) until it stops. Stop pressing the ‘T’ button at this stage
and take your photograph. Press the ‘W’ button to zoom out. Depress the shutter button half way to
focus the image, depress fully to take the photograph.
Once you have taken the photograph, press the picture playback button to assess the quality of the
photograph. If the photo is of poor quality, please take another image(s).
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Appendix 8 VenUS IV flow chart
Pre-trial screening forms of ineligible patients were
returned to the York Trials Unit
Ineligible patients whose sole reason for exclusion was
because they had gross leg oedema or high exudate
levels were rescreened once these conditions had
been managed
Eligible patients were given a patient information
leaflet (see Appendix 3) and given time to consider
whether they wished to participate within the trial
Participants allocated to four-layer high-compression
bandaging received their trial treatment immediately
after randomisation. Treatment details were recorded
in the treatment log: trial dressing log booklet
(see Appendix 5)   
Participants allocated to high-compression hosiery
received their trial treatment immediately after
randomisation. Treatment details were recorded in
the treatment log: trial dressing log booklet
(see Appendix 5)   
PRE-TRIAL SCREENING
RANDOMISATION AND BASELINE MEASUREMENTS
FOLLOW-UP
TRIAL EXIT
Treatment: Details of all further treatment visits for the treatment of venous leg ulcers on the reference leg
were recorded in treatment logs (trial dressing log booklets, see Appendix 5). If a participant could no longer
receive their allocated trial treatment, the reason for treatment change was recorded in the treatment log:
trial dressing log booklet (see Appendix 5). The participant then received an appropriate treatment
(as dictated by the treating nurse) and all subsequent treatment visits for the treatment of venous leg ulcers on
the reference leg were recorded in the treatment log: non-trial dressing log booklets (see Appendix 5)
Photographs: Digital photographs of the reference ulcer were taken on a monthly basis for a maximum of
12 months, or until healing occurred
Healing: When the reference ulcer was considered healed this was reported via the York Trials Unit
randomisation line and the ulcer healed form (see Appendix 5). A photograph of the healed site was taken on
the day of healing and then once per week for 4 weeks. Nurses were also required to report the date the
reference leg healed (i.e. was ulcer free)
Ulcer recurrence: If there was an ulcer recurrence after the reference leg was reported as healed, this
information was captured via the monthly nurse assessment form and also the participant postcard
Adverse events: Participants were monitored for any adverse events which were recorded as they occurred
via serious (see Appendix 5) and non-serious (see Appendix 5) adverse event forms
Other participant events: Details of participant hospitalisations or change to data collection was recorded
via a  participant event form (see Appendix 5)
Patients were screened for eligibility according to the pre-trial inclusion and exclusion criteria by nurses using
the pre-trial screening form (see Appendix 4)
Participant exited the trial 12 months post randomisation, or sooner if there was another reason for exit
The reason for exit was recorded in the participant event form (see Appendix 5)
Valid informed consent was obtained from those patients who wished to participate within the trial. Patients
signed a consent form (see Appendix 3) and completed a baseline questionnaire (see Appendix 4). Nurses completed
a patient record form (see Appendix 4) and took a digital photograph of the reference ulcer and reference leg
Nurses telephoned the York Trials Unit randomisation line (or used an online service) to randomise the patient.
The participant’s allocated treatment was recorded on the registration form (contained within patient record
form, Appendix 4)
PARTICIPANT QUESTIONNAIRES
Participants were sent questionnaire with the SE-12 and EQ-5D every three months from recruitmentt
They were also asked to complete a questionnaire about concordance at 1 month (see Appendix 6)   
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Appendix 9 Decision rules for verification
of the primary outcome measure (healing of
the reference ulcer)
1. If the two assessors disagree whether the reference ulcer has healed, there will be the following
combinations with regards to healing: yes/no, yes/unsure, no/unsure.
i. If the two assessors say: ‘yes/unsure’ then we will say the ulcer has healed, using the date provided
by the assessor who said ‘yes’.
ii. If the two assessors say ‘no/unsure’ then we will say the ulcer has not healed.
iii. If the two assessors say ‘unsure/unsure’ then we will say the ulcer has not healed.
iv. If the two assessors say ‘yes/no’ then the third assessor will be consulted and will decide if the
ulcer is healed or not. The third assessor’s decision will be final – the third assessor will decide
if the ulcer has healed or not. If she/he is unsure whether the ulcer has healed, the ulcer will be
considered unhealed.
2. If the two assessors agree that the ulcer is healed, but have chosen different dates of healing, we will
take a consistently conservative approach and say that the longer time is the right time.
3. If no photographs of the reference ulcer are available, the unblinded date the treating nurse recorded
will be used.
4. If the (treating) nurses say that the wound is healed and stop taking photographs but blinded assessors
says the wound is not healed then we will consider the wound healed.
5. If photos are taken of a participant for 12 months and the date of healing occurs beyond 12 months
post-randomisation, the participant will be regarded as unhealed at 12 months.
6. If an assessor says she/he is unsure whether a participant had healed, but provides a date of healing
anyway, the date of healing will not be recorded. This is because we are recording dates of healing only
if the assessor has selected the ‘yes’ option to indicate that the participant has healed.
7. Photos taken after a large interval of time has elapsed (i.e. ≥ 1 month) since the due date of the last
healed photo (post-healed photo 4) will not be included in the blinded outcome assessment.
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Appendix 10 Guidance for nurses regarding the
relationship between a non-serious adverse event
and trial treatment
Non-serious adverse events decision rules
An adverse event may be defined as any undesirable experience occurring in a participant, whether or not
considered related to the treatment being used in the trial. Where the adverse event is not considered to
be serious, the event is commonly referred to as a NSAE.
In VenUS IV, we ask that you diligently report both SAEs and NSAEs. When completing the NSAEs form,
you will be asked if you think that the event that occurred is related to trial treatment. You can choose
from the following options:
1. unrelated
2. unlikely to be related
3. possibly related
4. probably related
5. definitely related
6. not able to assess if related.
l We now recommend that any non-serious event involving a venous leg ulcer should be considered to
be, at the very least, possibly related to the trial treatment (bandages or stockings).
l We also ask that you let us know if the event occurred on the reference or non-reference leg.
l If there is an ulcer recurrence, please specify to which leg this applies.
We also provide the following guidance:
Classified as possibly related All other events involving the ulcer, ulcerated leg and/or skin, which are not
probably or definitely related and are not the result of an accident (defined as a trip/fall/DIY related,
not considered to be caused by the trial treatment), include ulcer recurrence and events caused by
treatments other than 4LB or stockings. State whether the event relates to the reference or
non-reference leg.
Classified as probably related Increase in ulcer size, increased pain, discolouration of treated leg,
new ulceration to treated leg, blistering to a treated leg. State whether the event relates to the reference
or non-reference leg.
Classified as definitely related Treatment-related skin trauma (i.e. skin damage attributable to the bandage
or stocking), strong evidence that bandage or stocking caused the event. Nurse to state whether event
relates to reference or non-reference leg.
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Appendix 11 Data from randomised controlled
trials used to inform the mixed-treatment
comparison network
All available studies
ID Studies Evaluated treatment
High or
not
Partsch
classification
Final
classification
No. of
patients
Follow-up
(weeks)
Studies including non-high-compression treatments
2 Cordts
199294
Hydrocolloid dressing (Duoderm) plus
cohesive elastic bandage (Coban)
Not Bc Bc 23 12
Unna’s boot (Dome-Paste, a zinc oxide
and calamine impregnated bandage)
Not Bz Bz 20 12
3 Eriksson
198695
Inner stocking impregnated with zinc
oxide paste plus an outer elastic
bandage (Tensoplast or Porelast Acryl)
High Bza Paste 17 12
Hydrocolloid dressing (Duoderm)
plus elastic bandage (Wero)
Not Be Be 17 12
4 Travers
1992126
Single-component system with elastic
cohesive bandage (Panelast Acryl)
applied from foot to below knee with
50% overlap
High Ba Ba 15 7
Three-component system applied from
foot to below knee: zinc oxide and
calamine paste bandage (Calaband);
non-adhesive elastic bandage
(Tensopress) applied with 50% overlap
and 50% stretch; and elasticated
tubular bandage (Tensogrip)
Not Bzee Bzee 12 7
6 Nelson
200796
Single-layer bandage (hydrocolloid-lined,
woven, elastomeric, adhesive bandage
applied in a figure-of-eight technique
from toe to knee)
Not Ba Ba+ 128 24
Original Charing Cross four-layer
bandage comprising wool, crepe,
Elset and Coban
High Beec 4LB 117 24
7 Danielsen
199897
Lower leg padded with gauze then
long-stretch, non-adhesive compression
bandage (Setopress) applied in a spiral
with 50% overlap and approximately
86% extension
Not Be Be 23 52
Lower leg padded with gauze then
short-stretch, non-adhesive compression
bandage (Comprilan) applied in a spiral
with 50% overlap
Not Bi Bi 20 52
8 Moody
199998
Undercast padding (Cellona) plus
short-stretch compression bandage
(Rosidal K)
Not Bi Bi 26 12
Undercast padding (SurePress padding)
plus long-stretch compression bandage
(SurePress bandage)
Not Be Be 26 12
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ID Studies Evaluated treatment
High or
not
Partsch
classification
Final
classification
No. of
patients
Follow-up
(weeks)
9 Moffatt
200399
Profore High Beec 4LB 57 12
2LB (Surepress) Not Be Be 52 12
10 Callam
1992100
Three-component compression system:
orthopaedic wool (Soffban Natural),
elastic bandage (Tensopress) and
cotton-elastic graduated compression
tubular support bandage (Tensoshape)
Not Bee Bee+ 65 12
Three-component compression system:
orthopaedic wool (Soffban Natural),
non-elastic cotton-elastic bandage
(Elastocrepe) and non-elastic cotton Lycra
cohesive bandage (Tensoplus Forte)
High Bic Bic 67 12
11 Gould
1998101
Three-component compression system:
medicated paste bandage, elastic
bandage (Setopress) and elasticated
viscose stockinette
Not Bze Bze 19 15
Three-component compression system:
medicated paste bandage, cotton crepe
bandage (Elastocrepe) and elasticated
viscose stockinette
Not Bzee Bzee 20 15
12 Meyer
2002102
Viscopaste bandage plus Tensopress
(elastic bandage) plus Tensoshape
(graduated cotton-elastic tubular
retaining bandage)
Not Bzee Bzee 57 40
Viscopaste bandage plus Elastocrepe
(inelastic bandage) plus Tensoshape
(graduated cotton-elastic tubular
retaining bandage)
Not Bzie Bzie 55 40
15 Moffatt
1999103
Original Charing Cross four-layer
bandage comprising wool, crepe,
Elset and Coban
High Beec 4LB 115 24
Profore High Beec 4LB 117 24
16 Vowden
2000104
Original Charing Cross four-layer
bandage system: orthopaedic wool
(Soffban), crepe bandage (Smith &
Nephew), elastic bandage (Elset,
Seton Scholl) and elastic cohesive
bandage (Coban)
High Beec 4LB 50 20
Modified Charing Cross four-layer
bandage system: orthopaedic wool
(Soffban), elastic bandage (K-Lite),
elastic bandage (K-Plus, Parema) and
adhesive elastic bandage (Coban)
High Beea 4LB 50 20
A four-layer bandage kit (Robinson
Ultra Four): wound dressing, Sohfast,
K-Lite, K-plus and Cohfast
High Beec 4LB 49 20
22 Knight
1996127
Profore High Beec 4LB 5 –
Unna’s boot (described as a
paste impregnated gauze
compression dressing)
Not Bz Bz 5 –
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ID Studies Evaluated treatment
High or
not
Partsch
classification
Final
classification
No. of
patients
Follow-up
(weeks)
24 Meyer
200325
Three-layer bandage: Steripaste
bandage plus Setopress bandage plus
Tubigrip bandage
Not Bzee Bzee 64 52
Four-layer bandage system: orthopaedic
wool (Velband); crepe bandage; elastic
bandage (Elset); and elastic cohesive
bandage (Coban)
High Beec 4LB 69 52
25 DePalma
1999125
Unna’s boot consisting of zinc oxide,
glycerin and gelatin impregnated
10 cm× 9m roller gauze bandage
(Medicopaste) covered by an elastic
Ace-type bandage
Not Bze Bze 19 12
Thera-Boot: a device consisting of a
series of interlocking, non-elastic bands
encircling the leg, and held in place by
hook and loop fasteners plus a foot
piece made of very low-stretch bands
High V V 19 12
27 Hendricks
1985105
Unna’s Boot compression system: zinc
oxide and calamine paste impregnated
bandage (Dome-Paste); gauze bandage
(Kerlix); and elastic bandage
Not Bzee Bzee 10 78
Open-toe, below-knee, elastic
compression stocking (Futuro)
Not H H 14 78
28 Koksal
2003106
Unna’s Boot containing calamine,
zinc oxide, glycerine, sorbitol, gelatine
and magnesium aluminium silicate
Not Bz Bz 27 16
Hydrocolloid dressing (Comfeel) plus
class II elastic compression stocking
Not H H 26 16
30 Polignano
200429
SSB (Comprilan) Not Bi Bi 29 12
SurePress Comfort (two knee-high
nylon and spandex stockings,
which are latex free; a medium
compression overstocking and light
compression understocking)
Not HH HH+ 27 12
31 Junger
2004107
Tubular compression device. The device
was knitted, knee length, heel-less,
and open toed; exerted graduated
pressure, corresponding to class III
compression stockings
Not H H 88 12
SSB (Rosidal K) Not Bi Bi 90 12
32 Milic
2007108
Cotton gauze without tension
(50% overlap) plus cotton crepe
bandage plus knee-length tubular
compression device (Tubulcus) plus
medium-stretch elastic compression
bandage (Niva)
Not BeH BeH 75 52
Cotton gauze without tension
(50% overlap) plus cotton crepe
bandage plus two medium-stretch
elastic compression bandages (Niva)
High Bee Bee 75 52
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ID Studies Evaluated treatment
High or
not
Partsch
classification
Final
classification
No. of
patients
Follow-up
(weeks)
33 Harley
2004109
Four-layer bandage system: orthopaedic
wool; crepe bandage; elastic bandage
(Elset); and elastic cohesive
bandage (Coban)
High Beec 4LB 16 –
Surepress: wool layer and long-stretch
bandage by ConvaTec
Not Be Be 14 –
35 Mariani
200830
Two layers of stocking (outer layer
is Sigvaris)
Not HH HH+ 26 16
SSB, applied with in two or more layers
with spiral turns or turns at eight
Not Bi Bi 30 16
36 Taradaj
200931
Medical compression stocking
(Sigvaris 702)
Not H H 40 8
SSB Not Bi Bi 40 8
37 Milic
2010110
The first and second layers were cotton
gauze without tension and cotton crepe
bandage, and the third layer was
tubular compression device (Tubulcus)
Not BeH BeH 42 26
Cotton gauze without tension
(50% overlap) plus cotton crepe
bandage plus knee-length tubular
compression device (Tubulcus) plus
medium-stretch elastic compression
bandage (Niva)
Not BeH BeH 46 26
The first and second layers were cotton
gauze without tension and cotton crepe
bandage; the third layer was tubular
compression device (Tubulcus) and the
final layer was two-layer elastic bandage
High BeHe BeHe 43 26
38 Brizzio
2010128
Open-toe elastic compression
stocking (Sigvaris)
Not H H 28 24
SSB Not Bi Bi 27 24
Studies including high-compression treatments
1 Kralj
1996112
Profore High Beec 4LB 20 24
Hydrocolloid dressing (Tegasorb) and
single-layer inelastic bandage (Porelast)
High Ba Ba 20 24
5 Colgan
1995113
Modified Unna’s boot, a compression
system with four components: paste
bandage; cotton crepe bandage
(Elastocrepe); elastic adhesive bandage
(Elastoplast); class II compression sock)
High BzeaH BzeaH 10 12
Profore High Beec 4LB 10 12
Polyurethane foam dressing
(Lyofoam dressing) plus elastic
bandage (Setopress)
Not Be Be 10 12
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ID Studies Evaluated treatment
High or
not
Partsch
classification
Final
classification
No. of
patients
Follow-up
(weeks)
13 Duby
1993114
Short-stretch system: orthopaedic wool;
two or more layers of SSB applied in
counter rotating directions (Comprilan);
and net covering (Tricofix)
High Bii SSB 25 12
Four-layer bandage system: orthopaedic
wool; crepe bandage; elastic bandage
(Elset); and elastic cohesive bandage
(Coban)
High Beec 4LB 25 12
Paste-bandage system: zinc and
ichthammol paste bandage (Icthopaste);
cotton crepe bandage (Elastocrepe); and
elastic tubular bandage (Tubigrip)
Not Bzee Bzee 26 12
14 Wilkinson
1997115
Charing Cross four-layer bandage
(Profore): dressing (Tricotex),
orthopaedic wool (Soffban), crepe
bandage, elastic bandage (Litepress)
and cohesive elastic bandage (Coplus)
High Beec 4LB 17 12
Alternative four-layer bandage: dressing
(Tricotex), elasticated viscose stockinette
(Tubifast), elastic bandage (Setopress)
and elasticated viscose stockinette
(Tubifast)
High BHeH BHeH 18 12
17 Scriven
1998116
Four-layer bandage system: orthopaedic
wool (Velband); crepe bandage;
elastic bandage (Elset); and elastic
cohesive bandage (Coban)
High Beec 4LB 32 52
Short-stretch system: orthopaedic
wool (Velband), 50% stretch and 50%
overlap between turns (Rosidal K),
and elastic cohesive bandage applied
without stretch (Coban)
High Biic SSB 32 52
18 Partsch
2001117
Profore High Beec 4LB 53 16
SSB: orthopaedic padding plus two
SSBs (Rosidal K) applied using the
Putter technique
High Bii SSB 59 16
19 Ukat
2003118
Profore High Beec 4LB 44 12
SSB comprising two bandages
10 cm wide
High Bii SSB 45 12
20 Franks
2004119
4L bandage (Flexiban, Setocrepe,
Elset, Coban)
High Beec 4LB 74 24
SSB (Flexiban, Actico) High Bc SSB 82 24
21 Iglesias
20047
Four-layer bandage: orthopaedic wool
padding, crepe retention bandage,
class 3A compression bandage and
cohesive compression bandage,
all applied with 50% overlap
High Beec 4LB 195 52
SSB: orthopaedic wool padding
covered with one or two short-stretch
compression bandages (Comprilan or
Rosidal K), applied using spiral,
figure-of-eight or modified
Putter techniques
High Bii SSB 192 52
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ID Studies Evaluated treatment
High or
not
Partsch
classification
Final
classification
No. of
patients
Follow-up
(weeks)
23 Polignano
2004120
Profore High Beec 4LB 39 24
Unna’s Boot comprising zinc oxide
paste bandage (Viscopaste) elastic
cohesive bandage (Tensoplast)
High Bzc Paste 29 24
26 Blecken
2005121
Adjustable compression boot system:
paraffin-impregnated gauze primary
dressing (Aquafor); sterile absorbent
gauze; pad cushion; surgical cotton
stockinette; individually adjustable
Velcro bands (CircAid); and elastic
anklet (Medi)
High HV HV 12 12
Four-layer bandage:
paraffin-impregnated gauze primary
dressing (Aquafor); single layer of sterile
absorbent gauze; 1-cm thick felt pad;
thick gauze bandage (Kerlix); and
elastic bandage
High Beec 4LB 12 12
29 Junger
200428
U-Stocking (VenoTrain ulcertec) High HH Hosiery 61 12
Two SSBs, wrapped around the leg in
opposite directions from the
metatarsophalangeal joint to the head
of the fibula
High Bii SSB 60 12
34 Moffatt
2008122
Four-layer compression
bandage (Profore)
High Beec 4LB 42 4
Two-layer compression (Coban) High Bic Bic 39 4
39 Szewczyk
2010123
Elastic compression class II in the form
of Maxis knee-length compression
stockings (PPH Real)
High 4LB 4LB 15 9
Two-layer ProGuide (Smith & Nephew)
compression (cotton wool and cotton
band plus compression bandage)
High 2LB 2LB 16 10
40 Wong
2012124
Four-layer compression bandaging
(Profore; Smith & Nephew, Hull, UK)
High 4LB 4LB 107 72
Short-stretch compression bandaging
(Rosidal sys; Lohmann and Rauscher
GmbH and Co KG, Rengsdorf,
Germany)
High SSB SSB 107 77
VenUS IV Compression hosiery High 4LB 4LB 224 157
4LB High HH HH 230 163
a, adhesive; B, bandage c, cohesive; e, elastic bandage; H, hosiery; I, inelastic bandage; V, Velcro device; z, zinc paste.
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Appendix 12 Network of evidence
In the network, a unique treatment category is indicated by a circle: high compression= green circles,non-high-compression treatments= smaller unshaded. Arrows between circles indicate that these
treatments had been compared in a trial [trials are identified using ‘( )’, numbered as in column ‘ID’
in Table 41].
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Appendix 13 Quality assessment of
mixed-treatment comparison estimates using iGRADE:
comparison with the GRADE tool
GRADE
category
GRADE definition
and guidance iGRADE category
iGRADE definitions
and guidance iGRADE issues
Limitations
in design
Risk of bias
l If you think any
limitations were
negligible
choose no
l If you think there
were serious
limitations
choose serious
l If you think there
were very serious
limitations choose
very serious
Limitations in design Use GRADE limitations in
design rating for DIRECT
links to assess the MTC
estimates to which these
links clearly contributed
No: GRADE limitations
in design category
recorded, as ‘no’ for all
links identified as informing
the MTC estimate
Serious: GRADE limitations
in design category recorded
as serious for one or more
links identified as informing
the MTC estimate, but
none identified as very
serious
Very serious: GRADE
limitations in design
category recorded as very
serious for one or more
links identified as informing
the MTC estimate
Qualitative assessment
of risk of bias difficult
for indirect evidence.
When direct and indirect
evidence are available,
this assessment may
be subjective
Inconsistency Unexplained
heterogeneity of results
l If you think any
inconsistency was
negligible
choose no
l If you think there
was serious
inconsistency
choose serious
l If you think there
was very serious
inconsistency
choose very serious
Sensitivity of results Judgement based on the
impact of sensitivity
analysis on the MTC
network and thus
estimates (e.g. removing
each trial in which there
are two or more
informing a link, or
sensitivity to alternative
priors in random-effects
analysis)
No: No or small change in
estimate and intervals
Serious: Some notable
change in estimate and
intervals
Very serious: Large
change in estimate
and intervals
Does not address
unexplained
heterogeneity per se
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GRADE
category
GRADE definition
and guidance iGRADE category
iGRADE definitions
and guidance iGRADE issues
Indirectness Indirect comparison
l If you think the
evidence is direct
choose no
l If you have serious
doubts about
directness
choose serious
l If you have very
serious doubts
about directness
choose very serious
Indirectness/Inconsistency:
Within GRADE the term
inconsistency is used to
refer to unexplained
heterogeneity. Within
MTC inconsistency has
meaning specific to
agreement between direct
and indirect data.
Furthermore, in GRADE
the presence of
indirectness is taken as a
reason to downgrade
evidence; however, in the
context of a MTC in
which indirect data are
expected and ideally adds
value, such an approach
does not make sense.
Thus we merged these
categories resulting in
joint assessment of
unexplained heterogeneity
and/or assessment of
inconsistency
where possible
Define the type of data
available for each MTC
comparison as follows:
1. Direct or indirect only:
no heterogeneity
2. Direct, indirect or mixed
(direct and indirect):
heterogeneity
3. Mixed: no
heterogeneity:
statistical inconsistencies
4. Mixed: no heterogeneity;
no statistical
inconsistencies
No: 1 and 4
Serious: 2, 3
Very serious: N/A
Assessment of
heterogeneity based in
DIRECT links is
challenging
Cannot always assess
for inconsistencies
Imprecision CIs around estimates
of treatment effect
l If you think the
results were
precise choose no
l If there was serious
imprecision
choose serious
l If there was very
serious imprecision
choose very serious
Imprecision Judged by the size of CrI
around ORs. As ORs were
used to analyse data
with relative high
number of events a more
conservative interval
width used than would
have been utilised were
data presented using
risk ratios
No: uncertainty judged
to be reasonable
(upper interval < 2.5)
Serious: judged to
be inadequate
(upper interval > 2.5< 5)
Very serious:
(upper interval > 5)
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GRADE
category
GRADE definition
and guidance iGRADE category
iGRADE definitions
and guidance iGRADE issues
Publication
bias
l If you think there
is no evidence of
publication bias
choose unlikely
l If there is high
probability of
publication bias
choose likely
l If there is very high
probability of
publication bias
choose very likely
Publication bias Use GRADE limitations in
design rating for DIRECT
links to assess the MTC
estimates to which these
links clearly contributed
Unlikely: GRADE
publication bias category
recorded as unlikely for
links identified as informing
the MTC estimate
Likely: Grade publication
bias category recorded as
likely for one or more links
identified as informing the
MTC estimate and none
identified as very likely
Very likely: for GRADE
publication bias category
recorded as very likely for
one or more link identified
as informing the MTC
estimate
Qualitative assessment
of publication bias
difficult for indirect
evidence
Again, in the presence
of both direct and
indirect evidence there is
the need to consider
potential publication bias
in the indirect links, as
well as the direct links
informing the same
comparison. Yet,
outlined in the
discussion of limitations,
assessing potential bias
in indirect comparison is
complex. If, for example,
AC is biased (missing
studies) favouring A and
BC is biased (missing
studies) favouring B,
then the AB indirect
estimate will be
unbiased if the bias in
AC is similar to the bias
in BC
N/A, not applicable; OR, odds ratio.
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Appendix 14 Search on cost-effectiveness
decision models
Search strategy
1. exp Stochastic Processes/ (11,513)
2. exp Models, Theoretical/ (681,838)
3. exp Models, Statistical/ (155,161)
4. exp Models, Economic/ (6040)
5. exp Monte Carlo Method/ (11,646)
6. exp Markov Chains/ (5630) ((stochastic or mathematical or statistical or theoretical or population or
process or probabili* or simulat* or monte carlo or markov) adj model*).tw. (34,897) ((economic* or
pharmacoeconomic* or decision* or cost*) adj model*).tw. (2041)
7. exp Economics, Medical/ (2817)
8. exp Health Care Costs/ (28,406)
9. exp “Costs and Cost Analysis”/ (89,053)
10. exp “Cost of Illness”/ (11,710) (cost-effective* or cost effective* or cost-utility or cost utility or
cost-benefit or cost benefit or cost-minimi* or cost minimi*).tw. (42,080)
11. or/1-13 (801,777)
12. exp Leg Ulcer/ (8068) (varicose ulcer* or venous ulcer* or leg ulcer* or stasis ulcer* or
(lower extremit* adj ulcer*) or crural ulcer* or ulcus cruris).tw. (3102)
13. or/15-16 (8640)
14. 14 and 17 (675)
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Appendix 15 Search on utilities
NHS Economic Evaluation Database (NHS EED), Issue 2 of 4,
April 2011; Database of Abstracts of Reviews of Effects (DARE),
Issue 2 of 4, April 2011; Health Technology Assessments (HTAs),
Issue 2 of 4 Apr 2011; Cochrane Central Register of Controlled
Trials (CENTRAL), Issue 2 of 4, April 2011; via The Cochrane
Library; Wiley http://onlinelibrary.wiley.com/
Date of search: 24 June 2011.
Search strategy
#1 ((utilit* NEXT approach*) or (health NEXT gain) or hui or hui2 or hui3):ti,ab (145)
#2 ((health NEXT measurement* NEXT scale*) or (health NEXT measurement* NEXT questionnaire*)):ti,
ab (4)
#3 ((standard NEXT gamble*) or (categor* NEXT scal*) or (linear NEXT scal*) or (linear NEXT analog*)
or (visual NEXT scal*) or (magnitude NEXT estimat*)):ti,ab (828)
#4 ((time NEXT trade NEXT off*) or (rosser* NEXT classif*) or (rosser* NEXT matrix) or (rosser* NEXT
distress*) or hrqol):ti,ab (747)
#5 ((index NEXT of NEXT wellbeing) or (quality NEXT of NEXT wellbeing) or qwb):ti,ab (30)
#6 ((multiattribute* NEXT health NEXT ind*) or (multi NEXT attribute* NEXT health NEXT ind*)):ti,ab (0)
#7 ((health NEXT utilit* NEXT index) or (health NEXT utilit* NEXT indices)):ti,ab (103)
#8 ((multiattribute* NEXT theor*) or (multi NEXT attribute* NEXT theor*) or (multiattribute* NEXT
analys*) or (multi NEXT attribute* NEXT analys*)):ti,ab 0
#9 ((health NEXT utilit* NEXT scale*) or (classification NEXT of NEXT illness NEXT state*)):ti,ab (2)
#10 health NEXT state* NEXT utilit*:ti,ab (34)
#11 well NEXT year*:ti,ab (2)
#12 ((multiattribute* NEXT utilit*) or (multi NEXT attribute* NEXT utilit*)):ti,ab (9)
#13 health NEXT utilit* NEXT scale*:ti,ab (1)
#14 ((euro NEXT qual) or (euro NEXT qol) or eq5d or (eq NEXT 5d) or euroqual or euroqol):ti,ab (631)
#15 (qualy or qaly or qualys or qalys or (quality NEXT adjusted NEXT life NEXT year*)):ti,ab (697)
#16 willingness NEXT to NEXT pay:ti,ab (316)
#17 (hye or hyes or (health* NEXT year* NEXT equivalent*)):ti,ab (2)
#18 ((person NEXT trade NEXT off*) or (person NEXT tradeoff*) or (time NEXT tradeoff*) or (time NEXT
trade NEXT off*)):ti,ab (122)
#19 theory NEXT utilit*:ti,ab (0)
#20 (sf36 or (sf NEXT 36)):ti,ab (1960)
#21 ((short NEXT form NEXT 36) or (shortform NEXT 36) or (sf NEXT thirtysix) or (sf NEXT thirty NEXT six)
or (shortform NEXT thirtysix) or (shortform NEXT thirty NEXT six) or (short NEXT form NEXT thirtysix) or
(short NEXT form NEXT thirty NEXT six)):ti,ab (843)
#22 ((sf NEXT 6d) or sf6d or (short NEXT form NEXT 6d) or (shortform NEXT 6d) or (sf NEXT six*)
or (shortform NEXT six*) or (short NEXT form NEXT six*)):ti,ab (77)
#23 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14
OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22) (5064)
#24 MeSH descriptor Leg Ulcer, this term only (332)
#25 MeSH descriptor Varicose Ulcer, this term only (333)
#26 ((varicose or venous or leg or stasis or crural) NEXT ulcer*):ti,ab (1195)
#27 (ulcus NEXT cruris):ti,ab (11)
#28 (#24 OR #25 OR #26 OR #27) (1320)
#29 (#23 AND #28) (11)
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MEDLINE In-Process & Other Non-Indexed Citations <June 23, 2011>
and MEDLINE <1948 to June Week 3> via OvidSP http://ovidsp.ovid.com/
Date of search: 24 June 2011.
Search strategy
1. (utilit$ approach$ or health gain or hui or hui2 or hui3).ti,ab. (1126)
2. (health measurement$ scale$ or health measurement$ questionnaire$).ti,ab. (31)
3. (standard gamble$ or categor$ scal$ or linear scal$ or linear analog$ or visual scal$ or magnitude
estimat$).ti,ab. (3795)
4. (time trade off$ or rosser$ classif$ or rosser$ matrix or rosser$ distress$ or hrqol).ti,ab. (5318)
5. (index of wellbeing or quality of wellbeing or qwb).ti,ab. (151)
6. (multiattribute$ health ind$ or multi attribute$ health ind$).ti,ab. (2)
7. (health utilit$ index or health utilit$ indices).ti,ab. (496)
8. (multiattribute$ theor$ or multi attribute$ theor$ or multiattribute$ analys$ or multi attribute$ analys
$).ti,ab. (9)
9. (health utilit$ scale$ or classification of illness state$).ti,ab. (8)
10. health state$ utilit$.ti,ab. (180)
11. well year$.ti,ab. (20)
12. (multiattribute$ utilit$ or multi attribute$ utilit$).ti,ab. (156)
13. health utilit$ scale$.ti,ab. (7)
14. (euro qual or euro qol or eq5d or eq 5d or euroqual or euroqol).ti,ab. (2376)
15. (qualy or qaly or qualys or qalys or quality adjusted life year$).ti,ab. (4743)
16. willingness to pay.ti,ab. (1556)
17. (hye or hyes or health$ year$ equivalent$).ti,ab. (58)
18. (person trade off$ or person tradeoff$ or time tradeoff$ or time trade off$).ti,ab. (787)
19. theory utilit$.ti,ab. (6)
20. (sf36 or sf 36).ti,ab. (9903)
21. (short form 36 or shortform 36 or sf thirtysix or sf thirty six or shortform thirtysix or shortform thirty six
or short form thirtysix or short form thirty six).ti,ab. (4559)
22. (sf 6d or sf6d or short form 6d or shortform 6d or sf six$ or shortform six$ or short form six$).ti,
ab. (254)
23. or/1-22 (27,228)
24. leg ulcer/ or varicose ulcer/ (9896)
25. (varicose ulcer$ or venous ulcer$ or leg ulcer$ or stasis ulcer$ or crural ulcer$ or ulcus cruris).ti,
ab. (6381)
26. 24 or 25 (11,292)
27. 23 and 26 (45)
EMBASE<1980 to 2011 Week 24> via OvidSP http://ovidsp.ovid.com/
Date of search: 24 June 2011.
Search strategy
1. (utilit$ approach$ or health gain or hui or hui2 or hui3).ti,ab. (1300)
2. (health measurement$ scale$ or health measurement$ questionnaire$).ti,ab. (44)
3. (standard gamble$ or categor$ scal$ or linear scal$ or linear analog$ or visual scal$ or magnitude
estimat$).ti,ab. (4017)
4. (time trade off$ or rosser$ classif$ or rosser$ matrix or rosser$ distress$ or hrqol).ti,ab. (6446)
5. (index of wellbeing or quality of wellbeing or qwb).ti,ab. (164)
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6. (multiattribute$ health ind$ or multi attribute$ health ind$).ti,ab. (2)
7. (health utilit$ index or health utilit$ indices).ti,ab. (550)
8. (multiattribute$ theor$ or multi attribute$ theor$ or multiattribute$ analys$ or multi attribute$
analys$).ti,ab. (13)
9. (health utilit$ scale$ or classification of illness state$).ti,ab. (8)
10. health state$ utilit$.ti,ab. (231)
11. well year$.ti,ab. (23)
12. (multiattribute$ utilit$ or multi attribute$ utilit$).ti,ab. (184)
13. health utilit$ scale$.ti,ab. (7)
14. (euro qual or euro qol or eq5d or eq 5d or euroqual or euroqol).ti,ab. (3146)
15. (qualy or qaly or qualys or qalys or quality adjusted life year$).ti,ab. (5735)
16. willingness to pay.ti,ab. (1868)
17. (hye or hyes or health$ year$ equivalent$).ti,ab. (71)
18. (person trade off$ or person tradeoff$ or time tradeoff$ or time trade off$).ti,ab. (856)
19. theory utilit$.ti,ab. (7)
20. (sf36 or sf 36).ti,ab. (12,365)
21. (short form 36 or shortform 36 or sf thirtysix or sf thirty six or shortform thirtysix or shortform thirty six
or short form thirtysix or short form thirty six).ti,ab. (5051)
22. (sf 6d or sf6d or short form 6d or shortform 6d or sf six$ or shortform six$ or
short form six$).ti,ab. (314)
23. or/1-22 (32,581)
24. leg ulcer/ (9588)
25. (varicose ulcer$ or venous ulcer$ or leg ulcer$ or stasis ulcer$ or crural ulcer$ or
ulcus cruris).ti,ab. (7662)
26. 24 or 25 (12,235)
27. 23 and 26 (59)
Cumulative Index to Nursing and Allied Health Literature
(CINAHL) via EBSCOhost, inception to 17 June 2011
Date of search: 24 June 2011.
Search strategy
1. S28 S23 and S27 (22)
2. S27 S24 or S25 or S26 (3186)
3. S26 TI (“varicose ulcer*” or “venous ulcer*” or “leg ulcer*” or “stasis ulcer*” or “crural ulcer*” or
“ulcus cruris” ) or AB ( “varicose ulcer*” or “venous ulcer*” or “leg ulcer*” or “stasis ulcer*” or
“crural ulcer*” or “ulcus cruris”) (1989)
4. S25 (MH “Venous Ulcer”) (1223)
5. S24 (MH “Leg Ulcer”) (1911)
6. S23 S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8 or S9 or S10 or S11 or S12 or S13 or S14 or S15 or
S16 or S17 or S18 or S19 or S20 or S21 or S22 (6687)
7. S22 TI ( “sf 6d” or sf6d or “short form 6d” or “shortform 6d” or “sf six*” or “shortform six*” or
“short form six*” ) or AB ( “sf 6d” or sf6d or “short form 6d” or “shortform 6d” or “sf six*” or
“shortform six*” or “short form six*” ) (73)
8. S21 TI ( “short form 36” or “shortform 36” or “sf thirtysix” or “sf thirty six” or “shortform thirtysix”
or “shortform thirty six” or “short form thirtysix” or “short form thirty six” ) or AB ( “short form 36”
or “shortform 36” or “sf thirtysix” or “sf thirty six” or “shortform thirtysix” or “shortform thirty six” or
“short form thirtysix” or “short form thirty six” ) (1408)
9. S20 TI ( sf36 or “sf 36” ) or AB ( sf36 or “sf 36” ) (2823)
10. S19 TI “theory utilit*” or AB “theory utilit*” (3)
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11. S18 TI ( “person trade off*” or “person tradeoff*” or “time tradeoff*” or “time trade off*” ) or
AB ( “person trade off*” or “person tradeoff*” or “time tradeoff*” or “time trade off*” ) (132)
12. S17 TI ( hye or hyes or “health* year* equivalent*” ) or AB ( hye or hyes or “health* year*
equivalent*” ) (5)
13. S16 TI “willingness to pay” or AB “willingness to pay” (301)_
14. S15 TI ( qualy or qaly or qualys or qalys or “quality adjusted life year*” ) or AB ( qualy or qaly or
qualys or qalys or “quality adjusted life year*” ) (999)
15. S14 TI ( “euro qual” or “euro qol” or eq5d or “eq 5d” or euroqual or euroqol ) or AB ( “euro qual”
or “euro qol” or eq5d or “eq 5d” or euroqual or euroqol ) (574)
16. S13 TI “health utilit* scale*” or AB “health utilit* scale*” (2)
17. S12 TI ( “multiattribute* utilit*” or “multi attribute* utilit*” ) or AB ( “multiattribute* utilit*” or
“multi attribute* utilit*” ) (42)
18. S11 TI “well year*” or AB “well year*” (4)
19. S10 TI “health state* utilit*” or AB “health state* utilit*” (35)
20. S9 TI (“health utilit* scale*” or “classification of illness state*” ) or AB (“health utilit* scale*” or
“classification of illness state*” ) (3)
21. S8 TI (“multiattribute* theor*” or “multi attribute* theor*” or “multiattribute* analys*” or
“multi attribute* analys*” ) or AB (“multiattribute* theor*” or “multi attribute* theor*” or
“multiattribute* analys*” or “multi attribute* analys*”) (3)
22. S7 TI (“health utilit* index” or “health utilit* indices”) or AB (“health utilit* index” or “health utilit*
indices”) (133)
23. S6 TI (“multiattribute* health ind*” or “multi attribute* health ind*” ) or AB (“multiattribute* health
ind*” or “multi attribute* health ind*”) (0)
24. S5 TI (“index of wellbeing” or “quality of wellbeing” or qwb ) or AB (“index of wellbeing” or
“quality of wellbeing” or qwb ) (48)
25. S4 TI (“time trade off*” or “rosser* classif*” or “rosser* matrix” or “rosser* distress*” or hrqol ) or
AB (“time trade off*” or “rosser* classif*” or “rosser* matrix” or “rosser* distress*” or hrqol ) (1333)
26. S3 TI (“standard gamble*” or “categor* scal*” or “linear scal*” or “linear analog*” or “visual scal*”
or “magnitude estimat*” ) or AB (“standard gamble*” or “categor* scal*” or “linear scal*” or
“linear analog*” or “visual scal*” or “magnitude estimat*”) (470)
27. S2 TI ( “health measurement* scale*” or “health measurement* questionnaire*” ) or
AB ( “health measurement* scale*” or “health measurement*” questionnaire* ) (6)
28. S1 TI ( “utilit* approach*” or “health gain” or hui or hui2 or hui3 ) or AB ( “utilit* approach*” or
“health gain” or hui or hui2 or hui3 ) (289)
British Nursing Index (BNI) and Archive <1985 to June 2011>
via OvidSP http://ovidsp.ovid.com/
Date of search: 24 June 2011.
Search strategy
1. (utilit$ approach$ or health gain or hui or hui2 or hui3).ti,ab. (20)
2. (health measurement$ scale$ or health measurement$ questionnaire$).ti,ab. (3)
3. (standard gamble$ or categor$ scal$ or linear scal$ or linear analog$ or visual scal$ or magnitude
estimat$).ti,ab. (11)
4. (time trade off$ or rosser$ classif$ or rosser$ matrix or rosser$ distress$ or hrqol).ti,ab. (55)
5. (index of wellbeing or quality of wellbeing or qwb).ti,ab. (0)
6. (multiattribute$ health ind$ or multi attribute$ health ind$).ti,ab. (0)
7. (health utilit$ index or health utilit$ indices).ti,ab. (2)
8. (multiattribute$ theor$ or multi attribute$ theor$ or multiattribute$ analys$ or multi attribute$
analys$).ti,ab. (0)
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9. (health utilit$ scale$ or classification of illness state$).ti,ab. (0)
10. health state$ utilit$.ti,ab. (0)
11. well year$.ti,ab. (1)
12. (multiattribute$ utilit$ or multi attribute$ utilit$).ti,ab. (5)
13. health utilit$ scale$.ti,ab. (0)
14. (euro qual or euro qol or eq5d or eq 5d or euroqual or euroqol).ti,ab. (12)
15. (qualy or qaly or qualys or qalys or quality adjusted life year$).ti,ab. (65)
16. willingness to pay.ti,ab. (13)
17. (hye or hyes or health$ year$ equivalent$).ti,ab. (3)
18. (person trade off$ or person tradeoff$ or time tradeoff$ or time trade off$).ti,ab. (2)
19. theory utilit$.ti,ab. (1)
20. (sf36 or sf 36).ti,ab. (65)
21. (short form 36 or shortform 36 or sf thirtysix or sf thirty six or shortform thirtysix or shortform thirty six
or short form thirtysix or short form thirty six).ti,ab. (24)
22. (sf 6d or sf6d or short form 6d or shortform 6d or sf six$ or shortform six$ or short form six$).ti,ab. (0)
23. or/1-22 (262)
24. Leg Ulcers/ (1500)
25. (varicose ulcer$ or venous ulcer$ or leg ulcer$ or stasis ulcer$ or crural ulcer$ or
ulcus cruris).ti,ab. (1375)
26. 24 or 25 (1780)
27. 23 and 26 (8)
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72 potentially relevant
studies
33 studies retrieved for
detailed review
8 studies resulted from the
literature review
39 studies excluded after
reviewing title and abstract
17 studies excluded after
detailed review
4 methodological papers
3 cost-effectiveness
studies
4 reviews
4 reporting other 
quality-of-life instruments
2 reporting incomplete
data
6 studies conducted
outside UK
3 studies considered
Additional considerations
excluded 3 studies
without EQ-5D index
scores
excluded 2 studies with
specific population
2 UK studies reported
from the same trial
APPENDIX 15
NIHR Journals Library www.journalslibrary.nihr.ac.uk
250
Appendix 16 Search on resource use
NHS Economic Evaluation Database (NHS EED), Issue 2 of 4, April 2011
via The Cochrane Library, Wiley http://onlinelibrary.wiley.com/
Date of search: 24 June 2011.
Search strategy
#1 MeSH descriptor Leg Ulcer, this term only (332)
#2 MeSH descriptor Varicose Ulcer, this term only (333)
#3 ((varicose or venous or leg or stasis or crural) NEXT ulcer*):ti,ab (1195)
#4 (ulcus NEXT cruris):ti,ab (11)
#5 (#1 OR #2 OR #3 OR #4) (1320)
#6 MeSH descriptor Compression Bandages explode all trees (98)
#7 (compression or bandag* or stocking* or hosiery or wrapp*):ti,ab (3213)
#8 (#6 OR #7) (3227)
#9 (#5 AND #8) (359)
#10 (#9), from 2000 to 2011 NHS EED only (9)
MEDLINE In-Process & Other Non-Indexed Citations (23 June 2011)
and MEDLINE <1948 to June Week 3> via OvidSP http://ovidsp.ovid.com/
Date of search: 24 June 2011.
Search strategy
1. economics/ (26,064)
2. exp “costs and cost analysis”/ (157,130)
3. economics, dental/ (1829)
4. exp “economics, hospital”/ (17,217)
5. economics, medical/ (8404)
6. economics, nursing/ (3848)
7. economics, pharmaceutical/ (2238)
8. (economic$ or cost or costs or costly or costing or price or prices or pricing or pharmacoeconomic$).ti,
ab. (359,832)
9. (expenditure$ not energy).ti,ab. (14,872)
10. value for money.ti,ab. (719)
11. budget$.ti,ab. (15,780)
12. or/1-11 (473,942)
13. ((energy or oxygen) adj cost).ti,ab. (2442)
14. (metabolic adj cost).ti,ab. (638)
15. ((energy or oxygen) adj expenditure).ti,ab. (13,676)
16. or/13-15 (16,123)
17. 12 not 16 (470,219)
18. letter.pt. (733,090)
19. editorial.pt. (286,936)
20. historical article.pt. (275,453)
21. or/18-20 (1,282,649)
22. 17 not 21 (445,614)
23. exp animals/ not humans/ (3,602,202)
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24. 22 not 23 (421,480)
25. Leg Ulcer/ (6902)
26. Varicose Ulcer/ (3428)
27. (varicose ulcer$ or venous ulcer$ or leg ulcer$ or stasis ulcer$ or crural ulcer$ or ulcus cruris).ti,
ab. (6381)
28. 25 or 26 or 27 (11,292)
29. exp Compression Bandages/ (704)
30. (compression or bandag$ or stocking$ or hosiery or wrapp$).ti,ab. (72,861)
31. 29 or 30 (73,121)
32. 24 and 28 and 31 (160)
33. limit 32 to (english language and yr= “2000 -Current”) (101)
EMBASE <1980 to 2011 Week 24> via OvidSP http://ovidsp.ovid.com/
Date of search: 24 June 2011.
Search strategy
1. Health Economics/ (30,145)
2. exp Economic Evaluation/ (166,705)
3. exp Health Care Cost/ (160,711)
4. PHARMACOECONOMICS/ (1872)
5. 1 or 2 or 3 or 4 (302,726)
6. (econom$ or cost or costs or costly or costing or price or prices or pricing or pharmacoeconomic$).ti,
ab. (428,178)
7. (expenditure$ not energy).ti,ab. (17,011)
8. (value adj2 money).ti,ab. (909)
9. budget$.ti,ab. (18,111)
10. 6 or 7 or 8 or 9 (446,579)
11. 5 or 10 (598,768)
12. letter.pt. (728,556)
13. editorial.pt. (372,044)
14. note.pt. (436,538)
15. 12 or 13 or 14 (1,537,138)
16. 11 not 15 (538,571)
17. (metabolic adj cost).ti,ab. (647)
18. ((energy or oxygen) adj cost).ti,ab. (2519)
19. ((energy or oxygen) adj expenditure).ti,ab. (14,940)
20. 17 or 18 or 19 (17,444)
21. 16 not 20 (534,623)
22. exp ANIMAL/ (1,615,378)
23. exp animal experiment/ (1,444,801)
24. Nonhuman/ (3,653,629)
25. (rat or rats or mouse or mice or hamster or hamsters or animal or animals or dog or dogs or cat or
cats or bovine or sheep).ti,ab,sh. (4,026,868)
26. 22 or 23 or 24 or 25 (5,824,661)
27. exp human/ (12,298,918)
28. exp human experiment/ (289,909)
29. 27 or 28 (12,300,300)
30. 26 not (26 and 29) (4,603,455)
31. 21 not 30 (492,736)
32. leg ulcer/ (9588)
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33. (varicose ulcer$ or venous ulcer$ or leg ulcer$ or stasis ulcer$ or crural ulcer$ or ulcus cruris).ti,
ab. (7662)
34. 32 or 33 (12,235)
35. exp compression therapy/ (5422)
36. compression bandage/ (534)
37. compression garment/ (1256)
38. (compression or bandag$ or stocking$ or hosiery or wrapp$).ti,ab. (80,270)
39. 35 or 36 or 37 or 38 (83,688)
40. 31 and 34 and 39 (270)
41. limit 40 to (english language and yr= “2000 -Current”) (179)
Cumulative Index to Nursing and Allied Health Literature
(CINAHL) <inception to 17 June 2011> via EBSCOhost
Date of search: 24 June 2011.
Search strategy
S29 S20 and S24 and S28 (66)
S28 S25 or S26 or S27 (7861)
S27 TI ( compression or bandag* or stocking* or hosiery or wrap* ) or AB ( compression or bandag* or
stocking* or hosiery or wrap* ) (6788)
S26 (MH “Compression Garments”) (1049)
S25 (MH “Compression Therapy”) (1201)
S24 S21 or S22 or S23 (3186)
S23 TI (“varicose ulcer*” or “venous ulcer*” or “leg ulcer*” or “stasis ulcer*”
or “crural ulcer*” or “ulcus cruris” ) or AB ( “varicose ulcer*” or “venous ulcer*”
or “leg ulcer*” or “stasis ulcer*” or “crural ulcer*” or “ulcus cruris” ) (1989)
S22 (MH “Venous Ulcer”) (1223)
S21 (MH “Leg Ulcer”) (1911)
S20 S18 NOT S19 (90,676)
S19 MH “Animal Studies” (21,419)
S18 S13 NOT S17 (90,826)
S17 S14 or S15 or S16 (280,532)
S16 PT commentary (121,332)
S15 PT letter (106,150)
S14 PT editorial (123,921)
S13 S11 OR S12 (98,558)
S12 TI (cost or costs or economic* or pharmacoeconomic* or price* or pricing*) OR AB (cost or costs or
economic* or pharmacoeconomic* or price* or pricing*) (67,795)
S11 S7 OR S10 (45,615)
S10 S8 OR S9 (11,490)
S9 MH “Health Resource Utilization” (6954)
S8 MH “Health Resource Allocation” (4784)
S7 S1 NOT S6 (38,036)
S6 S2 OR S3 or S4 OR S5 (349,628)
S5 MH “Business+” (52,830)
S4 MH “Financing, Organized+” (70,837)
S3 MH “Financial Support+” (223,713)
S2 MH “Financial Management+” (27,583)
S1 MH “Economics+” (354,431)
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British Nursing Index and Archive <1985 to June 2011> via
OvidSP http://ovidsp.ovid.com/
Date of search: 24 June 2011.
Search strategy
1. health economics/ (178)
2. (economic$ or cost or costs or costly or costing or price or prices or pricing or pharmacoeconomic$).ti,
ab. (4144)
3. (value adj2 money).ti,ab. (52)
4. budget$.ti,ab. (357)
5. (expenditure$ not energy).ti,ab. (75)
6. 1 or 2 or 3 or 4 or 5 (4598)
7. leg ulcers/ (1500)
8. (varicose ulcer$ or venous ulcer$ or leg ulcer$ or stasis ulcer$ or crural ulcer$ or ulcus cruris).ti,
ab. (1375)
9. 7 or 8 (1780)
10. dressings/ (1857)
11. (compression or bandag$ or stocking$ or hosiery or wrapp$).ti,ab. (755)
12. 10 or 11 (2171)
13. 6 and 9 and 12 (33)
14. limit 13 to yr= “2000 -Current” (29)
Flow chart of studies included in the literature review for resource use.
72 potentially relevant
studies
25 studies retrieved for
detailed review
9 UK relevant studies
resulted from the literature
reviews
47 studies excluded after
reviewing abstract
16 studies excluded after
detailed review
2 reporting no cost
6 reporting other non-
compression treatment
3 case studies
2 outside UK
1 review
2 unavailable
2 studies considered
Additional considerations
7 report no detail on
resource use
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Appendix 17 Search on recurrence
Search limiters – English language and publication dates of 2000 onwards.
Cochrane Central Register of Controlled Trials (CENTRAL), Issue 2 of 4,
April 2011 via The Cochrane Library, Wiley http://onlinelibrary.wiley.com/
Date of search: 17 June 2011.
Search strategy
#1 MeSH descriptor Leg Ulcer, this term only with qualifier: MO (0)
#2 MeSH descriptor Varicose Ulcer, this term only with qualifier: MO (0)
#3 (#1 OR #2) (0)
#4 mortalit* (37,094)
#5 fatal or fatality or fatalities (3771)
#6 death (23,269)
#7 MeSH descriptor Mortality, this term only (372)
#8 MeSH descriptor Life Expectancy, this term only (489)
#9 life expectancy (1973)
#10 (#4 OR #5 OR #6 OR #7 OR #8 OR #9) (49,828)
#11 varicose NEXT ulcer* or venous NEXT ulcer* or leg NEXT ulcer* or stasis NEXT ulcer* or crural NEXT
ulcer* or ulcus NEXT cruris (1417)
#12 MeSH descriptor Leg Ulcer, this term only (332)
#13 MeSH descriptor Varicose Ulcer, this term only (333)
#14 (#11 OR #12 OR #13) (1417)
#15 (#10 AND #14) (64)
#16 (#3 OR #15) (64)
Ovid MEDLINE(R) without revisions <1996 to June Week 2
2011> via OvidSP http://ovidsp.ovid.com/
Date of search: 17 June 2011.
Search strategy
1. leg ulcer/ or varicose ulcer/ (4044)
2. (varicose ulcer* or venous ulcer* or leg ulcer* or stasis ulcer* or crural ulcer* or ulcus cruris).ti,
ab. (3263)
3. or/1-2 (4700)
4. compression bandages/ (51)
5. stockings, compression/ (635)
6. (compression or bandag* or stocking* or hosiery or wrapp*).ti,ab. (39,597)
7. or/4-6 (39,854)
8. Recurrence/ (78,999)
9. Recurrence.ti,ab. (94,662)
10. reoccur*.ti. (26)
11. re-occur*.ti. (9)
12. reoccur*.ti,ab. (816)
13. re-occur*.ti,ab. (171)
14. or/8-13 (156,734)
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15. 3 and 7 and 14 (150)
16. 15 (150)
17. limit 16 to (english language and yr= “2000 -Current”) (107)
MEDLINE In-Process & Other Non-Indexed Citations <28 June
2011> via OvidSP http://ovidsp.ovid.com/
Date of search: 29 June 2011.
Search strategy
1. leg ulcer/ or varicose ulcer/ (0)
2. (varicose ulcer* or venous ulcer* or leg ulcer* or stasis ulcer* or crural ulcer* or ulcus cruris).ti,
ab. (200)
3. or/1-2 (200)
4. compression bandages/ (0)
5. stockings, compression/ (0)
6. (compression or bandag* or stocking* or hosiery or wrapp*).ti,ab. (5486)
7. or/4-6 (5486)
8. Recurrence/ (0)
9. Recurrence.ti,ab. (6165)
10. reoccur*.ti. (3)
11. re-occur*.ti. (2)
12. reoccur*.ti,ab. (61)
13. re-occur*.ti,ab. (18)
14. or/8-13 (6236)
15. 3 and 7 and 14 (8)
16. 15 (8)
17. limit 16 to (english language and yr= “2000 -Current”) (7)
EMBASE <1996 to 2011 Week 23> via OvidSP
Date of search: 17 June 2011.
Search strategy
1. leg ulcer/ (5167)
2. (varicose ulcer* or venous ulcer* or leg ulcer* or stasis ulcer* or crural ulcer* or ulcus cruris).ti,
ab. (4615)
3. or/1-2 (6738)
4. compression bandage/ (531)
5. compression garment/ (1247)
6. (compression or bandag* or stocking* or hosiery or wrapp*).ti,ab. (52,472)
7. or/4-6 (53390)
8. Recurrence risk/ (19,647)
9. Recurrence.ti,ab. (127,067)
10. reoccur*.ti. (30)
11. re-occur*.ti. (11)
12. reoccur*.ti,ab. (1207)
13. re-occur*.ti,ab. (224)
14. or/8-13 (137,016)
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15. 3 and 7 and 14 (158)
16. 15 (158)
17. limit 16 to (english language and yr= “2000 -Current”) (117)
Cumulative Index to Nursing and Allied Health Literature
(CINAHL) via EBSCOhost, inception to 17 June 2011
Date of search: 17 June 2011.
Search strategy
S23 s22 Limiters – English Language;
published date from: 1 January
2000 to 31 December 2011
Search modes – Boolean/phrase
Interface – EBSCOhost
Search screen – advanced
search
Database – CINAHL
S22 S9 and S16 and S21 Search modes – Boolean/phrase
S21 S17 or S18 or S19 or S20
S20 TI re-occur* or AB re-occur*
S19 TI reoccur* or AB reoccur*
S18 TI Recurrence or AB Recurrence
S17 (MH “Recurrence”)
S16 S10 or S11 or S12 or S13 or S14 or S15
S15 TI wrapp* or AB wrapp*
S14 TI hosiery or AB hosiery
S13 TI stocking* or AB stocking*
S12 TI bandag* or AB bandag*
S11 TI compression or AB compression
S10 (MH “Compression Garments”)
S9 S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8
S8 TI “ulcus cruris” or AB “ulcus cruris”
S7 TI “crural ulcer*” or AB “crural ulcer*”
S6 TI “stasis ulcer*” or AB “stasis ulcer*”
S5 TI “leg ulcer*” or AB “leg ulcer*”
S4 TI “venous ulcer*” or AB “venous ulcer*”
S3 TI “varicose ulcer*” or AB “varicose ulcer*”
S2 (MH “Venous Ulcer”)
S1 (MH “Leg Ulcer”)
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British Nursing Index (BNI) and Archive <1985 to June 2011>
via OvidSP http://ovidsp.ovid.com/
Date of search: 17 June 2011.
Search strategy
1. leg ulcers/ (1500)
2. (varicose ulcer* or venous ulcer* or leg ulcer* or stasis ulcer* or crural ulcer* or ulcus cruris).ti,ab. (1375)
3. or/1-2 (1780)
4. dressings/ (1857)
5. (compression or bandag* or stocking* or hosiery or wrapp*).ti,ab. (755)
6. or/4-5 (2171)
7. Recurrence.ti,ab. (183)
8. reoccur*.ti. (2)
9. re-occur*.ti. (0)
10. reoccur*.ti,ab. (4)
11. re-occur*.ti,ab. (0)
12. or/7-11 (186)
13. 3 and 6 and 12 (24)
14. limit 13 to yr= “2000 -Current” (18)
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Flow chart of studies included in the literature review for recurrence.
182 potentially relevant
studies
35 studies retrieved for
detailed review
10 relevant UK studies
resulted from the literature
review
147 studies excluded after
reviewing abstract
17 studies excluded after
detailed review
7 reviews
3 summaries
3 with no recurrence
1 case study
1 cost-effectiveness
study
2 studies unavailable 
8 studies conducted
outside UK
6 studies considered
Additional considerations
4 surgery treatments
2 prevention of
recurrence
4 not mentioning
prevention mechanism
excluded
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Appendix 18 Search on mortality
Cochrane Central Register of Controlled Trials (CENTRAL),
Issue 2 of 4, April 2011 via The Cochrane Library,
Wiley http://onlinelibrary.wiley.com/
Date of search: 28 June 2011.
Search strategy
#1 MeSH descriptor Leg Ulcer, this term only with qualifier: MO (0)
#2 MeSH descriptor Varicose Ulcer, this term only with qualifier: MO (0)
#3 (#1 OR #2) (0)
#4 mortalit* (37,094)
#5 fatal or fatality or fatalities (3771)
#6 death (23,269)
#7 MeSH descriptor Mortality, this term only (372)
#8 MeSH descriptor Life Expectancy, this term only (489)
#9 life expectancy (1973)
#10 (#4 OR #5 OR #6 OR #7 OR #8 OR #9) (49,828)
#11 varicose NEXT ulcer* or venous NEXT ulcer* or leg NEXT ulcer* or stasis NEXT ulcer* or crural NEXT
ulcer* or ulcus NEXT cruris (1417)
#12 MeSH descriptor Leg Ulcer, this term only (332)
#13 MeSH descriptor Varicose Ulcer, this term only (333)
#14 (#11 OR #12 OR #13) (1417)
#15 (#10 AND #14) (64)
#16 (#3 OR #15) (64)
Ovid MEDLINE(R) without revisions <1948 to June Week 3 2011>
via OvidSP http://ovidsp.ovid.com/
Date of search: 28 June 2011.
Search strategy
1. Leg Ulcer/mo [Mortality] (21)
2. Varicose Ulcer/mo [Mortality] (4)
3. 1 or 2 (25)
4. mortalit*.ti,ab. (349,434)
5. (fatal or fatality or fatalities).ti,ab. (81,658)
6. death.ti,ab. (361,068)
7. Mortality/ (30,881)
8. life expectancy.ti,ab. (14,583)
9. life expectancy/ (12,145)
10. or/4-9 (731,352)
11. (varicose ulcer* or venous ulcer* or leg ulcer* or stasis ulcer* or crural ulcer* or ulcus cruris).ti,
ab. (6183)
12. Leg Ulcer/ (6902)
13. Varicose Ulcer/ (3428)
14. or/11-13 (11094)
15. 10 and 14 (228)
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16. 3 or 15 (239)
17. 16 (239)
18. limit 17 to english language (196)
MEDLINE In-Process & Other Non-Indexed Citations <28 June 28 2011>
via OvidSP http://ovidsp.ovid.com/
Date of search: 29 June 2011.
Search strategy
1. Leg Ulcer/mo [Mortality] (0)
2. Varicose Ulcer/mo [Mortality] (0)
3. 1 or 2 (0)
4. mortalit*.ti,ab. (16,602)
5. (fatal or fatality or fatalities).ti,ab. (3556)
6. death.ti,ab. (15,616)
7. Mortality/ (4)
8. life expectancy.ti,ab. (657)
9. life expectancy/ (1)
10. or/4-9 (32836)
11. (varicose ulcer* or venous ulcer* or leg ulcer* or stasis ulcer* or crural ulcer* or ulcus cruris).ti,
ab. (200)
12. Leg Ulcer/ (0)
13. Varicose Ulcer/ (0)
14. or/11-13 (200)
15. 10 and 14 (3)
16. 3 or 15 (3)
17. 16 (3)
18. limit 17 to english language (2)
EMBASE <1980 to 2011 Week 25> via OvidSP http://ovidsp.ovid.com/
Date of search: 28 June 2011.
Search strategy
1. leg ulcer/ (9596)
2. (varicose ulcer* or venous ulcer* or leg ulcer* or stasis ulcer* or crural ulcer* or ulcus cruris).ti,
ab. (7665)
3. 1 or 2 (12244)
4. mortality/ (368517)
5. life expectancy/ (21572)
6. mortalit*.ti,ab. (419856)
7. (fatal or fatality or fatalities).ti,ab. (93807)
8. death.ti,ab. (419312)
9. life expectancy.ti,ab. (17088)
10. or/4-9 (996364)
11. 3 and 10 (406)
12. limit 11 to english language (342)
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Cumulative Index to Nursing and Allied Health Literature
(CINAHL) via EBSCOhost, inception to 17 June 2011
Date of search: 28 June 2011. A total of 31 records were retrieved.
Search strategy
S21 S3 or S20 Search modes: Boolean/phrase Interface: EBSCOhost
Search screen: advanced search
Database: CINAHL
S20 S12 and S19
S19 S13 or S14 or S15 or S16 or S17 or S18
S18 TI “life expectancy” or AB “life expectancy”
S17 (MH “Life Expectancy”)
S16 (MH “Mortality”)
S15 TI death or AB death
S14 TI ( fatal or fatality or fatalities ) or AB
(fatal or fatality or fatalities )
S13 TI mortalit* or AB mortalit*
S12 S4 or S5 or S6 or S7 or S8 or S9 or S10 or S11
S11 TI “ulcus cruris” or AB “ulcus cruris”
S10 TI “crural ulcer*” or AB “crural ulcer*”
S9 TI “stasis ulcer*” or AB “stasis ulcer*”
S8 TI “leg ulcer*” or AB “leg ulcer*”
S7 TI “venous ulcer*” or AB “venous ulcer*”
S6 TI “varicose ulcer*” or AB “varicose ulcer*”
S5 (MH “Venous Ulcer”)
S4 (MH “Leg Ulcer”)
S3 S1 or S2
S2 (MH “Venous Ulcer/MO”)
S1 (MH “Leg Ulcer/MO”)
British Nursing Index (BNI) and Archive <1985 to June 2011> via OvidSP
http://ovidsp.ovid.com/
Date of search: 28 June 2011. One record was retrieved.
Search strategy
1. leg ulcers/ (1500)
2. (varicose ulcer* or venous ulcer* or leg ulcer* or stasis ulcer* or crural ulcer* or ulcus cruris).ti,
ab. (1375)
3. 1 or 2 (1780)
4. mortalit*.ti,ab. (1317)
5. (fatal or fatality or fatalities).ti,ab. (151)
6. death.ti,ab. (2759)
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7. Community Medicine/ (929)
8. life expectancy.ti,ab. (107)
9. or/4-8 (4946)
10. 3 and 9 (1)
Flow chart of studies included in the literature review for mortality.
414 potentially relevant
studies
6 studies retrieved for
detailed review
1 study included in the
final literature review
408 studies excluded
after reviewing abstract
5 studies excluded after
detailed review
1 unavailable
4 from other counties
APPENDIX 18
NIHR Journals Library www.journalslibrary.nihr.ac.uk
264
Appendix 19 VenUS IV statistical analysis plan:
clinical analysis
Introduction
This is a randomised multicentred, pragmatic, two-armed controlled trial with equal randomisation
to demonstrate the clinical effectiveness and cost-effectiveness of compression hosiery compared
with 4LB. The purpose of this document is to provide the clinical statistical analysis plan for the study.
The cost-effectiveness analysis plan is documented elsewhere.
Study objectives
Primary objective
The objective of this multicentred, pragmatic, two-armed, parallel RCT is to assess the clinical effectiveness
and cost-effectiveness of compression hosiery compared with 4LB in terms of time to ulcer healing.
Secondary objectives
To compare:
l time to ulcer-free reference leg between the patients with compression hosiery and those with 4LB
l the longitudinal profile of health-related quality of life [collected at baseline then via postal survey at
3-monthly intervals (baseline, 3, 6, 9 and 12 months)] between the patients with compression hosiery
and those with 4LB
l the concordance to treatment (throughout trial) between the patients with compression hosiery and
those with 4LB
l ulcer recurrence rates between the patients with compression hosiery and those with 4LB
l the number of adverse events (throughout the trial) between the patients with compression hosiery
and those with 4LB.
Study design
Sample size calculation
The sample size estimation is based on VenUS I,7 a RCT that compared time to ulcer healing between two
groups of patients [4LB vs. SSB, HR 1.33 (95% CI 1.05 to 1.67), median time to healing 92 days vs.
126 days]. The aim of VenUS IV is to estimate the size of the difference between the compression hosiery
and 4LB rather than to look for a difference of any given size. Therefore, 400 patients (200 in each arm of
the study) will allow us to detect a HR of either 0.72 or 1.41 between the two groups, with 90% power
at the 5% significance level. Adjusting for centre variation and loss to follow-up of approximately 10%,
the estimated sample size is about 489 in both intervention groups. Hence we anticipate recruiting
489 patients within duration of 17 months. These patients will be followed up for a maximum duration of
12 months.
Randomisation and blinding
Eligible patients will be randomised in a 1 : 1 ratio to either compression hosiery or 4LB. Randomisation
will be stratified by baseline ulcer area (≤ 5 cm2 vs. > 5cm2) and baseline ulcer duration (≤ 6 months vs.
> 6 months) using permuted blocks design so that patients with these characteristics are approximately
equally distributed between the two intervention groups. Randomisation will be centralised and will be
undertaken at York Trials Unit. This is an unblinded study. It is not possible to blind the nurses or
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participants to the treatment being received. The interventions have different modes of application and
look different.
The assessment of the main outcome measure will be blinded. The status of an ulcer as healed will be
established by two independent assessors using digital photographs of the reference leg ulcers, taken by
the treating nurses at healing and then at weekly intervals after healing for 4 weeks.
Study outcomes and how they will be measured
Primary
The primary outcome is the time to healing of the largest eligible ulcer on the reference leg measured in
days. For each patient in the study this will be measured as the duration from randomisation to the time
when their reference leg ulcer heals, they withdraw from the study, they are lost to follow-up, they die
from any cause or they exit the trial after 12 months – whichever event comes first.
The time to healing of the reference leg ulcer is blinded in the sense that it will be determined from
photographs of the reference leg ulcer taken by the treating nurses when they feel the ulcer is healed.
The blinded outcome assessment will be conducted by two blinded clinical experts. Where agreement is
not reached between the reviewers, a third reviewer will be consulted, who will give a final decision. If no
photographs are available, unblinded survival time taken from the treating nurse records will be used
instead. In addition, if nurses say that the wound is healed and stop taking photographs but blinded
assessors says the wound is not healed then we will consider the wound healed.
Secondary
1. Non-blinded time to reference leg ulcer healing This will be measured similarly as the main outcome,
but the healing date will be determined by nurse decision and not based on blinded photographs.
2. Non-blinded time to an ulcer-free reference leg The reference leg is the leg with the largest eligible
ulcer that will be followed during the study. This outcome will be the time from randomisation to the
time when the patient either has an ulcer-free reference leg, withdrawn from the study, been lost to
follow-up or died from any cause, or time of data analysis (end of study) – whichever comes first.
3. Health-related quality-of-life scores at baseline and months 3, 6, 9 and 12 These scores are physical
scores (physical functioning, role physical, bodily pain and general health), mental scores (vitality, social
functioning, role emotional and mental health), Physical Component Score and Mental Component
Score. All of these scores will be measured by the SF-12 (version 2, standard recall) questionnaire168 and
will be scored using the QualityMetric Health Outcomes™ Scoring Software 2.0.169
4. Patient concordance to treatment This will be measured by (1) the proportion of patients changing
from their randomised treatment to another treatment in the compression hosiery group compared
with the 4LB group; (2) how often they wear compression hosiery during the day (everyday/most days/
some days/did not wear compression hosiery); (3) how many layers the patient wears and whether the
patient or carer applied the hosiery; (4) how often (everyday/most days/some days/not at all) patients
with 4LB wear 4LB; and (5) the number of times that the patients removed their bandages.
These outcomes are measured 1 month post randomisation.
5. The number of patients having the recurrence of a venous leg ulcer on the reference leg, in the two
intervention groups This will be measured by self-reported ulcer recurrence events in the two groups
and also reported by nurses in the monthly nurse assessment questionnaire.
6. The total number of each patient’s adverse events (SAEs) and NSAEs throughout the period of the trial
This will be measured from nurse-reported adverse events forms.
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Statistical methods
Pooling of data for analyses
The study will be conducted under a common protocol at each investigational site with the intention of
pooling the data for analysis. Every effort will be made to promote consistency in study execution at each
investigational site (study centre). Centres with very few participants will not be combined with other
centres because we are not interested in the actual estimates of the centre effects but rather we would
like to simply adjust for them.170
Statistical analyses
All analyses will be conducted at the 5% significance level. Estimates and their 95% CIs will be
constructed using SAS version 9.2 (SAS Institute Inc., Cary, NC, USA) and Stata version 11
(versions may change).
Primary analyses
The primary analysis will be performed as near to an intention to treat as we can. The primary analysis
involves the primary outcome as defined above. More specifically, the time to reference leg ulcer healing
will be right censored when any one of the following situations has occurred: (1) participant has
withdrawn from the study; (2) subject is lost to follow-up; (3) subject has died from any causes;
or (4) end of follow-up (12 months). For each intervention arm, the distribution of time to ulcer healing
will be described using Kaplan–Meier survival estimates (Table 63). Treatment differences will be evaluated
using the CPH model with shared centre frailty effects63–65 (Table 64). A shared frailty effect is a random
effect in a CPH model that has a multiplicative effect on the hazard of healing. In this case the shared
centre frailty effects will model the frailties as being specific to each centre hence describing the degree of
correlation of patients within centres (subjects within a centre are correlated because they share a common
frailty). From our experience with another study (VenUS III)13 patients from same centre are correlated,
hence this ought to be adjusted for in this study with centre shared frailty effects. The need for a centre
frailty effect will be evaluated via a likelihood ratio test that evaluates if the frailty variance is zero using a
50 : 50 mixture of chi-squared distributions. If there is a non-significant frailty effect then CPH model
without centre frailty effects will be fitted instead to the data.
Given that it is not known whether the effectiveness of the treatment will decrease, increase or remain
constant during follow-up, the proportional hazard assumption will be evaluated formally by a statistical
test using Schoenfeld residuals.66 Treatment effects will be adjusted by baseline characteristics (ulcer area,
ulcer duration, centre and patient mobility).7,61 Ulcer area and duration are continuous variables and will be
logarithmically transformed. Centre will be included as a shared frailty effect and patient mobility as a
three-level factor.
TABLE 63 Unadjusted Kaplan–Meier survival estimates and the log-rank test of the equality of the two
survival curves
Characteristic Compression hosiery (n= xxx) 4LB (n= xxx)
No. healing/total no. healed (%)
Unadjusted Kaplan–Meier estimates
25% percentile of time to healing (days) (95% CI)
50% percentile of time to healing (median) (days) (95% CI)
Log-rank test statistic, p-value
Wilcoxon test statistic, p-value
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Secondary analyses
Many of the secondary analyses will be performed using the secondary outcomes as outlined in the
‘study outcomes and how they will be measured’ section. In all analyses centre will be treated as a
random effect.
1. Time to event secondary endpoint (non-blinded time to ulcer healing) will be analysed like the primary
outcome with identical censoring strategy. The CPH model with a shared centre frailty effect here will
be further adjusted by the same covariates (e.g. ulcer area, ulcer duration, centre and patient mobility)
as in the primary analysis. All other model building procedures will be the same as for the primary
outcome (Tables 65 and 66).
2. Time to event secondary endpoint (non-blinded time to an ulcer free reference leg) will be analysed like
the primary outcome with identical censoring strategy. Treatment effects will be adjusted by ulcer area,
ulcer duration, centre and patient mobility. All other procedures are identical to the analysis of the
primary outcome.
3. The continuous physical scores (physical functioning, role physical, bodily pain and general health),
mental scores (vitality, social functioning, role, emotional and mental health), PCS and MCS will be
summarised with descriptive statistics (n, mean, SD, minimum, maximum, IQR and median) by
treatment group at baseline, and months 3, 6, 9 and 12 (Tables 67 and 68). As the PCS and MCS were
TABLE 64 Cox proportional hazard regression of blinded time to healing vs. treatment intervention adjusting for
baseline ulcer area, duration and patient mobility with and without the shared centre frailty parameter
Parameter Estimate (SE)
Hazard ratio
(95% CI) p-value
Test of PH assumption,
p-value
Without centre frailty effect
Compression hosiery vs. 4LB
Log (area)
Log (duration)
Mobility
Patient walks freely
Patient walks with difficulty
Patient is immobile
Global test of PH assumption assumption
With centre frailty effect
Compression hosiery vs. 4LB
Log (area)
Log (duration)
Mobility
Patient walks freely
Patient walks with difficulty
Patient is immobile
Theta
Global test of PH assumption
Test of significance of frailty parameter: Ho: Theta= 0 (χ2(df:01)= xxx. p-value= xxx.
Note: In the model with centre frailty effect the SEs of hazard ratios are conditional on theta. Theta is an estimate of the
frailty variance. If theta is significantly different from zero then there is centre heterogeneity.
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TABLE 65 Cox proportional hazard regression of non-blinded time to healing vs. treatment intervention adjusting
for baseline ulcer area, duration and patient mobility with and without the shared centre frailty parameter
Parameter Estimate (SE)
Hazard ratio
(95% CI) p-value
Test of PH assumption,
p-value
Without centre frailty effect
Compression hosiery vs. 4LB
Log (area)
Log (duration)
Mobility
Patient walks freely
Patient walks with difficulty
Patient is immobile
Global test of PH assumption
With centre frailty effect
Compression hosiery vs. 4LB
Log (area)
Log (duration)
Mobility
Patient walks freely
Patient walks with difficulty
Patient is immobile
Theta
Global test of PH assumption
Test of significance of frailty parameter: Ho: Theta= 0 (χ2(df:01)= xxx.
p value= xxx.
Note: In the model with centre frailty effect standard errors of hazard ratios are conditional on theta.
Theta is an estimate of the frailty variance. If theta is significantly different from zero then there is centre heterogeneity.
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TABLE 66 Cox proportional hazard regression of non-blinded time to an ulcer-free reference leg vs. treatment
intervention adjusting for baseline ulcer area, duration and patient mobility without and with the shared centre
frailty parameter
Parameter Estimate (SE)
Hazard ratio
(95% CI) p-value
Test of PH assumption
p-value
Without centre frailty effect
Compression hosiery vs. 4LB
Log (area)
Log (duration)
Mobility
Patient walks freely
Patient walks with difficulty
Patient is immobile
Global test of PH assumption
With centre frailty effect
Compression hosiery vs. 4LB
Log (area)
Log (duration)
Mobility
Patient walks freely
Patient walks with difficulty
Patient is immobile
Theta
Global test of PH assumption
Test of significance of frailty parameter: Ho: Theta= 0 (χ2(df:01)= xxx. p value= xxx.
Note: in the model with centre frailty effect standard errors of hazard ratios are conditional on theta. Theta is the estimate
of the frailty variance. If theta is significantly different from zero then there is centre heterogeneity.
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TABLE 67 Short Form questionnaire-12 items (version 2) standard recall PCSs and MCSs: summary
Timeline/statistic
PCSs MCSs
Compression
hosiery (n= xxx)
4LB
(n= xxx)
Overall
(N= xxx)
Compression
hosiery (n= xxx)
4LB
(n= xxx)
Overall
(N= xxx)
Baseline
Mean (SD)
Median
(min., max.)
IQR (25–75%)
Missing, n (%)
3 months
Mean (SD)
Median
(min., max.)
IQR (25–75%)
Missing, n (%)
6 months
Mean (SD)
Median
(min., max.)
IQR (25–75%)
Missing, n (%)
9 months
Mean (SD)
Median
(min., max.)
IQR (25–75%)
Missing, n (%)
12 months
Mean (SD)
Median
(min., max.)
IQR (25–75%)
Missing, n (%)
max., maximum; min., minimum.
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TABLE 68 Mean (standard) of other SF-12v2 standard recall Physical and Mental scores
Timeline/statistic
Compression
hosiery
(n= xxx)
4LB (n= xxx)
Overall
(N= xxx)
Compression
hosiery
(n= xxx)
4LB (n= xxx)
Overall
(N= xxx)Physical scores Mental Scores
Physical
functioning
Vitality
Baseline
3 months
6 months
9 months
12 months
Role physical Social functioning
Baseline
3 months
6 months
9 months
12 months
Bodily pain Role emotional
Baseline
3 months
6 months
9 months
12 months
General health Mental health
Baseline
3 months
6 months
9 months
12 months
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measured longitudinally with time (baseline and months 3, 6, 9 and 12), the relationship between PCS
or MCS with treatment will be evaluated through a LMM to account for the dependence of PCS or
MCS measured within the same patient as described by Verbeke and Molenberghs and also Fitzmaurice
et al.68,69 In the LMM the PCS or MCS will be adjusted by ulcer area, ulcer duration, time, centre and
patient mobility. To assess whether there are differences between the treatments during time of
follow-up, an interaction between treatment and time will be tested for inclusion in the models.
4. Patient concordance to treatment will be analysed as follows: (1) the proportion of patients changing
from their randomised treatment will be summarised by treatment randomised; (2) in compression
hosiery, the frequency (%) of wearing compression hosiery will be summarised by the four categories
(every day/most days/some days/did not wear compression hosiery); (3) the number of layers (one layer,
two layers) will be summarised as frequency (%); similarly, the subject (nurse, patient) applying the
stockings will be summarised by frequency (%), (4) for patients with 4LBs, the frequency of wearing
a 4LB will be summarised by the four categories (every day/most days/some days/not at all);
and (5) number of times (none, at least once) patients have removed any of the layers of bandages
themselves will be summarised as frequency (%) (Table 69).
5. The recurrence of a leg ulcer post healing is a binary outcome (recurrence yes, recurrence no).
This will be analysed using random-effects logistic regression70 adjusting for ulcer area, ulcer duration,
centre, patient mobility and duration between healing and end of study to ascertain whether the
recurrence rates are the same in the two treatment groups.
6. The total number of each patient’s adverse events is a count outcome. This will be analysed by a
random-effects Poisson regression model adjusting for ulcer area, ulcer duration, centre and patient
mobility. It is anticipated that the variability in the data will be higher than that modelled by the
random-effects Poisson regression model (experience from previous studies, VenUS II and VenUS III).13,61
In the event of such a scenario, a random-effects negative binomial regression model will be used
adjusting for the same covariates. Also, from previous experience (VenUS III),13 there will be an excess of
‘zeros’ (a lot of patients without adverse events throughout the whole period of the study). In the event
of this, a zero-inflated, random-effects Poisson regression model or a zero-inflated, random effects
negative binomial regression model70,71 will be fitted to the adverse events data adjusting for the same
covariates. This analysis will be repeated for NSAEs and SAEs separately (Table 70). If the numbers of
adverse events per participant is very small throughout follow-up then the adverse events data will also
be analysed by random-effects logistic regression. For each participant in the study a success will be
defined as having at least one adverse event during follow-up and failure will be defined as having no
adverse event during follow-up. Treatment differences will be compared adjusting for ulcer area,
ulcer duration, centre and patient mobility (Table 71).
Summary of baseline and follow-up characteristics
Baseline patient data
Categorical variables like gender, mobility, ankle mobility of reference leg and diabetes status will be
summarised as frequency (%) by treatment group. Continuous variables, such as age, height, weight and
BMI will be summarised with descriptive statistics (n, mean, SD, minimum, maximum, IQR and median)
(Table 72).
Baseline ulcer data
Categorical variables, such as baseline tracing, treatment preference, current treatments and baseline
questionnaire completed will be summarised as frequency (%) by treatment group. Continuous variables,
such as size of ulcer, ulcer duration and ankle circumference, will be summarised with descriptive statistics
(n, mean, SD, minimum, maximum, IQR and median) (Table 73).
Baseline reference limb data
Categorical variables like reference leg followed will be summarised as frequency (%) by treatment group.
Continuous variables, such as ABPI, total number of ulceration episodes, duration since first ulcer, duration
of reference ulcer, duration of oldest ulcer on reference leg and total number of ulcers per patient on the
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TABLE 69 Concordance to treatment intervention at 1 month during follow-up
Characteristic
Compression
hosiery (n= xxx) Characteristic
Four-layer high
compression (n= xxx)
Frequency of stockings wearing during day Frequency of 4LB wearing
Everyday Everyday
Most days Most days
Some days Some days
Did not wear Not all
Layers of stockings during the day Ever removed 4LB yourself?
One layer Yes
Two layers No
Frequency of stockings wearing during night
Every night – –
Most nights – –
Some nights – –
Did not wear – –
Layers of stockings during the night
One layer – –
Two layers – –
Who normally applies compression stockings?
Nurse – –
Yourself – –
If yourself, stockings easy to apply?
Yes – –
No – –
If friend/relative, stockings easy to apply?
Yes – –
No – –
Did not wear my stockings – –
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TABLE 70 Parameter estimate (SE), p-values and 95% CI of the random effects negative binomial regression model
fitted to the NSAE data, SAE data and number of SAEs and NSAEs combined
Parameter
NSAEs SAEs
Estimate (SE) p-value 95% CI Estimate (SE) p-value 95% CI
Fixed effects
Intercept
Compression hosiery vs. 4LB
Log (area)
Log (duration)
Mobility
Patient walks freely
Patient walks with difficulty
Patient is immobile
Covariance parameters
Centre effect
Dispersion parameter
Estimate (SE) (p-value) 95% CI – – –
Fixed effects
Intercept – – –
Compression hosiery vs. 4LB – – –
Log (area) – – –
Log (duration) – – –
Mobility – – –
Patient walks freely – – –
Patient walks with difficulty – – –
Patient is immobile – – –
Covariance parameters – – –
Centre effect – – –
Dispersion parameter – – –
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TABLE 71 Parameter estimate (SE), odds ratio (95% CI) and p-values of the random effects logistic regression
model for the NSAE data, SAE data and number of SAE and NSAE combined
Parameter
NSAEs SAEs
Estimate (SE)
Odds ratio
(95% CI) p-value Estimate (SE)
Odds ratio
(95% CI) p-value
Fixed effects
Compression hosiery
vs. 4LB
Log (area)
Log (duration)
Mobility
Patient walks freely
Patient walks with difficulty
Patient is immobile
Random effects
Centre
Measurement error
Estimate (SE)
Odds ratio
(95% CI) p-value – – –
Fixed effects – – –
Compression hosiery
vs. 4LB
– – –
Log (area) – – –
Log (duration) – – –
Mobility – – –
Patient walks freely – – –
Patient walks with difficulty – – –
Patient is immobile – – –
Random effects – – –
Centre
Measurement error
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TABLE 72 Baseline patient data
Characteristic
Compression hosiery
(n= xxx)
Four-layer high compression
(n= xxx)
Gender
Male
Female
Age
Mean (SD)
Median (min., max.)
IQR (25–75%)
Missing (%)
Height
Mean (SD)
Median (min., max.)
IQR (25–75%)
Missing (%)
Weight
Mean (SD)
Median (min., max.)
IQR (25–75%)
Missing (%)
BMI
Mean (SD)
Median (min., max.)
IQR (25–75%)
Missing (%)
Mobility
Patient walks freely
Patient walks with difficulty
Patient is immobile
Ankle mobility of reference leg
Patient has full range of motion
Patient has reduced range of ankle motion
Patient’s ankle is fixed
Diabetic
Yes
No
max., maximum; min., minimum.
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TABLE 73 Baseline ulcer data
Characteristic
Compression hosiery
(n= xxx)
Four-layer high compression
(n= xxx)
Size of ulcer
Mean (SD)
Median (min., max.)
IQR (25–75%)
Missing (%)
Ulcer duration
Mean (SD)
Median (min., max.)
IQR (25–75%)
Missing (%)
Ankle circumference
Mean (SD)
Median (min., max.)
IQR (25–75%)
Missing (%)
Baseline tracing done
Yes
No
Preference
Compression hosiery (stockings)
Four-layer compression bandaging
No preference
Current treatments
Four-layer compression bandaging
Short stretch bandaging
Compression hosiery
Other compression bandaging
Not receiving compression
Other treatment
Baseline questionnaire completed
Yes
No
max., maximum; min., minimum.
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reference leg, will be summarised with descriptive statistics (n, mean, SD, minimum, maximum, IQR and
median) (Table 74).
Centre enrolment, healing rates and adverse events
Enrolment is stratified by investigational site (centre) and within each centre this will be summarised as
frequency (%) by treatment received and overall. Within each centre the percentage healed and number
of adverse events (SAES and NSAEs) will be summarised as frequency (%) (Table 75).
Description of adverse events
Serious adverse events are further classified as death, persistent or significant disability/incapacity,
hospitalisation required/prolonged and other medically important condition. This will be summarised as
frequency (%) by treatment group. The outcome of the serious adverse event and their relationship with
treatment are categorical variables and will be summarised as frequency (%) by treatment received.
The relationship between non-serious adverse events and treatment received is a categorical variable and
will be summarised by frequency (%) (Tables 76 and 77).
Sensitivity analysis and missing data handling
Sensitivity analysis will be carried out in two ways, namely (1) comparing results with and without a centre
random effect and (2) comparing results with and without multiple imputation of the best model chosen in
‘(1)’. Ten data sets will be generated for each multiple imputation procedure. This will be done with all of
the statistical models fitted to the data.
In the comparison of results with and without a centre random effect, for the primary outcome (time to
ulcer healing) and for the survival type secondary outcomes (the non-blinded time to ulcer healing and the
non-blinded time to an ulcer free reference leg), a CPH model with a centre frailty effect will be compared
with one without a centre frailty effect (centre effects completely ignored) to ascertain the changes in the
treatment effect. For the other non-survival type secondary outcomes this will be addressed as follows: for
the PCS or MCS, the LMM with and without a centre random effect, will be compared; for the recurrence
of the leg ulcer post healing, the random-effects logistic regression, with and without a centre random
effect, will be compared; for the number of adverse events, a zero-inflated Poisson regression model,
with and without a centre random effect, will be compared.
Missing data will be estimated by multiple imputations. For this part of the sensitivity analysis it will be
assumed that the data are multivariate and normally distributed, and the missing data are missing at
random.171 That is, the probability that an observation is missing can depend on the observed values of the
individual but not on the missing variable values of the individual. We will also assume that the imputer’s
model (model used to impute the missing values) is the same as the analyst’s model (model used to
analyse the data). Therefore, multiple imputation will be conducted as follows. For the primary outcome
(time to ulcer healing) and for the survival type secondary outcomes (the non-blinded time to ulcer healing
and the non-blinded time to an ulcer-free reference leg), it will be further assumed that the outcomes and
their censoring status is completely known (we have designed our data collection to have complete data
on these outcomes) and the missing values for ulcer area, ulcer duration, centre and patient mobility will
be imputed. For the other non-survival secondary outcomes, the imputation will be as follows. For the PCS
or MCS, multiple imputations will be carried out on missing values (for PCS – ulcer area, ulcer duration,
centre and patient mobility; for MCS – ulcer area, ulcer duration, centre and patient mobility separately).
For the recurrence of the leg ulcer post healing, multiple imputation will be carried out on missing values
(recurrence (yes/no), ulcer area, ulcer duration, centre and patient mobility). For the number of adverse
events, multiple imputation will be carried out on missing values (NSAEs, SAEs, ulcer area, ulcer duration,
centre and patient mobility). In all imputations, ulcer area and ulcer duration will be logarithmically
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TABLE 74 Baseline reference limb data
Characteristic Compression hosiery (n= xxx) Four-layer high compression (n= xxx)
Reference leg
Left
Right
ABPI
Mean (SD)
Median (min., max.)
IQR (25–75%)
Missing (%)
Total of ulceration episodes
Mean (SD)
Median (min., max.)
IQR (25–75%)
Missing (%)
Duration since first ulcer
Mean (SD)
Median (min., max.)
IQR (25–75%)
Missing (%)
Duration of reference ulcer (years)
Mean (SD)
Median (min., max.)
IQR (25–75%)
Missing (%)
Duration of oldest ulcer on reference leg (years)
Mean (SD)
Median (min., max.)
IQR (25–75%)
Missing (%)
Total no. of ulcers per patient (reference leg)
Mean (SD)
Median (min., max.)
IQR (25–75%)
Missing (%)
max., maximum; min., minimum.
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TABLE 75 Centre enrolment, healing and adverse events (serious and non-serious)
Study centre
Compression hosiery
(n= xxx)
4LB
(n= xxx)
Overall
(N= xxx) % Healed
Bolton
Bradford
Brighton
Cambridge
Cornwall
Durham
Epsom
Harrogate
Hull
Kent
Kingston
Lancashire (Central)
Lancashire (North)
Leeds
Mid Yorks and Wakefield
Norfolk (Dereham)
Norfolk (Diss)
Norfolk (Norwich)
N Ireland
N Yorks
Nottingham
Redbridge
Suffolk (Sudbury)
South of Tyne and Wear
Whitby
York Hospital
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TABLE 76 Adverse events description
Characteristic
Compression hosiery
(n= xxx)
Four-layer high compression
(n= xxx)
SAE
Classification
Death
Life- or limb-threatening event
Hospitalisation required/prolonged
Persistent or significant disability/incapacity
Other medically important condition
Outcome of event
Recovered fully
Recovered partially
Died
Ongoing
Relationship of adverse event to treatment
(nurse’s classification)
Unrelated
Unlikely to be related
Possibly related
Probably related
Definitely related
Not able to assess if related
NSAE
Relationship of adverse event to treatment
Unrelated
Unlikely to be related
Possibly related
Probably related
Definitely related
Not able to assess if related
TABLE 77 Discomfort to treatment intervention at 1 month during follow-up
Characteristic
Compression hosiery
(n= xxx)
Four-layer high compression
(n= xxx)
Discomfort
Mean (SD)
Median (min, max)
IQR (25–75%)
Missing (%)
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transformed. Other outcomes (PCS, MCS, non serious adverse events, serious adverse events) will be
logarithmically transformed if need be.
Separate tables of the results of sensitivity analyses will not be produced but the results will be commented
on in the text, and emphasis placed on results that differ considerably between models with and without
multiple imputations. Our primary results are those without multiple imputations, so in an event that there
are differences between these results and those with multiple imputations, those without multiple
imputations will be taken as the primary results. Nonetheless, the differences will be explained explicitly.
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Appendix 20 VenUS IV statistical analysis plan:
cost-effectiveness analysis
This document provides the economic analysis plan for the VenUS IV study, a RCT of high-compressionhosiery (hosiery) compared with high-compression bandaging (4LB) in the treatment of venous
leg ulcers.
The VenUS IV protocol specifies that a within-trial analysis – a cost-effectiveness analysis using trial data
only – will be undertaken to assess the cost-effectiveness of hosiery compared with 4LB in study
participants. Although within-trial analysis is considered to have high internal validity, there is a growing
awareness that the findings from any RCT should not be considered in isolation but, in fact, are more
valuable from a decision-making context when used to update existing evidence on all treatments of
interest. Thus, in addition to conducting the trial-level analysis, a second, separate VenUS IV economic
analysis will be conducted to assess the cost-effectiveness of all relevant high-compression devices.
This second analysis will incorporate the findings from VenUS IV into the wider existing evidence base
including other, alternative, high-compression treatments. Such an analysis requires the development of a
decision-analytic model to accommodate multiple different information sources. This document will focus
on the conduct of both analyses, in turn.
Within-trial analysis: outline of the analysis
The within-trial economic analysis will be performed using individual patient-level data from VenUS IV trial.
The analytical approach will take the form of cost-effectiveness and cost–utility analyses. The difference
between the two approaches, in the case of VenUS IV, lies in the outcome measure used, which will be
ulcer healing for the cost-effectiveness analysis and QALYs for the cost–utility analysis. A QALY is defined
as a year lived with full health, calculated by multiplying quality of life and length of life. This is discussed
later in more detail. Based on trial evidence, incremental cost-effectiveness (or cost–utility) ratios will be
calculated by taking a ratio of the difference in the mean costs and mean effects (or utility measure).
Incremental NMB will be calculated by weighting the QALYs gained by the maximum willingness to pay for
a QALY and subtracting the cost difference.84
The economic analysis will be conducted using the perspective of the NHS and PSS.172 The period of
analysis is 12 months, which is the equal to the maximum period of patient follow-up in the trial. Hence,
future costs and health outcomes will not be discounted. The analyses will be conducted using Stata
version 10 or version 11.
Outcomes for the analysis
The outcome for the cost-effectiveness analysis is the same as the primary outcome of the clinical trial,
i.e. the time to healing of the largest eligible ulcer on the reference leg, measured in days. The outcome
for the cost–utility analysis is the quality-adjusted life-years over a period of 12 months, which is the
maximum period of follow-up of patients. Patients who have healed before the end of the study will be
followed up until the end of the study to collect utility (and resource use) data. This is important because
patients may have higher utility levels after healing, in which case the benefit of treatment in reducing the
time to healing will be reflected in higher total QALYs.
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Analysis methods
The economic analysis will address methodological issues that are particularly relevant to the VenUS IV
study. These include censoring of costs and outcomes data, potential cluster (centre) effect and competing
risks, and ulcer recurrence. A brief description of the current literature on methods to deal with
(some or all) the issues identified is presented below; the preferred approach is then discussed in detail.
Overview of methods
Censoring of costs and outcomes
The cost-effectiveness and cost–utility analyses will use patient-level information on healing and costs/utility
accumulated over the period of the study. Participants whose ulcers have not healed at the end of
follow-up, or who died or were lost to follow-up before healing took place, will be treated as censored
observations. Those participants lost to follow-up (before or after healing) will also have incomplete
information on costs/utility. Furthermore, when time to healing is observed, costs/utility data may be
incomplete if patients are censored beyond the point of healing and before the end of follow-up period.
Thus, censoring makes direct estimation of mean time to healing, mean costs and mean QALYs impossible
for the two treatment arms. Below we review the methods used in the literature to address censored costs
and outcomes.
Various methods have been proposed in the literature to address censoring of costs and outcomes in an
economic analysis. Naive approaches include the use of a full sample estimator and an uncensored case
estimator. The former approach is based on taking a simple mean of the observed costs and outcomes for
all individuals in the sample, irrespective of whether individuals were censored or not. This approach is
bound to underestimate total costs and QALYs as costs and outcomes beyond censoring are not observed.
The uncensored case estimator uses data only from patients who were uncensored during the study
interval. This approach is biased towards the costs and outcomes of patients with shorter time to event.
Hence, the naive approaches are inappropriate for handling censored data.173
A further potential approach is the use of standard survival analysis methods. These methods treat time
to event as the random variable of interest, and censoring time as the respective censoring variable to
estimate non-parametric Kaplan–Meier survival curves.174 When analysing costs, the total cost incurred is
the random variable of interest and cost at censoring time is the censoring variable. However, standard
survival analyses assume independence of the response variable and the respective censoring variable,
i.e. censoring is assumed to be non-informative. However, for costs and quality-of-life data this is usually
not true.175,176 The primary reason is that individuals accrue costs at different rates. For instance, individuals
in poor health tend to accumulate costs at much higher rates and, in turn, have higher cumulative costs at
censoring time and event time than those in better health.80 Different rates of cost accumulation (resource
use) lead to dependent censoring in costs with independent censoring in time.13 Censoring costs are hence
informative of the latent survival costs, even if censoring is completely independent of the survival time.
Another potential approach to address the challenge posed by censored data is to use imputation methods
to estimate costs and QALYs beyond the observed period. Imputation would require fitting parametric
survival curves with appropriate distribution functions to the data observed during the study period.177
The approach is based on extrapolation of the modelled survival distribution into the future and assumes
that the whole sample will eventually experience the event (i.e. heal) at the rate dictated by the fitted
distribution. However, unrealistic survival times may be imputed particularly when a large proportion of
survival times are censored. As a result, we do not consider this approach to be the most appropriate to
address the censoring issue at hand.
Other approaches that are commonly used in the literature include non-parametric weighted mean
estimators proposed separately by Lin et al.175 and Bang and Tsiatis.178 Both include alternative estimators
for situations when patient cost histories are available (Lin1175 and Bang and Tsiatis-Partitioned178)
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and when only total costs are observed at the end of the individual’s observation period (Lin2175 and Bang
and Tsiatis-Simple178). These estimators assume independence between time to event and censoring time
but not between costs at different time points for a particular patient. They further assume that patients
are not censored in the study because they have accumulated unusually high or low costs. Both Lin175 and
Bang and Tsiatis estimators work by dividing the study period into k small intervals. Lin175 estimators then
calculate the sum product of Kaplan–Meier probability of survival to the start of each interval k (Lin 1175)
or the probability of experiencing the event during each interval k (Lin2175) and the mean cost during the
interval. Lin1175 assumes that censoring occurs at only the endpoints of the intervals. This condition is a
potential limitation of the estimator, which was subsequently addressed by Bang and Tsiatis estimators.
Both Lin1175 and Lin2175 have been found to be consistent when censoring occurs either at the start or the
end of an interval.179
The Bang and Tsiatis estimators are based on IPW as proposed by Bang and Tsiatis.178 Bang and
Tsiatis-Simple178 uses cost information from uncensored individuals only, hence censoring is allowed to
occur anywhere during the interval. It works by weighting each complete cost observation by the inverse
of the probability of not being censored during the interval. Bang and Tsiatis178 also proposed the Bang
and Tsiatis-Partitioned estimator178 to be used when complete cost histories are available.
Recent studies have demonstrated that Lin2175 and Bang and Tsiatis-Simple estimators178 are less efficient,
more unstable and sensitive to the level of censoring than Lin1175 and Bang and Tsiatis-Partitioned
estimators178 respectively.173,179,180 However, when cost histories are not available, the Lin2175 175 and
BT-Simple estimators178 represent the preferred approach. When cost histories are available, both Lin1175
and Bang and Tsiatis-Partitioned estimators178 are found to perform well. However, when these two
estimators are compared, the Bang and Tsiatis-Partitioned estimator178 is preferred, as it is not restricted by
the pattern of censoring distribution.173
An important limitation of the non-parametric weighted estimators is that they do not directly allow for
covariate adjustment. Hence, any imbalance in the baseline characteristics, including utility levels, cannot
be controlled for using a non-parametric weighting approach alone. However, parametric applications of
these estimators have been demonstrated in the literature.81,181 Of particular note is Lin’s IPW estimator181
that uses IPW approach for each cost interval as used by both BT estimators. However, unlike BT
estimators that are non-parametric in nature, Lin’s IPW estimator181 uses regression models to estimate the
treatment effect while weighting the observations by IPW method to account for censored observations.
This regression approach allows controlling for covariates. Lin’s first IPW estimator181 was applied to linear
regression models. However, it is well known in the literature that cost and QALY distributions are usually
skewed.182 Lin80 later proposed the same IPW approach using generalised linear models (GLMs). GLM is a
flexible generalisation of the ordinary least squares that allows distributions other than the Gaussian
distribution to fit the empirical cost and outcome data.
Cluster (centre) effect
When patients in a study are recruited from multiple centres, there is a potential for heterogeneity of
treatment effects that vary across centres. Gomes et al.82 evaluated the relative performance of the
following analytical methods for cost-effectiveness analysis of cluster randomised trials: seemingly
unrelated regression (SUR) with and without robust standard errors, generalised estimating equation (GEE)
with robust standard errors, a two-stage non-parametric bootstrap method and a multilevel model (MLM).
The study found that SUR without robust standard errors performed poorly compared with the models
that accounted for cluster effect. In case of fewer clusters (< 20), the GEE and SUR (with robust SE)
performed badly. MLM was suggested to be the most appropriate method for a wide range of
circumstances with clustered data.
Statistical methods for the analysis of VenUS IV data
Based on the review of statistical methods for the economic analysis of censored data, the following
methods will be used for the cost-effectiveness and cost–utility analysis of VenUS IV.
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The VenUS IV study is recruiting patients from multiple centres across the UK. The statistical and economic
analysis need to be aware that there may be heterogeneity of treatment effects across centres. This may
be due to variation in bandaging skills, as some centres may have more experience with the use of
four-layer bandaging than others. Furthermore, there may be other unknown centre-level effects that may
be correlated with the treatment effect. Hence, for the economic analysis of VenUS IV study, we will be
using MLM with patient and centres specified as the two levels of the analysis. MLM can be specified
within the GLM framework using multilevel GLM (MGLM). To deal with censored costs and outcomes in
the study, we will use the IPW weighting method of Lin.80 Hence, in summary, our preferred approach is
to use inverse probability weighted multilevel generalised linear model (IPW-MGLM).
During the analysis, we will explore whether the cost and outcome equations can be programmed as a
system of bivariate or trivariate equations to allow for error correlation between equations. The analysis
will be conducted using Stata version 10.1 or a later version. In case of software limitations preventing
such analyses, the required cost and outcomes equations will be estimated independently as univariate
equations followed by estimation of uncertainty using non-parametric bootstrap method.
Although the primary event of interest in VenUS IV study is healing of the reference ulcer, other events
may compete with the primary event of interest. The primary competing event in the current case is death,
i.e. patients who die will not heal. Hence, death is a competing event and is also informative about the
event of interest. However, based on previous VenUS studies, we know that death is a rare event within
the study interval (two deaths reported by the end of April 2011). Hence, death can be treated as a
censoring event as it was treated in the previous VenUS analyses. Similarly, recurrence of the healed ulcer
will be recorded during the study period. We anticipate that the impact of recurrence of ulcer will be
reflected via increased costs and reduced utility level.
Data validation
The within-trial economic analysis will use the validated data set produced for the statistical analysis of the
RCT. Data on health services resource use and quality of life (EQ-5D) will be separately validated for
the economic analysis. Further validation of the data will be undertaken as follows:
l Participants for whom there are no cost and outcome data other than baseline will be considered as
censored 1 day after randomisation.
l Following data reporting validation, decisions will be made regarding queries about
participant-reported health services resource-use data.
Missing data
Missing data (other than censoring) will be evaluated to assess the occurrence of specific patterns.
If needed, missing data will be handled through the most adequate methodology in line with the statistical
analysis plan of VenUS IV study. Missing data on covariates will also be evaluated and, if necessary,
appropriate imputation methods will be used.
Costs
Analysis will be carried out from the perspective of the NHS and PSS. Data on resource use will be
collected for the entire duration of the trial for each participant. Costs will be calculated for each trial
participant as the product of resource units used and the relevant unit cost.
The following types of resource use will be used for cost estimation.
Costs of:
l treatments applied (trial or non-trial treatments)
l GP and nurse visits (cost/per average length of visit)
l outpatient visit and hospital inpatient stay.
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Information regarding resources equally probable to be used in the two arms of the trial will not be
considered in the economic analysis, as their effect is expected to annul in the incremental analysis.7
Individual participants’ resource use
Resource-use information will be available from study data record forms for each patient and will also be
collected from patients at each visit during the treatment of venous leg ulcer. For each participant the
relevant resource-use information will include:
l The type and number of trial treatments (source of data: trial application booklets completed by
treating health professional)
l The type and number of non-trial treatments (trial application booklets: completed by treating
health professional)
l The number of nurse visits for leg ulcer treatment (application booklets completed by treating
health professional)
l Dressing types (application booklets completed by treating health professional)
l Number of GP consultations at doctor’s surgery or home because of leg ulcer or other reasons
(self-reported in quarterly questionnaires)
l Number of nurse consultations at doctor’s surgery or home because of leg ulcer or other reasons
(self-reported in quarterly questionnaires)
l Number of doctor consultations in a hospital outpatient clinic or other location because of leg ulcer or
other reasons (self-reported in quarterly questionnaires)
l Number of nurse consultations in a hospital outpatient clinic or other location because of leg ulcer or
other reasons (self-reported in quarterly questionnaires)
l Number of hospital admissions without overnight stays because of leg ulcer or other reasons
(self-reported and data collected from nurses will be compared to establish the most accurate)
l Number of nights in hospital for inpatient stay because of leg ulcer or other reasons (self-reported and
data collected from nurses will be compared to establish the most accurate)
l Other costs over £5 in value, i.e. diagnostic tests will be costed on ad hoc basis.
Unit costs
The mid-year of the trial, i.e. 2011, will be used as the year of pricing. Unit costs associated with resource
use in each treatment arm will be estimated based on the appropriate version of NHS reference costs
database183 and Personal and Social Services Research database.168 Unit costs of treatment products will be
obtained from the appropriate edition of British National Formulary (BNF).184 In case the information is not
available in the BNF database, product costs will be obtained from the manufacturer.
Results
The results section will summarise the costs incurred and health benefits in terms of time to healing and
individual level utilities for the two treatment arms. Cost-effectiveness and cost–utility analyses will be
presented along with estimates of uncertainty. These are briefly discussed below.
Total costs
Descriptive statistics for cumulative costs will be summarised by trial arm at 3, 6, 9 and 12 months’
follow-up. Cost distributions will also be evaluated for total costs at 12 months. The IPW-MGLM regression
(discussed above) will be used to estimate the mean cost difference between treatment arms while
controlling for covariates and accounting for censoring.
Health benefits
Health benefits will be considered in two ways, one being the time required for the reference ulcer to heal
(for cost-effectiveness analysis) and second being the change in individual-level utility estimates over the
study period (for the cost–utility analysis).
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Time to healing
Health benefit will be defined as the difference in mean time to healing of the reference leg ulcer.
Death will be treated as a censoring event. As above, the IPW-MGLM regression will be used to estimate
the mean difference in time to healing between treatment arms while controlling for covariates.
The analysis will be conducted on an intention-to-treat basis.
Participant utilities
Changes in patient utility level will be measured using the EQ-5D questionnaire, which evaluates patient’s
quality of life on the following five dimensions: mobility, self-care, usual activities, pain/discomfort and
anxiety/depression. The EQ-5D questionnaire will be administered at baseline, and also at 3, 6, 9 and
12 months, to assess utility level at each time point. All EQ-5D data will be rechecked to ensure that all
scores are sensible. The utility scores will be weighted, based on the UK social tariffs obtained by elicitation
of health preferences through time trade-off in a large sample of the general population.176 Thus, EQ-5D
scores will be used to estimate QALYs for each patient over the 12-month period and evaluated within the
cost–utility analytical framework. Adjustment will be made for baseline EQ-5D data.
Mean EQ-5D scores will be presented for each follow-up time point by trial arm. Differences in the utility
score at baseline must be considered to adjust QALY between group differences. As above, we will use
IPW-MGLM approach to control for covariates and account for censoring.
Cost-effectiveness and cost–utility analyses
Cost-effectiveness of compression hosiery compared with compression bandaging will be expressed in
terms of ICER for cost per ulcer-free day. Point estimate of the ICER will be computed as difference in costs
and difference in time to healing for the two treatment arms, using the regression approach discussed
above. Uncertainty around the costs and effects will be presented using incremental cost-effectiveness
planes. To evaluate decision uncertainty cost-effectiveness acceptability curves will be presented, which will
evaluate the probability of compression hosiery being more cost-effective than compression bandaging.
Cost–utility analysis will be conducted in a similar manner as the cost-effectiveness analysis with QALYs
being the measure of health benefit.
Sensitivity analysis
Sensitivity analysis will be considered in line with the statistical analysis plan. Hence, first we will consider
undertaking the trial-based economic analysis with and without the centre effect. Second, the analysis will
also consider multiple imputation of model covariates. Further sensitivity analysis will also be considered,
including investigating the impact of assumptions around resource use and unit costs.
Decision model
Trials are designed to compare two or more alternative treatments. In general, however, it is not practically
possible for one experimental study to compare all available treatment options. This means that, for a
decision-maker, the information provided by head-to-head trial comparisons can be limited and
partial – they still need to know which treatment option is the most cost-effective one among all
treatments of interest. This limitation of head-to-head trial comparison can be overcome if available
evidence from multiple sources can be used. Decision-analytic models provide a structure within which
evidence from a range of sources can be synthesised to describe a specific problem, and through this
framework overall costs and effects can be estimated. The advantage of using this framework is that the
cost-effectiveness results can be based in all available evidence, across the full range of possible alternative
interventions and clinical strategies, over a relevant time horizon and for specific patient groups.185
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Decision problem
We will construct a decision-analytic model to allow estimation of the cost-effectiveness of all relevant
high-compression treatments, including 4LB and hosiery, for venous leg ulcers. The analysis will include
two health outcomes: a measure of ulcer healing and QALY. The choice of healing measure (e.g. time to
healing or healing rate) will depend on data availability. As mentioned above, a QALY is defined as a year
lived with full health, calculated by multiplying quality of life and length of life. Again, the choice of score
for health-related quality of life (or utility) for QALY calculation – for instance scores measured by EQ-5D or
Short Form questionnaire-6 Dimensions (SF-6D) – is subject to data availability. Cost will be presented in
UK pounds sterling. The mid-year of the trial, i.e. 2011, will be used as the year of pricing. The time
horizon will be defined based on data availability and if extrapolation is used relevant assumptions will be
evaluated. The study population comprises patients aged > 18 years with at least one venous leg ulcer,
and are able and willing to tolerate high compression. The analysis will be conducted based on the
perspective of the NHS and PSS, and findings are expected to inform decision-makers on which treatment
to adopt for use in the NHS, out of a set of alternatives.
Identifying the treatments of interest
Treatments considered within this evaluation should be those with the aim of achieving ‘high
compression’, defined as ‘ankle sub-bandage pressure of 35–40mmHg’. High compression is one of the
key factors for healing venous leg ulcers.19 The second consideration is that treatments of interest included
in this analysis should be relevant to the UK decision-making context. However, treatments that are not
currently used in general practice may ‘possibly’ be cost-effective and should be considered in the analysis.
We will identify compression treatments for venous leg ulcer from (1) the Cochrane review ‘Compression
for venous leg ulcer’,19 in which all RCTs investigating the effectiveness of compression treatments for
venous leg ulcer are recorded (planned update in 2011, these data will also be included); (2) the most
recent BNF,184 in which all current practices in the UK are listed; and (3) clinical experts who might provide
relevant alternative treatments to be considered for which no data exist. We will also check trial database
records to check ongoing or planned evaluation of any new intervention types. Given that high
compression is the main criterion for selecting treatments of interest, a survey will be conducted to
establish what treatments identified in the above formulary and review aim to deliver ‘high compression’,
as there are likely to be a number of ad hoc treatments about which we are not clear about. A group of
experts, clinicians and nurses will be invited to give their opinions. The treatments of interest will be those
treatments that have been classified as high compression. We will also work with clinicians to place
individual treatments into meaningful treatment groups (i.e. 4LB, SSB, high-compression hosiery, etc.).
Defining the model structure
A systematic literature review will be conducted to identify published economic evaluations using decision
analytic models regarding the treatment and/or prevention of venous leg ulcers. The purpose of the review
is to provide information of the current developments in the field in terms of model structure and
assumptions used in the analyses, and to prepare for potential issues that the project might encounter.
The systematic literature review will be conducted by two independent reviewers according to agreed
screening criteria:
l Does the study consider venous leg ulcers?
l Is the study a full economic evaluation (i.e. includes costs and benefits)?
l Does the study use any kind of model as a method to represent disease progression?
DOI: 10.3310/hta18570 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 57
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Ashby et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
291
Only studies that meet all of the above criteria (agreed by both reviewers) will be extracted and reviewed.
The information extracted will include treatment comparator, study population, model design, model
assumption, effectiveness, utility, cost and uncertainty. The findings of this review will be used to inform
the model structure.
Obtaining data to inform model
The model will be informed by a variety of parameters, such as data on effectiveness of over healing and
utilities. Procedures to obtain data and to synthesise available evidence are detailed below.
Effectiveness
Rather than conduct a separate review of effectiveness data we will utilise the Cochrane Review19 – This
review was conducted in 2009 and will be updated (in 2011) to include additional evidence of six recent
studies. The aim of the review is to evaluate the clinical effectiveness of compression bandage or stocking
systems in the treatment of venous leg ulceration. This review will serve as the major source of data on the
effectiveness of alternative treatments (AD).
Evidence synthesis on effectiveness
At this stage, we know from the Cochrane review19 that multiple trials evaluating the clinical effectiveness
of high-compression treatment on venous leg ulceration exist. We will use a MTC approach186 to estimate
the relative effectiveness multiple treatments by synthesising the existing evidence base of trials.
When trials have common comparators, this process allows relative effectiveness estimates to be
made for treatments not compared in head-to-head trials (i.e. indirect evidence) while maintaining
the randomisation of each trial. In this way, all available evidence can be used to estimate treatment
effects for pairs of treatments that have, at least, indirect evidence (i.e. for comparisons that have not been
examined in any trial). Currently, there is a lack of direct (head-to-head) evidence in the literature on the
relative effectiveness of hosiery in relation to 4LB. Using an MTC approach, the relative effectiveness
between hosiery and 4LB can be estimated based on available indirect evidence. The direct evidence
will be provided once the VenUS IV is completed (details of the inclusion of VenUS IV data in the
model are outlined below).
In defining the MTC model, we will aim to combine data from studies for which IPD is available to the
authors (e.g. VenUS I)7 with aggregate data identified from studies in the Cochrane review. We also aim
to incorporate (instead of exclude) trials that report alternative measures of healing (e.g. proportion of
patients healed or time to healing), by appropriately modelling these within the MTC. Inferences will be
obtained using Bayesian methods. If necessary, the sensitivity to prior distributions and the validity and
consistency of the MTC will be explored.187
Other model parameters
Other parameters possibly required for the model include utilities, resource use and cost parameters,
and death rates. Current evidence for these parameters, for different disease states (as defined in the
model) will be identified from the literature, if possible, we will work with the Centre for Reviews and
Dissemination to conduct these searches. However, if it is not feasible to obtain all the information
from the literature or if there is no evidence available then data extracted from the IPD sources (VenUS I7
and VenUS IV studies) may be used.
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Methods of analysis
To simultaneously address several of the elements included in decision-analytic modelling, i.e. evidence
synthesis based on MTC, estimation of other model inputs and evaluation of uncertainty, we will construct
a comprehensive probabilistic decision-analytic model evaluated using Markov chain Monte Carlo
simulation implemented in the specialist software WinBUGS. The model outputs will be the estimated
expected mean costs, effectiveness, and QALYs associated with each alternative treatment.
Estimated total costs and outcomes will be discounted properly according to the latest guidance of health
technology appraisal.
Decision uncertainty
Uncertainty regarding cost-effectiveness will be evaluated using probabilistic sensitivity analysis, where
inputs into the analysis are defined as probability distributions that reflect uncertainty. The estimated mean
QALYs and costs associated with each treatment option will be combined with a feasible range of values
for decision-makers’ willingness to pay (λ), to obtain distribution of net benefits at different levels of λ.
The uncertainty surrounding the decision to adopt a given treatment option as a cost-effective treatment
as different levels of willingness to pay will be represented in acceptability curves (CEACs). CEACs are a
graphical representation of the probability of an intervention being cost-effective (on the vertical axis) for a
range of willingness-to-pay values λ (on the horizontal axis) associated with the health outcome
of interest.188
Scenarios and sensitivity analysis
Scenario analyses Two scenarios will be investigated regarding the estimation of differential inputs
(model parameters). First, all model inputs will be defined based on evidence collected from the literature,
excluding the findings from VenUS IV (pre VenUS IV analysis). A second scenario will incorporate the
finding from VenUS IV alongside all of the evidence from the literature as described above (post VenUS IV
analysis). In the latter, the IPD data on effectiveness from VenUS IV will be incorporated in the existing
MTC. Other parameters for which VenUS IV evidence is available will also inform the model, alongside
existing evidence.
Sensitivity analysis The impact of assumptions undertaken in the analysis regarding the evidence over
parameters or relating to the decision model (such as extrapolation) will be evaluated, if possible.
Value of further research
As part of this analysis we will conduct a value of information analysis. Uncertainty around treatment
decisions means that in many cases there is always a chance that the ‘wrong’ decision will be made.162
With estimates of probability of error and the opportunity cost of error, the expected cost of uncertainty or
the expected opportunity loss surrounding the decisions can be calculated. This is also known as the EVPI
and can be used to indicate whether further research is potentially worthwhile. It would also be useful to
have indication of what type of additional evidence would be most valuable. Therefore the expect value of
perfect information for parameters is calculated to identify those parameters for which more precise
estimates would be most valuable.
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